text,text_id,timestamp,language,arxiv_id,hiv/aids,covid-19,takotsubo cardiomyopathy,tuberculoses,endocarditis,syphilis,multiple myeloma,hypertension,sarcoidoses,hepatitis b,ulcerative colitis,crohnâ€™s disease,chagas disease,3545003.0,3716002.0,3723001.0,4308002.0,6142004.0,6471006.0,7973008.0,8357008.0,menstruation,9829001.0,10743008.0,11381005.0,11654001.0,13746004.0,34486009.0,40930008.0,14669001.0,15188001.0,18193002.0,18718003.0,21134002.0,396275006.0,22298006.0,23502006.0,23919004.0,24693007.0,24700007.0,25458004.0,26889001.0,26929004.0,29384001.0,30811009.0,31384009.0,32398004.0,32798002.0,32914008.0,34840004.0,35489007.0,36971009.0,37340000.0,39400004.0,39621005.0,40733004.0,91302008,161712005.0,43116000.0,44054006.0,46635009.0,49049000.0,49601007.0,50829006.0,52448006.0,52702003.0,53741008.0,54150009.0,56317004.0,56925008.0,57182000.0,57406009.0,59927004.0,60862001.0,61462000.0,61599003.0,62315008.0,63102001.0,67362008.0,68566005.0,69322001.0,69896004.0,73211009.0,73442001.0,74732009.0,75694006.0,76376003.0,86044005.0,709044004.0,129103003.0,195967001.0,200936003.0,233604007.0,698247007.0,white/caucasian,black/african american,hispanic/latino,asian,native american/indigenous,pacific islander,male,female,non-binary,ibuprofen,acetaminophen,lidocaine,esomeprazole,pregabalin,oxycodone,fluticasone propionate,valsartan,doxycycline,eszopiclone,sildenafil,abiraterone,tadalafil,aspirin,aripiprazole,budesonide,pradaxa,celecoxib,ezetimibe,vytorin,nicotine,duloxetine,benicar,methylphenidate,insulin lispro,adalimumab,paracetamol,liraglutide,pemetrexed,fenofibrate,rivaroxaban,everolimus,capecitabine,darunavir,triamcinolone,buprenorphine,divalproex sodium,ranibizumab,castor oil,melatonin,epoetin alfa,fentanyl,hydrocodone bitartrate,ustekinumab,lyrica,rituximab,filgrastim,diovan,lantus,insulin glargine,quetiapine,tamiflu,xeloda,isentress,raltegravir,janumet,cinacalcet,atazanavir,hydrocortisone cream,novolog,insulin aspart,warfarin,rosuvastatin,lantus solostar,humira,januvia,sitagliptin,xolair,omalizumab,xarelto,vaccines,imatinib,evista,adderall xr,memantine,aranesp,darbepoetin alfa,sensipar,xgeva,denosumab,stelara,oxycontin,abilify,vyvanse,prezista,raloxifene,seroquel xr,lisdexamfetamine,copaxone,dexlansoprazole,metoprolol,trastuzumab,palivizumab,infliximab,abatacept,gravol,reyataz,pepto bismol,levemir,insulin detemir,tiotropium bromide,lucentis,tylenol pm,enbrel,etanercept,renvela,oseltamivir,crestor,aciphex,ventolin hfa,lunesta,celebrex,solifenacin,mometasone,benadryl,nexplanon,viagra,synthroid,prevnar 13,pitocin,rebif,nexium,cymbalta,flovent hfa,humalog,dexilant,epogen,adderall,remicade,cialis,proair hfa,avonex,fingolimod,synagis,alimta,humalog kwikpen,namenda,bevacizumab,lipitor,heparin,afinitor,nasonex,victoza,avonex pen,zetia,dabigatran,orencia,suboxone,neupogen,zytiga,telaprevir,ritalin,gilenya,atripla,symbicort,avastin,truvada,pegfilgrastim,levothyroxine,herceptin,complera,stribild,rabeprazole,glatiramer,neulasta,insulin,lovaza,atorvastatin,vesicare,restasis,androgel,ah amyloidosis,ahl amyloidosis,aids-related anal canal carcinoma,aids-related anal carcinoma,aids-related anal non-hodgkin lymphoma,aids-related burkitt lymphoma,aids-related burkitt lymphoma with plasmacytoid differentiation,aids-related carcinoma,aids-related cervical carcinoma,aids-related cervical kaposi sarcoma,aids-related diffuse large b-cell lymphoma arising in hhv8-positive multicentric castleman disease,aids-related diffuse large b-cell lymphoma,aids-related diffuse large cell lymphoma,aids-related diffuse mixed cell lymphoma,aids-related diffuse small cleaved cell lymphoma,aids-related gastric kaposi sarcoma,aids-related hodgkin lymphoma,aids-related immunoblastic lymphoma,aids-related kaposi sarcoma,aids-related lymphoblastic lymphoma,aids-related lymphoma,aids-related lymphoma by working formulation,aids-related malignant anal neoplasm,aids-related malignant cervical neoplasm,aids-related malignant neoplasm,aids-related non-hodgkin lymphoma,aids-related non-hodgkin lymphoma of the cervix,aids-related plasmablastic lymphoma,aids-related plasmablastic lymphoma of mucosa site,aids-related plasmablastic lymphoma of the oral mucosa,aids-related primary central nervous system lymphoma,aids-related primary diffuse large b-cell lymphoma of the central nervous system,aids-related primary effusion lymphoma,al amyloidosis,asph-positive head and neck squamous cell carcinoma,abdominal (mesenteric) fibromatosis,abdominal inflammatory myofibroblastic tumor,abdominal rhabdomyosarcoma,abdominal undifferentiated pleomorphic sarcoma,abducens nerve neoplasm,acantholytic acanthoma,acanthoma,acanthomatous ameloblastoma,"accelerated phase chronic myelogenous leukemia, bcr-abl1 positive",accelerated phase myeloproliferative neoplasm,accelerated phase primary myelofibrosis,accessory nerve neoplasm,accessory urethral gland carcinoma,accessory urethral gland neoplasm,acidophil stem cell pituitary neuroendocrine tumor,acinar cell adenoma,acinar cell carcinoma,acinar cell neoplasm,acquired cystic disease-associated renal cell carcinoma,acquired hemangioma,acquired progressive lymphangioma,acral fibromyxoma,acral lentiginous melanoma,acral nevus,acute adult t-cell leukemia/lymphoma,acute basophilic leukemia,acute bilineal leukemia,acute biphenotypic leukemia,acute eosinophilic leukemia,acute erythroid leukemia,acute leukemia,acute leukemia of ambiguous lineage,"acute leukemia of ambiguous lineage, not otherwise specified",acute lymphoblastic leukemia,acute lymphoblastic leukemia by gene expression profile,acute lymphoblastic leukemia by rose cluster,acute megakaryoblastic leukemia,acute megakaryoblastic leukemia with cbfa2t3-glis2,acute megakaryoblastic leukemia with nup98-kdm5a,acute monoblastic leukemia,acute monoblastic and monocytic leukemia,acute monocytic leukemia,acute myeloid leukemia,acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); rbm15-mkl1,acute myeloid leukemia arising from previous myelodysplastic syndrome,acute myeloid leukemia arising from previous myelodysplastic/myeloproliferative neoplasm,acute myeloid leukemia arising from previous myeloproliferative neoplasm,acute myeloid leukemia with bcr-abl1,acute myeloid leukemia with biallelic mutations of cebpa,acute myeloid leukemia with flt3/itd mutation,acute myeloid leukemia with gene mutations,acute myeloid leukemia with germline cebpa mutation,acute myeloid leukemia with mll rearrangement,acute myeloid leukemia with maturation,acute myeloid leukemia with minimal differentiation,acute myeloid leukemia with monoallelic mutations of cebpa,acute myeloid leukemia with multilineage dysplasia,acute myeloid leukemia with mutated cebpa,acute myeloid leukemia with mutated npm1,acute myeloid leukemia with mutated runx1,acute myeloid leukemia with myelodysplasia-related changes,acute myeloid leukemia with ram immunophenotype,acute myeloid leukemia with recurrent genetic abnormalities,acute myeloid leukemia with trisomy 8,acute myeloid leukemia with variant mll translocations,acute myeloid leukemia with a variant rara translocation,acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); cbfb-myh11,acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11,"acute myeloid leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); gata2, mecom","acute myeloid leukemia with inv(3) (q21.3;q26.2); gata2, mecom",acute myeloid leukemia with t(10;11)(p12;q23); mllt10-mll,acute myeloid leukemia with t(11;15)(p15;q35); nup98-jarid1a,acute myeloid leukemia with t(11;17)(q13;q21),acute myeloid leukemia with t(11;17)(q23;q21),acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11,acute myeloid leukemia with t(17;17)(q21;q21),"acute myeloid leukemia with t(3;3) (q21.3;q26.2); gata2, mecom",acute myeloid leukemia with t(5;11)(q35;p15); nup98-nsd1,acute myeloid leukemia with t(5;17)(q35;q21),acute myeloid leukemia with t(6;11)(q27;q23); mllt4-mll,acute myeloid leukemia with t(6;9) (p23;q34.1); dek-nup214,acute myeloid leukemia with t(7;12)(q36;p13); hlxb9-etv6,acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1,acute myeloid leukemia with t(9;11)(p21.3;q23.3); mllt3-mll,acute myeloid leukemia without maturation,acute myelomonocytic leukemia,acute myelomonocytic leukemia with abnormal eosinophils,acute myelomonocytic leukemia without abnormal eosinophils,acute panmyelosis with myelofibrosis,acute promyelocytic leukemia with pml-rara,acute undifferentiated leukemia,adamantinoma,adamantinomatous craniopharyngioma,adenocarcinofibroma,adenocarcinoma,adenocarcinoma in situ,adenocarcinoma in situ in adenomatous polyp,adenocarcinoma in situ in tubular adenoma,adenocarcinoma in situ in tubulovillous adenoma,adenocarcinoma in situ in villous adenoma,adenocarcinoma in situ in a polyp,adenocarcinoma in adenomatous polyp,adenocarcinoma in adenomatous polyposis coli,adenocarcinoma in multiple adenomatous polyps,adenocarcinoma in tubular adenoma,adenocarcinoma in tubulovillous adenoma,adenocarcinoma in villous adenoma,adenocarcinoma of skene gland origin,adenocarcinoma of unknown primary,adenocarcinoma with apocrine metaplasia,adenocarcinoma with cartilaginous metaplasia,adenocarcinoma with cartilaginous and osseous metaplasia,adenocarcinoma with metaplasia,adenocarcinoma with neuroendocrine differentiation,adenocarcinoma with osseous metaplasia,adenocarcinoma with spindle cell metaplasia,adenocarcinoma with squamous metaplasia,adenoid cystic carcinoma,adenoid cystic skin carcinoma,adenoma,adenoma of minor vestibular glands,adenoma of the colon with intramucosal adenocarcinoma,adenoma of the retinal pigment epithelium,adenomatoid odontogenic tumor,adenomatoid tumor,adenomatous polyp,adenomyoma,adenosarcoma,adenosquamous carcinoma,adenosquamous carcinoma of the penis,adnexal carcinoma,adnexal cribriform carcinoma,adnexal secretory carcinoma,adrenal cortical adenoma,adrenal cortical adenomatoid tumor,adrenal cortical carcinoma,adrenal cortical clear cell adenoma,adrenal cortical compact cell adenoma,adrenal cortical glomerulosa cell adenoma,adrenal cortical high grade carcinoma,adrenal cortical low grade carcinoma,adrenal cortical melanoma,adrenal cortical mixed cell adenoma,adrenal cortical myxoid carcinoma,adrenal cortical neoplasm,adrenal cortical oncocytic adenoma,adrenal cortical oncocytic carcinoma,adrenal cortical sarcomatoid carcinoma,adrenal cortical sex cord-stromal tumor,adrenal gland angiosarcoma,adrenal gland composite pheochromocytoma,adrenal gland ganglioneuroblastoma,"adrenal gland ganglioneuroblastoma, intermixed","adrenal gland ganglioneuroblastoma, nodular",adrenal gland ganglioneuroma,adrenal gland hemangioma,adrenal gland leiomyoma,adrenal gland leiomyosarcoma,adrenal gland lipoma,adrenal gland lymphangioma,adrenal gland lymphoma,adrenal gland neoplasm,adrenal gland neuroblastoma,adrenal gland pheochromocytoma,adrenal gland sarcoma,adrenal gland schwannoma,adrenal medulla neoplasm,adrenal rest tumor,adult acute basophilic leukemia,adult acute eosinophilic leukemia,adult acute erythroid leukemia,adult acute lymphoblastic leukemia,adult acute megakaryoblastic leukemia,adult acute monoblastic leukemia,adult acute monoblastic and monocytic leukemia,adult acute monocytic leukemia,adult acute myeloid leukemia,adult acute myeloid leukemia with maturation,adult acute myeloid leukemia with minimal differentiation,adult acute myeloid leukemia with recurrent genetic abnormalities,adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11,adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11,adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1,adult acute myeloid leukemia with t(9;11)(p21.3;q23.3); mllt3-mll,adult acute myeloid leukemia without maturation,adult acute myelomonocytic leukemia,adult acute promyelocytic leukemia with pml-rara,adult alveolar soft part sarcoma,adult anaplastic (malignant) meningioma,adult anaplastic astrocytoma,adult anaplastic ependymoma,adult anaplastic large cell lymphoma,adult anaplastic oligodendroglioma,adult angiosarcoma,adult astrocytic tumor,adult atypical meningioma,adult b acute lymphoblastic leukemia,adult b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1,adult b lymphoblastic lymphoma,adult botryoid-type embryonal rhabdomyosarcoma,adult brain ependymoma,adult brain glioblastoma,adult brain neoplasm,adult brain oligodendroglioma,adult brain stem astrocytoma,adult brain stem glioma,adult brain stem gliosarcoma,adult brain stem mixed glioma,adult brain stem neoplasm,adult burkitt leukemia,adult cardiac cellular rhabdomyoma,adult central nervous system choriocarcinoma,adult central nervous system embryonal carcinoma,"adult central nervous system embryonal tumor, not otherwise specified",adult central nervous system germ cell tumor,adult central nervous system germinoma,adult central nervous system immature teratoma,adult central nervous system mature teratoma,adult central nervous system mixed germ cell tumor,adult central nervous system neoplasm,"adult central nervous system solitary fibrous tumor, grade 3",adult central nervous system teratoma,adult cerebellar neoplasm,adult choroid plexus neoplasm,adult classic hodgkin lymphoma,adult clear cell sarcoma of soft tissue,adult combined hepatocellular carcinoma and cholangiocarcinoma,adult craniopharyngioma,adult cystic nephroma,adult cystic teratoma,adult desmoplastic small round cell tumor,adult diffuse astrocytoma,adult diffuse large cell lymphoma,adult diffuse mixed cell lymphoma,adult diffuse small cleaved cell lymphoma,"adult embryonal tumor with multilayered rosettes, c19mc-altered",adult ependymal tumor,adult ependymoma,adult epithelioid hemangioendothelioma,adult epithelioid sarcoma,adult erythroleukemia,adult extracardiac rhabdomyoma,adult extraskeletal myxoid chondrosarcoma,adult extraskeletal osteosarcoma,adult favorable prognosis hodgkin lymphoma,adult fibrolamellar carcinoma,adult fibrosarcoma,adult ganglioglioma,adult germ cell tumor,adult giant cell glioblastoma,adult glioblastoma,adult gliosarcoma,adult grade 1 meningioma,adult grade 2 meningioma,adult grade 3 meningioma,adult grade iii lymphomatoid granulomatosis,adult hepatocellular carcinoma,adult hodgkin lymphoma,adult infiltrating astrocytic tumor,adult intracranial germ cell tumor,adult intracranial meningioma,adult intracranial neoplasm,adult kidney wilms tumor,adult l1 acute lymphoblastic leukemia,adult l2 acute lymphoblastic leukemia,adult langerhans cell histiocytosis,adult leiomyosarcoma,adult liposarcoma,adult liver carcinoma,adult lymphoblastic lymphoma,adult lymphocyte-depleted classic hodgkin lymphoma,adult lymphocyte-rich classic hodgkin lymphoma,adult lymphoma,adult malignant brain neoplasm,adult malignant mesenchymoma,adult malignant peripheral nerve sheath tumor,adult medulloblastoma,adult meningeal melanoma,adult meningioma,adult mesenchymal chondrosarcoma,adult mixed cellularity classic hodgkin lymphoma,adult mixed glioma,adult myelodysplastic syndrome,adult myofibroma,adult myxopapillary ependymoma,adult nasal type extranodal nk/t-cell lymphoma,adult nodular lymphocyte predominant hodgkin lymphoma,adult nodular sclerosis classic hodgkin lymphoma,adult non-hodgkin lymphoma,adult non-hodgkin lymphoma by ann arbor stage,adult non-t non-b acute lymphoblastic leukemia,adult oligodendroglial tumor,adult oligodendroglioma,adult papillary meningioma,adult penile carcinoma,adult pilocytic astrocytoma,adult pineal gland astrocytoma,adult pineal parenchymal cell neoplasm,adult pineoblastoma,adult pineocytoma,adult pleomorphic hepatocellular carcinoma,adult pleomorphic rhabdomyosarcoma,adult pre-b acute lymphoblastic leukemia,adult primary cutaneous anaplastic large cell lymphoma,adult primary meningeal melanocytic neoplasm,adult pure erythroid leukemia,adult rhabdomyosarcoma,adult salivary gland carcinoma,adult soft tissue sarcoma,adult solid neoplasm,adult spinal cord ependymoma,adult spinal cord glioblastoma,adult spinal cord neoplasm,adult subependymal giant cell astrocytoma,adult subependymoma,"adult supratentorial embryonal tumor, not otherwise specified",adult synovial sarcoma,adult systemic anaplastic large cell lymphoma,adult t acute lymphoblastic leukemia,adult t lymphoblastic lymphoma,adult t-cell leukemia/lymphoma,adult t-cell leukemia/lymphoma by ann arbor stage,adult tdt negative acute lymphoblastic leukemia,adult tdt positive acute lymphoblastic leukemia,adult teratoma,adult type ovarian granulosa cell tumor,adult type testicular granulosa cell tumor,adult undifferentiated high grade pleomorphic sarcoma of bone,adult undifferentiated pleomorphic sarcoma,adult unfavorable prognosis hodgkin lymphoma,adult vaginal botryoid-type embryonal rhabdomyosarcoma,adult xanthogranuloma,adult yolk sac tumor,advanced adenocarcinoma,advanced adenocarcinoma of unknown primary,advanced adenoid cystic carcinoma,advanced adrenal gland pheochromocytoma,advanced adult hepatocellular carcinoma,advanced alveolar soft part sarcoma,advanced ampulla of vater carcinoma,advanced anal canal squamous cell carcinoma,advanced anal carcinoma,advanced anaplastic large cell lymphoma,advanced angiosarcoma,advanced appendix adenocarcinoma,advanced b-cell malignant neoplasm,advanced basal cell carcinoma,advanced bile duct carcinoma,advanced biliary tract carcinoma,advanced bladder carcinoma,advanced bladder urothelial carcinoma,advanced bone sarcoma,advanced breast adenocarcinoma,advanced breast carcinoma,advanced bronchogenic carcinoma,advanced carcinoid tumor,advanced carcinoma,advanced carcinoma of unknown primary,advanced carcinosarcoma,advanced cervical adenocarcinoma,advanced cervical adenosquamous carcinoma,advanced cervical carcinoma,advanced cervical squamous cell carcinoma,advanced childhood malignant brain neoplasm,advanced childhood malignant solid neoplasm,advanced cholangiocarcinoma,advanced chordoma,advanced chromophobe renal cell carcinoma,advanced clear cell renal cell carcinoma,advanced clear cell sarcoma of soft tissue,advanced colon adenocarcinoma,advanced colon carcinoma,advanced colorectal adenocarcinoma,advanced colorectal carcinoma,advanced cutaneous melanoma,advanced cutaneous melanoma of the extremity,advanced cutaneous squamous cell carcinoma of the head and neck,advanced dedifferentiated liposarcoma,advanced differentiated thyroid gland carcinoma,advanced diffuse large b-cell lymphoma,advanced digestive system carcinoma,advanced digestive system neuroendocrine neoplasm,advanced digestive system neuroendocrine tumor g1,advanced distal bile duct adenocarcinoma,advanced endometrial adenocarcinoma,advanced endometrial carcinoma,advanced endometrial endometrioid adenocarcinoma,advanced endometrial serous adenocarcinoma,advanced endometrioid adenocarcinoma,advanced epithelioid hemangioendothelioma,advanced epithelioid mesothelioma,advanced epithelioid sarcoma,advanced esophageal adenocarcinoma,advanced esophageal carcinoma,advanced esophageal squamous cell carcinoma,advanced extracranial malignant solid neoplasm,advanced extrahepatic bile duct carcinoma,advanced fallopian tube carcinoma,advanced favorable hodgkin lymphoma,advanced favorable non-hodgkin lymphoma,advanced fibrolamellar carcinoma,advanced fibrosarcoma,advanced follicular lymphoma,advanced gallbladder carcinoma,advanced gastric adenocarcinoma,advanced gastric carcinoma,advanced gastric large cell neuroendocrine carcinoma,advanced gastric neuroendocrine carcinoma,advanced gastric small cell neuroendocrine carcinoma,advanced gastroesophageal junction adenocarcinoma,advanced gastrointestinal stromal tumor,advanced genitourinary system carcinoma,advanced glioblastoma,advanced her2-low breast carcinoma,advanced her2-negative breast carcinoma,advanced her2-positive breast carcinoma,advanced head and neck carcinoma,advanced head and neck squamous cell carcinoma,advanced hepatocellular carcinoma,advanced hilar cholangiocarcinoma,advanced hodgkin lymphoma,advanced hormone receptor-positive breast carcinoma,advanced hypopharyngeal squamous cell carcinoma,advanced intrahepatic cholangiocarcinoma,advanced kaposi sarcoma,advanced kidney carcinoma,advanced kidney medullary carcinoma,advanced large cell neuroendocrine carcinoma,advanced laryngeal squamous cell carcinoma,advanced leiomyosarcoma,advanced liposarcoma,advanced lung adenocarcinoma,advanced lung adenosquamous carcinoma,advanced lung carcinoid tumor,advanced lung carcinoma,advanced lung large cell neuroendocrine carcinoma,advanced lung neuroendocrine neoplasm,advanced lung non-small cell carcinoma,advanced lung non-small cell squamous carcinoma,advanced lung non-squamous non-small cell carcinoma,advanced lung small cell carcinoma,advanced lung squamous cell carcinoma,advanced lymphoma,advanced malignant abdominal neoplasm,advanced malignant digestive system neoplasm,advanced malignant female reproductive system neoplasm,advanced malignant genitourinary system neoplasm,advanced malignant germ cell tumor,advanced malignant head and neck neoplasm,advanced malignant mesothelioma,advanced malignant mixed mesodermal (mullerian) tumor,advanced malignant neoplasm,advanced malignant pecoma,advanced malignant peripheral nerve sheath tumor,advanced malignant skin neoplasm,advanced malignant small intestinal neoplasm,advanced malignant solid neoplasm,advanced malignant testicular germ cell tumor,advanced malignant thoracic neoplasm,advanced malignant thymoma,advanced marginal zone lymphoma,advanced melanoma,advanced merkel cell carcinoma,advanced microsatellite stable colorectal carcinoma,advanced microsatellite stable endometrial carcinoma,advanced microsatellite stable ovarian carcinoma,advanced mucosal melanoma,advanced myxofibrosarcoma,advanced myxoid liposarcoma,advanced nut carcinoma,advanced nasopharyngeal carcinoma,advanced nasopharyngeal squamous cell carcinoma,advanced neuroendocrine carcinoma,advanced neuroendocrine neoplasm,advanced neuroendocrine tumor,advanced non-cutaneous melanoma,advanced non-functioning neuroendocrine tumor,advanced non-hodgkin lymphoma,advanced oral cavity squamous cell carcinoma,advanced oropharyngeal carcinoma,advanced oropharyngeal squamous cell carcinoma,advanced ovarian carcinoma,advanced ovarian carcinosarcoma,advanced ovarian clear cell adenocarcinoma,advanced ovarian endometrioid adenocarcinoma,advanced ovarian serous adenocarcinoma,advanced ovarian serous cystadenocarcinoma,advanced pancreatic adenocarcinoma,advanced pancreatic carcinoma,advanced pancreatic ductal adenocarcinoma,advanced pancreatic neuroendocrine neoplasm,advanced pancreatic neuroendocrine tumor,advanced pancreatobiliary carcinoma,advanced papillary renal cell carcinoma,advanced paraganglioma,advanced penile carcinoma,advanced pericardial malignant mesothelioma,advanced peritoneal malignant mesothelioma,advanced pharyngeal carcinoma,advanced pharyngeal squamous cell carcinoma,advanced platinum-resistant malignant germ cell tumor,advanced pleomorphic liposarcoma,advanced pleural malignant mesothelioma,advanced primary cutaneous t-cell non-hodgkin lymphoma,advanced primary malignant brain neoplasm,advanced primary malignant central nervous system neoplasm,advanced primary peritoneal carcinoma,advanced prostate adenocarcinoma,advanced prostate adenocarcinoma with neuroendocrine differentiation,advanced prostate carcinoma,advanced rectal adenocarcinoma,advanced rectal carcinoma,advanced rectal squamous cell carcinoma,advanced renal cell carcinoma,advanced renal pelvis carcinoma,advanced renal pelvis urothelial carcinoma,advanced renal pelvis and ureter urothelial carcinoma,advanced rhabdoid tumor,advanced round cell liposarcoma,advanced salivary gland carcinoma,advanced sarcoma,advanced sarcoma of the extremity,advanced sarcomatoid renal cell carcinoma,advanced skin squamous cell carcinoma,advanced small intestinal large cell neuroendocrine carcinoma,advanced small intestinal neuroendocrine carcinoma,advanced small intestinal small cell neuroendocrine carcinoma,advanced soft tissue leiomyosarcoma,advanced soft tissue sarcoma,advanced squamous cell carcinoma,advanced synovial sarcoma,advanced thymic carcinoma,advanced thymic neuroendocrine neoplasm,advanced thyroid gland anaplastic carcinoma,advanced thyroid gland carcinoma,advanced thyroid gland medullary carcinoma,advanced transformed non-hodgkin lymphoma,advanced transitional cell carcinoma,advanced triple-negative breast carcinoma,advanced unclassified renal cell carcinoma,advanced undifferentiated pleomorphic sarcoma,advanced unfavorable hodgkin lymphoma,advanced unfavorable non-hodgkin lymphoma,advanced unresectable gastric adenocarcinoma,advanced ureter urothelial carcinoma,advanced urethral urothelial carcinoma,advanced urothelial carcinoma,advanced uterine corpus cancer,advanced uterine corpus carcinosarcoma,advanced uveal melanoma,advanced vaginal adenocarcinoma,advanced vaginal adenosquamous carcinoma,advanced vaginal carcinoma,advanced vaginal squamous cell carcinoma,advanced vulvar carcinoma,aflatoxins-related hepatocellular carcinoma,aggravated malignant neoplasm,aggressive nk-cell leukemia,aggressive osteoblastoma,aggressive papillary tumor,aggressive prostate adenocarcinoma,aggressive systemic mastocytosis,aggressive systemic mastocytosis associated with germ cell tumor,aggressive variant prostate carcinoma,airway infantile hemangioma,alcohol-related carcinoma,alcohol-related esophageal squamous cell carcinoma,alcohol-related hepatocellular carcinoma,alcohol-related laryngeal carcinoma,aldosterone-producing adrenal cortical adenoma,aleukemic acute lymphoblastic leukemia,aleukemic acute lymphoblastic leukemia cutis,aleukemic chronic lymphocytic leukemia,aleukemic leukemia,aleukemic leukemia cutis,aleukemic lymphoid leukemia,aleukemic monocytic leukemia cutis,alkylating agent-related acute myeloid leukemia,alkylating agent-related acute myeloid leukemia and myelodysplastic syndrome,alkylating agent-related myelodysplastic syndrome,alpha heavy chain disease,alveolar adenoma,alveolar rhabdomyosarcoma,alveolar ridge squamous cell carcinoma,alveolar soft part sarcoma,amelanotic cutaneous melanoma,amelanotic melanoma,ameloblastic carcinoma,ameloblastic carcinoma derived from odontogenic cyst,ameloblastic carcinoma-primary type,ameloblastic carcinoma-secondary type (dedifferentiated),"ameloblastic carcinoma-secondary type (dedifferentiated), intraosseous","ameloblastic carcinoma-secondary type (dedifferentiated), peripheral",ameloblastic fibro-odontoma,ameloblastic fibrodentinoma,ameloblastic fibrodentinosarcoma,ameloblastic fibroma,ameloblastic fibroodontosarcoma,ameloblastic fibrosarcoma,ameloblastoma,ampulla of vater adenocarcinoma,"ampulla of vater adenoma, intestinal-type",ampulla of vater adenosquamous carcinoma,ampulla of vater carcinoma,ampulla of vater clear cell adenocarcinoma,ampulla of vater enterochromaffin cell serotonin-producing neuroendocrine tumor,ampulla of vater gangliocytic paraganglioma,ampulla of vater hepatoid adenocarcinoma,ampulla of vater intestinal-type adenocarcinoma,ampulla of vater invasive papillary adenocarcinoma,ampulla of vater large cell neuroendocrine carcinoma,ampulla of vater mixed adenoneuroendocrine carcinoma,ampulla of vater mucinous adenocarcinoma,ampulla of vater neoplasm,ampulla of vater neuroendocrine carcinoma,ampulla of vater neuroendocrine neoplasm,ampulla of vater neuroendocrine tumor,ampulla of vater neuroendocrine tumor g1,ampulla of vater neuroendocrine tumor g2,ampulla of vater neuroendocrine tumor g3,ampulla of vater pancreatobiliary type adenocarcinoma,ampulla of vater signet ring cell carcinoma,ampulla of vater small cell neuroendocrine carcinoma,ampulla of vater somatostatin-producing neuroendocrine tumor,ampulla of vater squamous cell carcinoma,ampulla of vater tubular adenoma,ampulla of vater tubulovillous adenoma,ampulla of vater undifferentiated carcinoma,ampulla of vater undifferentiated carcinoma with osteoclast-like giant cells,ampulla of vater villous adenoma,"ampullary flat intraepithelial neoplasia, high grade",ampullary noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia,ampullary noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia,"ampullary noninvasive papillary neoplasm, pancreatobiliary type",anal adenocarcinoma,anal adenocarcinoma within anorectal fistula,anal basaloid carcinoma,anal canal adenocarcinoma,anal canal carcinoma,anal canal cloacogenic carcinoma,anal canal intraepithelial neoplasia,anal canal large cell neuroendocrine carcinoma,anal canal mixed adenoneuroendocrine carcinoma,anal canal neuroendocrine carcinoma,anal canal neuroendocrine neoplasm,anal canal neuroendocrine tumor,anal canal neuroendocrine tumor g1,anal canal neuroendocrine tumor g2,anal canal paget disease,anal canal small cell neuroendocrine carcinoma,anal canal squamous cell carcinoma,anal canal squamous cell papilloma,anal canal undifferentiated carcinoma,anal carcinoma,anal condyloma acuminatum,anal extramucosal (perianal) adenocarcinoma,anal fibroadenoma,anal glands adenocarcinoma,anal hidradenoma papilliferum,anal intraepithelial neoplasia,anal intraepithelial neoplasia 2,anal intraepithelial neoplasia 3,anal kaposi sarcoma,anal leiomyoma,anal leiomyosarcoma,anal lymphoma,anal margin basal cell carcinoma,anal margin carcinoma,anal margin paget disease,anal margin squamous cell carcinoma,anal melanoma,anal mucinous adenocarcinoma,anal neoplasm,anal paget disease,anal rhabdomyosarcoma,anal sarcoma,anal squamous cell carcinoma,anal verrucous carcinoma,anaplastic (malignant) intracranial meningioma,anaplastic (malignant) intraspinal meningioma,anaplastic (malignant) meningioma,"anaplastic astroblastoma, mn1-altered",anaplastic astrocytoma,"anaplastic astrocytoma, idh-wildtype","anaplastic astrocytoma, not otherwise specified",anaplastic brain stem astrocytoma,anaplastic brain stem glioma,anaplastic diencephalic astrocytoma,anaplastic embryonal rhabdomyosarcoma,anaplastic ependymoma,anaplastic ganglioglioma,anaplastic kidney wilms tumor,anaplastic large cell lymphoma,"anaplastic large cell lymphoma, alk-negative","anaplastic large cell lymphoma, alk-positive","anaplastic large cell lymphoma, giant cell rich subtype","anaplastic large cell lymphoma, lymphomatoid papulosis-like histology","anaplastic large cell lymphoma, sarcomatoid subtype","anaplastic large cell lymphoma, signet ring-like subtype",anaplastic lymphoma post-transplant lymphoproliferative disorder,anaplastic malignant neoplasm,anaplastic medulloblastoma,anaplastic oligoastrocytoma,"anaplastic oligoastrocytoma, not otherwise specified",anaplastic oligodendroglioma,"anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted","anaplastic oligodendroglioma, not otherwise specified",anaplastic plasmacytoma,anaplastic pleomorphic xanthoastrocytoma,anaplastic sarcoma of the kidney,anastomosing hemangioma,ancient schwannoma,androgen-producing adrenal cortical adenoma,aneurysmal bone cyst,angiocentric glioma,angiocentric immunoproliferative lesion,angiofibroma,angiofibroma of soft tissue,angioimmunoblastic t-cell lymphoma by ann arbor stage,angioleiomyoma,angiolipoma,angioma serpiginosum,angiomatoid fibrous histiocytoma,angiomatosis,angiomatous meningioma,angiomyofibroblastoma,angiomyolipoma,angiomyosarcoma,angiomyxoma,angiosarcoma,angiosarcoma associated with lymphedema,angiosarcoma nci grade 2,angiosarcoma nci grade 3,angiosarcoma of the skin of the arm after radical mastectomy followed by lymphedema,ann arbor stage i aids-related lymphoma,ann arbor stage i adult burkitt lymphoma,ann arbor stage i adult hodgkin lymphoma,ann arbor stage i adult immunoblastic lymphoma,ann arbor stage i adult lymphoblastic lymphoma,ann arbor stage i adult non-hodgkin lymphoma,ann arbor stage i adult t-cell leukemia/lymphoma,ann arbor stage i aggressive adult non-hodgkin lymphoma,ann arbor stage i angioimmunoblastic t-cell lymphoma,ann arbor stage i b lymphoblastic lymphoma,ann arbor stage i b-cell non-hodgkin lymphoma,ann arbor stage i burkitt lymphoma,ann arbor stage i centroblastic lymphoma,ann arbor stage i childhood burkitt lymphoma,ann arbor stage i childhood hodgkin lymphoma,ann arbor stage i childhood lymphoblastic lymphoma,ann arbor stage i childhood non-hodgkin lymphoma,ann arbor stage i diffuse large b-cell lymphoma,ann arbor stage i enteropathy-associated t-cell lymphoma,ann arbor stage i extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,ann arbor stage i follicular lymphoma,ann arbor stage i grade 1 follicular lymphoma,ann arbor stage i grade 2 follicular lymphoma,ann arbor stage i grade 3 follicular lymphoma,ann arbor stage i hodgkin lymphoma,ann arbor stage i indolent adult non-hodgkin lymphoma,ann arbor stage i lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage i lymphoma,ann arbor stage i lymphoplasmacytic lymphoma,ann arbor stage i mantle cell lymphoma,ann arbor stage i marginal zone lymphoma,ann arbor stage i mature t- and nk-cell lymphoma,ann arbor stage i mixed cellularity classic hodgkin lymphoma,ann arbor stage i nasal type nk/t-cell lymphoma,ann arbor stage i nodal marginal zone lymphoma,ann arbor stage i nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage i nodular sclerosis classic hodgkin lymphoma,ann arbor stage i non-hodgkin lymphoma,ann arbor stage i noncutaneous anaplastic large cell lymphoma,ann arbor stage i noncutaneous childhood anaplastic large cell lymphoma,ann arbor stage i primary mediastinal (thymic) large b-cell lymphoma,ann arbor stage i small lymphocytic lymphoma,ann arbor stage i subdiaphragmatic hodgkin lymphoma,ann arbor stage i subdiaphragmatic lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage i subdiaphragmatic mixed cellularity classic hodgkin lymphoma,ann arbor stage i subdiaphragmatic nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage i subdiaphragmatic nodular sclerosis classic hodgkin lymphoma,ann arbor stage i supradiaphragmatic hodgkin lymphoma,ann arbor stage i supradiaphragmatic lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage i supradiaphragmatic mixed cellularity classic hodgkin lymphoma,ann arbor stage i supradiaphragmatic nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage i supradiaphragmatic nodular sclerosis classic hodgkin lymphoma,ann arbor stage i t-cell non-hodgkin lymphoma,ann arbor stage ia hodgkin lymphoma,ann arbor stage ib hodgkin lymphoma,ann arbor stage ii aids-related lymphoma,ann arbor stage ii adult burkitt lymphoma,ann arbor stage ii adult contiguous immunoblastic lymphoma,ann arbor stage ii adult hodgkin lymphoma,ann arbor stage ii adult immunoblastic lymphoma,ann arbor stage ii adult lymphoblastic lymphoma,ann arbor stage ii adult non-contiguous immunoblastic lymphoma,ann arbor stage ii adult non-hodgkin lymphoma,ann arbor stage ii adult t-cell leukemia/lymphoma,ann arbor stage ii aggressive adult non-hodgkin lymphoma,ann arbor stage ii angioimmunoblastic t-cell lymphoma,ann arbor stage ii b lymphoblastic lymphoma,ann arbor stage ii b-cell non-hodgkin lymphoma,ann arbor stage ii burkitt lymphoma,ann arbor stage ii centroblastic lymphoma,ann arbor stage ii childhood burkitt lymphoma,ann arbor stage ii childhood hodgkin lymphoma,ann arbor stage ii childhood lymphoblastic lymphoma,ann arbor stage ii childhood non-hodgkin lymphoma,ann arbor stage ii contiguous adult aggressive non-hodgkin lymphoma,ann arbor stage ii contiguous adult burkitt lymphoma,ann arbor stage ii contiguous adult indolent non-hodgkin lymphoma,ann arbor stage ii contiguous adult lymphoblastic lymphoma,ann arbor stage ii contiguous adult non-hodgkin lymphoma,ann arbor stage ii contiguous mantle cell lymphoma,ann arbor stage ii diffuse large b-cell lymphoma,ann arbor stage ii enteropathy-associated t-cell lymphoma,ann arbor stage ii extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,ann arbor stage ii follicular lymphoma,ann arbor stage ii grade 1 contiguous follicular lymphoma,ann arbor stage ii grade 1 follicular lymphoma,ann arbor stage ii grade 1 non-contiguous follicular lymphoma,ann arbor stage ii grade 2 contiguous follicular lymphoma,ann arbor stage ii grade 2 follicular lymphoma,ann arbor stage ii grade 2 non-contiguous follicular lymphoma,ann arbor stage ii grade 3 contiguous follicular lymphoma,ann arbor stage ii grade 3 follicular lymphoma,ann arbor stage ii grade 3 non-contiguous follicular lymphoma,ann arbor stage ii hodgkin lymphoma,ann arbor stage ii indolent adult non-hodgkin lymphoma,ann arbor stage ii lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage ii lymphoma,ann arbor stage ii lymphoplasmacytic lymphoma,ann arbor stage ii mantle cell lymphoma,ann arbor stage ii marginal zone lymphoma,ann arbor stage ii mature t- and nk-cell lymphoma,ann arbor stage ii mixed cellularity classic hodgkin lymphoma,ann arbor stage ii nasal type nk/t-cell lymphoma,ann arbor stage ii nodal marginal zone lymphoma,ann arbor stage ii nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage ii nodular sclerosis classic hodgkin lymphoma,ann arbor stage ii non-contiguous adult burkitt lymphoma,ann arbor stage ii non-contiguous adult indolent non-hodgkin lymphoma,ann arbor stage ii non-contiguous adult lymphoblastic lymphoma,ann arbor stage ii non-contiguous adult non-hodgkin lymphoma,ann arbor stage ii non-contiguous aggressive adult non-hodgkin lymphoma,ann arbor stage ii non-contiguous mantle cell lymphoma,ann arbor stage ii non-hodgkin lymphoma,ann arbor stage ii noncutaneous anaplastic large cell lymphoma,ann arbor stage ii noncutaneous childhood anaplastic large cell lymphoma,ann arbor stage ii primary mediastinal (thymic) large b-cell lymphoma,ann arbor stage ii small lymphocytic lymphoma,ann arbor stage ii subdiaphragmatic hodgkin lymphoma,ann arbor stage ii subdiaphragmatic lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage ii subdiaphragmatic mixed cellularity classic hodgkin lymphoma,ann arbor stage ii subdiaphragmatic nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage ii subdiaphragmatic nodular sclerosis classic hodgkin lymphoma,ann arbor stage ii supradiaphragmatic hodgkin lymphoma,ann arbor stage ii supradiaphragmatic lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage ii supradiaphragmatic mixed cellularity classic hodgkin lymphoma,ann arbor stage ii supradiaphragmatic nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage ii supradiaphragmatic nodular sclerosis classic hodgkin lymphoma,ann arbor stage ii t-cell non-hodgkin lymphoma,ann arbor stage iia hodgkin lymphoma,ann arbor stage iib hodgkin lymphoma,ann arbor stage iii aids-related lymphoma,ann arbor stage iii adult burkitt lymphoma,ann arbor stage iii adult hodgkin lymphoma,ann arbor stage iii adult immunoblastic lymphoma,ann arbor stage iii adult lymphoblastic lymphoma,ann arbor stage iii adult non-hodgkin lymphoma,ann arbor stage iii adult t-cell leukemia/lymphoma,ann arbor stage iii aggressive adult non-hodgkin lymphoma,ann arbor stage iii angioimmunoblastic t-cell lymphoma,ann arbor stage iii b lymphoblastic lymphoma,ann arbor stage iii b-cell non-hodgkin lymphoma,ann arbor stage iii burkitt lymphoma,ann arbor stage iii centroblastic lymphoma,ann arbor stage iii childhood burkitt lymphoma,ann arbor stage iii childhood hodgkin lymphoma,ann arbor stage iii childhood lymphoblastic lymphoma,ann arbor stage iii childhood non-hodgkin lymphoma,ann arbor stage iii diffuse large b-cell lymphoma,ann arbor stage iii enteropathy-associated t-cell lymphoma,ann arbor stage iii extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,ann arbor stage iii follicular lymphoma,ann arbor stage iii grade 1 follicular lymphoma,ann arbor stage iii grade 2 follicular lymphoma,ann arbor stage iii grade 3 follicular lymphoma,ann arbor stage iii hodgkin lymphoma,ann arbor stage iii indolent adult non-hodgkin lymphoma,ann arbor stage iii lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage iii lymphoma,ann arbor stage iii lymphoplasmacytic lymphoma,ann arbor stage iii mantle cell lymphoma,ann arbor stage iii marginal zone lymphoma,ann arbor stage iii mature t- and nk-cell lymphoma,ann arbor stage iii mixed cellularity classic hodgkin lymphoma,ann arbor stage iii nasal type nk/t-cell lymphoma,ann arbor stage iii nodal marginal zone lymphoma,ann arbor stage iii nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage iii nodular sclerosis classic hodgkin lymphoma,ann arbor stage iii non-hodgkin lymphoma,ann arbor stage iii noncutaneous anaplastic large cell lymphoma,ann arbor stage iii noncutaneous childhood anaplastic large cell lymphoma,ann arbor stage iii primary mediastinal (thymic) large b-cell lymphoma,ann arbor stage iii small lymphocytic lymphoma,ann arbor stage iii t-cell non-hodgkin lymphoma,ann arbor stage iiia hodgkin lymphoma,ann arbor stage iiib hodgkin lymphoma,ann arbor stage iix (bulky) diffuse large b-cell lymphoma,ann arbor stage iix (bulky) non-hodgkin lymphoma,ann arbor stage iv aids-related lymphoma,ann arbor stage iv adult burkitt lymphoma,ann arbor stage iv adult hodgkin lymphoma,ann arbor stage iv adult immunoblastic lymphoma,ann arbor stage iv adult lymphoblastic lymphoma,ann arbor stage iv adult non-hodgkin lymphoma,ann arbor stage iv adult t-cell leukemia/lymphoma,ann arbor stage iv aggressive adult non-hodgkin lymphoma,ann arbor stage iv angioimmunoblastic t-cell lymphoma,ann arbor stage iv b lymphoblastic lymphoma,ann arbor stage iv b-cell non-hodgkin lymphoma,ann arbor stage iv burkitt lymphoma,ann arbor stage iv centroblastic lymphoma,ann arbor stage iv childhood burkitt lymphoma,ann arbor stage iv childhood hodgkin lymphoma,ann arbor stage iv childhood lymphoblastic lymphoma,ann arbor stage iv childhood non-hodgkin lymphoma,ann arbor stage iv diffuse large b-cell lymphoma,ann arbor stage iv enteropathy-associated t-cell lymphoma,ann arbor stage iv extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,ann arbor stage iv follicular lymphoma,ann arbor stage iv grade 1 follicular lymphoma,ann arbor stage iv grade 2 follicular lymphoma,ann arbor stage iv grade 3 follicular lymphoma,ann arbor stage iv hodgkin lymphoma,ann arbor stage iv indolent adult non-hodgkin lymphoma,ann arbor stage iv lymphocyte-depleted classic hodgkin lymphoma,ann arbor stage iv lymphoma,ann arbor stage iv lymphoplasmacytic lymphoma,ann arbor stage iv mantle cell lymphoma,ann arbor stage iv marginal zone lymphoma,ann arbor stage iv mature t- and nk-cell lymphoma,ann arbor stage iv mixed cellularity classic hodgkin lymphoma,ann arbor stage iv nasal type nk/t-cell lymphoma,ann arbor stage iv nodal marginal zone lymphoma,ann arbor stage iv nodular lymphocyte predominant hodgkin lymphoma,ann arbor stage iv nodular sclerosis classic hodgkin lymphoma,ann arbor stage iv non-hodgkin lymphoma,ann arbor stage iv noncutaneous anaplastic large cell lymphoma,ann arbor stage iv noncutaneous childhood anaplastic large cell lymphoma,ann arbor stage iv primary mediastinal (thymic) large b-cell lymphoma,ann arbor stage iv small lymphocytic lymphoma,ann arbor stage iv t-cell non-hodgkin lymphoma,ann arbor stage iva hodgkin lymphoma,ann arbor stage ivb hodgkin lymphoma,anogenital papillomaviral intraepithelial neoplasia,anterior cranial fossa meningioma,anterior foramen magnum meningioma,anterior pituitary gland neoplasm,anterior tongue adenoid cystic carcinoma,anterior tongue carcinoma,anterior tongue mucoepidermoid carcinoma,anterior tongue neoplasm,anterior tongue squamous cell carcinoma,anterior urethral malignant neoplasm,anterior visual pathway meningioma,aortic angiosarcoma,aorticopulmonary paraganglioma,apocrine adenoma,apocrine carcinoma,apocrine hidrocystoma,apocrine neoplasm,appendix adenocarcinoma,appendix adenoma,appendix carcinoma,appendix enterochromaffin cell serotonin-producing neuroendocrine tumor,appendix goblet cell adenocarcinoma,appendix high grade intraepithelial neoplasia,appendix intraepithelial neoplasia,appendix kaposi sarcoma,appendix l-cell glucagon-like peptide-producing neuroendocrine tumor,appendix large cell neuroendocrine carcinoma,appendix leiomyoma,appendix leiomyosarcoma,appendix lipoma,appendix low grade intraepithelial neoplasia,appendix lymphoma,appendix mixed adenoneuroendocrine carcinoma,appendix mucinous adenocarcinoma,appendix mucinous cystadenocarcinoma,appendix mucinous cystadenoma,appendix mucinous neoplasm,appendix neoplasm,appendix neuroendocrine carcinoma,appendix neuroendocrine neoplasm,appendix neuroendocrine tumor,appendix neuroendocrine tumor g1,appendix neuroendocrine tumor g2,appendix neuroendocrine tumor g3,appendix serrated lesions and polyps,appendix signet ring cell carcinoma,appendix small cell neuroendocrine carcinoma,appendix traditional serrated adenoma,appendix tubular adenoma,appendix tubular carcinoid,appendix tubulovillous adenoma,appendix undifferentiated carcinoma,appendix villous adenoma,aromatic dyes-related malignant neoplasm,asbestos-related lung carcinoma,asbestos-related malignant mesothelioma,asbestos-related malignant neoplasm,ascending colon neuroendocrine tumor g1,askin tumor,astler-coller a colon carcinoma,astler-coller a colorectal carcinoma,astler-coller a rectal carcinoma,astler-coller b1 colon carcinoma,astler-coller b1 colorectal carcinoma,astler-coller b1 rectal carcinoma,astler-coller b2 colon carcinoma,astler-coller b2 colorectal carcinoma,astler-coller b2 rectal carcinoma,astler-coller b3 colon carcinoma,astler-coller b3 colorectal carcinoma,astler-coller b3 rectal carcinoma,astler-coller c1 colon carcinoma,astler-coller c1 colorectal carcinoma,astler-coller c1 rectal carcinoma,astler-coller c2 colon carcinoma,astler-coller c2 colorectal carcinoma,astler-coller c2 rectal carcinoma,astler-coller c3 colorectal carcinoma,astler-coller c3 rectal carcinoma,"astroblastoma, mn1-altered",astrocytic tumor,astrocytoma,"astrocytoma, idh-mutant","astrocytoma, idh-mutant, grade 2","astrocytoma, idh-mutant, grade 3","astrocytoma, idh-mutant, grade 4","astrocytoma, idh-wildtype","astrocytoma, not otherwise specified",asynchronous multifocal osteosarcoma,atrial myxoma,atrial paraganglioma,atypical adenoma,atypical adenomatous lung hyperplasia,atypical carcinoid tumor,atypical cartilaginous tumor,"atypical cartilaginous tumor/chondrosarcoma, grade 1",atypical choroid plexus papilloma,"atypical chronic myeloid leukemia, bcr-abl1 negative",atypical ewing sarcoma,atypical fibroxanthoma,atypical intradermal smooth muscle neoplasm,atypical lipomatous tumor/well differentiated liposarcoma,atypical lipomatous tumor/well differentiated liposarcoma of deep soft tissue,atypical melanocytic nevus of genital type,atypical meningioma,atypical neurofibromatous neoplasm of uncertain biologic potential,atypical parathyroid gland tumor,atypical pituitary neuroendocrine tumor,atypical polypoid adenomyoma,atypical small acinar proliferation of the prostate gland,atypical spindle cell/pleomorphic lipomatous tumor,atypical spitz nevus,atypical teratoid/rhabdoid tumor,atypical type a thymoma,autoimmune lymphoproliferative syndrome-related lymphoma,autonomic nervous system neoplasm,axillary lipoma,axillary neoplasm,b acute lymphoblastic leukemia,b acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21,b acute lymphoblastic leukemia with t(12;21)(p13.2;q22.1); etv6-runx1,b acute lymphoblastic leukemia with t(1;19)(q23;p13.3); e2a-pbx1 (tcf3-pbx1),b acute lymphoblastic leukemia with t(4;11)(q21;23),b acute lymphoblastic leukemia with t(5;14)(q31.1;q32.3); il3-igh,b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1,b acute lymphoblastic leukemia with t(v;11q23.3); mll rearranged,"b acute lymphoblastic leukemia, bcr-abl1-like","b acute lymphoblastic leukemia, philadelphia chromosome negative",b lymphoblastic leukemia/lymphoma,b lymphoblastic leukemia/lymphoma with hyperdiploidy,b lymphoblastic leukemia/lymphoma with hypodiploidy,b lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities,b lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); etv6-runx1,b lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); e2a-pbx1 (tcf3-pbx1),b lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3); il3-igh,b lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); bcr-abl1,b lymphoblastic leukemia/lymphoma with t(v;11q23.3); mll rearranged,"b lymphoblastic leukemia/lymphoma, bcr-abl1-like","b lymphoblastic leukemia/lymphoma, not otherwise specified",b lymphoblastic lymphoma,b-cell leukemia,"b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma",b-cell malignant neoplasm,b-cell neoplasm,b-cell non-hodgkin lymphoma by ann arbor stage,b-cell proliferation of uncertain malignant potential,b-cell prolymphocytic leukemia,b-lymphoblastic leukemia/lymphoma with intrachromosomal amplification of chromosome 21,bap1-inactivated melanocytoma,bap1-inactivated skin melanocytic neoplasm,bap1-mutant clear cell renal cell carcinoma,bcor itd sarcoma,bcor-ccnb3 sarcoma,brca-associated breast carcinoma,brca-associated malignant neoplasm,brca-associated ovarian carcinoma,bacterium-related malignant neoplasm,balloon cell melanoma,balloon cell nevus,barrett adenocarcinoma,bartholin gland adenocarcinoma,bartholin gland adenoid cystic carcinoma,bartholin gland adenoma,bartholin gland adenomyoma,bartholin gland adenosquamous carcinoma,bartholin gland carcinoma,bartholin gland neoplasm,bartholin gland small cell neuroendocrine carcinoma,bartholin gland squamous cell carcinoma,bartholin gland transitional cell carcinoma,basal cell ameloblastoma,basal cell carcinoma,basal cell neoplasm,basal ganglia neoplasm,basal cell carcinoma - first recurrence,basal cell carcinoma - multiple recurrences (more than three times),basal cell carcinoma - second recurrence,basal cell carcinoma - third recurrence,basal-like breast carcinoma,basal-like prostate carcinoma,basaloid (undifferentiated) penile intraepithelial neoplasia,basaloid carcinoma,basaloid squamous cell carcinoma,basaloid squamous cell carcinoma of the penis,basophilic adenocarcinoma,benign accessory urethral gland neoplasm,benign adrenal cortical neoplasm,benign adrenal gland neoplasm,benign adrenal medulla neoplasm,benign adult brain neoplasm,benign adult brain stem neoplasm,benign adult cerebellar neoplasm,benign adult cerebral neoplasm,benign ameloblastoma,benign anal granular cell tumor,benign anal neoplasm,benign anterior tongue neoplasm,benign apocrine neoplasm,benign appendix neoplasm,benign atrial neoplasm,benign axillary neoplasm,benign bartholin gland neoplasm,benign basal cell neoplasm,benign bladder neoplasm,benign blood vessel neoplasm,benign bone neoplasm,benign brain neoplasm,benign brain stem neoplasm,benign breast adenomyoepithelioma,benign breast neoplasm,benign breast phyllodes tumor,benign broad ligament neoplasm,benign buccal mucosa neoplasm,benign cardiac germ cell tumor,benign cardiac neoplasm,benign cecum neoplasm,"benign central nervous system mesenchymal, non-meningothelial neoplasm",benign central nervous system neoplasm,benign cerebellar neoplasm,benign cerebral neoplasm,benign cervical mixed epithelial and mesenchymal neoplasm,benign cervical neoplasm,benign cervical soft tissue neoplasm,benign chest wall neoplasm,benign childhood brain neoplasm,benign childhood central nervous system neoplasm,benign childhood cerebral neoplasm,benign childhood germ cell tumor,benign childhood supratentorial neoplasm,benign chondrogenic neoplasm,benign choroid neoplasm,benign choroid plexus neoplasm,benign ciliary body neoplasm,benign colon neoplasm,benign colorectal neoplasm,benign conjunctival neoplasm,benign connective and soft tissue neoplasm,benign corneal neoplasm,benign dermal neoplasm,benign diencephalic neoplasm,benign digestive system neoplasm,benign duodenal neoplasm,benign ear neoplasm,benign eccrine neoplasm,benign endocardial neoplasm,benign endocrine neoplasm,benign endometrial neoplasm,benign epicardial neoplasm,benign epididymal neoplasm,benign epiglottis neoplasm,benign epithelial neoplasm,benign epithelial skin neoplasm,benign epithelioid cell type gastrointestinal stromal tumor,benign esophageal neoplasm,benign ethmoid sinus neoplasm,benign exocrine pancreas neoplasm,benign external ear neoplasm,benign extragonadal germ cell tumor,benign extrahepatic bile duct neoplasm,benign extrahepatic bile duct non-epithelial neoplasm,benign extrahepatic bile duct soft tissue neoplasm,benign extraskeletal cartilaginous and osseous neoplasm,benign eye neoplasm,benign eyelid neoplasm,benign fallopian tube neoplasm,benign female breast neoplasm,benign female reproductive system neoplasm,benign fibroblastic neoplasm,benign fibrohistiocytic neoplasm,benign floor of the mouth neoplasm,benign frontal sinus neoplasm,benign gastric gastrointestinal stromal tumor,benign gastric granular cell tumor,benign gastric neoplasm,benign gastric soft tissue neoplasm,benign gastrointestinal stromal tumor,benign genitourinary system neoplasm,benign germ cell tumor,benign germinative follicular epithelium neoplasm,benign gingival neoplasm,benign glomus tumor,benign glottis neoplasm,benign granular cell tumor,benign great vessel neoplasm,benign hair follicle neoplasm,benign hard palate neoplasm,benign head and neck neoplasm,benign hemangioendothelioma,benign hemangiopericytoma,benign hypopharyngeal neoplasm,benign infratentorial neoplasm,benign inner ear neoplasm,benign intestinal neoplasm,benign intracranial meningioma,benign intracranial neoplasm,benign iris neoplasm,benign kidney hemangiopericytoma,benign kidney mixed epithelial and stromal tumor,benign kidney neoplasm,benign lacrimal drainage system neoplasm,benign lacrimal gland neoplasm,benign lacrimal system neoplasm,benign laryngeal neoplasm,benign laryngeal soft tissue neoplasm,benign lip neoplasm,benign lipomatous neoplasm,benign liver and intrahepatic bile duct epithelial neoplasm,benign lung hilum neoplasm,benign lung neoplasm,benign lung pecoma,benign lymph node neoplasm,benign lymphatic vessel neoplasm,benign major salivary gland neoplasm,benign male breast neoplasm,benign male reproductive system neoplasm,benign mastocytoma,benign maxillary sinus neoplasm,benign maxillofacial neoplasm,benign mediastinal germ cell tumor,benign mediastinal hemangiopericytoma,benign mediastinal neoplasm,benign mediastinal soft tissue neoplasm,benign meningioma,benign mesenchymoma,benign middle ear neoplasm,benign minor salivary gland neoplasm,benign mixed epithelial and mesenchymal hair follicle neoplasm,benign muscle neoplasm,benign musculoskeletal neoplasm,benign myocardial neoplasm,benign myoepithelioma,benign nasal cavity neoplasm,benign nasolacrimal duct neoplasm,benign nasopharyngeal neoplasm,benign neck neoplasm,benign neoplasm,benign neoplasm of lower jaw bone,benign neoplasm of the meninges,benign nervous system neoplasm,benign nipple neoplasm,benign notochordal cell tumor,benign odontogenic neoplasm,benign oral cavity neoplasm,benign oral cavity soft tissue neoplasm,benign oral neoplasm,benign orbit hemangiopericytoma,benign orbit neoplasm,benign oropharyngeal neoplasm,benign osteoclastic giant cell-rich tumor of bone,benign osteogenic neoplasm,benign outer hair sheath and infundibulum neoplasm,benign ovarian brenner tumor,benign ovarian clear cell tumor,benign ovarian endometrioid tumor,benign ovarian epithelial tumor,benign ovarian germ cell tumor,benign ovarian luteinized thecoma,benign ovarian mucinous tumor,benign ovarian neoplasm,benign ovarian partly luteinized thecoma,benign ovarian seromucinous tumor,benign ovarian serous tumor,benign ovarian sex cord-stromal tumor,benign ovarian thecoma,benign pecoma,benign palate neoplasm,benign pancreatic neoplasm,benign paranasal sinus neoplasm,benign parapharyngeal neoplasm,benign parathyroid gland neoplasm,benign parotid gland neoplasm,benign penile neoplasm,benign periampullary neoplasm,benign pericardial germ cell tumor,benign pericardial neoplasm,benign pericytic neoplasm,benign peripheral nerve granular cell tumor,benign peritoneal neoplasm,benign peritoneal and retroperitoneal neoplasm,benign pharyngeal neoplasm,benign phosphaturic mesenchymal tumor,benign phyllodes tumor,benign pilar-associated mesenchyme neoplasm,benign pineal region neoplasm,benign pituitary gland neoplasm,benign placental neoplasm,benign pleural neoplasm,benign posterior tongue neoplasm,benign prostate neoplasm,benign prostate phyllodes tumor,benign pyriform fossa neoplasm,benign rectal neoplasm,benign renal pelvis neoplasm,benign reproductive system neoplasm,benign respiratory system neoplasm,benign retinal neoplasm,benign retroperitoneal neoplasm,benign retropharyngeal neoplasm,benign salivary gland neoplasm,benign scrotal neoplasm,benign sebaceous neoplasm,benign seminal vesicle neoplasm,benign sertoli cell tumor,benign sinonasal neoplasm,benign sinonasal soft tissue neoplasm,benign skeletal muscle neoplasm,benign skin appendage neoplasm,benign skin fibroblastic neoplasm,benign skin fibrohistiocytic neoplasm,benign skin melanocytic nevus,benign skin neoplasm,benign skin vascular neoplasm,benign skull base neoplasm,benign skull neoplasm,benign small intestinal neoplasm,benign smooth muscle neoplasm,benign soft palate neoplasm,benign soft tissue neoplasm,benign soft tissue tumor of uncertain differentiation,benign sphenoid sinus neoplasm,benign spinal cord neoplasm,benign splenic neoplasm,benign squamous cell neoplasm,benign sternal neoplasm,benign stromal tumor,benign subglottis neoplasm,benign sublingual gland neoplasm,benign submandibular gland neoplasm,benign supraglottis neoplasm,benign supratentorial neoplasm,benign sweat gland neoplasm,benign synovial neoplasm,benign teratoma,benign testicular neoplasm,benign testicular sertoli cell tumor,benign thalamic neoplasm,benign thoracic neoplasm,benign thymoma,benign thymus neoplasm,benign thyroid gland neoplasm,benign tongue neoplasm,benign tonsillar neoplasm,benign tracheal neoplasm,benign ureter neoplasm,benign urethral neoplasm,benign urinary system neoplasm,benign uterine corpus mixed epithelial and mesenchymal neoplasm,benign uterine corpus neoplasm,benign uterine corpus pecoma,benign uterine ligament neoplasm,benign uterine neoplasm,benign uveal neoplasm,benign uvula neoplasm,benign vaginal melanocytic nevus,benign vaginal mixed epithelial and mesenchymal neoplasm,benign vaginal mixed tumor,benign vaginal neoplasm,benign vascular neoplasm,benign vulvar neoplasm,benign vulvar phyllodes tumor,benzene-related acute myeloid leukemia,beta-catenin-activated hepatocellular adenoma,beta-catenin-activated inflammatory hepatocellular adenoma,bilateral breast carcinoma,bilateral carcinoma,bilateral malignant neoplasm,bilateral optic nerve meningioma,bilateral retinoblastoma,bilateral synchronous sporadic renal cell carcinoma,bilateral thalamic glioma,bile duct adenocarcinoma,bile duct adenoma,bile duct biliary intraepithelial neoplasia,bile duct carcinoma,bile duct intraductal papillary neoplasm,bile duct intraductal papillary neoplasm with intermediate grade intraepithelial neoplasia,bile duct intraductal papillary neoplasm with an associated invasive carcinoma,"bile duct intraductal papillary neoplasm, high grade","bile duct intraductal papillary neoplasm, low grade",bile duct mucinous cystic neoplasm,bile duct mucinous cystic neoplasm with intermediate grade intraepithelial neoplasia,bile duct mucinous cystic neoplasm with an associated invasive carcinoma,"bile duct mucinous cystic neoplasm, high grade","bile duct mucinous cystic neoplasm, low grade",bile duct neoplasm,biliary adenofibroma,biliary intraepithelial neoplasia,biliary intraepithelial neoplasia-1,biliary intraepithelial neoplasia-2,biliary tract carcinoma,biochemically recurrent prostate carcinoma,biphasic mesothelioma,biphasic pulmonary blastoma,biphasic synovial sarcoma,biphenotypic sinonasal sarcoma,bizarre leiomyoma,bizarre parosteal osteochondromatous proliferation,bladder adenocarcinoma,bladder alveolar rhabdomyosarcoma,bladder alveolar soft part sarcoma,bladder angiosarcoma,bladder benign pecoma,bladder carcinoma,bladder clear cell adenocarcinoma,bladder diffuse clear cell adenocarcinoma,bladder embryonal rhabdomyosarcoma,bladder endometrioid adenocarcinoma,bladder enteric type adenocarcinoma,bladder flat urothelial carcinoma,bladder granular cell tumor,bladder hemangioma,bladder hepatoid adenocarcinoma,bladder inflammatory myofibroblastic tumor,bladder inverted papilloma,bladder large cell neuroendocrine carcinoma,bladder leiomyoma,bladder leiomyosarcoma,bladder lymphoma,bladder malignant pecoma,bladder melanoma,bladder mixed adenocarcinoma,bladder mucinous adenocarcinoma,bladder mucosa-associated lymphoid tissue lymphoma,bladder neoplasm,bladder neuroendocrine carcinoma,bladder neuroendocrine neoplasm,bladder neuroendocrine tumor,bladder neurofibroma,bladder non-invasive papillary urothelial carcinoma,"bladder non-invasive papillary urothelial carcinoma, high grade","bladder non-invasive papillary urothelial carcinoma, low grade",bladder non-invasive papillary urothelial neoplasm,bladder non-invasive urothelial neoplasm,bladder pecoma,bladder papillary clear cell adenocarcinoma,bladder papillary urothelial carcinoma,bladder papillary urothelial neoplasm,bladder papillary urothelial neoplasm of low malignant potential,bladder paraganglioma,bladder rhabdomyosarcoma,bladder sarcoma,bladder signet ring cell adenocarcinoma,bladder small cell neuroendocrine carcinoma,bladder soft tissue neoplasm,bladder solitary fibrous tumor,bladder squamous cell carcinoma,bladder squamous cell papilloma,bladder tubulo-cystic clear cell adenocarcinoma,bladder urachal adenocarcinoma,bladder urachal carcinoma,bladder urachal squamous cell carcinoma,bladder urachal urothelial carcinoma,bladder urothelial carcinoma,bladder urothelial carcinoma in situ,bladder urothelial dysplasia,bladder urothelial papilloma,bladder urothelial proliferation of uncertain malignant potential,bladder verrucous carcinoma,bladder villous adenoma,"blast phase chronic myelogenous leukemia, bcr-abl1 positive",blast phase myeloproliferative neoplasm,blast phase primary myelofibrosis,blastema predominant kidney wilms tumor,blastic granulocytic sarcoma,blastic plasmacytoid dendritic cell neoplasm,blastoma,blood vessel neoplasm,blue nevus,blue rubber bleb nevus,body cavity primary effusion lymphoma,bone angiosarcoma,bone epithelioid hemangioendothelioma,bone epithelioid hemangioma,bone erdheim-chester disease,bone fibrosarcoma,bone glomus tumor,bone hemangioma,bone hibernoma,bone langerhans cell histiocytosis,bone leiomyoma,bone leiomyosarcoma,bone lipoma,bone liposarcoma,bone malignant peripheral nerve sheath tumor,bone marrow neoplasm,bone neoplasm,bone osteosarcoma,bone sarcoma,bone schwannoma,bone surface (peripheral) osteosarcoma,borderline breast phyllodes tumor,borderline broad ligament serous tumor,borderline cystadenoma,borderline exocrine pancreatic neoplasm,borderline fallopian tube endometrioid tumor,borderline fallopian tube mucinous tumor,borderline fallopian tube neoplasm,borderline fallopian tube serous tumor,borderline ovarian brenner tumor,borderline ovarian clear cell adenofibroma,borderline ovarian clear cell cystadenofibroma,borderline ovarian clear cell tumor,borderline ovarian clear cell tumor/atypical proliferative ovarian clear cell tumor,borderline ovarian clear cell tumor/atypical proliferative ovarian clear cell tumor with intraepithelial carcinoma,borderline ovarian endometrioid adenofibroma,borderline ovarian endometrioid cystadenofibroma,borderline ovarian endometrioid tumor,borderline ovarian endometrioid tumor/atypical proliferative ovarian endometrioid tumor,borderline ovarian endometrioid tumor/atypical proliferative ovarian endometrioid tumor with microinvasion,borderline ovarian epithelial tumor,borderline ovarian mixed epithelial tumor/atypical proliferative ovarian mixed epithelial tumor,borderline ovarian mucinous adenofibroma,borderline ovarian mucinous tumor,"borderline ovarian mucinous tumor, endocervical-like","borderline ovarian mucinous tumor, intestinal type",borderline ovarian mucinous tumor/atypical proliferative ovarian mucinous tumor,borderline ovarian mucinous tumor/atypical proliferative ovarian mucinous tumor with intraepithelial carcinoma,borderline ovarian mucinous tumor/atypical proliferative ovarian mucinous tumor with microinvasion,borderline ovarian seromucinous tumor,borderline ovarian seromucinous tumor/atypical proliferative ovarian seromucinous tumor,borderline ovarian seromucinous tumor/atypical proliferative ovarian seromucinous tumor with microinvasion,borderline ovarian serous adenofibroma,borderline ovarian serous cystadenofibroma,borderline ovarian serous papillary cystic tumor,borderline ovarian serous surface papillary tumor,borderline ovarian serous tumor,borderline ovarian serous tumor-micropapillary variant/non-invasive low grade ovarian serous carcinoma,borderline ovarian serous tumor/atypical proliferative ovarian serous tumor,borderline ovarian serous tumor/atypical proliferative ovarian serous tumor with microinvasion,borderline papillary cystadenoma,borderline papillary mucinous cystadenoma,borderline papillary serous cystadenoma,borderline peritoneal serous tumor,borderline phyllodes tumor,borderline primary cutaneous cd30-positive t-cell lymphoproliferative disorder,borderline resectable carcinoma,borderline resectable malignant neoplasm,borderline resectable pancreatic adenocarcinoma,borderline resectable pancreatic carcinoma,borderline serous cystadenofibroma,borderline serous cystadenoma,borderline uterine ligament neoplasm,borderline vulvar phyllodes tumor,borrelia burgdoferi-associated cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue,botryoid-type embryonal rhabdomyosarcoma,bowen disease of the skin,brachial plexus neoplasm,brain astrocytoma,brain ependymoma,brain extraskeletal myxoid chondrosarcoma,brain germinoma,brain glioblastoma,brain hemangioma,brain liposarcoma,brain neoplasm,brain oligodendroglioma,brain sarcoma,brain stem astrocytoma,brain stem ependymoma,brain stem glioblastoma,brain stem glioma,brain stem hemangioblastoma,brain stem intraparenchymal clear cell meningioma,brain stem neoplasm,branch duct pancreatic intraductal papillary-mucinous neoplasm,breast acinic cell carcinoma,breast adenocarcinoma,breast adenocarcinoma with spindle cell metaplasia,breast adenocarcinoma with squamous metaplasia,breast adenoid cystic carcinoma,breast adenoma,breast adenomyoepithelioma,breast adenosquamous carcinoma,breast angiolipoma,breast angiomatosis,breast angiosarcoma,breast apocrine adenoma,breast apocrine carcinoma,breast apocrine carcinoma in situ,breast atypical ductal hyperplasia,breast atypical hyperplasia,breast atypical lobular hyperplasia,breast atypical medullary carcinoma,breast atypical myoepitheliosis,breast atypical papilloma,breast burkitt lymphoma,breast capillary hemangioma,breast carcinoma,breast carcinoma metastatic in the bone,breast carcinoma metastatic in the brain,breast carcinoma metastatic in the central nervous system,breast carcinoma metastatic in the liver,breast carcinoma metastatic in the lung,breast carcinoma metastatic in the lymph nodes,breast carcinoma metastatic in the spine,breast carcinoma by gene expression profile,breast carcinoma with chondroid metaplasia,breast carcinoma with choriocarcinomatous features,breast carcinoma with melanotic features,breast carcinoma with neuroendocrine differentiation,breast carcinoma with osseous metaplasia,breast carcinoma with osteoclast-like stromal giant cells,breast cellular fibroadenoma,breast central papilloma,breast classic lobular carcinoma in situ,breast classic lobular carcinoma in situ type a,breast classic lobular carcinoma in situ type b,breast columnar cell hyperplasia,breast columnar cell hyperplasia with atypia,breast columnar cell lesion,breast columnar cell mucinous carcinoma,breast complex fibroadenoma,breast diffuse large b-cell lymphoma,breast ductal adenoma,breast ductal carcinoma,breast ductal carcinoma in situ,breast ductal carcinoma in situ and invasive lobular carcinoma,breast ductal carcinoma in situ and lobular carcinoma,breast ductal carcinoma in situ and lobular carcinoma in situ,"breast ductal carcinoma in situ, comedo type","breast ductal carcinoma in situ, cribriform pattern","breast ductal carcinoma in situ, high grade","breast ductal carcinoma in situ, intermediate grade","breast ductal carcinoma in situ, low grade","breast ductal carcinoma in situ, non-comedo type","breast ductal carcinoma in situ, solid type",breast ductal carcinoma with squamous metaplasia,breast ductal hyperplasia,breast epithelioid hemangioma,breast extraskeletal osteosarcoma,breast fibroadenoma,breast fibroepithelial neoplasm,breast fibrosarcoma,breast flat ductal epithelial atypia,breast florid lobular carcinoma in situ,breast follicular lymphoma,breast giant fibroadenoma,breast granular cell tumor,breast hemangioma,breast hemangiopericytoma,breast histiocytoid carcinoma,breast hyperplasia,breast implant-associated anaplastic large cell lymphoma,breast inflammatory carcinoma,breast inflammatory myofibroblastic tumor,breast intracanalicular fibroadenoma,breast intracystic papillary carcinoma,breast intraductal  neoplasm,breast intraductal myoepitheliosis,breast intraductal papillary neoplasm,breast intraductal papilloma,breast intraductal papillomatosis,breast intraductal proliferative lesion,breast juvenile fibroadenoma,breast large cell neuroendocrine carcinoma,breast leiomyoma,breast leiomyosarcoma,breast lipid-rich carcinoma,breast lipoma,breast liposarcoma,breast lobular carcinoma,breast lobular carcinoma in situ,breast lobular neoplasia,breast lymphoma,breast malignant myoepithelioma,breast medullary carcinoma,breast melanoma,breast metaplastic carcinoma,breast micropapillary ductal carcinoma in situ,breast mixed carcinoma,breast mixed ductal and lobular carcinoma,breast mixed epithelial/mesenchymal metaplastic carcinoma,breast mucinous carcinoma,breast mucinous cystadenocarcinoma,breast mucoepidermoid carcinoma,breast mucosa-associated lymphoid tissue lymphoma,breast myoepithelial tumor,breast myoepitheliosis,breast myofibroblastoma,breast neoplasm,breast neuroendocrine carcinoma,breast neuroendocrine neoplasm,breast neuroendocrine tumor,breast neuroendocrine tumor g1,breast neuroendocrine tumor g2,breast neurofibroma,breast nevus,breast nodular fasciitis,breast non-hodgkin lymphoma,breast oncocytic carcinoma,breast paget disease,breast paget disease and intraductal carcinoma,breast paget disease with invasive ductal carcinoma,breast paget disease without invasive carcinoma,breast papillary carcinoma,breast papillary ductal carcinoma in situ,breast papillary ductal carcinoma in situ with invasion,breast papillary ductal hyperplasia,breast papillary neoplasm,breast pericanalicular fibroadenoma,breast periductal myoepitheliosis,breast periductal stromal tumor,breast peripheral papilloma,breast phyllodes tumor,breast pleomorphic adenoma,breast pleomorphic carcinoma,breast pleomorphic lobular carcinoma in situ,breast polymorphous adenocarcinoma,breast rhabdomyosarcoma,breast sarcoma,breast schwannoma,breast scirrhous carcinoma,breast sclerosing papilloma,breast sebaceous carcinoma,breast secretory carcinoma,breast signet ring cell carcinoma,breast small cell neuroendocrine carcinoma,breast soft tissue neoplasm,breast solid neuroendocrine carcinoma,breast solid papillary carcinoma,breast solid papillary carcinoma in situ,breast spiradenoma,breast squamous cell carcinoma,"breast squamous cell carcinoma, acantholytic variant","breast squamous cell carcinoma, large cell keratinizing variant","breast squamous cell carcinoma, spindle cell variant",breast t-cell non-hodgkin lymphoma,breast tall cell carcinoma with reversed polarity,breast tubular adenoma,breast tubular carcinoma,breast usual ductal hyperplasia,breast vascular neoplasm,brenner tumor,broad ligament adenocarcinoma,broad ligament adenosarcoma,broad ligament clear cell adenocarcinoma,broad ligament endometrioid adenocarcinoma,broad ligament ependymoma,broad ligament leiomyoma,broad ligament leiomyosarcoma,broad ligament mucinous adenocarcinoma,broad ligament neoplasm,broad ligament papillary cystadenoma,broad ligament serous adenocarcinoma,broad ligament serous adenofibroma,broad ligament serous cystadenofibroma,broad ligament serous cystadenoma,broad ligament wolffian tumor,bronchial glandular papilloma,bronchial intraepithelial neoplasia,bronchial mixed squamous cell and glandular papilloma,bronchial papilloma,bronchial squamous cell papilloma,bronchiolar adenoma/ciliated muconodular papillary tumor,bronchogenic carcinoma,buccal mucosa neoplasm,buccal mucosa squamous cell carcinoma,buccal mucosa verrucous carcinoma,buccal squamous cell papilloma,bulbomembranous urethral malignant neoplasm,burkitt leukemia,burkitt lymphoma post-transplant lymphoproliferative disorder,burkitt-like lymphoma post-transplant lymphoproliferative disorder,calla positive lymphoblastic leukemia,cic-dux4 sarcoma,cic-dux4l sarcoma,cic-rearranged sarcoma,calcifying aponeurotic fibroma,calcifying cystic odontogenic tumor,calcifying epithelial odontogenic tumor,calcifying fibrous tumor,calcifying nested stromal-epithelial tumor of the liver,campylobacter jejuni-associated small intestinal mucosa-associated lymphoid tissue lymphoma,cancer stage (antiquated),capillary hemangioma,carcinoid tumor,carcinoid tumor of uncertain malignant potential,carcinoma,carcinoma arising from craniopharyngioma,carcinoma arising in bladder diverticulum,carcinoma arising in nasal papillomatosis,carcinoma cuniculatum of the penis,carcinoma in situ,carcinoma in situ in a polyp,carcinoma simplex,carcinoma unspecified site,carcinoma ex pleomorphic adenoma,carcinoma in a polyp,carcinoma of cowper glands,carcinoma of littre glands,carcinoma of unknown primary,carcinomatosis,carcinosarcoma,cardiac angiosarcoma,cardiac biphasic synovial sarcoma,cardiac capillary hemangioma,cardiac cavernous hemangioma,cardiac diffuse large b-cell lymphoma,cardiac epithelioid hemangioendothelioma,cardiac extraskeletal osteosarcoma,cardiac fibrin-associated diffuse large b-cell lymphoma,cardiac fibroma,cardiac fibrosarcoma,cardiac germ cell tumor,cardiac granular cell tumor,cardiac hemangioma,cardiac inflammatory myofibroblastic tumor,cardiac intramuscular hemangioma,cardiac kaposi sarcoma,cardiac leiomyosarcoma,cardiac lipoma,cardiac lymphoma,cardiac malignant peripheral nerve sheath tumor,cardiac monophasic synovial sarcoma,cardiac myeloid sarcoma,cardiac myxofibrosarcoma,cardiac myxoma,cardiac neurofibroma,cardiac paraganglioma,cardiac rhabdomyoma,cardiac rhabdomyosarcoma,cardiac sarcoma,cardiac schwannoma,cardiac synovial sarcoma,cardiac teratoma,cardiac undifferentiated pleomorphic sarcoma,cardiac yolk sac tumor,cardiovascular neoplasm,carotid body paraganglioma,castration-naive prostate carcinoma,castration-resistant prostate carcinoma,castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents,castration-sensitive prostate carcinoma,cauda equina neoplasm,cauda equina neuroendocrine tumor,cavernous angioleiomyoma,cavernous hemangioma,cavernous hemangioma of the face,cavernous lymphangioma,cavernous sinus meningioma,cecum adenocarcinoma,cecum carcinoma,cecum lymphoma,cecum neoplasm,cecum neuroendocrine tumor g1,cecum non-hodgkin lymphoma,cecum villous adenoma,cellular angiofibroma,cellular blue nevus,cellular congenital mesoblastic nephroma,cellular ependymoma,cellular fibroma,cellular leiomyoma,cellular myxoma,cellular nerve sheath myxoma,cellular neurofibroma,cellular pleomorphic adenoma,cellular schwannoma,cemento-ossifying fibroma,cementoblastoma,central atypical cartilaginous tumor,"central atypical cartilaginous tumor/chondrosarcoma, grade 1","central chondrosarcoma, grade 1","central chondrosarcoma, grade 2","central chondrosarcoma, grade 3",central nervous system anaplastic large cell lymphoma,"central nervous system anaplastic large cell lymphoma, alk-negative","central nervous system anaplastic large cell lymphoma, alk-positive",central nervous system angiolipoma,central nervous system angiosarcoma,central nervous system b-cell non-hodgkin lymphoma,central nervous system cic-rearranged sarcoma,central nervous system carcinoma,central nervous system cavernous hemangioma,central nervous system chondroma,central nervous system choriocarcinoma,central nervous system dedifferentiated solitary fibrous tumor,central nervous system dermoid cyst,central nervous system desmoid fibromatosis,central nervous system embryonal carcinoma,central nervous system embryonal tumor,central nervous system embryonal tumor with rhabdoid features,"central nervous system embryonal tumor, not elsewhere classified","central nervous system embryonal tumor, not otherwise specified","central nervous system embryonal tumor, not otherwise specified with leptomeningeal spread",central nervous system epithelioid hemangioendothelioma,central nervous system erdheim-chester disease,central nervous system ewing sarcoma,central nervous system ewing sarcoma/peripheral primitive neuroectodermal tumor,central nervous system extraskeletal osteosarcoma,central nervous system fibrosarcoma,central nervous system ganglioneuroblastoma,central nervous system germ cell tumor,central nervous system germinoma,central nervous system hemangioblastoma,central nervous system hemangioma,central nervous system hematopoietic neoplasm,central nervous system hibernoma,central nervous system histiocytic sarcoma,central nervous system histiocytic and dendritic cell neoplasm,central nervous system hodgkin lymphoma,central nervous system immature teratoma,central nervous system inflammatory myofibroblastic tumor,central nervous system intravascular large b-cell lymphoma,central nervous system kaposi sarcoma,central nervous system langerhans cell histiocytosis,central nervous system leiomyoma,central nervous system leiomyosarcoma,central nervous system leukemia,central nervous system lipoma,central nervous system lymphoma,central nervous system lymphomatoid granulomatosis,central nervous system mature t-cell and nk-cell non-hodgkin lymphoma,central nervous system mature teratoma,central nervous system medulloepithelioma,central nervous system melanocytic neoplasm,central nervous system melanoma,central nervous system mesenchymal chondrosarcoma,"central nervous system mesenchymal, non-meningothelial neoplasm",central nervous system mixed germ cell tumor,central nervous system myofibroblastoma,central nervous system neoplasm,central nervous system neuroblastoma,"central nervous system neuroblastoma, foxr2-activated",central nervous system neuroepithelial neoplasm of uncertain origin,central nervous system non-hodgkin lymphoma,central nervous system nongerminomatous germ cell tumor,central nervous system paraganglioma,central nervous system rhabdomyoma,central nervous system rhabdomyosarcoma,central nervous system smarcb1/ini1-deficient tumor,central nervous system sarcoma,central nervous system solitary fibrous tumor,"central nervous system solitary fibrous tumor, grade 1","central nervous system solitary fibrous tumor, grade 2","central nervous system solitary fibrous tumor, grade 3",central nervous system t-cell non-hodgkin lymphoma,central nervous system teratoma,central nervous system teratoma with malignant transformation,central nervous system tumor with bcor internal tandem duplication,central nervous system undifferentiated pleomorphic sarcoma,central nervous system yolk sac tumor,central neurocytoma,centroblastic lymphoma post-transplant lymphoproliferative disorder,cerebellar astrocytoma,cerebellar glioblastoma,cerebellar glioneuronal and neuronal tumors,cerebellar hemangioblastoma,cerebellar liponeurocytoma,cerebellar neoplasm,cerebellar papillary meningioma,cerebellar paraganglioma,cerebellar peduncle neoplasm,cerebellar pilocytic astrocytoma,cerebellar sarcoma,cerebellar vermis medulloblastoma,"cerebellopontine angle embryonal tumor, not otherwise specified",cerebellopontine angle meningioma,cerebellopontine angle neoplasm,cerebellopontine angle schwannoma,cerebral astrocytoma,cerebral convexity meningioma,"cerebral embryonal tumor, not otherwise specified",cerebral glioblastoma,cerebral hemangioblastoma,cerebral hemangioma,cerebral hemisphere lipoma,cerebral hodgkin lymphoma,cerebral lymphoma,cerebral lymphoma in immunocompetent host,cerebral meningioma,cerebral neoplasm,cerebral non-hodgkin lymphoma,ceruminous adenocarcinoma,ceruminous adenoma,ceruminous neoplasm,cervical adenocarcinoma,cervical adenocarcinoma admixed with neuroendocrine carcinoma,cervical adenocarcinoma in situ,cervical adenofibroma,cervical adenoid basal carcinoma,cervical adenoid cystic carcinoma,cervical adenomyoma,"cervical adenomyoma, endocervical-type","cervical adenomyoma, mesonephric-type",cervical adenosarcoma,cervical adenosquamous carcinoma,cervical alveolar soft part sarcoma,cervical angiosarcoma,cervical atypical polypoid adenomyoma,cervical basaloid carcinoma,cervical blue nevus,cervical carcinoma,cervical carcinosarcoma,cervical condyloma acuminatum,cervical endometrioid adenocarcinoma,cervical endometrioid stromal and related neoplasms,cervical esophagus adenocarcinoma,cervical esophagus squamous cell carcinoma,cervical germ cell tumor,cervical glandular intraepithelial neoplasia,cervical glandular neoplasm,cervical intraepithelial neoplasia,cervical intraepithelial neoplasia grade 2/3,cervical intraspinal meningioma,cervical invasive stratified mucinous adenocarcinoma,cervical keratinizing squamous cell carcinoma,cervical large cell neuroendocrine carcinoma,cervical leiomyoma,cervical leiomyosarcoma,cervical low grade endometrioid stromal sarcoma,cervical lymphoepithelioma-like carcinoma,cervical malignant peripheral nerve sheath tumor,cervical melanoma,cervical mesonephric adenocarcinoma,cervical microglandular polyp,cervical micropapillary adenocarcinoma,cervical mixed epithelial and mesenchymal neoplasm,cervical mucinous adenocarcinoma,"cervical mucinous adenocarcinoma, intestinal-type","cervical mucinous adenocarcinoma, signet ring cell-type",cervical mucoepidermoid carcinoma,cervical mullerian papilloma,cervical neoplasm,cervical neuroendocrine carcinoma,cervical neuroendocrine neoplasm,cervical neuroendocrine tumor,cervical neuroendocrine tumor g1,cervical neuroendocrine tumor g2,cervical non-keratinizing squamous cell carcinoma,cervical papillary squamous cell carcinoma,cervical poorly differentiated adenosquamous carcinoma,cervical rhabdomyoma,cervical rhabdomyosarcoma,cervical serous adenocarcinoma,cervical small cell neuroendocrine carcinoma,cervical soft tissue neoplasm,cervical spine neoplasm,cervical squamotransitional carcinoma,cervical squamous cell carcinoma,cervical squamous cell carcinoma in situ,"cervical squamous cell carcinoma, not otherwise specified",cervical squamous cell papilloma,cervical squamous intraepithelial neoplasia,cervical squamous intraepithelial neoplasia 1,cervical squamous intraepithelial neoplasia 2,cervical squamous neoplasm,cervical stratified mucin-producing intraepithelial lesion,cervical symmetrical lipomatosis,cervical undifferentiated carcinoma,cervical verrucous carcinoma,cervical villoglandular adenocarcinoma,cervical warty carcinoma,cervical wilms tumor,cervical yolk sac tumor,cervicomedullary junction neoplasm,chemotherapy-related leukemia,cherry hemangioma,cherry hemangioma of lip,chest wall fibromatosis,chest wall hodgkin lymphoma,chest wall lipoma,chest wall lymphoma,chest wall neoplasm,chest wall parachordoma,chest wall plexiform fibrohistiocytic tumor,chest wall sarcoma,chest wall solitary plasmacytoma,childhood acute basophilic leukemia,childhood acute eosinophilic leukemia,childhood acute erythroid leukemia,childhood acute leukemia,childhood acute lymphoblastic leukemia,childhood acute megakaryoblastic leukemia,childhood acute monoblastic leukemia,childhood acute monoblastic and monocytic leukemia,childhood acute monocytic leukemia,childhood acute myeloid leukemia,childhood acute myeloid leukemia not otherwise specified,childhood acute myeloid leukemia with abnormalities of chromosome 5q,childhood acute myeloid leukemia with abnormalities of chromosome 7,childhood acute myeloid leukemia with maturation,childhood acute myeloid leukemia with minimal differentiation,childhood acute myeloid leukemia with nup98 rearrangement,childhood acute myeloid leukemia without maturation,childhood acute myelomonocytic leukemia,childhood acute promyelocytic leukemia with pml-rara,childhood adrenal gland pheochromocytoma,childhood alveolar rhabdomyosarcoma,childhood alveolar soft part sarcoma,childhood anaplastic astrocytoma,childhood anaplastic ependymoma,childhood anaplastic large cell lymphoma,childhood anaplastic oligoastrocytoma,childhood anaplastic oligodendroglioma,childhood angiosarcoma,childhood astrocytic tumor,childhood astrocytoma,childhood atypical choroid plexus papilloma,childhood atypical teratoid/rhabdoid tumor,childhood b acute lymphoblastic leukemia,childhood b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1,childhood b lymphoblastic lymphoma,childhood bladder carcinoma,childhood botryoid-type embryonal rhabdomyosarcoma,childhood brain anaplastic astrocytoma,childhood brain germ cell tumor,childhood brain germinoma,childhood brain glioblastoma,childhood brain neoplasm,childhood brain oligodendroglioma,childhood brain stem astrocytoma,childhood brain stem glioma,childhood brain stem gliosarcoma,childhood brain stem mixed glioma,childhood brain stem neoplasm,childhood breast carcinoma,childhood burkitt leukemia,childhood burkitt lymphoma,childhood central nervous system choriocarcinoma,childhood central nervous system embryonal carcinoma,childhood central nervous system embryonal tumor,"childhood central nervous system embryonal tumor, not otherwise specified",childhood central nervous system ganglioneuroblastoma,childhood central nervous system germ cell tumor,childhood central nervous system germinoma,childhood central nervous system immature teratoma,childhood central nervous system mature teratoma,childhood central nervous system mixed germ cell tumor,childhood central nervous system neoplasm,childhood central nervous system neuroblastoma,childhood central nervous system teratoma,childhood central nervous system yolk sac tumor,childhood cerebellar anaplastic astrocytoma,childhood cerebellar astrocytoma,childhood cerebellar neoplasm,childhood cerebral anaplastic astrocytoma,childhood cerebral astrocytoma,childhood cerebral diffuse astrocytoma,"childhood cerebral embryonal tumor with multilayered rosettes, c19mc-altered","childhood cerebral ependymoma, not otherwise specified",childhood choriocarcinoma,childhood choroid plexus carcinoma,childhood choroid plexus neoplasm,childhood choroid plexus papilloma,"childhood chronic myelogenous leukemia, bcr-abl1 positive",childhood classic hodgkin lymphoma,childhood clear cell sarcoma of soft tissue,childhood colorectal carcinoma,childhood conventional osteosarcoma,childhood craniopharyngioma,childhood cystic nephroma,childhood desmoplastic small round cell tumor,childhood diffuse astrocytoma,childhood diffuse large b-cell lymphoma,childhood diffuse large cell lymphoma,childhood embryonal carcinoma,childhood embryonal rhabdomyosarcoma,"childhood embryonal tumor with multilayered rosettes, c19mc-altered",childhood ependymal tumor,childhood ependymoma,childhood epithelioid hemangioendothelioma,childhood epithelioid sarcoma,childhood esophageal carcinoma,childhood extracranial germ cell tumor,childhood extragonadal malignant germ cell tumor,childhood extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,childhood extraocular retinoblastoma,childhood extraskeletal myxoid chondrosarcoma,childhood extraskeletal osteosarcoma,childhood favorable prognosis hodgkin lymphoma,childhood fibrillary astrocytoma,childhood fibrosarcoma,childhood ganglioglioma,childhood ganglioneuroblastoma,"childhood ganglioneuroblastoma, intermixed","childhood ganglioneuroblastoma, nodular",childhood gastric carcinoma,childhood gastrointestinal stromal tumor,childhood gemistocytic astrocytoma,childhood germ cell tumor,childhood germinomatous germ cell tumor,childhood giant cell glioblastoma,childhood glioblastoma,childhood gliomatosis cerebri,childhood gliosarcoma,childhood gonadal germ cell tumor,childhood grade iii lymphomatoid granulomatosis,childhood hematopoietic neoplasm,childhood hepatocellular carcinoma,childhood hodgkin lymphoma,childhood immature teratoma,childhood immunoblastic lymphoma,"childhood infratentorial embryonal tumor with multilayered rosettes, c19mc-altered",childhood infratentorial ependymoma,childhood infratentorial neoplasm,childhood intracranial meningioma,childhood intracranial neoplasm,childhood intraocular retinoblastoma,childhood kidney angiomyolipoma,childhood kidney neoplasm,childhood kidney wilms tumor,childhood l1 acute lymphoblastic leukemia,childhood l2 acute lymphoblastic leukemia,childhood langerhans cell histiocytosis,childhood langerhans cell histiocytosis with risk organ involvement,childhood langerhans cell histiocytosis without risk organ involvement,childhood large cell lymphoma,childhood laryngeal carcinoma,childhood leiomyosarcoma,childhood leukemia,childhood liposarcoma,childhood liver and intrahepatic bile duct neoplasm,childhood lung non-small cell carcinoma,childhood lung small cell carcinoma,childhood lymphoblastic lymphoma,childhood lymphocyte-depleted classic hodgkin lymphoma,childhood lymphocyte-rich classic hodgkin lymphoma,childhood lymphoma,childhood lymphomatoid granulomatosis,childhood malignant brain neoplasm,childhood malignant central nervous system neoplasm,childhood malignant germ cell tumor,childhood malignant kidney neoplasm,childhood malignant liver neoplasm,childhood malignant mesenchymoma,childhood malignant neoplasm,childhood malignant ovarian germ cell tumor,childhood malignant penile neoplasm,childhood malignant peripheral nerve sheath tumor,childhood malignant small intestinal neoplasm,childhood malignant solid neoplasm,childhood malignant testicular germ cell tumor,childhood mature t-cell and nk-cell non-hodgkin lymphoma,childhood mature teratoma,childhood mediastinal neurogenic neoplasm,childhood medulloblastoma,childhood melanoma,childhood meningeal melanoma,childhood meningioma,childhood mesenchymal chondrosarcoma,childhood mixed cellularity classic hodgkin lymphoma,childhood mixed germ cell tumor,childhood mixed glioma,childhood multilocular cystic renal neoplasm,childhood myelodysplastic syndrome,childhood myxopapillary ependymoma,childhood nasal cavity carcinoma,childhood nasal type extranodal nk/t-cell lymphoma,childhood neoplasm,childhood neuroblastoma,childhood neuroendocrine tumor g1,childhood nodular lymphocyte predominant hodgkin lymphoma,childhood nodular sclerosis classic hodgkin lymphoma,childhood non-hodgkin lymphoma,childhood non-hodgkin lymphoma by ann arbor stage,childhood non-t non-b acute lymphoblastic leukemia,childhood nongerminomatous germ cell tumor,childhood oligoastrocytoma,childhood oligodendroglioma,childhood osteosarcoma,childhood ovarian choriocarcinoma,childhood ovarian dysgerminoma,childhood ovarian embryonal carcinoma,childhood ovarian germ cell tumor,childhood ovarian immature teratoma,childhood ovarian mature teratoma,childhood ovarian mixed germ cell tumor,childhood ovarian nongerminomatous germ cell tumor,childhood ovarian teratoma,childhood ovarian yolk sac tumor,childhood paranasal sinus carcinoma,childhood parathyroid gland carcinoma,childhood parosteal osteosarcoma,childhood periosteal osteosarcoma,childhood pilocytic astrocytoma,childhood pilomyxoid astrocytoma,childhood pineal parenchymal cell neoplasm,childhood pineal parenchymal tumor of intermediate differentiation,childhood pineoblastoma,childhood pleomorphic rhabdomyosarcoma,childhood pleomorphic xanthoastrocytoma,childhood pre-b acute lymphoblastic leukemia,childhood primary cutaneous anaplastic large cell lymphoma,childhood protoplasmic astrocytoma,childhood rectal carcinoma,childhood renal cell carcinoma,childhood rhabdomyosarcoma,childhood rhabdomyosarcoma with mixed embryonal and alveolar features,childhood salivary gland carcinoma,childhood seminoma,childhood small intestinal carcinoma,childhood small intestinal leiomyosarcoma,childhood soft tissue sarcoma,childhood solid neoplasm,childhood spinal cord ependymoma,childhood spinal cord neoplasm,childhood spindle cell rhabdomyosarcoma,childhood subependymal giant cell astrocytoma,"childhood supratentorial embryonal tumor with multilayered rosettes, c19mc-altered","childhood supratentorial embryonal tumor, not otherwise specified","childhood supratentorial ependymoma, not otherwise specified",childhood supratentorial neoplasm,childhood synovial sarcoma,childhood systemic anaplastic large cell lymphoma,childhood t acute lymphoblastic leukemia,childhood t lymphoblastic leukemia/lymphoma,childhood t lymphoblastic lymphoma,childhood tdt negative acute lymphoblastic leukemia,childhood tdt positive acute lymphoblastic leukemia,childhood teratoma,childhood testicular choriocarcinoma,childhood testicular embryonal carcinoma,childhood testicular germ cell tumor,childhood testicular immature teratoma,childhood testicular mature teratoma,childhood testicular mixed embryonal carcinoma and teratoma,childhood testicular mixed germ cell tumor,childhood testicular neoplasm,childhood testicular non-seminomatous germ cell tumor,childhood testicular teratoma,childhood testicular yolk sac tumor,childhood thyroid gland carcinoma,childhood thyroid gland follicular carcinoma,childhood thyroid gland medullary carcinoma,childhood thyroid gland papillary carcinoma,childhood undifferentiated high grade pleomorphic sarcoma of bone,childhood undifferentiated pleomorphic sarcoma,childhood unfavorable prognosis hodgkin lymphoma,childhood vaginal botryoid-type embryonal rhabdomyosarcoma,childhood visual pathway astrocytoma,childhood visual pathway glioma,childhood vulvar botryoid-type embryonal rhabdomyosarcoma,childhood yolk sac tumor,chlamydia psittaci-associated ocular adnexal mucosa-associated lymphoid tissue lymphoma,cholangiocarcinoma,cholangiolocellular carcinoma,chondroblastic osteosarcoma,chondroblastoma,chondrogenic neoplasm,chondroid chordoma,chondroid lipoma,chondroid syringoma,chondroma,chondromatosis,chondromyxoid fibroma,chondrosarcoma,chondrosarcoma nci grade 1,chondrosarcoma nci grade 2,chondrosarcoma nci grade 3,"chondrosarcoma, grade 1","chondrosarcoma, grade 2","chondrosarcoma, grade 3",chordoid glioma,chordoid meningioma,chordoma,choriocarcinoma,choriocarcinoma combined with other germ cell elements,choroid epithelioid cell melanoma,choroid hemangioma,choroid intermediate cell type melanoma,choroid melanoma,choroid mixed cell melanoma,choroid necrotic melanoma,choroid neoplasm,choroid nevus,choroid plexus carcinoma,choroid plexus meningioma,choroid plexus neoplasm,choroid plexus papilloma,choroid spindle cell melanoma,choroid spindle cell type a melanoma,choroid spindle cell type b melanoma,chromophobe hepatocellular carcinoma,chromophobe renal cell carcinoma,chromophobe renal cell carcinoma associated with birt-hogg-dube syndrome,chronic adult t-cell leukemia/lymphoma,chronic eosinophilic leukemia with fip1l1-pdgfra,"chronic eosinophilic leukemia, not otherwise specified",chronic leukemia,chronic lymphoblastic lymphoma,chronic lymphocytic leukemia,chronic lymphocytic leukemia with immunoglobulin heavy chain variable-region gene somatic hypermutation,chronic lymphocytic leukemia with plasmacytoid differentiation,chronic lymphocytic leukemia with unmutated immunoglobulin heavy chain variable-region gene,chronic lymphocytic leukemia- binet staging system,chronic lymphocytic leukemia- modified rai staging system,chronic monocytic leukemia,"chronic myelogenous leukemia, bcr-abl1 positive",chronic myelomonocytic leukemia,chronic myelomonocytic leukemia with eosinophilia,chronic myelomonocytic leukemia with eosinophilia associated with t(5;12)(q31;p12),chronic myelomonocytic leukemia-0,chronic myelomonocytic leukemia-1,chronic myelomonocytic leukemia-2,chronic neutrophilic leukemia,"chronic phase chronic myelogenous leukemia, bcr-abl1 positive",chronic phase primary myelofibrosis,ciliary body adenocarcinoma,ciliary body adenoma,ciliary body benign medulloepithelioma,ciliary body benign teratoid medulloepithelioma,ciliary body epithelioid cell melanoma,ciliary body intermediate cell type melanoma,ciliary body leiomyoma,ciliary body malignant medulloepithelioma,ciliary body medulloepithelioma,ciliary body melanoma,ciliary body mixed cell melanoma,ciliary body neoplasm,ciliary body nevus,ciliary body spindle cell melanoma,ciliary body spindle cell type a melanoma,ciliary body spindle cell type b melanoma,ciliary body teratoid medulloepithelioma,circumscribed meningeal melanocytic neoplasm,classic congenital mesoblastic nephroma,classic hodgkin lymphoma,classic hodgkin lymphoma type post-transplant lymphoproliferative disorder,classic kaposi sarcoma,classic medulloblastoma,classic rhabdomyoma,classic thyroid gland papillary carcinoma,classic type atypical fibroxanthoma,classic type trichilemmoma,classic type trichoepithelioma,classic variant of chromophobe renal cell carcinoma,classical glioblastoma,classical low grade fibromyxoid sarcoma,classical poroma,clear cell acanthoma,clear cell adenocarcinoma,clear cell adenofibroma,clear cell adenoma,clear cell chondrosarcoma,clear cell cystadenofibroma,clear cell ependymoma,clear cell hepatocellular carcinoma,clear cell hidradenoma,clear cell intrahepatic cholangiocarcinoma,clear cell malignant neoplasm,clear cell meningioma,clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres,clear cell neoplasm,clear cell odontogenic carcinoma,clear cell papillary cystadenoma,clear cell papillary renal neoplasm,clear cell renal cell carcinoma,clear cell sarcoma of soft tissue,clear cell sarcoma of the kidney,clear cell squamous cell carcinoma of the penis,clear cell variant thyroid gland papillary carcinoma,clitoral carcinoma,clivus chondroid chordoma,clivus chordoma,clivus meningioma,coccygeal body neoplasm,cockade nevus,collecting duct carcinoma,colon adenocarcinoma,colon adenoma,colon adenoma with severe dysplasia,colon adenomatous polyp,colon adenosquamous carcinoma,colon burkitt lymphoma,colon cancer by astler-coller stage,colon carcinoma,colon carcinoma metastatic in the liver,colon carcinoma metastatic in the lung,colon cavernous hemangioma,colon conventional adenoma,colon cribriform comedo-type adenocarcinoma,colon diffuse large b-cell lymphoma,colon enterochromaffin cell serotonin-producing neuroendocrine tumor,colon ganglioneuroma,colon hodgkin lymphoma,colon intramucosal adenocarcinoma,colon kaposi sarcoma,colon l-cell glucagon-like peptide-producing neuroendocrine tumor,colon large cell neuroendocrine carcinoma,colon leiomyoma,colon leiomyosarcoma,colon lipoma,colon liposarcoma,colon lymphangioma,colon lymphoma,colon mantle cell lymphoma,colon medullary carcinoma,colon micropapillary adenocarcinoma,colon mucinous adenocarcinoma,colon mucosa-associated lymphoid tissue lymphoma,colon neoplasm,colon neuroendocrine neoplasm,colon neuroendocrine tumor,colon neuroendocrine tumor g1,colon neuroendocrine tumor g2,colon neuroendocrine tumor g3,colon non-hodgkin lymphoma,colon sarcoma,colon serrated adenocarcinoma,colon serrated lesions and polyps,colon signet ring cell adenocarcinoma,colon small cell neuroendocrine carcinoma,colon squamous cell carcinoma,colon traditional serrated adenoma,colon tubular adenoma,colon tubulovillous adenoma,colon undifferentiated carcinoma,colon villous adenoma,colorectal adenocarcinoma,colorectal adenocarcinoma metastatic in the liver,colorectal adenoma,colorectal adenoma with mild dysplasia,colorectal adenoma with moderate dysplasia,colorectal adenoma with severe dysplasia,colorectal adenoma-like adenocarcinoma,colorectal adenomatous polyp,colorectal adenosquamous carcinoma,colorectal angiosarcoma,colorectal benign granular cell tumor,colorectal burkitt lymphoma,colorectal cancer by astler-coller stage,colorectal carcinoma,colorectal carcinoma metastatic in the liver,colorectal carcinoma metastatic in the lung,colorectal conventional adenoma,colorectal cribriform comedo-type adenocarcinoma,colorectal diffuse large b-cell lymphoma,colorectal enterochromaffin cell serotonin-producing neuroendocrine tumor,colorectal filiform serrated adenoma,colorectal ganglioneuroma,colorectal gastrointestinal stromal tumor,"colorectal high grade b-cell lymphoma, not otherwise specified",colorectal high grade intraepithelial neoplasia,colorectal hodgkin lymphoma,colorectal intraepithelial neoplasia,colorectal kaposi sarcoma,colorectal l-cell glucagon-like peptide-producing neuroendocrine tumor,colorectal large cell neuroendocrine carcinoma,colorectal leiomyoma,colorectal leiomyosarcoma,colorectal lipoma,colorectal low grade intraepithelial neoplasia,colorectal lymphoma,colorectal mantle cell lymphoma,colorectal medullary carcinoma,colorectal micropapillary adenocarcinoma,colorectal mixed adenoneuroendocrine carcinoma,colorectal mucinous adenocarcinoma,colorectal mucosa-associated lymphoid tissue lymphoma,colorectal neoplasm,colorectal neuroendocrine carcinoma,colorectal neuroendocrine neoplasm,colorectal neuroendocrine tumor,colorectal neuroendocrine tumor g1,colorectal neuroendocrine tumor g2,colorectal neuroendocrine tumor g3,colorectal non-hodgkin lymphoma,colorectal perineurioma,colorectal poorly cohesive adenocarcinoma,colorectal sarcoma,colorectal sarcomatoid carcinoma,colorectal schwannoma,colorectal serrated adenocarcinoma,colorectal serrated lesions and polyps,colorectal signet ring cell carcinoma,colorectal small cell neuroendocrine carcinoma,colorectal squamous cell carcinoma,colorectal traditional serrated adenoma,colorectal tubular adenoma,colorectal tubulovillous adenoma,colorectal undifferentiated carcinoma,colorectal villous adenoma,columnar cell change of the breast,columnar cell change of the breast with atypia,columnar cell variant thyroid gland papillary carcinoma,combined bap1-inactivated nevus,combined carcinoid and adenocarcinoma,combined hepatocellular carcinoma and cholangiocarcinoma,combined lung carcinoma,combined lung large cell neuroendocrine carcinoma,combined lung small cell carcinoma,combined lung small cell carcinoma and lung adenocarcinoma,combined lung small cell and squamous cell carcinoma,combined nevus,combined thymic epithelial neoplasm,comedocarcinoma,common acute lymphoblastic leukemia,common blue nevus,common variant anaplastic large cell lymphoma,complex endometrial hyperplasia,complex endometrial hyperplasia with atypia,complex epithelial neoplasm,composite gangliocytoma/neuroma and neuroendocrine tumor,"composite ganglioneuroblastoma, schwannian stroma-rich and stroma-poor","composite ganglioneuroblastoma, stroma-dominant and stroma-poor",composite hemangioendothelioma,composite lymphoma,composite paraganglioma,compound nevus,condyloma acuminatum,condyloma acuminatum with dysplasia,congenital cystic hygroma,congenital melanocytic nevus,congenital mesoblastic nephroma,congenital non-progressive hemangioma,congenital peribronchial myofibroblastic tumor,congenital/infantile spindle cell rhabdomyosarcoma with vgll2/ncoa2/cited2 rearrangements,conjunctival adenosquamous carcinoma,conjunctival angiosarcoma,conjunctival blue nevus,conjunctival carcinoma,conjunctival compound nevus,conjunctival diffuse large b-cell lymphoma,conjunctival follicular lymphoma,conjunctival hemangioma,conjunctival junctional nevus,conjunctival kaposi sarcoma,conjunctival keratoacanthoma,conjunctival leiomyosarcoma,conjunctival lymphangioma,conjunctival melanocytic intraepithelial neoplasia,conjunctival melanoma,conjunctival mucosa-associated lymphoid tissue lymphoma,conjunctival myxoma,conjunctival neoplasm,conjunctival nevus,conjunctival non-hodgkin lymphoma,conjunctival oncocytoma,conjunctival rhabdomyosarcoma,conjunctival sarcoma,conjunctival sebaceous carcinoma,conjunctival spindle cell carcinoma,conjunctival spitz nevus,conjunctival squamous cell carcinoma,conjunctival squamous intraepithelial neoplasia,conjunctival squamous papilloma,conjunctival stromal tumor,conjunctival subepithelial nevus,connective and soft tissue neoplasm,connective and soft tissue neoplasm (antiquated),contralateral breast carcinoma,conus medullaris neoplasm,conventional alveolar rhabdomyosarcoma,conventional angiosarcoma,conventional cardiac rhabdomyoma,conventional chordoma,conventional dermatofibrosarcoma protuberans,conventional extraskeletal myxoid chondrosarcoma,conventional fibrosarcoma,conventional follicular dendritic cell sarcoma,conventional leiomyosarcoma,conventional lipoma,conventional malignant hemangiopericytoma,conventional osteosarcoma,conventional schwannoma,core binding factor acute myeloid leukemia,corneal kaposi sarcoma,corneal melanoma,corneal neoplasm,corneal squamous cell carcinoma,corneal squamous intraepithelial neoplasia,corpus callosum lipoma,corpus callosum neoplasm,corticotroph pituitary neuroendocrine tumor,cortisol-producing adrenal cortical adenoma,cranial nerve neoplasm,cranial nodular fasciitis,craniofacial fibrous dysplasia,craniopharyngioma,cribriform adenocarcinoma of minor salivary gland,cribriform carcinoma,cribriform neuroepithelial tumor,crohn disease-associated colorectal adenocarcinoma,crooke cell tumor,cutaneous adult t-cell leukemia/lymphoma,cutaneous angioimmunoblastic t-cell lymphoma,cutaneous b lymphoblastic leukemia/lymphoma,cutaneous burkitt lymphoma,cutaneous chronic lymphocytic leukemia,cutaneous erdheim-chester disease,cutaneous follicular lymphoma,cutaneous ganglioneuroma,cutaneous granular cell tumor,cutaneous hematopoietic and lymphoid cell neoplasm,cutaneous histiocytic and dendritic cell neoplasm,cutaneous indeterminate dendritic cell tumor,cutaneous langerhans cell histiocytosis,cutaneous lymphoma,cutaneous lymphomatoid granulomatosis,cutaneous malignant melanoma 2,cutaneous mantle cell lymphoma,cutaneous mastocytosis,cutaneous mature b-cell neoplasm,cutaneous mature t-cell and nk-cell neoplasm,cutaneous melanoma,cutaneous melanoma of the extremity,cutaneous nasal type extranodal nk/t-cell lymphoma,cutaneous neural neoplasm,cutaneous neurofibroma,cutaneous nodular melanoma,cutaneous perineurioma,cutaneous plasmacytoma,cutaneous precursor lymphoid neoplasm,cutaneous schwannoma,cutaneous squamous cell carcinoma of the head and neck,cutaneous t lymphoblastic leukemia/lymphoma,cylindrocarcinoma,cylindroma,cystadenocarcinoma,cystadenofibroma,cystadenoma,cystic hygroma,cystic neoplasm,cystic oncocytic neoplasm,cystic partially differentiated kidney nephroblastoma,cystic teratoma,cystic tumor of the atrioventricular node,cytogenetically normal acute myeloid leukemia,ddit4l acute lymphoblastic leukemia,dartoic leiomyoma,dedifferentiated chondrosarcoma,dedifferentiated chordoma,dedifferentiated dermatofibrosarcoma protuberans,dedifferentiated gastrointestinal stromal tumor,dedifferentiated leiomyosarcoma,dedifferentiated liposarcoma,dedifferentiated solitary fibrous tumor,deep (aggressive) angiomyxoma,deep fibrous histiocytoma,deep hemangioma,deep leiomyoma,deep lipoma,deep penetrating nevus,deletion of chromosome 22 associated meningioma,deletion of chromosome 3p associated meningioma,deletion of the short arm of chromosome 1 (1p) associated meningioma,"dendritic cell tumor, not otherwise specified",densely granulated corticotroph pituitary neuroendocrine tumor,densely granulated lactotroph pituitary neuroendocrine tumor,densely granulated somatotroph pituitary neuroendocrine tumor,dentinogenic ghost cell tumor,dermal duct tumor,dermal fibroma,dermal neoplasm,dermal nerve sheath myxoma,dermal nevus,dermatofibrosarcoma protuberans,dermatofibrosarcoma protuberans with giant cell fibroblastoma-like differentiation,dermatofibrosarcoma protuberans with myoid differentiation,dermatomyofibroma,dermoid cyst,dermoid cyst of the skin,dermoid cyst of the spinal cord,descending colon neuroendocrine tumor g1,desmoid fibromatosis,desmoplastic ameloblastoma,desmoplastic fibroma,desmoplastic infantile astrocytoma,desmoplastic infantile ganglioglioma,desmoplastic melanoma,desmoplastic mesothelioma,"desmoplastic myxoid tumor of the pineal region, smarcb1-mutant",desmoplastic neurotropic melanoma,desmoplastic nevus,desmoplastic small round cell tumor,desmoplastic spitz nevus,desmoplastic trichilemmoma,desmoplastic trichoepithelioma,desmoplastic/nodular medulloblastoma,diaphragma sellae meningioma,diencephalic astrocytoma,diencephalic glioblastoma,diencephalic neoplasm,differentiated (simplex) penile intraepithelial neoplasia,differentiated granulocytic sarcoma,differentiated high grade thyroid gland carcinoma,differentiated intraepithelial neoplasia,differentiated retinoblastoma,differentiated thyroid gland carcinoma,differentiating neuroblastoma,diffuse astrocytoma,"diffuse astrocytoma, idh-wildtype","diffuse astrocytoma, myb-altered","diffuse astrocytoma, mybl1-altered","diffuse astrocytoma, not otherwise specified",diffuse centroblastic-centrocytic lymphoma,diffuse cutaneous mastocytosis,diffuse glioma,diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters,"diffuse hemispheric glioma, h3 g34-mutant",diffuse intraductal papillomatosis,diffuse intrinsic pontine glioma,diffuse large b-cell lymphoma arising in hhv8-positive multicentric castleman disease,diffuse large b-cell lymphoma post-transplant lymphoproliferative disorder,diffuse leptomeningeal glioneuronal tumor,diffuse lipomatosis,"diffuse low grade glioma, braf p.v600e-mutant","diffuse low grade glioma, fgfr1 tyrosine kinase domain-duplicated","diffuse low grade glioma, fgfr1-mutant","diffuse low grade glioma, mapk pathway-altered",diffuse malignant lymphoma,diffuse malignant mesothelioma,diffuse midline glioma,diffuse midline glioma with ezhip overexpression,"diffuse midline glioma, egfr-mutant","diffuse midline glioma, h3 k27-altered","diffuse midline glioma, h3 k27m-mutant",diffuse mixed cell lymphoma,diffuse neurofibroma,diffuse non-pontine midline glioma,diffuse pediatric-type high grade glioma mycn,diffuse pediatric-type high grade glioma rtk1,diffuse pediatric-type high grade glioma rtk2,"diffuse pediatric-type high grade glioma, h3-wildtype and idh-wildtype",diffuse pulmonary lymphangiomatosis,diffuse retinoblastoma,diffuse sclerosing variant thyroid gland papillary carcinoma,diffuse type adenocarcinoma,diffusion restriction,digestive system adenoma,digestive system carcinoma,digestive system carcinoma in situ,digestive system diffuse large b-cell lymphoma,digestive system filiform serrated adenoma,digestive system hemangioma,digestive system hodgkin lymphoma,digestive system inflammatory myofibroblastic tumor,digestive system intraepithelial neoplasia,digestive system kaposi sarcoma,digestive system large cell neuroendocrine carcinoma,digestive system leiomyoma,digestive system leiomyosarcoma,digestive system lipoma,digestive system lymphoma,digestive system mixed adenoneuroendocrine carcinoma,digestive system neoplasm,digestive system neuroendocrine carcinoma,digestive system neuroendocrine neoplasm,digestive system neuroendocrine tumor,digestive system neuroendocrine tumor g1,digestive system neuroendocrine tumor g2,digestive system neuroendocrine tumor g3,digestive system non-hodgkin lymphoma,digestive system rhabdomyosarcoma,digestive system sarcoma,digestive system small cell neuroendocrine carcinoma,digestive system soft tissue neoplasm,digestive system solitary fibrous tumor,digital papillary adenocarcinoma,digital papillary adenoma,disseminated adenocarcinoma,disseminated carcinoma,disseminated juvenile xanthogranuloma,disseminated malignant neoplasm,disseminated peritoneal leiomyomatosis,disseminated squamous cell carcinoma,distal bile duct adenocarcinoma,distal bile duct carcinoma,distal esophagus adenocarcinoma,distal esophagus squamous cell carcinoma,distal urethral carcinoma,distal-type epithelioid sarcoma,distant intracranial metastasis,distantly metastatic malignant neoplasm,double pituitary neuroendocrine tumors of distinct lineages,double-negative prostate carcinoma,drop metastasis,drop metastasis in the spinal cord,ductal eccrine adenocarcinoma,ductal eccrine carcinoma with abundant fibromyxoid stroma,ductal eccrine carcinoma with spindle cell elements,duodenal adenocarcinoma,duodenal adenoma,duodenal carcinoma,duodenal extraskeletal osteosarcoma,duodenal gastrin-producing neuroendocrine tumor,duodenal neoplasm,duodenal neuroendocrine tumor,duodenal neuroendocrine tumor g1,duodenal neuroendocrine tumor g2,duodenal neuroendocrine tumor g3,duodenal somatostatin-producing neuroendocrine tumor,duodenal villous adenoma,dural extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,dysembryoplastic neuroepithelial tumor,dysembryoplastic neuroepithelial-like tumor of the septum pellucidum,dysplastic cerebellar gangliocytoma,dysplastic nevus,ebv-associated smooth muscle tumor,"ebv-positive diffuse large b-cell lymphoma, not otherwise specified",ebv-positive inflammatory follicular dendritic cell sarcoma,ebv-positive inflammatory follicular dendritic cell sarcoma of the digestive system,ebv-positive t-cell lymphoproliferative disorder of childhood,ebv-related burkitt lymphoma,ebv-related carcinoma,ebv-related clonal post-transplant lymphoproliferative disorder,ebv-related gastric carcinoma,ebv-related hodgkin lymphoma,ebv-related leiomyosarcoma,ebv-related lymphoma,ebv-related malignant neoplasm,ebv-related non-hodgkin lymphoma,ebv-related sarcoma,elp1-associated medulloblastoma,ewsr1-negative small round cell tumor,ewsr1-smad3-positive fibroblastic tumor,ear carcinoma,ear neoplasm,ear polyp,early favorable hodgkin lymphoma,early gastric cancer,early hepatocellular carcinoma,early invasive cervical adenocarcinoma,early invasive cervical squamous cell carcinoma,early primary cutaneous t-cell non-hodgkin lymphoma,early stage breast carcinoma,early stage pancreatic ductal adenocarcinoma,early stage triple-negative breast carcinoma,early t acute lymphoblastic leukemia,early unfavorable hodgkin lymphoma,eccrine carcinoma,eccrine hidrocystoma,eccrine neoplasm,ectomesenchymal chondromyxoid tumor,ectomesenchymoma,ectopic cervical thymoma,ectopic hamartomatous thymoma,ectopic meningioma,ectopic pituitary neuroendocrine tumor,elastofibroma,embryonal carcinoma,embryonal neoplasm,embryonal rhabdomyosarcoma,embryonal tumor with multilayered rosettes,embryonal tumor with multilayered rosettes without c19mc alteration,"embryonal tumor with multilayered rosettes, c19mc-altered","embryonal tumor with multilayered rosettes, dicer1-mutated",encapsulated breast papillary carcinoma,encapsulated breast papillary carcinoma with invasion,encapsulated neoplasm,encapsulated thymoma,encapsulated variant thyroid gland papillary carcinoma,encephalocraniocutaneous lipomatosis,enchondroma,enchondromatosis,endemic african kaposi sarcoma,endemic burkitt lymphoma,endobronchial hamartoma,endobronchial leiomyoma,endobronchial lipoma,endocardial neoplasm,"endocervical adenocarcinoma, usual-type",endocervical polyp,endocervical undifferentiated sarcoma,endocrine mucin-producing sweat gland carcinoma,endocrine neoplasm,endolymphatic sac tumor,endometrial adenocarcinoma,endometrial adenosquamous carcinoma,endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia,endometrial carcinoma,endometrial clear cell adenocarcinoma,endometrial dedifferentiated carcinoma,endometrial endometrioid adenocarcinoma,endometrial endometrioid adenocarcinoma with clear cell change,endometrial endometrioid adenocarcinoma with metaplastic changes,endometrial endometrioid adenocarcinoma with papillae,"endometrial endometrioid adenocarcinoma with small glands, tubules or cords",endometrial endometrioid adenocarcinoma with small nonvillous papillae,endometrial endometrioid adenocarcinoma with spindled epithelial cells,endometrial endometrioid adenocarcinoma with a poorly differentiated carcinomatous component,endometrial endometrioid adenocarcinoma with an undifferentiated carcinomatous component,"endometrial endometrioid adenocarcinoma, ciliated variant","endometrial endometrioid adenocarcinoma, secretory variant","endometrial endometrioid adenocarcinoma, variant with squamous differentiation",endometrial large cell neuroendocrine carcinoma,endometrial mesonephric-like adenocarcinoma,endometrial mixed cell adenocarcinoma,endometrial mucinous adenocarcinoma,"endometrial mucinous adenocarcinoma, gastric-type","endometrial mucinous adenocarcinoma, intestinal-type",endometrial mucosa-associated lymphoid tissue lymphoma,endometrial neoplasm,endometrial neuroendocrine carcinoma,endometrial polyp,endometrial serous adenocarcinoma,endometrial small cell neuroendocrine carcinoma,endometrial squamous cell carcinoma,endometrial stromal nodule,endometrial transitional cell carcinoma,endometrial undifferentiated carcinoma,endometrioid adenocarcinoma,"endometrioid adenocarcinoma, variant with squamous differentiation",endometrioid stromal sarcoma,endometrioid stromal sarcoma of the cervix,endometrioid stromal sarcoma of the vagina,endometrioid stromal and related neoplasms,endometrioid tumor,"endometrioid tumor, variant with squamous differentiation",enostosis,enterochromaffin-like cell neuroendocrine tumor g1,enteroglucagonoma,enteropathy-associated t-cell lymphoma,environment-related malignant neoplasm,environment-related neoplasm,eosinophilic granuloma,eosinophilic variant of chromophobe renal cell carcinoma,ependymal pituicytoma,ependymal tumor,ependymoma,epicardial lipoma,epicardial neoplasm,epidermolytic acanthoma,epididymal adenocarcinoma,epididymal adenomatoid tumor,epididymal cystadenoma,epididymal melanotic neuroectodermal tumor,epididymal neoplasm,epididymal papillary cystadenoma,epidural spinal canal angiolipoma,epidural spinal canal meningioma,epidural spinal canal neoplasm,epiglottic carcinoma,epiglottic squamous cell carcinoma,epiglottis neoplasm,epipodophyllotoxin-related myelodysplastic syndrome,epithelial neoplasm,epithelial neoplasm (antiquated),epithelial predominant kidney wilms tumor,epithelial predominant pulmonary blastoma,epithelial skin neoplasm,epithelial synovial sarcoma,epithelial-myoepithelial carcinoma,epithelioid angiomyolipoma,epithelioid cell melanoma,epithelioid cell nevus,epithelioid cell type gastrointestinal stromal tumor,epithelioid glioblastoma,epithelioid hemangioendothelioma,epithelioid hemangioendothelioma with wwtr1-camta1 gene fusion,epithelioid hemangioendothelioma with yap1-tfe3 gene fusion,epithelioid hemangioma,epithelioid leiomyosarcoma,epithelioid malignant peripheral nerve sheath tumor,epithelioid malignant peripheral nerve sheath tumor of the skin,epithelioid mesothelioma,epithelioid myxofibrosarcoma,epithelioid neurofibroma,epithelioid sarcoma,epithelioid sarcoma nci grade 2,epithelioid sarcoma nci grade 3,epithelioid schwannoma,epithelioid trophoblastic tumor,erdheim-chester disease,erythroid neoplasm,erythroleukemia,esophageal adenocarcinoma,esophageal adenoid cystic carcinoma,esophageal adenosquamous carcinoma,esophageal basaloid carcinoma,esophageal carcinoma,esophageal carcinoma cuniculatum,esophageal diffuse large b-cell lymphoma,esophageal fibroma,esophageal gastrointestinal stromal tumor,esophageal glandular intraepithelial neoplasia,esophageal granular cell tumor,esophageal hemangioma,esophageal high grade intraepithelial neoplasia,esophageal hodgkin lymphoma,esophageal intraepithelial neoplasia,esophageal intramucosal adenocarcinoma,esophageal kaposi sarcoma,esophageal large cell neuroendocrine carcinoma,esophageal leiomyoma,esophageal leiomyosarcoma,esophageal lipoma,esophageal liposarcoma,esophageal low grade intraepithelial neoplasia,esophageal lymphoma,esophageal malignant peripheral nerve sheath tumor,esophageal melanoma,esophageal mixed adenoneuroendocrine carcinoma,esophageal moderately differentiated squamous cell carcinoma,esophageal mucoepidermoid carcinoma,esophageal mucosa-associated lymphoid tissue lymphoma,esophageal neoplasm,esophageal neuroendocrine carcinoma,esophageal neuroendocrine neoplasm,esophageal neuroendocrine tumor,esophageal neuroendocrine tumor g1,esophageal neuroendocrine tumor g2,esophageal neuroendocrine tumor g3,esophageal neurofibroma,esophageal non-hodgkin lymphoma,esophageal polyp,esophageal poorly differentiated squamous cell carcinoma,esophageal rhabdomyosarcoma,esophageal sarcoma,esophageal schwannoma,esophageal small cell neuroendocrine carcinoma,esophageal soft tissue neoplasm,esophageal spindle cell carcinoma,esophageal squamous cell carcinoma,esophageal squamous cell papilloma,esophageal squamous intraepithelial neoplasia,esophageal synovial sarcoma,esophageal undifferentiated carcinoma,esophageal verrucous carcinoma,esophageal well differentiated squamous cell carcinoma,essential thrombocythemia,estrogen-producing adrenal cortical adenoma,ethmoid sinus adenocarcinoma,ethmoid sinus adenoid cystic carcinoma,ethmoid sinus inverted papilloma,ethmoid sinus neoplasm,ethmoid sinus papilloma,ethmoid sinus primary ectopic meningioma,ethmoid sinus squamous cell carcinoma,ewing sarcoma,ewing sarcoma of bone,ewing sarcoma pediatric,ewing sarcoma/peripheral primitive neuroectodermal tumor,ewing sarcoma/peripheral primitive neuroectodermal tumor of bone,exocervical carcinoma,extensive stage lung small cell carcinoma,external ear actinic keratosis,external ear basal cell carcinoma,external ear carcinoma,external ear lipoma,external ear neoplasm,external ear polyp,external ear squamous cell carcinoma,extra-adrenal paraganglioma,extra-adrenal retroperitoneal paraganglioma,extra-adrenal sympathetic paraganglioma,extraabdominal fibromatosis,extracardiac rhabdomyoma,extracavitary primary effusion lymphoma,extracranial neuroblastoma,extracranial solid neoplasm,extracutaneous mastocytoma,extracutaneous merkel cell carcinoma,extragastrointestinal gastrointestinal stromal tumor,extragonadal embryonal carcinoma,extragonadal germ cell tumor,extragonadal seminoma,extrahepatic bile duct adenocarcinoma,"extrahepatic bile duct adenocarcinoma, biliary type","extrahepatic bile duct adenocarcinoma, gastric foveolar type","extrahepatic bile duct adenocarcinoma, intestinal type",extrahepatic bile duct adenoma,extrahepatic bile duct adenosquamous carcinoma,extrahepatic bile duct benign granular cell tumor,extrahepatic bile duct biliary intraepithelial neoplasia,extrahepatic bile duct carcinoma,extrahepatic bile duct carcinosarcoma,extrahepatic bile duct clear cell adenocarcinoma,extrahepatic bile duct embryonal rhabdomyosarcoma,extrahepatic bile duct fibroma,extrahepatic bile duct intraductal papillary neoplasm,extrahepatic bile duct intraductal papillary neoplasm with an associated invasive carcinoma,extrahepatic bile duct kaposi sarcoma,extrahepatic bile duct large cell neuroendocrine carcinoma,extrahepatic bile duct leiomyoma,extrahepatic bile duct leiomyosarcoma,extrahepatic bile duct lipoma,extrahepatic bile duct lymphoma,extrahepatic bile duct mixed adenoneuroendocrine carcinoma,extrahepatic bile duct mucinous adenocarcinoma,extrahepatic bile duct mucinous cystic neoplasm,extrahepatic bile duct mucinous cystic neoplasm with an associated invasive carcinoma,extrahepatic bile duct mucoepidermoid carcinoma,extrahepatic bile duct neoplasm,extrahepatic bile duct neuroendocrine carcinoma,extrahepatic bile duct neuroendocrine neoplasm,extrahepatic bile duct neuroendocrine tumor,extrahepatic bile duct neuroendocrine tumor g1,extrahepatic bile duct neuroendocrine tumor g2,extrahepatic bile duct neuroendocrine tumor g3,extrahepatic bile duct papillary adenoma,extrahepatic bile duct rhabdomyosarcoma,extrahepatic bile duct sarcoma,extrahepatic bile duct signet ring cell carcinoma,extrahepatic bile duct small cell neuroendocrine carcinoma,extrahepatic bile duct squamous cell carcinoma,extrahepatic bile duct tubular adenoma,extrahepatic bile duct tubulopapillary adenoma,extrahepatic bile duct undifferentiated carcinoma,extramammary paget disease,extramedullary disease in plasma cell myeloma involving the central nervous system,extramedullary disease in plasma cell myeloma involving the kidney,extramedullary disease in plasma cell myeloma involving the leptomeninges,extramedullary disease in plasma cell myeloma involving the liver,extramedullary disease in plasma cell myeloma involving the lung,extramedullary disease in plasma cell myeloma involving the skin,extramedullary disease in plasma cell myeloma involving the spleen,extramedullary disease in plasma cell myeloma involving the uterine corpus,extranodal lymphoma,extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue involving the digestive system,extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue by ann arbor stage,extranodal nk- and t-cell lymphoma nasal type,extranodal non-hodgkin lymphoma,extraocular cutaneous sebaceous carcinoma,extraocular retinoblastoma,extraosseous/peripheral ameloblastoma,extrapulmonary small cell neuroendocrine carcinoma,extrarenal rhabdoid tumor,extrarenal rhabdoid tumor of the liver,extrarenal rhabdoid tumor of the ovary,extrarenal rhabdoid tumor of the prostate,extraskeletal cartilaginous and osseous neoplasm,extraskeletal ewing sarcoma,extraskeletal ewing sarcoma/peripheral primitive neuroectodermal tumor,extraskeletal myxoid chondrosarcoma,extraskeletal osteoma,extraskeletal osteosarcoma,extraventricular neurocytoma,eye carcinoma,eye lymphoma,eye melanocytoma,eye neoplasm,eye sebaceous carcinoma,eyelid basal cell carcinoma,eyelid capillary hemangioma,eyelid carcinoma,eyelid melanoma,eyelid neoplasm,eyelid nevus,eyelid papilloma,eyelid sebaceous gland carcinoma,eyelid seborrheic keratosis,eyelid squamous cell papilloma,figo grade 1 endometrial endometrioid adenocarcinoma,figo grade 1 endometrial mucinous adenocarcinoma,figo grade 2 endometrial endometrioid adenocarcinoma,figo grade 2 endometrial mucinous adenocarcinoma,figo grade 3 endometrial mucinous adenocarcinoma,figo stage i gestational trophoblastic tumor,figo stage ia gestational trophoblastic tumor,figo stage ib gestational trophoblastic tumor,figo stage ic gestational trophoblastic tumor,figo stage ii gestational trophoblastic tumor,figo stage iia gestational trophoblastic tumor,figo stage iib gestational trophoblastic tumor,figo stage iic gestational trophoblastic tumor,figo stage iii gestational trophoblastic tumor,figo stage iiia gestational trophoblastic tumor,figo stage iiib gestational trophoblastic tumor,figo stage iiic gestational trophoblastic tumor,figo stage iv gestational trophoblastic tumor,figo stage iva gestational trophoblastic tumor,figo stage ivb gestational trophoblastic tumor,figo stage ivc gestational trophoblastic tumor,fsh-producing pituitary neuroendocrine tumor,facial nerve neoplasm,fallopian tube adenocarcinoma,fallopian tube adenomatoid tumor,fallopian tube adenosarcoma,fallopian tube carcinoma,fallopian tube carcinosarcoma,fallopian tube clear cell adenocarcinoma,fallopian tube endometrioid adenocarcinoma,fallopian tube endometrioid polyp,fallopian tube endometrioid tumor,fallopian tube germ cell tumor,fallopian tube gestational choriocarcinoma,fallopian tube high grade serous adenocarcinoma,fallopian tube leiomyoma,fallopian tube leiomyosarcoma,fallopian tube lymphoma,fallopian tube metaplastic papillary tumor,fallopian tube mucinous adenocarcinoma,fallopian tube mucinous neoplasm,fallopian tube neoplasm,fallopian tube papillary adenocarcinoma,fallopian tube serous adenocarcinoma,fallopian tube serous adenofibroma,fallopian tube serous cystadenofibroma,fallopian tube serous neoplasm,fallopian tube serous papilloma,fallopian tube soft tissue neoplasm,fallopian tube squamous cell carcinoma,fallopian tube teratoma,fallopian tube transitional cell carcinoma,fallopian tube undifferentiated carcinoma,falx cerebri meningioma,familial adenomatous polyposis associated medulloblastoma,familial adrenal gland pheochromocytoma,familial myelodysplastic syndrome,familial neuroblastoma,familial nonmedullary thyroid gland carcinoma,familial paraganglioma,familial testicular germ cell tumor,familial waldenstrom macroglobulinemia,fascial fibroma,fascial fibrosarcoma,favorable hodgkin lymphoma,female breast carcinoma,female breast carcinoma in situ,female malignant nipple neoplasm,female reproductive system adenofibroma,female reproductive system carcinoma,female reproductive system neoplasm,female reproductive system smooth muscle tumor of uncertain malignant potential,female urethral malignant neoplasm,fetal rhabdomyoma,fibrillary astrocytoma,fibroadenoma of anogenital mammary-type glands,fibroblastic liposarcoma,fibroblastic neoplasm,fibroblastic osteosarcoma,fibroblastic reticular cell tumor,fibrocartilaginous mesenchymoma,fibroepithelial neoplasm,fibrofolliculoma,fibrohistiocytic neoplasm,fibrolamellar carcinoma,fibrolipoma,fibroma,fibromatosis,fibromatosis colli,fibromyxoid tumor,fibromyxolipoma,fibroosseous pseudotumor of digits,fibrosarcoma,fibrosarcoma nci grade 2,fibrosarcomatous dermatofibrosarcoma protuberans,fibrous dysplasia,fibrous hamartoma of infancy,fibrous histiocytoma,fibrous histiocytoma of bone,fibrous meningioma,fibrous synovial sarcoma,flat adenoma,flexural skin nevus,floor of mouth adenoid cystic carcinoma,floor of mouth basaloid squamous cell carcinoma,floor of mouth mucoepidermoid carcinoma,floor of mouth squamous cell carcinoma,floor of the mouth carcinoma,floor of the mouth neoplasm,focal intraductal papillomatosis,follicular ameloblastoma,follicular dendritic cell sarcoma,follicular myxoma,follicular variant thyroid gland papillary carcinoma,follicular lymphoma,"follicular-derived thyroid gland carcinoma, high grade",folliculotropic mycosis fungoides,foramen magnum meningioma,foregut neuroendocrine tumor g1,fourth ventricle medulloblastoma,foveolar-type adenoma,frontal convexity meningioma,frontal lobe anaplastic astrocytoma,frontal lobe anaplastic oligodendroglioma,frontal lobe neoplasm,frontal sinus inverted papilloma,frontal sinus neoplasm,frontal sinus papilloma,frontal sinus squamous cell carcinoma,fumarate hydratase-deficient renal cell carcinoma,functioning endocrine neoplasm,functioning lung carcinoid tumor,functioning pancreatic neuroendocrine tumor,functioning pancreatic neuroendocrine tumor g2,functioning pituitary neuroendocrine tumor,functioning pituitary neuroendocrine tumor/macroadenoma,functioning pituitary neuroendocrine tumor/microadenoma,fundic gland polyp,fusion-negative alveolar rhabdomyosarcoma,fusion-negative rhabdomyosarcoma,fusion-positive alveolar rhabdomyosarcoma,fusion-positive rhabdomyosarcoma,gallbladder adenocarcinoma,gallbladder adenocarcinoma with squamous metaplasia,"gallbladder adenocarcinoma, biliary type","gallbladder adenocarcinoma, gastric foveolar type","gallbladder adenocarcinoma, intestinal-type",gallbladder adenoma,"gallbladder adenoma, intestinal-type",gallbladder adenosquamous carcinoma,gallbladder angiosarcoma,gallbladder benign granular cell tumor,gallbladder benign neoplasm,gallbladder benign non-epithelial neoplasm,gallbladder biliary intraepithelial neoplasia,gallbladder carcinoma,gallbladder carcinosarcoma,gallbladder clear cell adenocarcinoma,gallbladder cribriform carcinoma,gallbladder flat biliary intraepithelial neoplasia,gallbladder goblet cell carcinoid,gallbladder hepatoid adenocarcinoma,gallbladder intracholecystic papillary (tubular) neoplasm with intermediate grade intraepithelial neoplasia,gallbladder intracholecystic papillary neoplasm,gallbladder intracholecystic papillary neoplasm with an associated invasive carcinoma,"gallbladder intracholecystic papillary neoplasm, high grade","gallbladder intracholecystic papillary neoplasm, low grade",gallbladder kaposi sarcoma,gallbladder large cell neuroendocrine carcinoma,gallbladder leiomyoma,gallbladder leiomyosarcoma,gallbladder lipoma,gallbladder lymphoma,gallbladder malignant neoplasm,gallbladder melanoma,gallbladder mixed adenoneuroendocrine carcinoma,gallbladder mucinous adenocarcinoma,gallbladder mucinous cystic neoplasm,gallbladder mucinous cystic neoplasm with intermediate grade intraepithelial neoplasia,gallbladder mucinous cystic neoplasm with an associated invasive carcinoma,"gallbladder mucinous cystic neoplasm, high grade","gallbladder mucinous cystic neoplasm, low grade",gallbladder neoplasm,gallbladder neuroendocrine carcinoma,gallbladder neuroendocrine neoplasm,gallbladder neuroendocrine tumor,gallbladder neuroendocrine tumor g1,gallbladder neuroendocrine tumor g2,gallbladder neuroendocrine tumor g3,gallbladder neurofibroma,gallbladder papillary adenoma,gallbladder papillary biliary intraepithelial neoplasia,gallbladder pyloric gland adenoma,gallbladder rhabdomyosarcoma,gallbladder sarcoma,gallbladder signet ring cell carcinoma,gallbladder small cell neuroendocrine carcinoma,gallbladder soft tissue neoplasm,gallbladder squamous cell carcinoma,gallbladder tubular adenoma,gallbladder tubular carcinoid,gallbladder tubulopapillary adenoma,gallbladder undifferentiated carcinoma,"gallbladder undifferentiated carcinoma, spindle and giant cell type",gangliocytoma,ganglioglioma,ganglioneuroblastoma,"ganglioneuroblastoma, intermixed","ganglioneuroblastoma, nodular",ganglioneuroma,ganglioneuromatosis,gardner fibroma,gasserian meningioma,gastric adenocarcinoma,gastric adenoma,"gastric adenoma, gastric-type","gastric adenoma, intestinal-type",gastric adenosquamous carcinoma,gastric body carcinoma,gastric burkitt lymphoma,gastric carcinoma,gastric carcinoma with lymphoid stroma,gastric cardia adenocarcinoma,gastric cardia carcinoma,gastric cardia squamous cell carcinoma,gastric choriocarcinoma,gastric diffuse adenocarcinoma,gastric diffuse large b-cell lymphoma,gastric enterochromaffin cell serotonin-producing neuroendocrine tumor,gastric fundus carcinoma,gastric gastrin-producing neuroendocrine tumor,gastric gastrointestinal stromal tumor,gastric gastrointestinal stromal tumor of uncertain malignant potential,gastric germ cell tumor,gastric glomus tumor,gastric granular cell tumor,gastric hemangioma,gastric hepatoid adenocarcinoma,gastric hodgkin lymphoma,gastric inflammatory myofibroblastic tumor,gastric intestinal-type adenocarcinoma,gastric intraepithelial neoplasia,gastric intramucosal adenocarcinoma,gastric kaposi sarcoma,gastric large cell neuroendocrine carcinoma,gastric leiomyoma,gastric leiomyosarcoma,gastric lipoma,gastric liposarcoma,gastric lymphangioma,gastric lymphoma,gastric malignant gastrointestinal stromal tumor,gastric melanoma,gastric mixed adenocarcinoma,gastric mixed adenoneuroendocrine carcinoma,gastric mucinous adenocarcinoma,gastric mucosa-associated lymphoid tissue lymphoma,gastric neoplasm,gastric neuroendocrine carcinoma,gastric neuroendocrine neoplasm,gastric neuroendocrine tumor,gastric neuroendocrine tumor g1,gastric neuroendocrine tumor g2,gastric neuroendocrine tumor g3,gastric non-hodgkin lymphoma,gastric papillary adenocarcinoma,gastric parietal cell adenocarcinoma,gastric plexiform fibromyxoma,gastric poorly cohesive adenocarcinoma,gastric pyloric gland adenoma,gastric pylorus carcinoma,gastric sarcoma,gastric schwannoma,gastric signet ring cell adenocarcinoma,gastric small cell neuroendocrine carcinoma,gastric soft tissue neoplasm,gastric squamous cell carcinoma,gastric synovial sarcoma,gastric t-cell non-hodgkin lymphoma,gastric teratoma,gastric tubular adenocarcinoma,gastric tubular adenoma,gastric tubulovillous adenoma,gastric undifferentiated carcinoma,gastric villous adenoma,gastrin-producing neuroendocrine tumor,gastroblastoma,gastroesophageal junction adenocarcinoma,gastroesophageal junction large cell neuroendocrine carcinoma,gastroesophageal junction neuroendocrine carcinoma,gastroesophageal junction small cell neuroendocrine carcinoma,gastroesophageal cancer,gastrointestinal autonomic nerve tumor,gastrointestinal carcinomatosis,gastrointestinal clear cell sarcoma/malignant gastrointestinal neuroectodermal tumor,gastrointestinal stromal tumor,gastrointestinal stromal tumor of uncertain malignant potential,gastrointestinal stromal tumor of the gastrointestinal tract,"gastrointestinal tract adenoma, intestinal-type",gastrointestinal anastomotic tumor recurrence,gemistocytic astrocytoma,"gemistocytic astrocytoma, idh-mutant",genital rhabdomyoma,genitourinary system carcinoma,genitourinary system neoplasm,germ cell tumor,germ cell tumor (antiquated),germinative follicular epithelium neoplasm,germinomatous germ cell tumor,gestational choriocarcinoma,gestational trophoblastic tumor,gestational trophoblastic tumor by figo stage,ghost cell odontogenic carcinoma,giant cell angioblastoma,giant cell angiofibroma,giant cell carcinoma,giant cell fibroblastoma,giant cell glioblastoma,giant cell lesion of small bones,giant cell neoplasm,giant cell sarcoma,giant cell tumor,giant cell tumor of bone,giant cell tumor of soft tissue,giant cell and spindle cell carcinoma,giant cell-rich osteosarcoma,giant condyloma acuminatum,giant congenital nevus,giant fibrovascular esophageal polyp,giant hemangioma,gingival angiofibroma,gingival carcinoma,gingival hemangioma,gingival neoplasm,gingival spindle cell carcinoma,gingival squamous cell carcinoma,glandular cell intraepithelial neoplasia,glandular cell neoplasm,glandular malignant peripheral nerve sheath tumor,glandular papilloma,glandular papillomatosis,glassy cell carcinoma,glioblastoma,glioblastoma by gene expression profile,glioblastoma with primitive neuronal component,"glioblastoma, idh-wildtype","glioblastoma, not otherwise specified",gliofibroma,glioma,gliomatosis cerebri,gliomatosis cerebri type i,gliomatosis cerebri type ii,glioneuronal tumor with neuropil-like islands,glioneuronal and neuronal tumors,gliosarcoma,glomangioma,glomangiomatosis,glomangiomyoma,glomeruloid hemangioma,glomus tumor,glomus tumor of uncertain malignant potential,glossopharyngeal nerve neoplasm,glottic squamous cell carcinoma,glottis carcinoma,glottis neoplasm,glottis verrucous carcinoma,glycogen-rich carcinoma,"glycogen-rich, clear cell breast carcinoma",gonadal polyembryoma,gonadal teratoma,gonadoblastoma,gonadotroph pituitary neuroendocrine tumor,good prognosis metastatic gestational trophoblastic tumor,grade 1 clear cell renal cell carcinoma,grade 1 colon adenocarcinoma,grade 1 colorectal adenocarcinoma,grade 1 cutaneous follicular lymphoma,grade 1 invasive breast carcinoma,grade 1 malignant neoplasm,grade 1 meningioma,grade 1 nodular sclerosis classic hodgkin lymphoma,grade 1 ovarian teratoma,grade 1 rectal adenocarcinoma,grade 1 teratoma,grade 2 clear cell renal cell carcinoma,grade 2 colon adenocarcinoma,grade 2 colorectal adenocarcinoma,grade 2 cutaneous follicular lymphoma,grade 2 invasive breast carcinoma,grade 2 malignant neoplasm,grade 2 meningioma,grade 2 nodular sclerosis classic hodgkin lymphoma,grade 2 rectal adenocarcinoma,grade 2 vaginal intraepithelial neoplasia,grade 3 clear cell renal cell carcinoma,grade 3 colon adenocarcinoma,grade 3 colorectal adenocarcinoma,grade 3 cutaneous follicular lymphoma,grade 3 invasive breast carcinoma,grade 3 malignant neoplasm,grade 3 meningioma,grade 3 rectal adenocarcinoma,grade 3a malignant neoplasm,grade 3b malignant neoplasm,grade 4 clear cell renal cell carcinoma,grade 4 malignant neoplasm,grade i lymphomatoid granulomatosis,grade i neuroendocrine carcinoma,grade ii glandular intraepithelial neoplasia,grade ii intraepithelial neoplasia,grade ii lymphomatoid granulomatosis,grade ii neuroendocrine carcinoma,grade ii penile intraepithelial neoplasia,grade ii prostatic intraepithelial neoplasia,grade ii squamous intraepithelial neoplasia,grade iii glandular intraepithelial neoplasia,grade iii lymphomatoid granulomatosis,grade iii neuroendocrine carcinoma,grade iii prostatic intraepithelial neoplasia,granular cell ameloblastoma,granular cell astrocytoma,granular cell carcinoma,granular cell glioblastoma,granular cell leiomyosarcoma,granular cell odontogenic fibroma,granular cell tumor,granular cell tumor of the sellar region,granular renal cell carcinoma,granulocytic sarcoma,granulomatous slack skin disease,granulosa cell-theca cell tumor,great vessel neoplasm,her2-low breast carcinoma,her2-negative breast carcinoma,her2-positive breast carcinoma,"hhv8-positive diffuse large b-cell lymphoma, not otherwise specified",hhv8-related malignant neoplasm,hiv lipodystrophy,hnf1alpha-inactivated hepatocellular adenoma,htlv-1-related malignant neoplasm,hair follicle neoplasm,hairy cell leukemia,hairy cell leukemia variant,halo nevus,hand-schuller-christian disease,hard palate adenoid cystic carcinoma,hard palate carcinoma,hard palate monomorphic adenoma,hard palate mucoepidermoid carcinoma,hard palate pleomorphic adenoma,hard palate squamous cell carcinoma,head and neck basaloid carcinoma,head and neck carcinoma,head and neck carcinoma of unknown primary,head and neck follicular dendritic cell sarcoma,head and neck heterotopia-associated carcinoma,head and neck histiocytic and dendritic cell neoplasm,head and neck keratinizing squamous cell carcinoma,head and neck langerhans cell histiocytosis,head and neck large cell neuroendocrine carcinoma,head and neck melanocytic neoplasm,head and neck merkel cell carcinoma,head and neck nut carcinoma,head and neck neoplasm,head and neck neuroendocrine carcinoma,head and neck neuroendocrine neoplasm,head and neck neuroendocrine tumor,head and neck neuroendocrine tumor g1,head and neck neuroendocrine tumor g2,head and neck nevus,head and neck paraganglioma,head and neck sarcoma,head and neck sebaceous carcinoma,head and neck small cell neuroendocrine carcinoma,head and neck squamous cell carcinoma,heart neoplasm,heavy chain deposition disease,helicobacter pylori-associated gastric mucosa-associated lymphoid tissue lymphoma,helicobacter pylori-related carcinoma,helicobacter pylori-related gastric adenocarcinoma,helicobacter pylori-related malignant neoplasm,helicobacter pylori-related non-hodgkin lymphoma,hemangioblastic meningioma,hemangioblastoma,hemangioendothelioma,hemangioma,hemangioma of peripheral nerve,hemangiomatosis with thrombocytopenia,hemangiopericytic neoplasm,hemangiopericytoma,hematologic malignancy-associated skin squamous cell carcinoma,hematopoietic and lymphoid cell neoplasm,hematopoietic and lymphoid neoplasm (antiquated),hematopoietic and lymphoid system neoplasm,hemispheric anaplastic astrocytoma,hemolymphangioma,hemosiderotic fibrolipomatous tumor,hepatitis b virus-related hepatocellular carcinoma,hepatitis c virus-related hepatocellular carcinoma,hepatitis virus-related hepatocellular carcinoma,hepatobiliary neoplasm,hepatobiliary soft tissue neoplasm,hepatoblastoma,hepatocellular adenoma,hepatocellular carcinoma,hepatocellular large cell change,"hepatocellular malignant neoplasm, not otherwise specified",hepatocellular small cell change,hepatoid adenocarcinoma,hepatosplenic t-cell lymphoma,hereditary breast carcinoma,hereditary clear cell renal cell carcinoma,hereditary colon carcinoma,hereditary fallopian tube carcinoma,hereditary female breast carcinoma,hereditary gastric diffuse adenocarcinoma,hereditary glomangioma,hereditary kidney oncocytoma,hereditary kidney wilms tumor,hereditary leiomyomatosis and renal cell carcinoma,hereditary male breast carcinoma,hereditary malignant neoplasm,hereditary malignant urinary system neoplasm,hereditary melanoma,hereditary meningioma,hereditary ovarian carcinoma,hereditary pancreatic carcinoma,hereditary papillary renal cell carcinoma,hereditary prostate carcinoma,hereditary renal cell carcinoma,hereditary retinoblastoma,hereditary thyroid gland medullary carcinoma,hibernoma,hidradenocarcinoma,hidradenoma,hidradenoma papilliferum,hidrocystoma,high grade anal canal intraepithelial neoplasia,high grade anal intraepithelial neoplasia,high grade appendix mucinous adenocarcinoma,high grade appendix mucinous neoplasm,high grade astrocytic tumor,high grade astrocytoma with piloid features,high grade bladder urothelial carcinoma,high grade breast mucoepidermoid carcinoma,high grade burkitt-like lymphoma,high grade cervical glandular intraepithelial neoplasia,high grade cervical intraepithelial neoplasia,high grade cervical squamous intraepithelial neoplasia,high grade conjunctival squamous intraepithelial neoplasia,high grade corneal squamous intraepithelial neoplasia,high grade endometrial endometrioid adenocarcinoma,high grade esophageal glandular intraepithelial neoplasia,high grade esophageal squamous intraepithelial neoplasia,high grade gastric intraepithelial neoplasia,high grade glandular intraepithelial neoplasia,high grade intraepithelial neoplasia,high grade liver dysplastic nodule,high grade lymphoma,high grade malignant neoplasm,high grade malignant peripheral nerve sheath tumor,high grade pancreatic intraepithelial neoplasia,high grade paranasal sinus sarcoma,high grade penile intraepithelial neoplasia,high grade prostatic intraepithelial neoplasia,"high grade prostatic intraepithelial neoplasia, foamy variant","high grade prostatic intraepithelial neoplasia, inverted variant","high grade prostatic intraepithelial neoplasia, mucinous variant","high grade prostatic intraepithelial neoplasia, signet ring variant","high grade prostatic intraepithelial neoplasia, small cell neuroendocrine variant",high grade renal pelvis urothelial carcinoma,high grade salivary gland carcinoma,high grade salivary gland mucoepidermoid carcinoma,high grade squamous intraepithelial neoplasia,high grade surface osteosarcoma,high grade t-cell lymphoma,high grade ureter urothelial carcinoma,high grade urothelial carcinoma,high grade vaginal intraepithelial neoplasia,high grade vulvar squamous intraepithelial lesion,high risk colorectal gastrointestinal stromal tumor,high risk esophageal gastrointestinal stromal tumor,high risk gastric gastrointestinal stromal tumor,high risk gastrointestinal stromal tumor,high risk neuroblastoma,high risk small intestinal gastrointestinal stromal tumor,high-csd melanoma,high-grade biliary intraepithelial neoplasia,hilar cholangiocarcinoma,hindgut neuroendocrine tumor g1,histiocytic sarcoma,histiocytic and dendritic cell neoplasm,histiocytoma,hobnail hemangioma,hobnail variant thyroid gland papillary carcinoma,hodgkin lymphoma,hodgkin lymphoma during pregnancy,hodgkin lymphoma by clinical course,hodgkin lymphoma nodular lymphocyte-predominant,hodgkin-like adult t-cell leukemia/lymphoma,hodgkin-like post-transplant lymphoproliferative disorder,hormone receptor-negative breast carcinoma,hormone receptor-positive breast carcinoma,hormone-resistant breast carcinoma,hormone-resistant prostate carcinoma,human papillomavirus-independent cervical adenocarcinoma,human papillomavirus-independent cervical adenocarcinoma in situ,"human papillomavirus-independent cervical adenocarcinoma, clear cell-type","human papillomavirus-independent cervical adenocarcinoma, gastric-type",human papillomavirus-independent cervical squamous cell carcinoma,human papillomavirus-independent vaginal squamous cell carcinoma,human papillomavirus-independent vulvar squamous cell carcinoma,human papillomavirus-negative squamous cell carcinoma,human papillomavirus-related adenocarcinoma,human papillomavirus-related adenosquamous carcinoma,human papillomavirus-related anal squamous cell carcinoma,human papillomavirus-related carcinoma,human papillomavirus-related cervical adenocarcinoma,human papillomavirus-related cervical adenocarcinoma in situ,human papillomavirus-related cervical carcinoma,human papillomavirus-related cervical squamous cell carcinoma,human papillomavirus-related esophageal squamous cell carcinoma,human papillomavirus-related head and neck squamous cell carcinoma of unknown primary,human papillomavirus-related malignant neoplasm,human papillomavirus-related malignant neoplasm in aids patient,human papillomavirus-related mucosal head and neck squamous cell carcinoma,human papillomavirus-related penile intraepithelial neoplasia,human papillomavirus-related squamous cell carcinoma,human papillomavirus-related squamous cell carcinoma of the penis,human papillomavirus-related urethral squamous cell carcinoma,human papillomavirus-related vaginal adenocarcinoma,human papillomavirus-related vaginal squamous cell carcinoma,human papillomavirus-related verrucous carcinoma,human papillomavirus-related vulvar squamous cell carcinoma,hybrid nerve sheath tumor,hybrid odontogenic fibroma,hybrid salivary gland carcinoma,hybrid salivary gland tumor,hydroa vacciniforme-like lymphoproliferative disorder,hyperdiploid b acute lymphoblastic leukemia,hypermutated colorectal carcinoma,hypocellular myelodysplastic syndrome,hypodiploid b acute lymphoblastic leukemia,hypoglossal nerve neoplasm,hypopharyngeal carcinoma,hypopharyngeal neoplasm,hypopharyngeal squamous cell carcinoma,hypothalamic gangliocytoma,hypothalamic neoplasm,hypothalamic-chiasmatic pilomyxoid astrocytoma,iatrogenic kaposi sarcoma,igm monoclonal gammopathy of undetermined significance,ileal neoplasm,ileal neuroendocrine tumor,ileal neuroendocrine tumor g1,ileal neuroendocrine tumor g2,ileal neuroendocrine tumor g3,immature extragonadal teratoma,immature gastric teratoma,immature granulocytic sarcoma,immature ovarian teratoma,immature pit1 lineage pituitary neuroendocrine tumor,immature teratoma,immature testicular teratoma,immunoblastic lymphoma post-transplant lymphoproliferative disorder,immunodeficiency-related burkitt lymphoma,immunodeficiency-related central nervous system lymphoma,immunodeficiency-related malignant neoplasm,immunodeficiency-related neoplasm,in situ follicular neoplasia,in situ mantle cell neoplasia,incidental gallbladder carcinoma,inclusion body fibromatosis,indeterminate dendritic cell tumor,indolent systemic mastocytosis,indolent t-cell lymphoproliferative disorder of the gastrointestinal tract,indolent lymphoma,infant acute biphenotypic leukemia,infant acute lymphoblastic leukemia,infant acute lymphoblastic leukemia with mll rearrangement,infant acute lymphoblastic leukemia without mll gene rearrangement,infant acute undifferentiated leukemia,infant leukemia,infant t acute lymphoblastic leukemia,infant-type hemispheric glioma,"infant-type hemispheric glioma, alk-altered","infant-type hemispheric glioma, met-altered","infant-type hemispheric glioma, ntrk-altered","infant-type hemispheric glioma, ros1-altered",infantile fibrosarcoma,infantile hemangioma,infantile hemangiopericytoma,infantile myofibroma,infantile myofibromatosis 1,infantile myofibromatosis 2,infection-related malignant neoplasm,infection-related neoplasm,inferior vena cava leiomyosarcoma,infiltrating angiolipoma,infiltrating bladder carcinoma,infiltrating bladder lymphoepithelioma-like carcinoma,infiltrating bladder mixed carcinoma,infiltrating bladder urothelial carcinoma,infiltrating bladder urothelial carcinoma associated with urethral carcinoma,infiltrating bladder urothelial carcinoma with giant cells,infiltrating bladder urothelial carcinoma with glandular differentiation,infiltrating bladder urothelial carcinoma with squamous differentiation,infiltrating bladder urothelial carcinoma with trophoblastic differentiation,"infiltrating bladder urothelial carcinoma, clear cell variant","infiltrating bladder urothelial carcinoma, lipid-rich variant","infiltrating bladder urothelial carcinoma, lymphoma-like variant","infiltrating bladder urothelial carcinoma, microcystic variant","infiltrating bladder urothelial carcinoma, micropapillary variant","infiltrating bladder urothelial carcinoma, nested variant","infiltrating bladder urothelial carcinoma, plasmacytoid variant","infiltrating bladder urothelial carcinoma, sarcomatoid variant","infiltrating bladder urothelial carcinoma, sarcomatoid variant with heterologous elements","infiltrating bladder urothelial carcinoma, sarcomatoid variant without heterologous elements",infiltrating cervical carcinoma,infiltrating intramuscular lipoma,infiltrating lipoma,infiltrating papillary adenocarcinoma,"infiltrating renal pelvis urothelial carcinoma, sarcomatoid variant",infiltrating renal pelvis and ureter urothelial carcinoma,infiltrating ureter urothelial carcinoma with glandular differentiation,infiltrating ureter urothelial carcinoma with mixed differentiation,infiltrating ureter urothelial carcinoma with squamous differentiation,infiltrating urothelial carcinoma,"infiltrating urothelial carcinoma, sarcomatoid variant",inflamed juvenile conjunctival nevus,inflammatory atypical lipomatous tumor/well differentiated liposarcoma,inflammatory bowel disease-associated colorectal adenocarcinoma,inflammatory fibroid polyp,inflammatory hepatocellular adenoma,inflammatory leiomyosarcoma,inflammatory malignant fibrous histiocytoma nci grade 2,inflammatory malignant fibrous histiocytoma nci grade 3,inflammatory myofibroblastic tumor,infratentorial glioblastoma,infratentorial neoplasm,infrequent neoplasm,inner ear lipoma,inner ear neoplasm,interdigitating dendritic cell sarcoma,intermediate (locally aggressive) blood vessel neoplasm,intermediate (rarely metastasizing) blood vessel neoplasm,intermediate atypical prostate carcinoma,intermediate blood vessel neoplasm,intermediate bone neoplasm,intermediate chondrogenic neoplasm,intermediate fibroblastic neoplasm,intermediate fibrohistiocytic neoplasm,intermediate grade lung neuroendocrine neoplasm,intermediate grade lymphoma,intermediate grade malignant neoplasm,intermediate grade salivary gland mucoepidermoid carcinoma,intermediate immature teratoma,intermediate lipomatous neoplasm,intermediate osteoclastic giant cell-rich tumor of bone,intermediate osteogenic neoplasm,intermediate rhabdomyoma,intermediate risk colorectal gastrointestinal stromal tumor,intermediate risk esophageal gastrointestinal stromal tumor,intermediate risk gastric gastrointestinal stromal tumor,intermediate risk gastrointestinal stromal tumor,intermediate risk small intestinal gastrointestinal stromal tumor,intermediate sinonasal soft tissue neoplasm,intermediate soft tissue neoplasm,intermediate soft tissue tumor of uncertain differentiation,intermediate vascular neoplasm,internal auditory canal meningioma,intestinal composite gangliocytoma/neuroma and neuroendocrine tumor,intestinal follicular lymphoma,intestinal intraepithelial neoplasia,intestinal neoplasm,intestinal neuroendocrine carcinoma,intestinal neuroendocrine neoplasm,intestinal neuroendocrine tumor,intestinal neuroendocrine tumor g1,intestinal neuroendocrine tumor g2,intestinal neuroendocrine tumor g3,intestinal soft tissue neoplasm,intestinal t-cell lymphoma,intestinal-type adenocarcinoma,intimal sarcoma,intra-abdominal hemangioma,intra-abdominal lymphangioma,intra-abdominal paraganglioma,intracerebral cystic meningioma,intracranial cavernous hemangioma,"intracranial embryonal tumor, not otherwise specified",intracranial fibrous histiocytoma,intracranial germinoma,intracranial hemangioma,intracranial lipoma,intracranial melanoma,intracranial meningioma,"intracranial mesenchymal tumor, fet-creb fusion-positive",intracranial myeloid sarcoma,intracranial neoplasm,intraductal papilloma,intraductal papillomatosis,intraductal prostate carcinoma,intradural extramedullary cauda equina astrocytoma,intradural extramedullary spinal canal neoplasm,intraepidermal epithelioma of jadassohn,intraepithelial neoplasia,intraepithelial neoplasia in barrett esophagus,intrahepatic bile duct adenoma,intrahepatic bile duct biliary intraepithelial neoplasia,intrahepatic bile duct intraductal papillary neoplasm,intrahepatic bile duct intraductal papillary neoplasm with an associated invasive carcinoma,intrahepatic bile duct microcystic adenoma,intrahepatic bile duct mucinous cystic neoplasm,intrahepatic bile duct mucinous cystic neoplasm with an associated invasive carcinoma,intrahepatic cholangiocarcinoma,intramedullary spinal cord teratoma,intramucosal adenocarcinoma,intramuscular hemangioma,intramuscular lipoma,intramuscular myxoma,intraneural perineurioma,intraocular malignant peripheral nerve sheath tumor,intraocular retinoblastoma,intraocular schwannoma,intraorbital meningioma,intraosseous spindle cell rhabdomyosarcoma with tfcp2/ncoa2 rearrangements,intrapulmonary thymoma,intrasellar meningioma,intraspinal neoplasm,intrathoracic paravertebral paraganglioma,intrathyroid thymic carcinoma,intrathyroidal thymoma,intratubular large cell hyalinizing sertoli cell neoplasia,intratubular non-seminoma,intratubular seminoma,intravascular angioleiomyoma,intravascular nodular fasciitis,intravenous leiomyomatosis,intraventricular brain neoplasm,intraventricular meningioma,invasive adenocarcinoma in adenomatous polyp,invasive breast apocrine carcinoma,invasive breast carcinoma,invasive breast carcinoma by histologic grade,invasive breast carcinoma of no special type,invasive breast carcinoma of no special type with predominant intraductal component,invasive breast cribriform carcinoma,invasive breast ductal carcinoma and invasive lobular carcinoma,invasive breast ductal carcinoma and lobular carcinoma,invasive breast ductal carcinoma and lobular carcinoma in situ,invasive breast lobular carcinoma,invasive breast lobular carcinoma with extracellular mucin,invasive breast lobular carcinoma with predominant in situ component,"invasive breast lobular carcinoma, alveolar variant","invasive breast lobular carcinoma, pleomorphic variant","invasive breast lobular carcinoma, signet ring variant","invasive breast lobular carcinoma, solid variant","invasive breast lobular carcinoma, tubulolobular variant",invasive breast micropapillary carcinoma,invasive breast papillary carcinoma,invasive breast solid papillary carcinoma,invasive carcinoma,invasive cutaneous melanoma,invasive encapsulated follicular variant thyroid gland papillary carcinoma,invasive female breast carcinoma,invasive follicular variant thyroid gland papillary carcinoma,invasive hydatidiform mole,invasive lung mucinous adenocarcinoma,invasive lung non-mucinous adenocarcinoma,invasive male breast carcinoma,invasive malignant neoplasm,invasive malignant thymoma,invasive pancreatic micropapillary adenocarcinoma,invasive prostate carcinoma,invasive thymoma,inverted follicular keratosis,inverted papilloma,inverted squamous cell papilloma,inverted transitional cell papilloma,inverted urothelial papilloma,ionizing radiation-related malignant neoplasm,iris epithelioid cell melanoma,iris intermediate cell type melanoma,iris melanoma,iris mixed cell melanoma,iris neoplasm,iris nevus,iris spindle cell melanoma,islet cell adenoma,ivory exostosis,jejunal adenocarcinoma,jejunal carcinoma,jejunal melanoma,jejunal neoplasm,jejunal neuroendocrine tumor,jejunal neuroendocrine tumor g1,jejunal neuroendocrine tumor g2,jejunal neuroendocrine tumor g3,jejunal somatostatin-producing neuroendocrine tumor,jugular foramen meningioma,jugular foramen neoplasm,jugular foramen schwannoma,jugulotympanic paraganglioma,junctional nevus,juvenile breast papillomatosis,juvenile myelomonocytic leukemia,juvenile pilocytic astrocytoma,juvenile type bilateral ovarian granulosa cell tumor,juvenile type ovarian granulosa cell tumor,juvenile type testicular granulosa cell tumor,juvenile xanthogranuloma,juxta-articular myxoma,juxtaglomerular cell tumor,kadish stage a olfactory neuroblastoma,kadish stage b olfactory neuroblastoma,kadish stage c olfactory neuroblastoma,kaposi sarcoma,kaposi sarcoma nci grade 2,kaposi sarcoma nci grade 3,kaposi sarcoma related to immunosuppressive treatment,kaposiform hemangioendothelioma,keratinizing primary intraosseous squamous cell carcinoma-solid type,keratinizing squamous cell carcinoma,keratoacanthoma,kidney adenoma,kidney angiomyolipoma,kidney angiosarcoma,kidney burkitt lymphoma,kidney carcinoma,kidney diffuse large b-cell lymphoma,kidney epithelioid angiomyolipoma,kidney ewing sarcoma,kidney extraskeletal osteosarcoma,kidney fibrosarcoma,kidney germ cell tumor,kidney hemangioma,kidney hemangiopericytoma,kidney large cell neuroendocrine carcinoma,kidney leiomyoma,kidney leiomyosarcoma,kidney lipoma,kidney liposarcoma,kidney lymphangioma,kidney lymphoma,kidney medullary carcinoma,kidney mixed epithelial and stromal tumor,kidney mixed epithelial and stromal tumor family,kidney neoplasm,kidney neuroendocrine carcinoma,kidney neuroendocrine neoplasm,kidney neuroendocrine tumor,kidney oncocytoma,kidney paraganglioma,kidney rhabdomyosarcoma,kidney sarcoma,kidney schwannoma,kidney small cell neuroendocrine carcinoma,kidney solitary fibrous tumor,kidney synovial sarcoma,kidney wilms tumor,kidney and ureter neoplasm,krukenberg tumor,l-cell glucagon-like peptide-producing neuroendocrine tumor,l1 acute lymphoblastic leukemia,l2 acute lymphoblastic leukemia,lh-producing pituitary neuroendocrine tumor,lztr1 schwannomatosis 2,labia majora carcinoma,labia minora carcinoma,lacrimal drainage system adenocarcinoma,lacrimal drainage system adenoid cystic carcinoma,lacrimal drainage system carcinoma,lacrimal drainage system diffuse large b-cell lymphoma,lacrimal drainage system exophytic papilloma,lacrimal drainage system inverted papilloma,lacrimal drainage system lymphoepithelial carcinoma,lacrimal drainage system melanoma,lacrimal drainage system mucoepidermoid carcinoma,lacrimal drainage system mucosa-associated lymphoid tissue lymphoma,lacrimal drainage system neoplasm,lacrimal drainage system non-hodgkin lymphoma,lacrimal drainage system non-keratinizing squamous cell carcinoma,lacrimal drainage system squamous cell carcinoma,lacrimal gland acinic cell carcinoma,lacrimal gland adenocarcinoma,lacrimal gland adenoid cystic carcinoma,lacrimal gland carcinoma,lacrimal gland carcinoma ex pleomorphic adenoma,lacrimal gland carcinosarcoma,lacrimal gland diffuse large b-cell lymphoma,lacrimal gland epithelial-myoepithelial carcinoma,lacrimal gland follicular lymphoma,lacrimal gland mucoepidermoid carcinoma,lacrimal gland mucosa-associated lymphoid tissue lymphoma,lacrimal gland myoepithelial carcinoma,lacrimal gland myoepithelioma,lacrimal gland neoplasm,lacrimal gland non-hodgkin lymphoma,lacrimal gland oncocytic adenocarcinoma,lacrimal gland oncocytoma,lacrimal gland pleomorphic adenoma,lacrimal gland warthin tumor,lacrimal system carcinoma,lacrimal system diffuse large b-cell lymphoma,lacrimal system mucosa-associated lymphoid tissue lymphoma,lacrimal system neoplasm,lacrimal system non-hodgkin lymphoma,lactating adenoma,lactotroph pituitary neuroendocrine tumor,langerhans cell histiocytosis,"langerhans cell histiocytosis, disseminated","langerhans cell histiocytosis, monostotic","langerhans cell histiocytosis, polyostotic",langerhans cell sarcoma,large cell acanthoma,large cell carcinoma,large cell medulloblastoma,large cell neuroendocrine carcinoma,large cell/anaplastic medulloblastoma,large duct intrahepatic cholangiocarcinoma,laryngeal acantholytic squamous cell carcinoma,laryngeal adenoid cystic carcinoma,laryngeal adenosquamous carcinoma,laryngeal basaloid carcinoma,laryngeal carcinoid tumor,laryngeal carcinoma,laryngeal chondroma,laryngeal chondrosarcoma,laryngeal giant cell carcinoma,laryngeal granular cell tumor,laryngeal inflammatory myofibroblastic tumor,laryngeal large cell neuroendocrine carcinoma,laryngeal leiomyoma,laryngeal leiomyosarcoma,laryngeal liposarcoma,laryngeal lymphoepithelial carcinoma,laryngeal mucoepidermoid carcinoma,laryngeal neoplasm,laryngeal neuroendocrine carcinoma,laryngeal neuroendocrine neoplasm,laryngeal neuroendocrine tumor,laryngeal neuroendocrine tumor g1,laryngeal neuroendocrine tumor g2,laryngeal papillary squamous cell carcinoma,laryngeal papillomatosis,laryngeal paraganglioma,laryngeal pleomorphic adenoma,laryngeal sarcoma,laryngeal small cell neuroendocrine carcinoma,laryngeal soft tissue neoplasm,laryngeal soft tissue sarcoma,laryngeal squamous cell carcinoma,"laryngeal squamous cell carcinoma, spindle cell variant",laryngeal squamous cell papilloma,laryngeal undifferentiated carcinoma,laryngeal verrucous carcinoma,lateral ventricle meningioma,leiomyoma,leiomyomatosis,leiomyosarcoma,leiomyosarcoma nci grade 2,leiomyosarcoma nci grade 3,leiomyosarcoma of deep soft tissue,leiomyosarcoma of vessels,lentigo maligna melanoma,lepidic adenocarcinoma,leptomeningeal neoplasm,leptomeningeal sarcoma,letterer-siwe disease,leukemia,leukemia (antiquated),leukemia cutis,leukemic nonnodal mantle cell lymphoma,leukemic phase of lymphoma,lichen planus-like keratosis,light chain deposition disease,light and heavy chain deposition disease,limited stage lung small cell carcinoma,lip basal cell carcinoma,lip carcinoma,lip neoplasm,lip squamous cell carcinoma,lip and oral cavity carcinoma,lip and oral cavity squamous cell carcinoma,lipid-rich carcinoma,lipidized glioblastoma,lipoadenoma,lipoblastoma,lipofibromatosis,lipoma,lipoma-like atypical lipomatous tumor/well differentiated liposarcoma,lipomatosis,lipomatosis of nerve,lipomatous hemangiopericytoma,lipomatous neoplasm,liposarcoma,liquid tumor,liver adenosquamous carcinoma,liver angiomyolipoma,liver angiosarcoma,liver carcinosarcoma,liver cavernous hemangioma,liver diffuse large b-cell lymphoma,liver dysplastic nodule,liver embryonal sarcoma,liver epithelioid hemangioendothelioma,liver extraskeletal osteosarcoma,liver fibrosarcoma,liver germ cell tumor,liver hemangioma,liver infantile hemangioma,liver inflammatory myofibroblastic tumor,liver kaposi sarcoma,liver large cell neuroendocrine carcinoma,liver leiomyoma,liver leiomyosarcoma,liver lipoma,liver lymphangioma,liver lymphangiomatosis,liver lymphoma,liver mixed adenoneuroendocrine carcinoma,liver mucosa-associated lymphoid tissue lymphoma,liver neuroendocrine carcinoma,liver neuroendocrine neoplasm,liver neuroendocrine tumor,liver neuroendocrine tumor g1,liver neuroendocrine tumor g2,liver neuroendocrine tumor g3,liver non-hodgkin lymphoma,liver plasmacytoma,liver rhabdomyosarcoma,liver sarcoma,liver small cell neuroendocrine carcinoma,liver solitary fibrous tumor,liver synovial sarcoma,liver teratoma,liver undifferentiated carcinoma,liver yolk sac tumor,liver and intrahepatic bile duct benign non-epithelial neoplasm,liver and intrahepatic bile duct carcinoma,liver and intrahepatic bile duct epithelial neoplasm,liver and intrahepatic bile duct malignant non-epithelial neoplasm,liver and intrahepatic bile duct neoplasm,liver and intrahepatic bile duct non-epithelial neoplasm,liver and intrahepatic bile duct soft tissue neoplasm,lobular capillary hemangioma,lobular capillary hemangioma of skin and subcutaneous tissue,local recurrence following an in situ lesion of the same site,local recurrence of an invasive tumor,local recurrence of malignant melanoma of skin,local recurrence of malignant tumor of bone,local recurrence of malignant tumor of breast,local recurrence of malignant tumor of buccal cavity,local recurrence of malignant tumor of cervix,local recurrence of malignant tumor of colon,local recurrence of malignant tumor of esophagus,local recurrence of malignant tumor of gallbladder,local recurrence of malignant tumor of kidney,local recurrence of malignant tumor of lung,local recurrence of malignant tumor of pancreas,local recurrence of malignant tumor of prostate,local recurrence of malignant tumor of rectum,local recurrence of malignant tumor of skin,local recurrence of malignant tumor of soft tissue,local recurrence of malignant tumor of stomach,local recurrence of malignant tumor of thyroid gland,local recurrence of malignant tumor of tongue,local recurrence of malignant tumor of urinary bladder,localized adult undifferentiated high grade pleomorphic sarcoma of bone,localized alveolar soft part sarcoma,localized anaplastic large cell lymphoma,localized angiosarcoma,localized askin tumor,localized bone ewing sarcoma,localized brain neoplasm,localized breast carcinoma,localized carcinoma,localized cerebral neoplasm,localized childhood rhabdomyosarcoma,localized childhood soft tissue sarcoma,localized childhood undifferentiated high grade pleomorphic sarcoma of bone,localized chondrosarcoma,localized digestive system neuroendocrine tumor g1,localized epithelioid sarcoma,localized esophageal carcinoma,localized ewing sarcoma,localized ewing sarcoma/peripheral primitive neuroectodermal tumor,localized extrahepatic bile duct carcinoma,localized extraskeletal ewing sarcoma,localized extraskeletal osteosarcoma,localized fibrosarcoma,localized gallbladder carcinoma,localized gastric carcinoma,localized gastroesophageal junction adenocarcinoma,localized head and neck carcinoma,localized leiomyosarcoma,localized liposarcoma,localized lung carcinoma,localized lymphoma,localized malignant brain neoplasm,localized malignant gallbladder neoplasm,localized malignant mesothelioma,localized malignant neoplasm,localized malignant pancreatic neoplasm,localized muscle invasive bladder urothelial carcinoma,localized neoplasm,localized osteosarcoma,localized pancreatic adenocarcinoma,localized parathyroid gland carcinoma,localized peripheral primitive neuroectodermal tumor,localized peripheral primitive neuroectodermal tumor of bone,localized pleural malignant mesothelioma,localized primitive neuroectodermal tumor,localized prostate carcinoma,localized renal pelvis and ureter urothelial carcinoma,localized resectable adult hepatocellular carcinoma,localized resectable adult liver carcinoma,localized resectable neuroblastoma,localized sarcoma,localized synovial sarcoma,localized unresectable adult hepatocellular carcinoma,localized unresectable adult liver carcinoma,localized unresectable neuroblastoma,locally advanced adenocarcinoma,locally advanced adenoid cystic carcinoma,locally advanced adrenal cortical carcinoma,locally advanced adrenal gland pheochromocytoma,locally advanced alveolar soft part sarcoma,locally advanced ampulla of vater carcinoma,locally advanced anal carcinoma,locally advanced angiosarcoma,locally advanced basal cell carcinoma,locally advanced bile duct carcinoma,locally advanced biliary tract carcinoma,locally advanced bladder carcinoma,locally advanced bladder urothelial carcinoma,locally advanced bone sarcoma,locally advanced breast adenocarcinoma,locally advanced breast carcinoma,locally advanced carcinoid tumor,locally advanced carcinoma,locally advanced cervical adenocarcinoma,locally advanced cervical carcinoma,locally advanced cervical squamous cell carcinoma,locally advanced cholangiocarcinoma,locally advanced chondrosarcoma,locally advanced chordoma,locally advanced chromophobe renal cell carcinoma,locally advanced clear cell renal cell carcinoma,locally advanced colon carcinoma,locally advanced colorectal carcinoma,locally advanced cutaneous melanoma,locally advanced cutaneous squamous cell carcinoma of the head and neck,locally advanced dedifferentiated liposarcoma,locally advanced desmoplastic small round cell tumor,locally advanced digestive system carcinoma,locally advanced digestive system neuroendocrine carcinoma,locally advanced digestive system neuroendocrine neoplasm,locally advanced digestive system neuroendocrine tumor g1,locally advanced digestive system neuroendocrine tumor g2,locally advanced distal bile duct carcinoma,locally advanced endometrial adenocarcinoma,locally advanced endometrial carcinoma,locally advanced endometrial endometrioid adenocarcinoma,locally advanced endometrioid adenocarcinoma,locally advanced epithelioid hemangioendothelioma,locally advanced epithelioid sarcoma,locally advanced esophageal adenocarcinoma,locally advanced esophageal carcinoma,locally advanced esophageal squamous cell carcinoma,locally advanced ewing sarcoma,locally advanced extrahepatic bile duct carcinoma,locally advanced fallopian tube carcinoma,locally advanced fibrosarcoma,locally advanced gallbladder carcinoma,locally advanced gastric adenocarcinoma,locally advanced gastric carcinoma,locally advanced gastroesophageal junction adenocarcinoma,locally advanced gastrointestinal stromal tumor,locally advanced genitourinary system carcinoma,locally advanced glioblastoma,locally advanced glioma,locally advanced her2-negative breast carcinoma,locally advanced her2-positive breast carcinoma,locally advanced head and neck carcinoma,locally advanced head and neck squamous cell carcinoma,locally advanced hepatocellular carcinoma,locally advanced high grade sarcoma,locally advanced hormone receptor-positive breast carcinoma,locally advanced hypopharyngeal carcinoma,locally advanced hypopharyngeal squamous cell carcinoma,locally advanced intrahepatic cholangiocarcinoma,locally advanced kidney carcinoma,locally advanced large cell neuroendocrine carcinoma,locally advanced laryngeal carcinoma,locally advanced laryngeal squamous cell carcinoma,locally advanced leiomyosarcoma,locally advanced lip and oral cavity carcinoma,locally advanced liposarcoma,locally advanced liver carcinoma,locally advanced lung adenocarcinoma,locally advanced lung adenosquamous carcinoma,locally advanced lung carcinoma,locally advanced lung large cell neuroendocrine carcinoma,locally advanced lung neuroendocrine neoplasm,locally advanced lung non-small cell carcinoma,locally advanced lung non-small cell squamous carcinoma,locally advanced lung non-squamous non-small cell carcinoma,locally advanced lung small cell carcinoma,locally advanced lymphoma,locally advanced malignant digestive system neoplasm,locally advanced malignant female reproductive system neoplasm,locally advanced malignant glomus tumor,locally advanced malignant head and neck neoplasm,locally advanced malignant mesothelioma,locally advanced malignant neoplasm,locally advanced malignant peripheral nerve sheath tumor,locally advanced malignant skin neoplasm,locally advanced malignant solid neoplasm,locally advanced melanoma,locally advanced merkel cell carcinoma,locally advanced microsatellite stable colon carcinoma,locally advanced microsatellite stable colorectal carcinoma,locally advanced midgut neuroendocrine tumor,locally advanced myxofibrosarcoma,locally advanced nasal cavity squamous cell carcinoma,locally advanced nasopharyngeal squamous cell carcinoma,locally advanced neuroendocrine carcinoma,locally advanced neuroendocrine neoplasm,locally advanced neuroendocrine tumor,locally advanced non-cutaneous melanoma,locally advanced ocular melanoma,locally advanced oral cavity carcinoma,locally advanced oral cavity squamous cell carcinoma,locally advanced oropharyngeal carcinoma,locally advanced oropharyngeal squamous cell carcinoma,locally advanced osteosarcoma,locally advanced ovarian carcinoma,locally advanced ovarian serous adenocarcinoma,locally advanced ovarian serous cystadenocarcinoma,locally advanced pancreatic adenocarcinoma,locally advanced pancreatic carcinoma,locally advanced pancreatic ductal adenocarcinoma,locally advanced pancreatic neuroendocrine carcinoma,locally advanced pancreatic neuroendocrine tumor,locally advanced pancreatobiliary carcinoma,locally advanced papillary renal cell carcinoma,locally advanced paraganglioma,locally advanced paranasal sinus carcinoma,locally advanced paranasal sinus squamous cell carcinoma,locally advanced parathyroid gland carcinoma,locally advanced penile carcinoma,locally advanced pharyngeal carcinoma,locally advanced pituitary neuroendocrine tumor,locally advanced pleural malignant mesothelioma,locally advanced primary malignant brain neoplasm,locally advanced primary malignant central nervous system neoplasm,locally advanced primary peritoneal carcinoma,locally advanced prostate adenocarcinoma,locally advanced prostate carcinoma,locally advanced prostate neuroendocrine carcinoma,locally advanced rectal adenocarcinoma,locally advanced rectal carcinoma,locally advanced rectal squamous cell carcinoma,locally advanced renal cell carcinoma,locally advanced renal pelvis carcinoma,locally advanced renal pelvis urothelial carcinoma,locally advanced renal pelvis and ureter urothelial carcinoma,locally advanced rhabdomyosarcoma,locally advanced salivary gland carcinoma,locally advanced sarcoma,locally advanced sarcomatoid renal cell carcinoma,locally advanced sinonasal squamous cell carcinoma,locally advanced skin squamous cell carcinoma,locally advanced small cell neuroendocrine carcinoma,locally advanced small intestinal adenocarcinoma,locally advanced small intestinal carcinoma,locally advanced soft tissue leiomyosarcoma,locally advanced soft tissue sarcoma,locally advanced squamous cell carcinoma,locally advanced squamous cell carcinoma of unknown primary,locally advanced synovial sarcoma,locally advanced thymic carcinoma,locally advanced thyroid gland anaplastic carcinoma,locally advanced thyroid gland carcinoma,locally advanced thyroid gland medullary carcinoma,locally advanced thyroid gland oncocytic carcinoma,locally advanced transitional cell carcinoma,locally advanced triple-negative breast carcinoma,locally advanced unclassified renal cell carcinoma,locally advanced undifferentiated pleomorphic sarcoma,locally advanced unresectable basal cell carcinoma,locally advanced unresectable bone sarcoma,locally advanced unresectable breast carcinoma,locally advanced unresectable carcinoma,locally advanced unresectable cervical adenocarcinoma,locally advanced unresectable cervical carcinoma,locally advanced unresectable cholangiocarcinoma,locally advanced unresectable colon adenocarcinoma,locally advanced unresectable colorectal adenocarcinoma,locally advanced unresectable digestive system neuroendocrine neoplasm,locally advanced unresectable endometrial carcinoma,locally advanced unresectable esophageal adenocarcinoma,locally advanced unresectable fallopian tube carcinoma,locally advanced unresectable gallbladder carcinoma,locally advanced unresectable gastric adenocarcinoma,locally advanced unresectable gastroesophageal junction adenocarcinoma,locally advanced unresectable her2-negative breast carcinoma,locally advanced unresectable her2-positive breast carcinoma,locally advanced unresectable hormone receptor-positive breast carcinoma,locally advanced unresectable lung non-small cell squamous carcinoma,locally advanced unresectable malignant neoplasm,locally advanced unresectable malignant pecoma,locally advanced unresectable ovarian high grade serous adenocarcinoma,locally advanced unresectable pancreatic adenocarcinoma,locally advanced unresectable primary central chondrosarcoma,locally advanced unresectable primary peritoneal carcinoma,locally advanced unresectable prostate adenocarcinoma,locally advanced unresectable prostate carcinoma,locally advanced unresectable rectal adenocarcinoma,locally advanced unresectable renal cell carcinoma,locally advanced unresectable sarcoma,locally advanced unresectable soft tissue sarcoma,locally advanced unresectable triple-negative breast carcinoma,locally advanced ureter urothelial carcinoma,locally advanced urethral urothelial carcinoma,locally advanced urothelial carcinoma,locally advanced uterine corpus leiomyosarcoma,locally advanced vaginal carcinoma,locally advanced vulvar carcinoma,locally invasive desmoid-type fibromatosis,locally recurrent anal canal squamous cell carcinoma,locally recurrent chordoma,locally recurrent head and neck squamous cell carcinoma,locally recurrent malignant neoplasm,locally recurrent merkel cell carcinoma,locally recurrent skin squamous cell carcinoma,locally recurrent uterine corpus leiomyosarcoma,low grade anal canal intraepithelial neoplasia,low grade anal intraepithelial neoplasia,low grade appendix mucinous neoplasm,low grade astrocytoma,low grade biliary intraepithelial neoplasia,low grade breast adenosquamous carcinoma,low grade breast mucoepidermoid carcinoma,low grade broad ligament serous adenocarcinoma,low grade central osteosarcoma,low grade cervical glandular intraepithelial neoplasia,low grade cervical intraepithelial neoplasia,low grade cervical squamous intraepithelial neoplasia,low grade conjunctival squamous intraepithelial neoplasia,low grade corneal squamous intraepithelial neoplasia,low grade endometrial endometrioid adenocarcinoma,low grade endometrioid stromal sarcoma,low grade esophageal glandular intraepithelial neoplasia,low grade esophageal squamous intraepithelial neoplasia,low grade fallopian tube serous adenocarcinoma,low grade fibromyxoid sarcoma,low grade fibromyxoid sarcoma with giant collagen rosettes,low grade gastric intraepithelial neoplasia,low grade glandular intraepithelial neoplasia,low grade glioma,low grade intraepithelial neoplasia,low grade liver dysplastic nodule,low grade lung neuroendocrine neoplasm,low grade lymphoma,low grade malignant neoplasm,low grade malignant peripheral nerve sheath tumor,low grade myofibroblastic sarcoma,low grade pancreatic intraepithelial neoplasia,low grade papillary schneiderian carcinoma,low grade paranasal sinus sarcoma,low grade penile intraepithelial neoplasia,low grade prostatic intraepithelial neoplasia,low grade salivary gland carcinoma,low grade salivary gland mucoepidermoid carcinoma,low grade squamous intraepithelial neoplasia,low grade t-cell lymphoma,low grade vaginal intraepithelial neoplasia,low grade vulvar squamous intraepithelial lesion,low risk colorectal gastrointestinal stromal tumor,low risk esophageal gastrointestinal stromal tumor,low risk gastric gastrointestinal stromal tumor,low risk gastrointestinal stromal tumor,low risk small intestinal gastrointestinal stromal tumor,low risk thyroid gland neoplasm,low-csd melanoma,lower alveolar ridge squamous cell carcinoma,lower clivus meningioma,lower gingival carcinoma,lower gingival squamous cell carcinoma,lower gingival verrucous carcinoma,lumbar intraspinal meningioma,lumbar plexus neoplasm,lumbar spine neoplasm,lumbosacral lipoma,lumbosacral spine neoplasm,luminal a breast carcinoma,luminal a prostate carcinoma,luminal b breast carcinoma,luminal b prostate carcinoma,lung acinar adenocarcinoma,lung adenocarcinoma,lung adenocarcinoma in situ,lung adenocarcinoma with mixed bronchioloalveolar and invasive components,"lung adenocarcinoma, mixed subtype",lung adenofibroma,lung adenoid cystic carcinoma,lung adenoma,lung adenosquamous carcinoma,lung alveolar soft part sarcoma,lung anaplastic large cell lymphoma,lung atypical carcinoid tumor,lung basaloid large cell carcinoma,lung basaloid squamous cell  carcinoma,lung biphasic synovial sarcoma,lung carcinoid tumor,lung carcinoma,lung carcinoma metastatic in the bone,lung carcinoma metastatic in the brain,lung carcinoma metastatic in the central nervous system,lung carcinoma metastatic in the liver,lung carcinosarcoma,lung chondroma,lung clear cell adenocarcinoma,lung clear cell tumor,lung colloid adenocarcinoma,lung diffuse large b-cell lymphoma,lung enteric adenocarcinoma,lung epithelial-myoepithelial carcinoma,lung epithelioid hemangioendothelioma,lung fetal adenocarcinoma,lung fibroma,lung follicular lymphoma,lung germ cell tumor,lung giant cell carcinoma,lung hilum carcinoma,lung hilum neoplasm,lung hodgkin lymphoma,lung hyalinizing clear cell carcinoma,lung inflammatory myofibroblastic tumor,lung intravascular large b-cell lymphoma,lung kaposi sarcoma,lung keratinizing squamous cell carcinoma,lung large cell carcinoma,lung large cell carcinoma with rhabdoid phenotype,"lung large cell carcinoma, clear cell variant",lung large cell neuroendocrine carcinoma,lung leiomyoma,lung leiomyosarcoma,lung lymphangioleiomyomatosis,lung lymphoepithelial carcinoma,lung lymphoma,lung malignant pecoma,lung mature b-cell neoplasm,lung melanoma,lung meningioma,lung micropapillary adenocarcinoma,lung monophasic synovial sarcoma,lung mucinous adenocarcinoma in situ,lung mucinous cystadenoma,lung mucoepidermoid carcinoma,lung mucosa-associated lymphoid tissue lymphoma,lung mucous gland adenoma,lung myoepithelial carcinoma,lung myoepithelial tumor,lung myoepithelioma,lung myolipoma,lung neoplasm,lung neuroendocrine carcinoma,lung neuroendocrine neoplasm,lung non-hodgkin lymphoma,lung non-keratinizing squamous cell carcinoma,lung non-mucinous adenocarcinoma in situ,lung non-small cell carcinoma,lung non-small cell squamous carcinoma,lung osteosarcoma,lung pecoma,lung papillary adenocarcinoma,lung papillary adenoma,lung plasmacytoma,lung pleomorphic adenoma,lung pleomorphic carcinoma,lung rhabdomyosarcoma,lung sarcoma,lung sarcomatoid carcinoma,lung secretory carcinoma,lung signet ring cell carcinoma,lung small cell carcinoma,lung soft tissue neoplasm,lung spindle cell carcinoma,lung squamous cell carcinoma,lung squamous cell carcinoma in situ,"lung squamous cell carcinoma, clear cell variant","lung squamous cell carcinoma, papillary variant","lung squamous cell carcinoma, small cell variant",lung synovial sarcoma,lung teratoma,lung typical carcinoid tumor,lymph node neoplasm,lymphadenopathic kaposi sarcoma,lymphangioleiomyoma,lymphangioleiomyomatosis,lymphangioma,lymphangioma circumscriptum,lymphangiomatosis,lymphangiosarcoma,lymphangitic carcinomatosis,lymphatic vessel neoplasm,lymphoblastic lymphoma,lymphocyte-depleted classic hodgkin lymphoma,lymphocyte-rich classic hodgkin lymphoma,lymphocyte-rich hepatocellular carcinoma,lymphocytic neoplasm,lymphoepithelioma-like carcinoma of the penis,lymphohistiocytic variant anaplastic large cell lymphoma,lymphohistiocytoid mesothelioma,lymphoid leukemia,lymphoma,lymphoma by ann arbor stage,lymphoma by lukes-collins classification (antiquated),lymphoma by site,lymphoma by stage,lymphoma by working formulation (antiquated),lymphomatoid granulomatosis,lymphomatoid papulosis,lymphomatoid papulosis with dusp22-irf4 gene rearrangement,lymphomatous adult t-cell leukemia/lymphoma,lymphoplasmacyte-rich meningioma,lymphosarcoma,lymphosarcoma involving spleen,mgmt-methylated glioblastoma,mgmt-unmethylated glioblastoma,myod1-mutant spindle cell/sclerosing rhabdomyosarcoma,macrofollicular variant thyroid gland papillary carcinoma,macrometastasis greater than 2.0 mm,macrotrabecular hepatoblastoma,macrotrabecular massive hepatocellular carcinoma,main duct pancreatic intraductal papillary-mucinous neoplasm,major salivary gland acinic cell carcinoma,major salivary gland adenocarcinoma,major salivary gland adenoid cystic carcinoma,major salivary gland carcinoma,major salivary gland carcinoma ex pleomorphic adenoma,major salivary gland mucoepidermoid carcinoma,major salivary gland neoplasm,major salivary gland non-hodgkin lymphoma,major salivary gland sarcoma,major salivary gland squamous cell carcinoma,male breast carcinoma,male breast carcinoma in situ,male malignant nipple neoplasm,male reproductive system carcinoma,male reproductive system neoplasm,male reproductive system precancerous condition,male urethral malignant neoplasm,malignancy in giant cell tumor of bone,malignant abdominal neoplasm,malignant accessory urethral gland neoplasm,malignant adrenal cortical neoplasm,malignant adrenal gland neoplasm,malignant adrenal medulla neoplasm,malignant adult hemangiopericytoma,malignant ampulla of vater neoplasm,malignant anal neoplasm,malignant anterior tongue neoplasm,malignant aortic neoplasm,malignant apocrine neoplasm,malignant appendix neoplasm,malignant basal cell neoplasm,malignant bladder neoplasm,malignant blood vessel neoplasm,malignant bone marrow neoplasm,malignant bone neoplasm,malignant brain glioma,malignant brain neoplasm,malignant brain stem neoplasm,malignant breast adenomyoepithelioma,malignant breast neoplasm,malignant breast phyllodes tumor,malignant breast spiradenoma,malignant broad ligament neoplasm,malignant bronchial neoplasm,malignant buccal mucosa neoplasm,malignant cardiac germ cell tumor,malignant cardiac hemangiopericytoma,malignant cardiac neoplasm,malignant cardiovascular neoplasm,malignant cecum neoplasm,malignant central nervous system germ cell tumor,"malignant central nervous system mesenchymal, non-meningothelial neoplasm",malignant central nervous system neoplasm,malignant cerebellar neoplasm,malignant cerebral neoplasm,malignant cervical neoplasm,malignant cervical soft tissue neoplasm,malignant chest wall bone neoplasm,malignant chest wall neoplasm,malignant childhood hemangiopericytoma,malignant choroid neoplasm,malignant choroid plexus neoplasm,malignant ciliary body neoplasm,malignant clitoral neoplasm,malignant coccygeal body neoplasm,malignant colon neoplasm,malignant colorectal neoplasm,malignant conjunctival neoplasm,malignant corneal neoplasm,malignant cranial nerve neoplasm,malignant cutaneous granular cell tumor,malignant dermal neoplasm,malignant diencephalic neoplasm,malignant digestive system neoplasm,malignant duodenal neoplasm,malignant ear neoplasm,malignant eccrine neoplasm,malignant endocardial neoplasm,malignant endocervical neoplasm,malignant endocrine neoplasm,malignant endometrial neoplasm,malignant enteroglucagonoma,malignant epicardial neoplasm,malignant epididymal neoplasm,malignant epiglottis neoplasm,malignant epithelioid cell type gastrointestinal stromal tumor,malignant esophageal neoplasm,malignant esophageal neoplasm by anatomic region,malignant esophageal neoplasm by topographic region,malignant ethmoid sinus neoplasm,malignant exocervical neoplasm,malignant exocrine pancreas neoplasm,malignant external ear neoplasm,malignant extragonadal germ cell tumor,malignant extragonadal nongerminomatous germ cell tumor,malignant extrahepatic bile duct neoplasm,malignant extraskeletal cartilaginous and osseous neoplasm,malignant eye neoplasm,malignant eyelid neoplasm,malignant fallopian tube neoplasm,malignant female reproductive system neoplasm,malignant fibrohistiocytic neoplasm,malignant floor of the mouth neoplasm,malignant frontal sinus neoplasm,malignant fundus neoplasm,malignant gastric germ cell tumor,malignant gastric granular cell tumor,malignant gastric neoplasm,malignant gastrinoma,malignant gastrointestinal stromal tumor,malignant genitourinary system neoplasm,malignant germ cell tumor,malignant germinative follicular epithelium neoplasm,malignant giant cell neoplasm,malignant gingival neoplasm,malignant glioma,malignant glomus tumor,malignant glottis neoplasm,malignant granular cell tumor,malignant great vessel neoplasm,malignant hair follicle neoplasm,malignant hard palate neoplasm,malignant head and neck neoplasm,malignant hemangiopericytoma,malignant hemangiopericytoma nci grade 2,malignant hemangiopericytoma nci grade 3,malignant hepatobiliary neoplasm,malignant histiocytosis,malignant hypopharyngeal neoplasm,malignant hypothalamic neoplasm,malignant inferior vena cava neoplasm,malignant infratentorial neoplasm,malignant inner ear neoplasm,malignant intestinal neoplasm,malignant intracranial germ cell tumor,malignant intracranial neoplasm,malignant intracranial neoplasm by morphology,malignant iris neoplasm,malignant jejunal neoplasm,malignant kidney neoplasm,malignant kidney neoplasm except pelvis,malignant labia majora neoplasm,malignant labia minora neoplasm,malignant lacrimal drainage system neoplasm,malignant lacrimal gland neoplasm,malignant lacrimal system neoplasm,malignant laryngeal neoplasm,malignant laryngeal soft tissue neoplasm,malignant leptomeningeal neoplasm,malignant lip neoplasm,malignant lung hilum neoplasm,malignant lung neoplasm,malignant lung and pleural neoplasm,malignant lymph node neoplasm,"malignant lymphoma centroblastic, follicular","malignant lymphoma follicular, large cleaved cell type","malignant lymphoma follicular, large noncleaved cell type",malignant lymphoma by cell type (working formulation),"malignant lymphoma, convoluted","malignant lymphoma, histiocytic, diffuse","malignant lymphoma, large cell type","malignant lymphoma, large cell, cleaved","malignant lymphoma, large cell, cleaved and non-cleaved","malignant lymphoma, non-cleaved cell type","malignant lymphoma, non-cleaved, diffuse",malignant major salivary gland neoplasm,malignant male reproductive system neoplasm,malignant mastocytosis,malignant maxillary sinus neoplasm,malignant mediastinal germ cell tumor,malignant mediastinal germ cell tumor stage grouping of the pediatric study group,malignant mediastinal germ cell tumor with associated hematologic malignancy,malignant mediastinal hemangiopericytoma,malignant mediastinal neoplasm,malignant mediastinal nongerminomatous germ cell tumor,malignant mediastinal soft tissue neoplasm,malignant melanoma in precancerous melanosis,malignant melanotic peripheral nerve sheath tumor,malignant melanotic peripheral nerve sheath tumor of the mediastinum,malignant melanotic psammomatous peripheral nerve sheath tumor,malignant meningeal neoplasm,malignant mesenchymoma,malignant mesothelioma,malignant middle ear neoplasm,malignant minor salivary gland neoplasm,malignant mixed epithelial and mesenchymal neoplasm of the cervix,malignant mixed epithelial and stromal tumor of the kidney,malignant mixed mesodermal (mullerian) tumor,malignant mixed neoplasm,malignant mixed tumor of the major salivary gland,malignant mixed tumor of the minor salivary gland,malignant mixed tumor of the salivary gland,malignant mixed tumor of the skin,"malignant mixed tumor, not otherwise specified",malignant muscle neoplasm,malignant musculoskeletal neoplasm,malignant myocardial neoplasm,malignant myoepithelioma,malignant nasal cavity neoplasm,malignant nasolacrimal duct neoplasm,malignant nasopharyngeal neoplasm,malignant neck neoplasm,malignant neoplasm,malignant neoplasm by grade,malignant neoplasm of lower jaw bone,malignant neoplasm of lung - multiple primary sites,malignant neoplasm of multiple primary sites,malignant neoplasm of the abdominal esophagus,malignant neoplasm of the cervical esophagus,malignant neoplasm of the lower third of the esophagus,malignant neoplasm of the middle third of the esophagus,malignant neoplasm of the thoracic esophagus,malignant neoplasm of the upper third of the esophagus,malignant neoplasm with regional lymph node involvement,"malignant neoplasm, uncertain whether primary or metastatic",malignant nervous system neoplasm,malignant nipple neoplasm,"malignant non-hodgkin lymphoma, cleaved cell",malignant oculomotor nerve neoplasm,malignant odontogenic neoplasm,malignant olfactory nerve neoplasm,malignant optic nerve neoplasm,malignant oral cavity neoplasm,malignant oral neoplasm,malignant orbit hemangiopericytoma,malignant orbit neoplasm,malignant oropharyngeal neoplasm,malignant ossifying fibromyxoid tumor,malignant osteoclastic giant cell-rich tumor of bone,malignant outer hair sheath and infundibulum neoplasm,malignant ovarian brenner tumor,malignant ovarian clear cell tumor,malignant ovarian cyst,malignant ovarian endometrioid tumor,malignant ovarian epithelial tumor,malignant ovarian germ cell tumor,malignant ovarian granulosa cell tumor,malignant ovarian luteinized thecoma,malignant ovarian mucinous tumor,malignant ovarian neoplasm,malignant ovarian serous tumor,malignant ovarian sex cord-stromal tumor,malignant ovarian steroid cell tumor,malignant ovarian teratoma,malignant ovarian thecoma,malignant pecoma,malignant palate neoplasm,malignant pancreatic gastrinoma,malignant pancreatic glucagonoma,malignant pancreatic insulinoma,malignant pancreatic neoplasm,malignant pancreatic somatostatinoma,malignant pancreatic vipoma,malignant paranasal sinus neoplasm,malignant parapharyngeal neoplasm,malignant parathyroid gland neoplasm,malignant parotid gland mixed tumor,malignant parotid gland neoplasm,malignant pelvic neoplasm,malignant penile neoplasm,malignant pericardial germ cell tumor,malignant pericardial neoplasm,malignant pericarditis,malignant pericytic neoplasm,malignant peripheral nerve sheath tumor,malignant peripheral nerve sheath tumor of the skin,malignant peripheral nerve sheath tumor with mesenchymal differentiation,malignant peripheral nerve sheath tumor with perineurial differentiation,malignant peripheral nervous system neoplasm,malignant peritoneal germ cell tumor,malignant peritoneal neoplasm,malignant peritoneal and retroperitoneal neoplasm,malignant pharyngeal neoplasm,malignant phosphaturic mesenchymal tumor,malignant phyllodes tumor,malignant pineal region germ cell tumor,malignant pineal region neoplasm,malignant pituitary gland neoplasm,malignant placental neoplasm,malignant pleural neoplasm,malignant postcricoid neoplasm,malignant posterior tongue neoplasm,malignant proliferating pilar tumor,malignant prostate neoplasm,malignant prostate phyllodes tumor,malignant pulmonary artery neoplasm,malignant pulmonary vein neoplasm,malignant pylorus neoplasm,malignant pyriform fossa neoplasm,malignant rectal neoplasm,malignant rectosigmoid neoplasm,malignant renal pelvis neoplasm,malignant reproductive system neoplasm,malignant respiratory system neoplasm,malignant retinal neoplasm,malignant retroperitoneal neoplasm,malignant retropharyngeal neoplasm,malignant salivary gland neoplasm,malignant scrotal neoplasm,malignant sebaceous neoplasm,malignant seminal vesicle neoplasm,malignant sex cord-stromal tumor,malignant sinonasal neoplasm,malignant sinonasal soft tissue neoplasm,malignant skeletal muscle neoplasm,malignant skin appendage neoplasm,malignant skin hemangiopericytoma,malignant skin neoplasm,malignant skin vascular neoplasm,malignant skull base neoplasm,malignant skull neoplasm,malignant small intestinal neoplasm,malignant smooth muscle neoplasm,malignant soft palate neoplasm,malignant soft tissue neoplasm,malignant soft tissue tumor of uncertain differentiation,malignant solid neoplasm,malignant solitary fibrous tumor,malignant somatostatinoma,malignant spermatic cord neoplasm,malignant sphenoid sinus neoplasm,malignant spinal cord neoplasm,malignant spindle cell neoplasm,malignant splenic neoplasm,malignant splenic soft tissue neoplasm,malignant sternal neoplasm,malignant subglottis neoplasm,malignant sublingual gland neoplasm,malignant submandibular gland mixed tumor,malignant submandibular gland neoplasm,malignant superior sulcus neoplasm,malignant superior vena cava neoplasm,malignant supraglottis neoplasm,malignant supratentorial neoplasm,malignant sweat gland neoplasm,malignant synovial neoplasm,malignant tenosynovial giant cell tumor,malignant teratoma,malignant testicular germ cell tumor,malignant testicular leydig cell tumor,malignant testicular neoplasm,malignant testicular non-seminomatous germ cell tumor,malignant testicular sertoli cell tumor,malignant testicular sex cord-stromal tumor,malignant thalamic neoplasm,malignant thoracic neoplasm,malignant thymoma,malignant thymus neoplasm,malignant thyroid gland neoplasm,malignant tongue neoplasm,malignant tonsillar neoplasm,malignant tracheal neoplasm,malignant triton tumor,malignant trophoblastic teratoma,"malignant tumor, small cell type",malignant type a thymoma,malignant type ab thymoma,malignant type b1 thymoma,malignant type b2 thymoma,malignant ureter neoplasm,malignant urethral neoplasm,malignant urinary system neoplasm,malignant uterine corpus mixed epithelial and mesenchymal neoplasm,malignant uterine corpus neoplasm,malignant uterine ligament neoplasm,malignant uterine neoplasm,malignant uveal neoplasm,malignant uvula neoplasm,malignant vaginal mixed epithelial and mesenchymal neoplasm,malignant vaginal mixed tumor resembling synovial sarcoma,malignant vaginal neoplasm,malignant vascular neoplasm,malignant vestibulocochlear nerve neoplasm,malignant vipoma,malignant visual pathway neoplasm,malignant vulvar neoplasm,malignant vulvar phyllodes tumor,malignant vulvar sweat gland neoplasm,malignant peritoneal local recurrence,mammary-type myofibroblastoma,mammosomatotroph pituitary neuroendocrine tumor,mantle cell lymphoma,marginal zone lymphoma,mast cell leukemia,mast cell leukemia associated with another hematological neoplasm,mast cell neoplasm,mast cell sarcoma,mastocytoma,mastocytosis,mature ganglioneuroma,mature gastric teratoma,mature glial implant,mature mediastinal teratoma,mature ovarian teratoma,mature pancreatic teratoma,mature pericardial teratoma,mature plurihormonal pit1 lineage pituitary neuroendocrine tumor,mature t- and nk-cell lymphoma by ann arbor stage,mature t-all,mature teratoma,mature testicular teratoma,maturing ganglioneuroma,maxillary sinus adenocarcinoma,maxillary sinus adenoid cystic carcinoma,maxillary sinus carcinoma,maxillary sinus inverted papilloma,maxillary sinus neoplasm,maxillary sinus papilloma,maxillary sinus squamous cell carcinoma,maxillofacial chondroblastoma,maxillofacial chondroma,maxillofacial chondromyxoid fibroma,maxillofacial chondrosarcoma,maxillofacial desmoplastic fibroma,maxillofacial mesenchymal chondrosarcoma,maxillofacial neoplasm,maxillofacial osteoblastoma,maxillofacial osteoid osteoma,maxillofacial osteoma,maxillofacial osteosarcoma,maxillofacial sarcoma,meckel diverticulum neuroendocrine tumor g1,mediastinal angiosarcoma,"mediastinal b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma",mediastinal chondroma,mediastinal choriocarcinoma,mediastinal embryonal carcinoma,mediastinal epithelioid hemangioendothelioma,mediastinal extraskeletal osteosarcoma,mediastinal follicular dendritic cell sarcoma,mediastinal ganglioneuroblastoma,mediastinal ganglioneuroma,mediastinal germ cell tumor,mediastinal germ cell tumor with somatic-type malignancy,mediastinal granular cell tumor,mediastinal granulocytic sarcoma,mediastinal hemangioma,mediastinal hodgkin lymphoma,mediastinal immature teratoma,mediastinal leiomyoma,mediastinal leiomyosarcoma,mediastinal lipoma,mediastinal lipomatosis,mediastinal liposarcoma,mediastinal lymphangioma,mediastinal lymphoma,mediastinal malignant peripheral nerve sheath tumor,mediastinal melanotic schwannoma,mediastinal mixed embryonal carcinoma and teratoma,mediastinal mixed germ cell tumor,mediastinal mixed nongerminomatous germ cell tumor,mediastinal myeloid sarcoma,mediastinal neoplasm,mediastinal neuroblastoma,mediastinal neurofibroma,mediastinal neurogenic neoplasm,mediastinal non-hodgkin lymphoma,mediastinal paraganglioma,mediastinal psammomatous schwannoma,mediastinal rhabdomyoma,mediastinal rhabdomyosarcoma,mediastinal sarcoma,mediastinal schwannoma,mediastinal seminoma,mediastinal soft tissue neoplasm,mediastinal solitary fibrous tumor,mediastinal synovial sarcoma,mediastinal t acute lymphoblastic leukemia,mediastinal t lymphoblastic leukemia/lymphoma,mediastinal t lymphoblastic lymphoma,mediastinal teratoma,mediastinal thymoma,mediastinal yolk sac tumor,mediastinal gray-zone lymphoma,mediastinal/thymic nut carcinoma,medium/large size posterior uveal melanoma,"medullary carcinoma, not otherwise specified",medullary hemangioblastoma,medulloblastoma,medulloblastoma with extensive nodularity,medulloblastoma with leptomeningeal spread,"medulloblastoma, molecularly defined","medulloblastoma, non-wnt/non-shh","medulloblastoma, non-wnt/non-shh, group 3","medulloblastoma, non-wnt/non-shh, group 4","medulloblastoma, not otherwise specified","medulloblastoma, shh-activated","medulloblastoma, shh-activated, tp53-mutant","medulloblastoma, shh-activated, tp53-wildtype","medulloblastoma, wnt-activated",medulloepithelioma not otherwise specified,medullomyoblastoma,megakaryocytic neoplasm,melanoacanthoma,melanocytic matricoma,melanocytic medulloblastoma,melanocytic neoplasm,melanocytic nevus,melanocytoma,melanoma,melanoma arising from blue nevus,melanoma arising in giant congenital nevus,melanoma metastatic in the brain,melanoma metastatic in the central nervous system,melanoma in congenital melanocytic nevus,melanoma in junctional nevus,melanoma of unknown primary,melanomatosis,melanotic neuroectodermal tumor,melanotic neurofibroma,melanotic schwannoma,meningeal carcinomatosis,"meningeal central nervous system solitary fibrous tumor, grade 3","meningeal chronic myelogenous leukemia, bcr-abl1 positive",meningeal gliomatosis,meningeal leukemia,meningeal lymphoma,meningeal melanocytoma,meningeal melanocytoma of intermediate grade,meningeal melanocytosis,meningeal melanoma,meningeal melanomatosis,meningeal neoplasm,meningeal sarcoma,meningeal sarcomatosis,meningeal solitary fibrous tumor,meningioma,meningioma by site,meningiomatosis,meningothelial cell neoplasm,meningothelial meningioma,merkel cell carcinoma,mesenchymal cell neoplasm,mesenchymal chondrosarcoma,mesenchymal chondrosarcoma of bone,mesenchymal extraskeletal chondrosarcoma,mesenchymal glioblastoma,mesenchymoma,mesenteric gastrointestinal stromal tumor,mesonephric adenocarcinoma,mesonephric-like adenocarcinoma,mesothelial neoplasm,mesothelioma,metachronous kidney wilms tumor,metachronous malignant neoplasm,metachronous osteosarcoma,metanephric adenofibroma,metanephric adenoma,metanephric stromal tumor,metanephric tumor,metaplastic carcinoma,metaplastic meningioma,metaplastic thymoma,metastasizing ameloblastoma,metastasizing chondroblastoma,metastasizing pleomorphic adenoma of the salivary gland,metastatic acral lentiginous melanoma,metastatic adenocarcinoma,metastatic adenoid cystic carcinoma,metastatic adrenal cortical carcinoma,metastatic adrenal gland composite pheochromocytoma,metastatic adrenal gland pheochromocytoma,metastatic adult malignant neoplasm in the brain,metastatic adult soft tissue sarcoma,metastatic alveolar soft part sarcoma,metastatic ampulla of vater carcinoma,metastatic anal canal carcinoma,metastatic anal canal squamous cell carcinoma,metastatic anal carcinoma,metastatic anal squamous cell carcinoma,metastatic angiosarcoma,metastatic appendix adenocarcinoma,metastatic appendix carcinoma,metastatic appendix mucinous adenocarcinoma,metastatic brca-associated breast carcinoma,metastatic basal cell carcinoma,metastatic benign neoplasm,metastatic bile duct carcinoma,metastatic biliary tract carcinoma,metastatic bladder carcinoma,metastatic bladder large cell neuroendocrine carcinoma,metastatic bladder paraganglioma,metastatic bladder small cell neuroendocrine carcinoma,metastatic bladder squamous cell carcinoma,metastatic bladder urachal urothelial carcinoma,metastatic bladder urothelial carcinoma,metastatic bone ewing sarcoma,metastatic bone sarcoma,metastatic breast adenocarcinoma,metastatic breast carcinoma,metastatic breast carcinoma in the skin,metastatic breast ductal carcinoma,metastatic breast inflammatory carcinoma,metastatic breast lobular carcinoma,metastatic breast neuroendocrine neoplasm,metastatic breast neuroendocrine tumor g1,metastatic breast signet ring cell carcinoma,metastatic breast squamous cell carcinoma,metastatic carcinoid tumor,metastatic carcinoma,metastatic carcinoma in the adrenal cortex,metastatic carcinoma in the adrenal medulla,metastatic carcinoma in the bone,metastatic carcinoma in the liver,metastatic carcinoma in the lung,metastatic carcinoma in the pancreas,metastatic carcinoma in the peritoneum,metastatic carcinoma in the rectum,metastatic carcinoma in the skin,metastatic carcinoma in the uterine cervix,metastatic carcinosarcoma,metastatic cardiac paraganglioma,metastatic carotid body paraganglioma,metastatic cervical adenocarcinoma,metastatic cervical adenosquamous carcinoma,metastatic cervical carcinoma,metastatic cervical squamous cell carcinoma,metastatic childhood malignant brain neoplasm,metastatic childhood malignant neoplasm in the brain,metastatic childhood soft tissue sarcoma,metastatic cholangiocarcinoma,metastatic chondrosarcoma,metastatic chordoma,metastatic choroid melanoma,metastatic chromophobe renal cell carcinoma,metastatic clear cell renal cell carcinoma,metastatic clear cell sarcoma of soft tissue,metastatic colon adenocarcinoma,metastatic colon carcinoma,metastatic colorectal adenocarcinoma,metastatic colorectal carcinoma,metastatic colorectal mucinous adenocarcinoma,metastatic conjunctival melanoma,metastatic corticotroph pituitary neuroendocrine tumor,metastatic cutaneous melanoma,metastatic cutaneous squamous cell carcinoma of the head and neck,metastatic dedifferentiated liposarcoma,metastatic desmoplastic small round cell tumor,metastatic differentiated thyroid gland carcinoma,metastatic digestive system carcinoma,metastatic digestive system mixed adenoneuroendocrine carcinoma,metastatic digestive system neuroendocrine carcinoma,metastatic digestive system neuroendocrine neoplasm,metastatic digestive system neuroendocrine tumor g1,metastatic digestive system neuroendocrine tumor g2,metastatic distal bile duct adenocarcinoma,metastatic distal bile duct carcinoma,metastatic distal esophagus adenocarcinoma,metastatic embryonal rhabdomyosarcoma,metastatic endometrial adenocarcinoma,metastatic endometrial adenosquamous carcinoma,metastatic endometrial carcinoma,metastatic endometrial clear cell adenocarcinoma,metastatic endometrial endometrioid adenocarcinoma,metastatic endometrial mixed cell adenocarcinoma,metastatic endometrial serous adenocarcinoma,metastatic endometrioid adenocarcinoma,metastatic epithelioid hemangioendothelioma,metastatic epithelioid sarcoma,metastatic esophageal adenocarcinoma,metastatic esophageal carcinoma,metastatic esophageal squamous cell carcinoma,metastatic ewing sarcoma,metastatic ewing sarcoma/peripheral primitive neuroectodermal tumor,metastatic extra-adrenal paraganglioma,metastatic extracranial malignant solid neoplasm,metastatic extrahepatic bile duct carcinoma,metastatic extraskeletal ewing sarcoma,metastatic extraskeletal myxoid chondrosarcoma,metastatic extraskeletal osteosarcoma,metastatic fallopian tube carcinoma,metastatic fallopian tube high grade serous adenocarcinoma,metastatic fibrolamellar carcinoma,metastatic fibrosarcoma,metastatic gallbladder carcinoma,metastatic gastric adenocarcinoma,metastatic gastric carcinoma,metastatic gastric neuroendocrine carcinoma,metastatic gastroesophageal junction adenocarcinoma,metastatic gastrointestinal stromal tumor,metastatic genitourinary system carcinoma,metastatic glioblastoma,metastatic glioma,metastatic her2-low breast carcinoma,metastatic her2-negative breast carcinoma,metastatic her2-positive breast carcinoma,metastatic head and neck carcinoma,metastatic head and neck squamous cell carcinoma,metastatic hepatocellular carcinoma,metastatic high grade sarcoma,metastatic hilar cholangiocarcinoma,metastatic hormone receptor-positive breast carcinoma,metastatic human papillomavirus-related malignant neoplasm,metastatic hydatidiform mole,metastatic hypopharyngeal carcinoma,metastatic hypopharyngeal squamous cell carcinoma,metastatic infiltrating bladder urothelial carcinoma with giant cells,"metastatic infiltrating bladder urothelial carcinoma, clear cell variant","metastatic infiltrating bladder urothelial carcinoma, lipid-rich variant","metastatic infiltrating bladder urothelial carcinoma, micropapillary variant","metastatic infiltrating bladder urothelial carcinoma, nested variant","metastatic infiltrating bladder urothelial carcinoma, plasmacytoid variant","metastatic infiltrating bladder urothelial carcinoma, sarcomatoid variant",metastatic intracranial malignant neoplasm,metastatic intrahepatic cholangiocarcinoma,metastatic intrathoracic paravertebral paraganglioma,metastatic jugulotympanic paraganglioma,metastatic kaposi sarcoma,metastatic kidney carcinoma,metastatic kidney medullary carcinoma,metastatic lactotroph pituitary neuroendocrine tumor,metastatic large cell neuroendocrine carcinoma,metastatic laryngeal carcinoma,metastatic laryngeal squamous cell carcinoma,metastatic leiomyosarcoma,metastatic lesion,metastatic lip carcinoma,metastatic lip squamous cell carcinoma,metastatic lip and oral cavity carcinoma,metastatic liposarcoma,metastatic liver carcinoma,metastatic low grade astrocytoma,metastatic low grade glioma,metastatic lung adenocarcinoma,metastatic lung adenosquamous carcinoma,metastatic lung carcinoid tumor,metastatic lung carcinoma,metastatic lung large cell neuroendocrine carcinoma,metastatic lung neuroendocrine neoplasm,metastatic lung non-small cell carcinoma,metastatic lung non-small cell squamous carcinoma,metastatic lung non-squamous non-small cell carcinoma,metastatic lung small cell carcinoma,metastatic lung squamous cell carcinoma,metastatic malignant abdominal neoplasm,metastatic malignant breast neoplasm,metastatic malignant colorectal neoplasm,metastatic malignant digestive system neoplasm,metastatic malignant female reproductive system neoplasm,metastatic malignant genitourinary system neoplasm,metastatic malignant germ cell tumor,metastatic malignant glomus tumor,metastatic malignant head and neck neoplasm,metastatic malignant hemangiopericytoma,metastatic malignant mesothelioma,metastatic malignant mixed mesodermal (mullerian) tumor,metastatic malignant neoplasm,metastatic malignant neoplasm in the abdominal cavity,metastatic malignant neoplasm in the adrenal gland,metastatic malignant neoplasm in the anus,metastatic malignant neoplasm in the axilla,metastatic malignant neoplasm in the bladder,metastatic malignant neoplasm in the bone,metastatic malignant neoplasm in the bone marrow,metastatic malignant neoplasm in the brain,metastatic malignant neoplasm in the brain stem,metastatic malignant neoplasm in the breast,metastatic malignant neoplasm in the central nervous system,metastatic malignant neoplasm in the chest wall,metastatic malignant neoplasm in the choroid,metastatic malignant neoplasm in the ciliary body,metastatic malignant neoplasm in the colon,metastatic malignant neoplasm in the conjunctiva,metastatic malignant neoplasm in the digestive system,metastatic malignant neoplasm in the epididymis,metastatic malignant neoplasm in the esophagus,metastatic malignant neoplasm in the extrahepatic bile ducts,metastatic malignant neoplasm in the eye,metastatic malignant neoplasm in the gallbladder,metastatic malignant neoplasm in the head and neck,metastatic malignant neoplasm in the heart,metastatic malignant neoplasm in the hypopharynx,metastatic malignant neoplasm in the iris,metastatic malignant neoplasm in the kidney,metastatic malignant neoplasm in the lacrimal drainage system,metastatic malignant neoplasm in the lacrimal gland,metastatic malignant neoplasm in the lacrimal system,metastatic malignant neoplasm in the large intestine,metastatic malignant neoplasm in the larynx,metastatic malignant neoplasm in the leptomeninges,metastatic malignant neoplasm in the lip,metastatic malignant neoplasm in the liver,metastatic malignant neoplasm in the lung,metastatic malignant neoplasm in the lymph nodes,metastatic malignant neoplasm in the mediastinal lymph nodes,metastatic malignant neoplasm in the mediastinum,metastatic malignant neoplasm in the nasopharynx,metastatic malignant neoplasm in the neck,metastatic malignant neoplasm in the nervous system,metastatic malignant neoplasm in the orbit,metastatic malignant neoplasm in the oropharynx,metastatic malignant neoplasm in the ovary,metastatic malignant neoplasm in the pancreas,metastatic malignant neoplasm in the parathyroid glands,metastatic malignant neoplasm in the pelvic cavity,metastatic malignant neoplasm in the penis,metastatic malignant neoplasm in the pericardium,metastatic malignant neoplasm in the peritoneum,metastatic malignant neoplasm in the pharynx,metastatic malignant neoplasm in the pituitary gland,metastatic malignant neoplasm in the placenta,metastatic malignant neoplasm in the pleura,metastatic malignant neoplasm in the prostate gland,metastatic malignant neoplasm in the rectum,metastatic malignant neoplasm in the regional lymph nodes,metastatic malignant neoplasm in the retina,metastatic malignant neoplasm in the sellar region,metastatic malignant neoplasm in the seminal vesicle,metastatic malignant neoplasm in the skin,metastatic malignant neoplasm in the small intestine,metastatic malignant neoplasm in the soft tissues,metastatic malignant neoplasm in the spinal cord,metastatic malignant neoplasm in the spine,metastatic malignant neoplasm in the sternum,metastatic malignant neoplasm in the stomach,metastatic malignant neoplasm in the supraclavicular lymph nodes,metastatic malignant neoplasm in the testis,metastatic malignant neoplasm in the thoracic cavity,metastatic malignant neoplasm in the thymus,metastatic malignant neoplasm in the thyroid gland,metastatic malignant neoplasm in the trachea,metastatic malignant neoplasm in the ureter,metastatic malignant neoplasm in the urethra,metastatic malignant neoplasm in the urinary system,metastatic malignant neoplasm in the uterine cervix,metastatic malignant neoplasm in the uvea,metastatic malignant neoplasm in the vagina,metastatic malignant neoplasm in the viscera,metastatic malignant neoplasm in the visual pathway,metastatic malignant neoplasm in the vulva,metastatic malignant neoplasm of unknown primary,metastatic malignant nongerminomatous germ cell tumor,metastatic malignant pecoma,metastatic malignant pancreatic neoplasm,metastatic malignant peripheral nerve sheath tumor,metastatic malignant skin neoplasm,metastatic malignant small intestinal neoplasm,metastatic malignant solid neoplasm,metastatic malignant testicular germ cell tumor,metastatic malignant thoracic neoplasm,metastatic medulloblastoma,metastatic melanoma,metastatic meningioma,metastatic merkel cell carcinoma,metastatic mesonephric adenocarcinoma,metastatic microsatellite stable colon carcinoma,metastatic microsatellite stable colorectal carcinoma,metastatic microsatellite stable endometrial carcinoma,metastatic microsatellite stable ovarian carcinoma,metastatic midgut neuroendocrine tumor,metastatic mucosal melanoma,metastatic myxofibrosarcoma,metastatic myxoid liposarcoma,metastatic nut carcinoma,metastatic nasal cavity squamous cell carcinoma,metastatic nasopharyngeal carcinoma,metastatic nasopharyngeal keratinizing squamous cell carcinoma,metastatic nasopharyngeal nonkeratinizing carcinoma,metastatic nasopharyngeal squamous cell carcinoma,metastatic nasopharyngeal undifferentiated carcinoma,metastatic neuroblastoma,metastatic neuroendocrine carcinoma,metastatic neuroendocrine neoplasm,metastatic neuroendocrine tumor,metastatic non-cutaneous melanoma,metastatic non-functioning neuroendocrine tumor,metastatic non-small cell carcinoma,metastatic ocular melanoma,metastatic oral cavity adenoid cystic carcinoma,metastatic oral cavity carcinoma,metastatic oral cavity mucoepidermoid carcinoma,metastatic oral cavity squamous cell carcinoma,metastatic oropharyngeal carcinoma,metastatic oropharyngeal squamous cell carcinoma,metastatic osteosarcoma,metastatic ovarian carcinoma,metastatic ovarian carcinosarcoma,metastatic ovarian clear cell adenocarcinoma,metastatic ovarian endometrioid adenocarcinoma,metastatic ovarian high grade serous adenocarcinoma,metastatic ovarian mucinous adenocarcinoma,metastatic ovarian serous adenocarcinoma,metastatic ovarian serous cystadenocarcinoma,"metastatic ovarian small cell carcinoma, hypercalcemic type",metastatic ovarian undifferentiated carcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic carcinoma,metastatic pancreatic ductal adenocarcinoma,metastatic pancreatic neuroendocrine carcinoma,metastatic pancreatic neuroendocrine neoplasm,metastatic pancreatic neuroendocrine tumor,metastatic pancreatobiliary carcinoma,metastatic papillary renal cell carcinoma,metastatic paraganglioma,metastatic paranasal sinus squamous cell carcinoma,metastatic parathyroid gland carcinoma,metastatic penile carcinoma,metastatic peripheral primitive neuroectodermal tumor of bone,metastatic peritoneal malignant mesothelioma,metastatic pharyngeal carcinoma,metastatic pharyngeal squamous cell carcinoma,metastatic pituitary neuroendocrine tumor,metastatic platinum-resistant malignant germ cell tumor,metastatic platinum-resistant ovarian carcinoma,metastatic pleomorphic liposarcoma,metastatic pleural malignant mesothelioma,metastatic poorly differentiated thyroid gland carcinoma,metastatic primary central chondrosarcoma,metastatic primary malignant brain neoplasm,metastatic primary malignant central nervous system neoplasm,metastatic primary peritoneal adenocarcinoma,metastatic primary peritoneal carcinoma,metastatic primary peritoneal high grade serous adenocarcinoma,metastatic primary peritoneal serous adenocarcinoma,metastatic prostate adenocarcinoma,metastatic prostate adenocarcinoma with neuroendocrine differentiation,metastatic prostate carcinoma,metastatic prostate neuroendocrine carcinoma,metastatic prostate small cell neuroendocrine carcinoma,metastatic proximal gastric adenocarcinoma,metastatic rectal adenocarcinoma,metastatic rectal carcinoma,metastatic rectal squamous cell carcinoma,metastatic renal cell carcinoma,metastatic renal pelvis carcinoma,metastatic renal pelvis urothelial carcinoma,metastatic renal pelvis and ureter urothelial carcinoma,metastatic rhabdoid tumor,metastatic rhabdomyosarcoma,metastatic round cell liposarcoma,metastatic salivary gland carcinoma,metastatic salivary gland squamous cell carcinoma,metastatic sarcoma,metastatic sarcoma in the peritoneum,metastatic sarcomatoid renal cell carcinoma,metastatic signet ring cell carcinoma,metastatic sinonasal squamous cell carcinoma,metastatic skin squamous cell carcinoma,metastatic small cell neuroendocrine carcinoma,metastatic small intestinal adenocarcinoma,metastatic small intestinal carcinoma,metastatic small intestinal neuroendocrine carcinoma,metastatic soft tissue leiomyosarcoma,metastatic soft tissue sarcoma,metastatic somatotroph pituitary neuroendocrine tumor,metastatic squamous cell carcinoma,metastatic squamous cell carcinoma in the breast,metastatic squamous cell carcinoma in the cervical lymph nodes,metastatic squamous cell carcinoma in the skin,metastatic squamous cell carcinoma of the penis,metastatic synovial sarcoma,metastatic thymic carcinoma,metastatic thymic neuroendocrine neoplasm,metastatic thyroid gland anaplastic carcinoma,metastatic thyroid gland carcinoma,metastatic thyroid gland follicular carcinoma,metastatic thyroid gland medullary carcinoma,metastatic thyroid gland oncocytic carcinoma,metastatic thyroid gland papillary carcinoma,metastatic thyrotroph pituitary neuroendocrine tumor,metastatic transitional cell carcinoma,metastatic triple-negative breast carcinoma,metastatic triple-negative breast inflammatory carcinoma,metastatic unclassified renal cell carcinoma,metastatic undifferentiated pleomorphic sarcoma,metastatic unresectable basal cell carcinoma,metastatic unresectable carcinoma,metastatic unresectable gastric adenocarcinoma,metastatic unresectable malignant neoplasm,metastatic unresectable pituitary neuroendocrine tumor,metastatic unresectable sarcoma,metastatic ureter carcinoma,metastatic ureter urothelial carcinoma,metastatic urethral carcinoma,metastatic urethral urothelial carcinoma,metastatic urothelial carcinoma,metastatic uterine corpus carcinosarcoma,metastatic uterine corpus leiomyosarcoma,metastatic uveal melanoma,metastatic vaginal adenocarcinoma,metastatic vaginal adenosquamous carcinoma,metastatic vaginal carcinoma,metastatic vaginal squamous cell carcinoma,metastatic vulvar carcinoma,metastatic vulvar squamous cell carcinoma,methotrexate-associated diffuse large b-cell lymphoma,methotrexate-associated follicular lymphoma,methotrexate-associated hodgkin lymphoma,methotrexate-associated lymphoma,methotrexate-associated peripheral t-cell lymphoma,methotrexate-related burkitt lymphoma,meyerson nevus,mit family translocation-associated renal cell carcinoma,microcystic adenoma,microcystic adnexal carcinoma,microcystic meningioma,microcystic/reticular schwannoma,microgranular acute promyelocytic leukemia,microinvasive anal carcinoma,microinvasive breast carcinoma,microinvasive malignant neoplasm,microinvasive squamous cell carcinoma,micrometastasis,micrometastasis 0.2 mm to 2.0 mm,micronodular thymoma with lymphoid stroma,micropapillary carcinoma,micropapillary serous carcinoma,micropapillary transitional cell carcinoma,microsatellite stable colon carcinoma,microsatellite stable colorectal carcinoma,microsatellite stable endometrial carcinoma,microsatellite stable ovarian carcinoma,microsatellite stable rectal carcinoma,microscopic thymoma,middle cranial fossa meningioma,middle ear adenocarcinoma,middle ear adenoma,middle ear carcinoma,middle ear carcinoma in situ,middle ear embryonal rhabdomyosarcoma,middle ear neoplasm,middle ear paraganglioma,middle ear polyp,middle ear squamous cell carcinoma,midgut neuroendocrine tumor,midgut neuroendocrine tumor g1,midgut neuroendocrine tumor g2,midgut neuroendocrine tumor g3,minimal deviation melanoma,minimally invasive lung adenocarcinoma,minimally invasive lung mixed non-mucinous and mucinous adenocarcinoma,minimally invasive lung mucinous adenocarcinoma,minimally invasive lung non-mucinous adenocarcinoma,minimally invasive thymoma,minor salivary gland acinic cell carcinoma,minor salivary gland adenocarcinoma,minor salivary gland adenoid cystic carcinoma,minor salivary gland carcinoma,minor salivary gland carcinoma ex pleomorphic adenoma,minor salivary gland intraductal papillary neoplasm,minor salivary gland intraductal papillary-mucinous neoplasm,minor salivary gland mucoepidermoid carcinoma,minor salivary gland neoplasm,minor salivary gland small cell neuroendocrine carcinoma,minor salivary gland squamous cell carcinoma,minor salivary gland undifferentiated carcinoma,miscellaneous neoplasm,mismatch repair-deficient endometrial endometrioid adenocarcinoma,mixed astrocytoma-ependymoma,mixed astrocytoma-ependymoma-oligodendroglioma,mixed carcinoma,mixed cell adenocarcinoma,mixed cell adenoma,mixed cell lymphoma,mixed cell type gastrointestinal stromal tumor,mixed cell type kidney wilms tumor,mixed cellularity classic hodgkin lymphoma,mixed congenital mesoblastic nephroma,mixed embryonal carcinoma and teratoma,mixed endometrial stromal and smooth muscle neoplasm,mixed epithelial and mesenchymal hair follicle neoplasm,mixed epithelial and mesenchymal hepatoblastoma,mixed epithelioid and spindle cell melanoma,mixed gangliocytoma-pituitary neuroendocrine tumor,mixed germ cell tumor,mixed germ cell-sex cord-stromal tumor,mixed glioma,mixed hepatoblastoma with teratoid features,mixed liposarcoma,mixed mesodermal (mullerian) tumor,mixed neoplasm,mixed neuroendocrine non-neuroendocrine neoplasm,mixed osteosarcoma,mixed phenotype acute leukemia,mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2); bcr-abl1,mixed phenotype acute leukemia with t(v;11q23.3); mll rearranged,"mixed phenotype acute leukemia, b/myeloid, not otherwise specified","mixed phenotype acute leukemia, b/t, not otherwise specified","mixed phenotype acute leukemia, b/t/myeloid, not otherwise specified","mixed phenotype acute leukemia, not otherwise specified, rare subtypes","mixed phenotype acute leukemia, t/myeloid, not otherwise specified",mixed somatotroph and lactotroph pituitary neuroendocrine tumor,mixed squamous cell carcinoma of the penis,mixed teratoma and seminoma,mixed testicular sex cord-stromal tumor,mixed trophoblastic tumor,mixed tumor of the parotid gland,mixed tumor of the salivary gland,"mixed tumor, not otherwise specified",mixed type pancreatic intraductal papillary-mucinous neoplasm,moderately differentiated hepatocellular carcinoma,moderately differentiated malignant neoplasm,moderately differentiated ovarian sertoli-leydig cell tumor,"moderately differentiated ovarian sertoli-leydig cell tumor, variant with heterologous elements",moderately differentiated prostate adenocarcinoma,monoblastic sarcoma,monoclonal gammopathy of renal significance,monoclonal gammopathy of undetermined significance,monoclonal immunoglobulin deposition disease,monoclonal polymorphic post-transplant lymphoproliferative disorder,monodermal testicular teratoma,monomorphic b-cell post-transplant lymphoproliferative disorder,monomorphic epitheliotropic intestinal t-cell lymphoma,monomorphic post-transplant lymphoproliferative disorder,monomorphic t/nk-cell post-transplant lymphoproliferative disorder,monomorphous plurihormonal pituitary neuroendocrine tumor,monophasic synovial sarcoma,monostotic fibrous dysplasia,mucin-producing adenocarcinoma,mucin-producing carcinoma,mucin-producing intrahepatic cholangiocarcinoma,mucin-rich endometrial endometrioid adenocarcinoma,mucinous adenocarcinoma,mucinous adenofibroma,mucinous cystadenocarcinoma,mucinous cystadenofibroma,mucinous cystadenoma,mucinous neoplasm,mucinous tubular and spindle cell carcinoma of the kidney,mucoepidermoid carcinoma,mucoepidermoid skin carcinoma,mucosal lentiginous melanoma,mucosal melanoma,mucosal melanoma of the digestive system,mucosal melanoma of the female genital tract,mucosal melanoma of the genitourinary system,mucosal melanoma of the head and neck,mucosal melanoma of the urinary system,mucosal nodular melanoma,mucous membrane hemangioma,multicentric breast carcinoma,multicentric thyroid gland papillary carcinoma,multicystic mesothelioma,multifocal breast carcinoma,multifocal glioblastomas,multifocal lymphomatous polyposis,multifocal osteosarcoma,multilocular cystic renal neoplasm of low malignant potential,multinodular and vacuolated neuronal tumor,multiple adenomatous polyps,multiple endocrine neoplasia,multiple endocrine neoplasia type 1,multiple endocrine neoplasia type 2,multiple endocrine neoplasia type 2a,multiple endocrine neoplasia type 2b,multiple endocrine neoplasia type 4,multiple endocrine neoplasia type 5,multiple intraspinal meningiomas,multiple lobular capillary hemangiomas,multiple osteochondromas,multiple pulmonary hamartomas,multiple skull base meningiomas,multiple solitary plasmacytoma of bone,multiple synchronous pituitary neuroendocrine tumors of distinct lineages,multiple myeloma,muscle invasive bladder carcinoma,muscle invasive bladder urothelial carcinoma,musculoskeletal neoplasm,mycosis fungoides,mycosis fungoides (working formulation),mycosis fungoides variant,myelodysplastic syndrome,myelodysplastic syndrome with excess blasts,myelodysplastic syndrome with excess blasts and fibrosis,myelodysplastic syndrome with excess blasts-1,myelodysplastic syndrome with excess blasts-2,myelodysplastic syndrome with isolated del(5q),myelodysplastic syndrome with multilineage dysplasia,myelodysplastic syndrome with ring sideroblasts,myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia,myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia,myelodysplastic syndrome with single lineage dysplasia,myelodysplastic syndrome with somatic mutations,"myelodysplastic syndrome, unclassifiable","myelodysplastic syndrome, unclassifiable, based on defining cytogenetic abnormality","myelodysplastic syndrome, unclassifiable, with 1 percent blasts","myelodysplastic syndrome, unclassifiable, with single lineage dysplasia",myelodysplastic/myeloproliferative neoplasm,myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis,"myelodysplastic/myeloproliferative neoplasm, unclassifiable",myeloid leukemia,myeloid leukemia associated with down syndrome,myeloid neoplasm,myeloid neoplasms with germline ankrd26 mutation,myeloid neoplasms with germline ddx41 mutation,myeloid neoplasms with germline etv6 mutation,myeloid neoplasms with germline gata2 mutation,myeloid neoplasms with germline predisposition,myeloid neoplasms with germline predisposition associated with inherited bone marrow failure syndromes,myeloid neoplasms with germline predisposition associated with other organ dysfunction,myeloid neoplasms with germline predisposition associated with telomerase biology disorders,myeloid neoplasms with germline predisposition and preexisting platelet disorders,myeloid neoplasms with germline predisposition without a preexisting disorder or organ dysfunction,myeloid neoplasms with germline runx1 mutation,myeloid neoplasms with germline samd9 mutation,myeloid neoplasms with germline samd9l mutation,myeloid proliferations associated with down syndrome,myeloid sarcoma,"myeloid/lymphoid neoplasms with eosinophilia and rearrangement of pdgfra, pdgfrb, or fgfr1, or with pcm1-jak2",myeloid/lymphoid neoplasms with fgfr1 rearrangement,myeloid/lymphoid neoplasms with pcm1-jak2,myeloid/lymphoid neoplasms with pdgfra rearrangement,myeloid/lymphoid neoplasms with pdgfrb rearrangement,myeloproliferative neoplasm,"myeloproliferative neoplasm, unclassifiable",myocardial neoplasm,myoepithelial tumor,myofibroblastoma,myofibroma,myofibromatosis,myolipoma,myomatous neoplasm,myopericytoma,myositis ossificans,myxofibrosarcoma,myxoid chondrosarcoma nci grade 1,myxoid chondrosarcoma nci grade 2,myxoid dermatofibrosarcoma protuberans,myxoid glioneuronal tumor,myxoid glioneuronal tumor of the septum pellucidum,myxoid leiomyoma,myxoid leiomyosarcoma,myxoid liposarcoma,myxoid pleomorphic liposarcoma,myxoinflammatory fibroblastic sarcoma,myxoma,myxopapillary ependymoma,myxosarcoma,nf1-associated malignant peripheral nerve sheath tumor,nk- and t-cell lymphoma,ntrk-rearranged spindle cell neoplasm,nut carcinoma,nail matrix nevus,nasal cavity adenocarcinoma,nasal cavity carcinoma,nasal cavity diffuse large b-cell lymphoma,nasal cavity exophytic papilloma,nasal cavity extranodal nk/t-cell lymphoma,nasal cavity inverted papilloma,nasal cavity keratinizing squamous cell carcinoma,nasal cavity lymphoma,nasal cavity neoplasm,nasal cavity non-hodgkin lymphoma,nasal cavity olfactory neuroblastoma,nasal cavity papilloma,nasal cavity squamous cell carcinoma,nasal type extranodal nk/t-cell lymphoma,nasal type nk/t-cell lymphoma by ann arbor stage,nasal vestibule squamous cell papilloma,nasolacrimal duct neoplasm,nasopharyngeal adenoid cystic carcinoma,nasopharyngeal angiofibroma,nasopharyngeal basaloid carcinoma,nasopharyngeal carcinoma,nasopharyngeal differentiated carcinoma,nasopharyngeal hodgkin lymphoma,nasopharyngeal keratinizing squamous cell carcinoma,nasopharyngeal lymphoma,nasopharyngeal melanoma,nasopharyngeal neoplasm,nasopharyngeal non-hodgkin lymphoma,nasopharyngeal nonkeratinizing carcinoma,nasopharyngeal papillary adenocarcinoma,nasopharyngeal paraganglioma,nasopharyngeal pituitary neuroendocrine tumor,nasopharyngeal polyp,nasopharyngeal squamous cell carcinoma,nasopharyngeal squamous cell papilloma,nasopharyngeal undifferentiated carcinoma,nasopharyngeal-type undifferentiated carcinoma,natural killer cell lymphoblastic leukemia/lymphoma,neck carcinoma,neck carcinoma of unknown primary,neck neoplasm,neck squamous cell carcinoma of unknown primary,necrotic neoplasm,neoantigen-positive malignant solid neoplasm,neoplasm,neoplasm by cause,neoplasm by morphology,neoplasm by obsolete classification,neoplasm of uncertain histogenesis,neoplasm of uncertain malignant potential,"neoplasm, uncertain whether benign or malignant",neoplastic c-cell hyperplasia,neoplastic polyp,neoplastic post-transplant lymphoproliferative disorder,nerve plexus neoplasm,nerve root neoplasm,nerve sheath myxoma,nerve sheath neoplasm,nervous system neoplasm,nervous system neoplasm (antiquated),neural glioblastoma,neuroblastic tumor,neuroblastoma,neuroblastoma of the adrenal gland and sympathetic nervous system,neuroendocrine carcinoma,neuroendocrine carcinoma of unknown primary,neuroendocrine neoplasm,neuroendocrine tumor,neuroepithelial neoplasm,"neuroepithelial, perineurial, and schwann cell neoplasm",neurofibroma,neurofibroma with atypia,neurofibromatosis 1 and 2 (nf1 and nf2),neuronevus,neutrophil-rich hepatocellular carcinoma,nevoid basal cell carcinoma syndrome associated medulloblastoma,nevoid melanoma,nevus spilus,nevus of female genitalia,nipple adenoma,nipple carcinoma,nipple duct carcinoma,nipple neoplasm,nipple paget disease,nipple syringomatous tumor,no specific molecular profile endometrial endometrioid adenocarcinoma,nodular fasciitis,nodular hidradenoma,nodular lymphocyte predominant hodgkin lymphoma,nodular neoplasm,nodular sclerosis classic hodgkin lymphoma,"nodular sclerosis classic hodgkin lymphoma, cellular phase","nodular sclerosis classic hodgkin lymphoma, syncytial variant",non-cutaneous leiomyosarcoma,non-cutaneous melanoma,non-encapsulated neoplasm,non-functioning adrenal cortical adenoma,non-functioning corticotroph pituitary neuroendocrine tumor,non-functioning densely granulated corticotroph pituitary neuroendocrine tumor,non-functioning endocrine neoplasm,non-functioning lung carcinoid tumor,non-functioning pancreatic delta cell neuroendocrine tumor,non-functioning pancreatic neuroendocrine tumor,non-functioning pancreatic neuroendocrine tumor g1,non-functioning pancreatic neuroendocrine tumor g2,non-functioning pituitary neuroendocrine tumor,non-functioning pituitary neuroendocrine tumor/macroadenoma,non-functioning pituitary neuroendocrine tumor/microadenoma,non-functioning sparsely granulated corticotroph pituitary neuroendocrine tumor,non-gestational ovarian choriocarcinoma,non-hematologic malignancy,non-hereditary clear cell renal cell carcinoma,non-hodgkin lymphoma,non-hodgkin lymphoma by ann arbor stage,non-human papillomavirus-related penile intraepithelial neoplasia,non-human papillomavirus-related squamous cell carcinoma of the penis,non-igm monoclonal gammopathy of undetermined significance,non-invasive cribriform carcinoma,non-invasive pancreatic mucinous-cystic neoplasm,non-invasive papillary squamous cell carcinoma,non-invasive papillary transitional cell carcinoma,non-invasive urothelial neoplasm,non-invasive verrucous carcinoma of the penis,non-involuting congenital hemangioma,non-keratinizing large cell squamous cell carcinoma,non-keratinizing primary intraosseous squamous cell carcinoma -solid type,non-keratinizing small cell squamous cell carcinoma,non-lytic metastatic lesion,non-malignant neoplasm,non-metastatic adrenal gland composite pheochromocytoma,non-metastatic adrenal gland pheochromocytoma,non-metastatic carotid body paraganglioma,non-metastatic gestational trophoblastic tumor,non-metastatic paraganglioma,non-muscle invasive bladder carcinoma,non-muscle invasive bladder urothelial carcinoma,non-ossifying fibroma,non-small cell adenocarcinoma,non-small cell carcinoma,non-t non-b calla negative adult acute lymphoblastic leukemia,non-t non-b calla negative childhood acute lymphoblastic leukemia,non-t non-b calla positive adult acute lymphoblastic leukemia,non-t non-b calla positive childhood acute lymphoblastic leukemia,non-clear cell renal cell carcinoma,nonanaplastic kidney wilms tumor,noncutaneous childhood anaplastic large cell lymphoma by ann arbor stage,nonestrogen-dependent malignant neoplasm,nongerminomatous germ cell tumor,noninvasive malignant thymoma,nonossifying fibromyxoid tumor,nonpigmented nevus,normal breast-like subtype of breast carcinoma,notochordal tumor,nuchal-type fibroma,null cell pituitary neuroendocrine tumor,obesity-related malignant neoplasm,occipital lobe neoplasm,occult breast carcinoma,occult lung adenocarcinoma,occult lung adenosquamous carcinoma,occult lung carcinoma,occult lung large cell carcinoma,occult lung non-small cell carcinoma,occult lung small cell carcinoma,occult lung squamous cell carcinoma,occupational malignant neoplasm,occupational neoplasm,ocular adnexal mucosa-associated lymphoid tissue lymphoma,ocular adnexal non-hodgkin lymphoma,ocular melanoma,ocular melanoma with extraocular extension,ocular surface squamous neoplasia,oculomotor nerve neoplasm,odontoameloblastoma,odontogenic carcinoma,odontogenic carcinosarcoma,odontogenic fibroma,odontogenic myxofibroma,odontogenic myxoma,odontogenic neoplasm,odontogenic sarcoma,old burn scar-related cutaneous melanoma,old burn scar-related neoplasm,old burn scar-related skin squamous cell carcinoma,olfactory groove meningioma,olfactory nerve neoplasm,olfactory neuroblastoma,olfactory neurocytoma,olfactory neurogenic tumor,oligoastrocytoma,"oligoastrocytoma, not otherwise specified",oligodendroblastoma,oligodendroglial tumor,oligodendroglioma,"oligodendroglioma, idh-mutant and 1p/19q-codeleted","oligodendroglioma, not otherwise specified",oligometastatic breast carcinoma,oligometastatic colorectal carcinoma,oligometastatic esophageal adenocarcinoma,oligometastatic gastric adenocarcinoma,oligometastatic lung carcinoma,oligometastatic malignant solid neoplasm,oligometastatic pancreatic ductal adenocarcinoma,oligometastatic prostate carcinoma,omentum gastrointestinal stromal tumor,oncocytic adenocarcinoma,oncocytic adenoma,oncocytic neoplasm,oncocytic variant thyroid gland papillary carcinoma,opisthorchis viverrini-related cholangiocarcinoma,optic chiasm neoplasm,optic disc melanocytoma,optic nerve astrocytoma,optic nerve glioma,optic nerve neoplasm,optic nerve sheath meningioma,optic nerve sheath solitary fibrous tumor,optic tract neoplasm,oral cavity adenocarcinoma,oral cavity adenoid cystic carcinoma,oral cavity adenoma,oral cavity benign granular cell tumor,oral cavity carcinoma,oral cavity carcinoma cuniculatum,oral cavity granular cell tumor,oral cavity kaposi sarcoma,oral cavity leiomyoma,oral cavity lipoma,oral cavity low grade myofibroblastic sarcoma,oral cavity monomorphic adenoma,oral cavity mucoepidermoid carcinoma,oral cavity mucosal melanoma,oral cavity myeloid sarcoma,oral cavity neoplasm,oral cavity pleomorphic adenoma,oral cavity sarcoma,oral cavity soft tissue neoplasm,oral cavity soft tissue sarcoma,oral cavity squamous cell carcinoma,oral cavity verrucous carcinoma,oral intraepithelial neoplasia,oral melanocytic nevus,oral mucosa langerhans cell histiocytosis,oral mucosa lobular capillary hemangioma,oral neoplasm,oral squamous cell papilloma,oral verruca vulgaris,orbit alveolar rhabdomyosarcoma,orbit capillary hemangioma,orbit cavernous hemangioma,orbit dermoid cyst,orbit embryonal rhabdomyosarcoma,orbit hemangioma,orbit hemangiopericytoma,orbit lymphoma,orbit neoplasm,orbit paraganglioma,orbit rhabdomyosarcoma,orbit sarcoma,orbital alveolar soft part sarcoma,orbital melanoma,oropharyngeal adenoid cystic carcinoma,oropharyngeal basaloid carcinoma,oropharyngeal carcinoma,oropharyngeal hodgkin lymphoma,oropharyngeal human papillomavirus-negative squamous cell carcinoma,oropharyngeal human papillomavirus-positive squamous cell carcinoma,oropharyngeal lymphoma,oropharyngeal neoplasm,oropharyngeal non-hodgkin lymphoma,oropharyngeal pleomorphic adenoma,oropharyngeal polymorphous adenocarcinoma,oropharyngeal polyp,oropharyngeal poorly differentiated carcinoma,oropharyngeal squamous cell carcinoma,oropharyngeal squamous cell papilloma,oropharyngeal undifferentiated carcinoma,oropharyngeal p16ink4a-negative squamous cell carcinoma,ossifying fibroma,ossifying fibromyxoid tumor,ossifying renal tumor of infancy,osteoblastic osteosarcoma,osteoblastoma,osteochondroma,osteochondromyxoma,osteoclastic giant cell-rich tumor of bone,osteogenic neoplasm,osteoid osteoma,osteolytic neoplasm,osteoma,osteosarcoma,osteosarcoma arising in paget disease of bone,outer hair sheath and infundibulum neoplasm,ovarian adenocarcinoma,ovarian adenomatoid tumor,ovarian adenosarcoma,ovarian angiosarcoma,ovarian biphasic or triphasic teratoma,ovarian brenner tumor,ovarian carcinoid tumor,ovarian carcinoma,ovarian carcinosarcoma,ovarian cellular fibroma,ovarian choriocarcinoma,ovarian clear cell adenocarcinofibroma,ovarian clear cell adenocarcinoma,ovarian clear cell adenofibroma,ovarian clear cell cystadenocarcinoma,ovarian clear cell cystadenofibroma,ovarian clear cell tumor,ovarian cystadenocarcinoma,ovarian cystadenoma,ovarian cystic teratoma,ovarian dedifferentiated carcinoma,ovarian dermoid cyst,ovarian dermoid cyst with adenocarcinoma,ovarian dermoid cyst with angiosarcoma,ovarian dermoid cyst with corticotropin secreting adenoma,ovarian dermoid cyst with leiomyosarcoma,ovarian dermoid cyst with melanocytic nevus,ovarian dermoid cyst with melanoma,ovarian dermoid cyst with prolactin secreting adenoma,ovarian dermoid cyst with sebaceous adenoma,ovarian dermoid cyst with sebaceous carcinoma,ovarian dermoid cyst with secondary carcinoma,ovarian dermoid cyst with secondary melanocytic lesion,ovarian dermoid cyst with secondary pituitary-type tumor,ovarian dermoid cyst with secondary sarcoma,ovarian dermoid cyst with secondary sebaceous tumor,ovarian dermoid cyst with secondary tumor,ovarian dermoid cyst with somatic-type malignancy,ovarian dermoid cyst with squamous cell carcinoma,ovarian dysgerminoma,ovarian embryonal carcinoma,ovarian endometrioid adenocarcinofibroma,ovarian endometrioid adenocarcinoma,ovarian endometrioid adenocarcinoma with squamous differentiation,ovarian endometrioid adenofibroma,ovarian endometrioid cystadenofibroma,ovarian endometrioid cystadenoma,ovarian endometrioid stromal and related neoplasms,ovarian endometrioid tumor,ovarian epithelial tumor,ovarian fetiform teratoma,ovarian fibroma,ovarian fibrosarcoma,ovarian germ cell tumor,ovarian gestational choriocarcinoma,ovarian gonadoblastoma,ovarian granulosa cell tumor,ovarian granulosa-stromal cell tumor,ovarian gynandroblastoma,ovarian high grade serous adenocarcinoma,ovarian hilus cell tumor,ovarian insular carcinoid tumor,ovarian large cell neuroendocrine carcinoma,ovarian leiomyoma,ovarian leiomyosarcoma,ovarian leydig cell tumor,"ovarian leydig cell tumor, non-hilar type","ovarian leydig cell tumor, not otherwise specified",ovarian liposarcoma,ovarian low grade endometrioid stromal sarcoma,ovarian low grade serous adenocarcinoma,ovarian luteinized thecoma,ovarian luteinized thecoma associated with sclerosing peritonitis,ovarian lymphoma,ovarian malignant mesothelioma,ovarian melanoma,ovarian mesonephric-like adenocarcinoma,ovarian microcystic stromal tumor,ovarian mixed cell adenocarcinoma,ovarian mixed germ cell tumor,ovarian mixed germ cell-sex cord-stromal tumor,"ovarian mixed germ cell-sex cord-stromal tumor, unclassified",ovarian monodermal teratoma,ovarian monodermal and highly specialized teratoma,ovarian mucinous adenocarcinofibroma,ovarian mucinous adenocarcinoma,ovarian mucinous adenofibroma,ovarian mucinous carcinoid tumor,ovarian mucinous cystadenocarcinoma,ovarian mucinous cystadenofibroma,ovarian mucinous cystadenoma,ovarian mucinous cystic tumor associated with pseudomyxoma peritonei,ovarian mucinous cystic tumor with mural nodules,ovarian mucinous tumor,ovarian myxoid liposarcoma,ovarian myxoma,ovarian neoplasm,ovarian neuroectodermal-type tumor,ovarian neuroendocrine carcinoma,ovarian neuroendocrine neoplasm,ovarian non-dysgerminomatous germ cell tumor,ovarian papillary cystadenoma,ovarian papillary tumor,ovarian polyembryoma,ovarian primitive germ cell tumor,ovarian retiform sertoli-leydig cell tumor,"ovarian retiform sertoli-leydig cell tumor, variant with heterologous elements",ovarian rhabdomyosarcoma,ovarian sarcoma,ovarian sclerosing stromal tumor,ovarian seromucinous adenofibroma,ovarian seromucinous carcinoma,ovarian seromucinous cystadenoma,ovarian seromucinous tumor,ovarian serous adenocarcinofibroma,ovarian serous adenocarcinoma,ovarian serous adenofibroma,ovarian serous cystadenocarcinoma,ovarian serous cystadenofibroma,ovarian serous cystadenoma,ovarian serous surface papillary adenocarcinoma,ovarian serous tumor,ovarian sertoli cell tumor,ovarian sertoli cell tumor with lipid storage,ovarian sertoli-leydig cell tumor,ovarian sertoli-leydig cell tumor with heterologous elements,ovarian sertoli-leydig cell tumor with retiform elements,ovarian sertoli-stromal cell tumor,ovarian sex cord tumor with annular tubules,ovarian sex cord-stromal tumor,ovarian sex cord-stromal tumor associated with peutz-jeghers syndrome,"ovarian sex cord-stromal tumor, not otherwise specified",ovarian signet ring cell carcinoma,ovarian signet ring stromal tumor,ovarian small cell carcinoma,"ovarian small cell carcinoma, hypercalcemic type","ovarian small cell carcinoma, pulmonary-type",ovarian smooth muscle neoplasm,ovarian smooth muscle tumor of uncertain malignant potential,ovarian soft tissue neoplasm,ovarian solid teratoma,ovarian squamous cell carcinoma,ovarian steroid cell tumor,"ovarian steroid cell tumor, not otherwise specified",ovarian stromal luteoma,ovarian stromal tumor with minor sex cord elements,ovarian stromal-leydig cell tumor,ovarian surface papilloma,ovarian teratoma,ovarian teratoma with carcinoid tumor,ovarian thecoma,ovarian trabecular carcinoid tumor,ovarian transitional cell carcinoma,ovarian tumor of the thecoma/fibroma group,ovarian undifferentiated carcinoma,ovarian undifferentiated sarcoma,ovarian wilms tumor,ovarian wolffian tumor,ovarian yolk sac tumor,"ovarian yolk sac tumor, glandular pattern","ovarian yolk sac tumor, hepatoid pattern","ovarian yolk sac tumor, polyvesicular vitelline pattern",overt primary myelofibrosis,oxyntic gland adenoma,oxyphilic endometrial endometrioid adenocarcinoma,palb2-associated breast carcinoma,palb2-associated malignant neoplasm,pecoma,poems syndrome,pole-ultramutated endometrial endometrioid adenocarcinoma,pacinian neurofibroma,paget disease,pagetoid reticulosis,palate carcinoma,palate kaposi sarcoma,palate neoplasm,palate squamous cell carcinoma,palisaded lymph node myofibroblastoma,palmar fibromatosis,pancreatic acth-producing neuroendocrine tumor,pancreatic acinar cell carcinoma,pancreatic acinar cell cystadenocarcinoma,pancreatic acinar cell neoplasm,pancreatic adenocarcinoma,pancreatic adenosquamous carcinoma,pancreatic alpha cell adenoma,pancreatic beta cell adenoma,pancreatic carcinoma,pancreatic colloid carcinoma,pancreatic cystadenocarcinoma,pancreatic cystadenoma,pancreatic delta cell adenoma,pancreatic delta cell neuroendocrine tumor,pancreatic ductal adenocarcinoma,pancreatic exocrine neoplasm,pancreatic foamy gland adenocarcinoma,pancreatic g-cell adenoma,pancreatic gastrin-producing neuroendocrine tumor,pancreatic gastrinoma,pancreatic glucagon-producing neuroendocrine tumor,pancreatic glucagonoma,pancreatic hepatoid adenocarcinoma,pancreatic insulin-producing neuroendocrine tumor,pancreatic insulinoma,pancreatic intraductal neoplasm,"pancreatic intraductal papillary mucinous neoplasm, gastric-type","pancreatic intraductal papillary mucinous neoplasm, intestinal-type","pancreatic intraductal papillary mucinous neoplasm, oncocytic-type","pancreatic intraductal papillary mucinous neoplasm, pancreatobiliary-type",pancreatic intraductal papillary-mucinous carcinoma,pancreatic intraductal papillary-mucinous neoplasm,pancreatic intraductal papillary-mucinous neoplasm with intermediate grade dysplasia,pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma,"pancreatic intraductal papillary-mucinous neoplasm, high grade","pancreatic intraductal papillary-mucinous neoplasm, low grade",pancreatic intraductal tubulopapillary neoplasm,pancreatic intraductal tubulopapillary neoplasm with an associated invasive carcinoma,pancreatic intraepithelial neoplasia,pancreatic intraepithelial neoplasia-1,pancreatic intraepithelial neoplasia-1a,pancreatic intraepithelial neoplasia-1b,pancreatic intraepithelial neoplasia-2,pancreatic large cell neuroendocrine carcinoma,pancreatic leiomyosarcoma,pancreatic lymphoma,pancreatic macrocystic serous cystadenoma,pancreatic medullary carcinoma,pancreatic mixed acinar-ductal carcinoma,pancreatic mixed acinar-ductal neuroendocrine carcinoma,pancreatic mixed acinar-neuroendocrine carcinoma,pancreatic mixed adenoneuroendocrine carcinoma,pancreatic mixed ductal-neuroendocrine carcinoma,pancreatic mixed ductal-neuroendocrine neoplasm,pancreatic moderately differentiated ductal adenocarcinoma,pancreatic mucinous cystadenocarcinoma,pancreatic mucinous cystadenoma,pancreatic mucinous-cystic neoplasm,pancreatic mucinous-cystic neoplasm with intermediate grade dysplasia,pancreatic mucinous-cystic neoplasm with an associated invasive carcinoma,"pancreatic mucinous-cystic neoplasm, high grade","pancreatic mucinous-cystic neoplasm, low grade",pancreatic neoplasm,pancreatic neuroendocrine carcinoma,pancreatic neuroendocrine microtumor,pancreatic neuroendocrine neoplasm,pancreatic neuroendocrine tumor,pancreatic neuroendocrine tumor g1,pancreatic neuroendocrine tumor g2,pancreatic neuroendocrine tumor g3,pancreatic non-hodgkin lymphoma,pancreatic non-invasive mucinous cystadenocarcinoma,pancreatic polypeptide tumor,pancreatic poorly cohesive adenocarcinoma,pancreatic poorly differentiated ductal adenocarcinoma,pancreatic precancerous condition,pancreatic sarcoma,pancreatic serotonin-producing neuroendocrine tumor,pancreatic serous adenoma,pancreatic serous cystadenocarcinoma,pancreatic serous cystadenoma,pancreatic serous neoplasm,pancreatic signet ring cell carcinoma,pancreatic small cell neuroendocrine carcinoma,pancreatic solid serous adenoma,pancreatic somatostatin-producing neuroendocrine tumor,pancreatic somatostatinoma,pancreatic squamous cell carcinoma,pancreatic teratoma,pancreatic undifferentiated carcinoma,pancreatic undifferentiated carcinoma with osteoclast-like giant cells,pancreatic undifferentiated carcinoma with rhabdoid cells,pancreatic vip-producing neuroendocrine tumor,pancreatic vipoma,pancreatic well differentiated ductal adenocarcinoma,pancreatobiliary carcinoma,pancreatoblastoma,papillary adenocarcinoma,papillary adenofibroma,papillary adenoma,papillary carcinoma,papillary carcinoma in situ,papillary carcinoma of the penis,papillary craniopharyngioma,papillary cystadenocarcinoma,papillary cystadenoma,papillary cystic neoplasm,papillary eccrine adenoma,papillary eccrine carcinoma,papillary ependymoma,papillary epithelial neoplasm,papillary fibroelastoma,papillary glioneuronal tumor,papillary intralymphatic angioendothelioma,papillary meningioma,papillary mucinous cystadenocarcinoma,papillary mucinous cystadenoma,papillary neoplasm,papillary renal cell carcinoma,papillary serous cystadenocarcinoma,papillary serous cystadenoma,papillary squamous cell carcinoma,papillary transitional cell carcinoma,papillary tumor of the pineal region,papillary urothelial neoplasm,papillary-basaloid carcinoma of the penis,papilloma,papillomatosis,parachordoma,paraganglioma,paraganglioma-like dermal melanocytic tumor,paranasal sinus adenocarcinoma,paranasal sinus adenoid cystic carcinoma,paranasal sinus carcinoma,paranasal sinus diffuse large b-cell lymphoma,paranasal sinus inverted papilloma,paranasal sinus keratinizing squamous cell carcinoma,paranasal sinus lymphoma,paranasal sinus mucoepidermoid carcinoma,paranasal sinus neoplasm,paranasal sinus non-hodgkin lymphoma,paranasal sinus olfactory neuroblastoma,paranasal sinus papilloma,paranasal sinus sarcoma,paranasal sinus squamous cell carcinoma,parapharyngeal neoplasm,parasagittal meningioma,parasite-related carcinoma,parasite-related malignant neoplasm,parasympathetic paraganglioma,paratesticular adenomatoid tumor,paratesticular biphasic mesothelioma,paratesticular cellular angiofibroma,paratesticular deep (aggressive) angiomyxoma,paratesticular epithelioid mesothelioma,paratesticular hemangioma,paratesticular leiomyoma,paratesticular leiomyosarcoma,paratesticular lipoma,paratesticular liposarcoma,paratesticular malignant mesothelioma,paratesticular mammary-type myofibroblastoma,paratesticular melanotic neuroectodermal tumor,paratesticular neoplasm,paratesticular paraganglioma,paratesticular rhabdomyoma,paratesticular rhabdomyosarcoma,paratesticular sarcomatoid mesothelioma,paratesticular schwannoma,paratesticular soft tissue neoplasm,paratesticular squamous cell carcinoma,paratesticular wilms tumor,parathyroid gland adenoma,parathyroid gland carcinoma,parathyroid gland chief cell adenoma,parathyroid gland clear cell adenoma,parathyroid gland lipoadenoma,parathyroid gland mixed cell type adenoma,parathyroid gland neoplasm,parathyroid gland oncocytic adenoma,parathyroid gland water-clear cell adenoma,parietal lobe anaplastic astrocytoma,parietal lobe neoplasm,parosteal osteosarcoma,parotid gland acinic cell carcinoma,parotid gland adenocarcinoma,parotid gland adenoid cystic carcinoma,parotid gland carcinoma,parotid gland carcinoma ex pleomorphic adenoma,parotid gland carcinosarcoma,parotid gland diffuse large b-cell lymphoma,parotid gland follicular lymphoma,parotid gland hemangioma,parotid gland kaposi sarcoma,parotid gland lipoma,parotid gland liposarcoma,parotid gland lymphangioma,parotid gland mantle cell lymphoma,parotid gland monomorphic adenoma,parotid gland mucoepidermoid carcinoma,parotid gland mucosa-associated lymphoid tissue lymphoma,parotid gland neoplasm,parotid gland nodular fasciitis,parotid gland non-hodgkin lymphoma,parotid gland pleomorphic adenoma,parotid gland sarcoma,parotid gland sebaceous lymphadenoma,parotid gland sialolipoma,parotid gland squamous cell carcinoma,parotid gland undifferentiated carcinoma,parotid gland warthin tumor,partially involuting congenital hemangioma,patient-specific neoantigen-positive malignant solid neoplasm,pediatric nodal marginal zone lymphoma,pelvic fibromatosis,pelvic lipomatosis,pelvic rhabdomyosarcoma,pelvic sarcoma,pelvic undifferentiated high grade pleomorphic sarcoma,penile angiosarcoma,penile basal cell carcinoma,penile bowenoid papulosis,penile carcinoma,penile carcinoma in situ,penile cutaneous melanoma,penile epithelioid hemangioendothelioma,penile epithelioid hemangioma,penile fibromatosis,penile glomus tumor,penile hemangioma,penile intraepithelial neoplasia,penile kaposi sarcoma,penile leiomyoma,penile leiomyosarcoma,penile lymphangioma,penile lymphoma,penile malignant peripheral nerve sheath tumor,penile melanoma,penile mucosal melanoma,penile myointimoma,penile neoplasm,penile neurofibroma,penile paget disease,penile rhabdomyosarcoma,penile sarcoma,penile schwannoma,penile soft tissue neoplasm,penile undifferentiated pleomorphic sarcoma,penile urethral malignant neoplasm,periampullary adenocarcinoma,perianal intraepithelial neoplasia,pericardial adenomatoid tumor,pericardial angiosarcoma,pericardial carcinomatosis,pericardial germ cell tumor,pericardial leiomyoma,pericardial malignant mesothelioma,pericardial mesothelioma,pericardial neoplasm,pericardial primary effusion lymphoma,pericardial sarcoma,pericardial solitary fibrous tumor,pericardial synovial sarcoma,pericardial teratoma,pericardial yolk sac tumor,pericytic neoplasm,perifollicular fibroma,perineural hemangioma,perineurioma,periocular meningioma,periosteal chondroma,periosteal chondrosarcoma,periosteal fibroma,periosteal fibrosarcoma,periosteal osteosarcoma,peripheral ganglioneuroblastoma,peripheral hemangioblastoma,peripheral intraneural angiosarcoma,peripheral nerve schwannoma,peripheral nervous system neoplasm,peripheral neuroblastoma,peripheral odontogenic fibroma,peripheral primitive neuroectodermal tumor,peripheral primitive neuroectodermal tumor of bone,peripheral primitive neuroectodermal tumor of soft tissues,peripheral primitive neuroectodermal tumor of the kidney,"peripheral t-cell lymphoma, large cell",peripheral t-cell lymphoma,peritoneal adenomatoid tumor,peritoneal biphasic mesothelioma,peritoneal calcifying fibrous tumor,peritoneal carcinomatosis,peritoneal desmoplastic small round cell tumor,peritoneal epithelioid mesothelioma,peritoneal gastrointestinal stromal tumor,peritoneal implant,peritoneal low grade endometrioid stromal sarcoma,peritoneal malignant mesothelioma,peritoneal mesothelioma,peritoneal multicystic mesothelioma,peritoneal neoplasm,peritoneal primary effusion lymphoma,peritoneal sarcomatoid mesothelioma,peritoneal sarcomatosis,peritoneal solitary fibrous tumor,peritoneal well differentiated papillary mesothelial tumor,peritoneal and retroperitoneal neoplasm,petroclival meningioma,petrous apex meningioma,ph-like acute lymphoblastic leukemia,pharyngeal adenoid cystic carcinoma,pharyngeal carcinoma,pharyngeal hodgkin lymphoma,pharyngeal lymphoma,pharyngeal melanoma,pharyngeal neoplasm,pharyngeal non-hodgkin lymphoma,pharyngeal squamous cell carcinoma,philadelphia chromosome negative bcr-abl1 negative chronic myelogenous leukemia,"philadelphia chromosome negative, bcr-abl1 positive chronic myelogenous leukemia","philadelphia chromosome positive, bcr-abl1 positive chronic myelogenous leukemia",philadelphia-negative myelogenous leukemia,philadelphia-positive myelogenous leukemia,phosphaturic mesenchymal tumor,phyllodes tumor,phyllodes tumor of anogenital mammary-type glands,pigmented adrenal cortical adenoma,pigmented dermatofibrosarcoma protuberans,pigmented epithelioid melanocytoma,pigmented nevus,pigmented spindle cell nevus,pilar leiomyoma,pilar sheath acanthoma,pilar-associated mesenchyme neoplasm,pilocytic astrocytoma,pilomatrical carcinoma,pilomatricoma,pilomyxoid astrocytoma,pineal gland astrocytoma,pineal parenchymal cell neoplasm,pineal parenchymal tumor of intermediate differentiation,pineal region choriocarcinoma,pineal region dysgerminoma,pineal region germ cell tumor,pineal region germinoma,pineal region immature teratoma,pineal region mature teratoma,pineal region meningioma,pineal region neoplasm,pineal region teratoma,pineal region yolk sac tumor,pineoblastoma,pineocytoma,pituicytoma,pituitary gland acidophil adenoma,pituitary gland acidophil carcinoma,pituitary gland basophil adenoma,pituitary gland basophil carcinoma,pituitary gland blastoma,pituitary gland chromophobe adenoma,pituitary gland diffuse large b-cell lymphoma,pituitary gland mixed acidophil-basophil adenoma,pituitary gland mixed acidophil-basophil carcinoma,pituitary gland neoplasm,pituitary gland neoplasm (antiquated),pituitary gland non-hodgkin lymphoma,pituitary neuroendocrine tumor,pituitary neuroendocrine tumor of pit1-lineage,pituitary neuroendocrine tumor of sf1-lineage,pituitary neuroendocrine tumor of tpit-lineage,pituitary neuroendocrine tumor without distinct lineage differentiation,pituitary neuroendocrine tumor/macroadenoma,pituitary neuroendocrine tumor/microadenoma,pituitary stalk meningioma,placental choriocarcinoma,placental hemangioma,placental neoplasm,placental polyp,placental site trophoblastic tumor,plantar fibromatosis,plantar verrucous carcinoma,plaque-like cd34-positive dermal fibroma,plaque-like dermatofibrosarcoma protuberans,plasma cell leukemia,plasma cell myeloma post-transplant lymphoproliferative disorder,plasma cell myeloma-induced bone disease,plasma cell post-transplant lymphoproliferative disorder,plasma cell dyscrasia,plasmacytoma-like post-transplant lymphoproliferative disorder,platinum-refractory fallopian tube carcinoma,platinum-refractory malignant female reproductive system neoplasm,platinum-refractory ovarian carcinoma,platinum-refractory primary peritoneal carcinoma,platinum-resistant fallopian tube carcinoma,platinum-resistant head and neck carcinoma,platinum-resistant lung small cell carcinoma,platinum-resistant malignant female reproductive system neoplasm,platinum-resistant malignant germ cell tumor,platinum-resistant ovarian carcinoma,platinum-resistant primary peritoneal carcinoma,platinum-resistant urothelial carcinoma,platinum-sensitive endometrial serous adenocarcinoma,platinum-sensitive fallopian tube carcinoma,platinum-sensitive lung small cell carcinoma,platinum-sensitive ovarian carcinoma,platinum-sensitive primary peritoneal carcinoma,pleomorphic adenoma,pleomorphic carcinoma,pleomorphic fibroma,pleomorphic hepatocellular carcinoma,pleomorphic hyalinizing angiectatic tumor of soft parts,pleomorphic leiomyosarcoma,pleomorphic lipoma,pleomorphic liposarcoma,pleomorphic rhabdomyosarcoma,pleomorphic xanthoastrocytoma,pleural adenomatoid tumor,pleural biphasic mesothelioma,pleural biphasic synovial sarcoma,pleural calcifying fibrous tumor,pleural carcinomatosis,pleural desmoplastic mesothelioma,pleural epithelioid hemangioendothelioma,pleural epithelioid mesothelioma,pleural leiomyosarcoma,pleural lipoma,pleural lymphoma,pleural malignant mesothelioma,pleural mesothelioma,pleural mesothelioma in situ,pleural monophasic synovial sarcoma,pleural neoplasm,pleural primary effusion lymphoma,pleural proximal-type epithelioid sarcoma,pleural sarcomatoid mesothelioma,pleural schwannoma,pleural solitary fibrous tumor,pleural synovial sarcoma,pleural well differentiated papillary mesothelial tumor,pleuropulmonary blastoma,plexiform ameloblastoma,plexiform fibrohistiocytic tumor,plexiform neurofibroma,plexiform schwannoma,plurihormonal pituitary neuroendocrine tumor,plurimorphous plurihormonal pituitary neuroendocrine tumor,polar spongioblastoma,polyclonal polymorphic post-transplant lymphoproliferative disorder,polycythemia vera,"polycythemia vera, polycythemic phase","polycythemia vera, post-polycythemic myelofibrosis phase",polygonal cell carcinoma,polymorphic post-transplant lymphoproliferative disorder,polymorphous low grade neuroepithelial tumor of the young,polymorphus hemangioendothelioma,polyostotic fibrous dysplasia,polyposis,poor prognosis metastatic gestational trophoblastic tumor,poorly differentiated angiosarcoma,poorly differentiated chordoma,poorly differentiated fibrosarcoma,poorly differentiated hepatocellular carcinoma,poorly differentiated malignant neoplasm,poorly differentiated neuroblastoma,poorly differentiated ovarian sertoli-leydig cell tumor,"poorly differentiated ovarian sertoli-leydig cell tumor, variant with heterologous elements",poorly differentiated prostate adenocarcinoma,poorly differentiated thyroid gland carcinoma,porocarcinoma,porocarcinoma in situ,poroma,postcricoid carcinoma,postcricoid squamous cell carcinoma,posterior foramen magnum meningioma,posterior fossa ependymoma,"posterior fossa ependymoma, group a (pfa)","posterior fossa ependymoma, group b (pfb)","posterior fossa ependymoma, not elsewhere classified","posterior fossa ependymoma, not otherwise specified",posterior fossa meningioma,posterior fossa neoplasm,posterior pharyngeal wall carcinoma,posterior pharyngeal wall squamous cell carcinoma,posterior pituitary gland neoplasm,posterior tongue adenoid cystic carcinoma,posterior tongue carcinoma,posterior tongue mucoepidermoid carcinoma,posterior tongue neoplasm,posterior tongue squamous cell carcinoma,posterior urethral malignant neoplasm,postradiation breast angiosarcoma,pre t-all,pre-b acute lymphoblastic leukemia,pre-pre-b acute lymphoblastic leukemia,precancerous polyp,precursor lymphoid neoplasm,prefibrotic/early primary myelofibrosis,preinvasive neoplasm of the ampullary region,premalignant neoplasm,primary amyloidosis,primary bone diffuse large b-cell lymphoma,primary bone hodgkin lymphoma,primary bone lymphoma,primary bone non-hodgkin lymphoma,primary bone osteosarcoma,primary brain neoplasm,primary brain stem neoplasm,primary breast angiosarcoma,primary central chondrosarcoma,primary central nervous system neoplasm,primary choroidal non-hodgkin lymphoma,primary ciliary body non-hodgkin lymphoma,primary cutaneous acral cd8-positive t-cell lymphoma,primary cutaneous anaplastic large cell lymphoma,primary cutaneous b-cell non-hodgkin lymphoma,primary cutaneous cd30-positive t-cell lymphoproliferative disorder,primary cutaneous cd4-positive small/medium t-cell lymphoproliferative disorder,primary cutaneous cd8-positive aggressive epidermotropic cytotoxic t-cell lymphoma,primary cutaneous diffuse large b-cell lymphoma,"primary cutaneous diffuse large b-cell lymphoma, leg type","primary cutaneous diffuse large b-cell lymphoma, other",primary cutaneous follicle center lymphoma,primary cutaneous gamma-delta t-cell lymphoma,primary cutaneous hodgkin lymphoma,primary cutaneous intravascular large b-cell lymphoma,primary cutaneous lymphoma,primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue,primary cutaneous meningioma,primary cutaneous mucinous carcinoma,primary cutaneous non-hodgkin lymphoma,"primary cutaneous peripheral t-cell lymphoma, rare subtype",primary cutaneous plasmablastic lymphoma,primary cutaneous t-cell non-hodgkin lymphoma,primary cutaneous t-cell/histiocyte-rich large b-cell lymphoma,primary diffuse large b-cell lymphoma of the central nervous system,primary ebv-positive nodal t-cell or nk-cell lymphoma,primary effusion lymphoma,"primary intracranial sarcoma, dicer1-mutant",primary intraocular non-hodgkin lymphoma,primary intraosseous squamous cell carcinoma,primary intraosseous squamous cell carcinoma derived from keratocystic odontogenic tumor,primary intraosseous squamous cell carcinoma derived from odontogenic cyst,primary intraosseous squamous cell carcinoma-solid type,primary iris non-hodgkin lymphoma,primary low grade b-cell dural lymphoma,primary lung meningioma,primary malignant hemangiopericytoma,primary malignant liver neoplasm,primary malignant neoplasm,primary malignant pelvic neoplasm,primary mediastinal (thymic) large b-cell lymphoma,primary meningeal melanocytic neoplasm,primary middle ear meningioma,primary myelofibrosis,primary neoplasm,primary parapharyngeal meningioma,primary peritoneal adenocarcinoma,primary peritoneal carcinoma,primary peritoneal carcinosarcoma,primary peritoneal clear cell adenocarcinoma,primary peritoneal endometrioid adenocarcinoma,primary peritoneal high grade serous adenocarcinoma,primary peritoneal low grade serous adenocarcinoma,primary peritoneal serous adenocarcinoma,primary peritoneal serous papillary adenocarcinoma,primary peritoneal transitional cell carcinoma,primary peritoneal undifferentiated carcinoma,primary prostate urothelial carcinoma,primary pulmonary myxoid sarcoma with ewsr1-creb1 fusion,primary retinal non-hodgkin lymphoma,primary sinonasal meningioma,primary systemic amyloidosis,"primary systemic anaplastic large cell lymphoma, alk-negative","primary systemic anaplastic large cell lymphoma, alk-positive",primary systemic mastocytosis,primary uveal non-hodgkin lymphoma,primary vitreoretinal diffuse large b-cell lymphoma,primary vitreoretinal non-hodgkin lymphoma,primary mediastinal b-cell lymphoma,primitive neuroectodermal tumor,primitive non-neural granular cell tumor,primordial odontogenic tumor,progesterone receptor expressing malignant neoplasm,progressive hairy cell leukemia initial treatment,proliferating trichilemmal tumor,proliferative fasciitis,proliferative myositis,proliferative nodules in congenital melanocytic nevus,prolymphocytic leukemia,proneural glioblastoma,prostate acinar adenocarcinoma,"prostate acinar adenocarcinoma, atrophic variant","prostate acinar adenocarcinoma, foamy gland variant","prostate acinar adenocarcinoma, lymphoepithelioma-like variant","prostate acinar adenocarcinoma, microcystic variant","prostate acinar adenocarcinoma, oncocytic variant","prostate acinar adenocarcinoma, pleomorphic giant cell variant","prostate acinar adenocarcinoma, pseudohyperplastic variant","prostate acinar adenocarcinoma, sarcomatoid variant","prostate acinar adenocarcinoma, signet ring-like cell variant",prostate acinar mucinous adenocarcinoma,prostate adenocarcinoma,prostate adenocarcinoma with neuroendocrine differentiation,prostate adenocarcinoma with paneth cell-like neuroendocrine differentiation,prostate adenocarcinoma without neuroendocrine differentiation,prostate adenoid cystic carcinoma,prostate adenoma,prostate adenosquamous carcinoma,prostate alveolar rhabdomyosarcoma,prostate angiosarcoma,prostate basal cell carcinoma,prostate carcinoma,prostate carcinoma metastatic in the bone,prostate carcinoma metastatic in the lung,prostate carcinoma metastatic in the lymph nodes,prostate carcinoma metastatic in the pelvic cavity,prostate carcinoma metastatic in the soft tissue,prostate cystadenoma,prostate diffuse large b-cell lymphoma,prostate ductal adenocarcinoma,"prostate ductal adenocarcinoma, cribriform pattern","prostate ductal adenocarcinoma, papillary pattern","prostate ductal adenocarcinoma, solid pattern",prostate embryonal rhabdomyosarcoma,prostate fibroma,prostate follicular lymphoma,prostate granular cell tumor,prostate hemangioma,prostate inflammatory myofibroblastic tumor,prostate kaposi sarcoma,prostate large cell neuroendocrine carcinoma,prostate leiomyoma,prostate leiomyosarcoma,prostate lymphoma,prostate malignant solitary fibrous tumor,prostate mantle cell lymphoma,prostate melanoma,prostate myeloid sarcoma,prostate neoplasm,prostate neuroendocrine carcinoma,prostate neuroendocrine neoplasm,prostate neuroendocrine tumor,prostate non-hodgkin lymphoma,prostate osteosarcoma,prostate paraganglioma,prostate phyllodes tumor,prostate rhabdomyosarcoma,prostate sarcoma,prostate small cell neuroendocrine carcinoma,prostate small lymphocytic lymphoma,prostate soft tissue neoplasm,prostate solitary fibrous tumor,prostate squamous cell carcinoma,prostate stromal sarcoma,prostate stromal tumor of uncertain malignant potential,prostate synovial sarcoma,prostate undifferentiated carcinoma,prostate undifferentiated pleomorphic sarcoma,prostate wilms tumor,prostatic duct urothelial carcinoma,prostatic intraepithelial neoplasia,prostatic urethra urothelial carcinoma,prostatic urethral malignant neoplasm,protoplasmic astrocytoma,proximal gastric adenocarcinoma,proximal urethral carcinoma,proximal-type epithelioid sarcoma,psammocarcinoma,psammomatous meningioma,pseudoglandular carcinoma of the penis,pseudoglandular squamous cell carcinoma,pseudohyperplastic carcinoma of the penis,pseudolymphoma,pseudomyogenic hemangioendothelioma,pseudomyxoma peritonei,pterygium,pulmonary adenomatosis,pulmonary artery angiosarcoma,pulmonary artery choriocarcinoma,pulmonary artery intimal sarcoma,pulmonary artery leiomyosarcoma,pulmonary blastoma,pulmonary hamartoma,pulmonary langerhans cell histiocytosis,pulmonary lymphomatoid granulomatosis,pulmonary sulcus neoplasm,pulmonary vein leiomyosarcoma,pure cutaneous mastocytosis,pure erythroid leukemia,pyothorax-associated lymphoma,pyriform fossa carcinoma,pyriform fossa neoplasm,pyriform fossa squamous cell carcinoma,rose cluster 1,rose cluster 2,rose cluster 3,rose cluster 4,rose cluster 5,rose cluster 6,rose cluster 7,rose cluster 8,radiation-induced intracranial meningioma,radiation-induced malignant peripheral nerve sheath tumor,radiation-related angiosarcoma,radiation-related leukemia,radiation-related malignant neoplasm,radiation-related neoplasm,radiation-related osteosarcoma,radiation-related sarcoma,rapidly involuting congenital hemangioma,rare childhood malignant neoplasm,rectal adenocarcinoma,rectal adenoma,rectal adenoma with severe dysplasia,rectal adenomatous polyp,rectal adenosquamous carcinoma,rectal cancer by astler-coller stage,rectal carcinoma,rectal carcinoma metastatic in the liver,rectal cloacogenic carcinoma,rectal conventional adenoma,rectal cribriform comedo-type adenocarcinoma,rectal epithelioid cell melanoma,rectal kaposi sarcoma,rectal large cell neuroendocrine carcinoma,rectal leiomyoma,rectal leiomyosarcoma,rectal lipoma,rectal lymphoma,rectal medullary carcinoma,rectal melanoma,rectal micropapillary adenocarcinoma,rectal mucinous adenocarcinoma,rectal neoplasm,rectal neuroendocrine neoplasm,rectal neuroendocrine tumor,rectal neuroendocrine tumor g1,rectal neuroendocrine tumor g2,rectal neuroendocrine tumor g3,rectal rhabdomyosarcoma,rectal sarcoma,rectal sarcomatoid carcinoma,rectal serrated adenocarcinoma,rectal serrated lesions and polyps,rectal signet ring cell adenocarcinoma,rectal small cell neuroendocrine carcinoma,rectal squamous cell carcinoma,rectal traditional serrated adenoma,rectal tubular adenoma,rectal tubulovillous adenoma,rectal undifferentiated carcinoma,rectal villous adenoma,rectosigmoid adenocarcinoma,rectosigmoid carcinoma,rectosigmoid mucinous adenocarcinoma,rectosigmoid neoplasm,rectosigmoid signet ring cell carcinoma,recurrent aids-related anal canal carcinoma,recurrent al amyloidosis,recurrent abdominal neuroendocrine neoplasm,recurrent acral lentiginous melanoma,recurrent acute bilineal leukemia,recurrent acute biphenotypic leukemia,recurrent acute erythroid leukemia,recurrent acute leukemia,recurrent acute leukemia of ambiguous lineage,recurrent acute lymphoblastic leukemia,recurrent acute megakaryoblastic leukemia,recurrent acute monoblastic and monocytic leukemia,recurrent acute myeloid leukemia,recurrent acute myeloid leukemia not otherwise specified,recurrent acute myeloid leukemia with multilineage dysplasia,recurrent acute myeloid leukemia with myelodysplasia-related changes,recurrent acute myeloid leukemia with recurrent genetic abnormalities,recurrent acute myeloid leukemia with t (9;11) (p21.3; q23.3); mllt3-mll,recurrent acute myelomonocytic leukemia,recurrent acute promyelocytic leukemia with pml-rara,recurrent acute undifferentiated leukemia,recurrent adamantinomatous craniopharyngioma,recurrent adenocarcinoma,recurrent adenoid cystic carcinoma,recurrent adrenal cortical carcinoma,recurrent adrenal gland pheochromocytoma,recurrent adult acute lymphoblastic leukemia,recurrent adult acute myeloid leukemia,recurrent adult brain neoplasm,recurrent adult diffuse large cell lymphoma,recurrent adult diffuse mixed cell lymphoma,recurrent adult diffuse small cleaved cell lymphoma,recurrent adult grade iii lymphomatoid granulomatosis,recurrent adult hepatocellular carcinoma,recurrent adult hodgkin lymphoma,recurrent adult liver carcinoma,recurrent adult lymphoblastic lymphoma,recurrent adult soft tissue sarcoma,recurrent adult spinal cord neoplasm,recurrent adult t-cell leukemia/lymphoma,recurrent adult undifferentiated high grade pleomorphic sarcoma of bone,recurrent aggressive nk-cell leukemia,recurrent alveolar rhabdomyosarcoma,recurrent alveolar soft part sarcoma,recurrent ampulla of vater adenocarcinoma,recurrent anal adenocarcinoma,recurrent anal canal carcinoma,recurrent anal canal squamous cell carcinoma,recurrent anal mucinous adenocarcinoma,recurrent anal squamous cell carcinoma,recurrent anaplastic (malignant) meningioma,recurrent anaplastic astrocytoma,recurrent anaplastic ependymoma,recurrent anaplastic ganglioglioma,recurrent anaplastic large cell lymphoma,recurrent anaplastic oligoastrocytoma,recurrent anaplastic oligodendroglioma,recurrent anaplastic pleomorphic xanthoastrocytoma,recurrent angioimmunoblastic t-cell lymphoma,recurrent angiosarcoma,recurrent anterior pituitary gland neoplasm,recurrent appendix adenocarcinoma,recurrent appendix carcinoma,recurrent appendix mucinous adenocarcinoma,recurrent askin tumor,"recurrent astrocytoma, idh-mutant","recurrent astrocytoma, idh-mutant, grade 4",recurrent atypical meningioma,recurrent atypical teratoid/rhabdoid tumor,recurrent b acute lymphoblastic leukemia,recurrent b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1,recurrent b lymphoblastic lymphoma,"recurrent b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma",recurrent b-cell prolymphocytic leukemia,recurrent brca- associated ovarian carcinoma,recurrent bile duct carcinoma,recurrent biliary tract carcinoma,recurrent bladder adenocarcinoma,recurrent bladder carcinoma,recurrent bladder squamous cell carcinoma,recurrent bladder urothelial carcinoma,recurrent blastic plasmacytoid dendritic cell neoplasm,recurrent bone ewing sarcoma,recurrent borderline ovarian surface epithelial-stromal tumor,recurrent brain neoplasm,recurrent breast acinic cell carcinoma,recurrent breast adenocarcinoma,recurrent breast angiosarcoma,recurrent breast carcinoma,recurrent breast implant-associated anaplastic large cell lymphoma,recurrent breast inflammatory carcinoma,recurrent breast lymphoma,recurrent breast paget disease,recurrent breast sarcoma,recurrent bronchogenic carcinoma,recurrent burkitt leukemia,recurrent carcinoma,recurrent carcinoma of unknown primary,recurrent central nervous system lymphoma,recurrent central nervous system non-hodgkin lymphoma,recurrent cervical adenocarcinoma,recurrent cervical adenosquamous carcinoma,recurrent cervical carcinoma,recurrent cervical squamous cell carcinoma,recurrent childhood acute lymphoblastic leukemia,recurrent childhood acute myeloid leukemia,recurrent childhood anaplastic astrocytoma,recurrent childhood anaplastic large cell lymphoma,recurrent childhood anaplastic oligoastrocytoma,recurrent childhood anaplastic oligodendroglioma,recurrent childhood astrocytic tumor,recurrent childhood brain neoplasm,recurrent childhood brain stem astrocytoma,recurrent childhood brain stem glioma,recurrent childhood burkitt lymphoma,recurrent childhood central nervous system embryonal neoplasm,recurrent childhood central nervous system neoplasm,recurrent childhood cerebellar astrocytoma,recurrent childhood cerebral astrocytoma,recurrent childhood diffuse astrocytoma,recurrent childhood ependymoma,recurrent childhood fibrillary astrocytoma,recurrent childhood gemistocytic astrocytoma,recurrent childhood giant cell glioblastoma,recurrent childhood glioblastoma,recurrent childhood gliomatosis cerebri,recurrent childhood gliosarcoma,recurrent childhood grade iii lymphomatoid granulomatosis,recurrent childhood hepatocellular carcinoma,recurrent childhood hodgkin lymphoma,recurrent childhood kidney neoplasm,recurrent childhood large cell lymphoma,recurrent childhood lymphoblastic lymphoma,recurrent childhood lymphoma,recurrent childhood lymphomatoid granulomatosis,recurrent childhood malignant germ cell tumor,recurrent childhood malignant liver neoplasm,recurrent childhood malignant neoplasm,recurrent childhood malignant solid neoplasm,recurrent childhood medulloblastoma,recurrent childhood non-hodgkin lymphoma,recurrent childhood oligoastrocytoma,recurrent childhood oligodendroglioma,recurrent childhood optic nerve astrocytoma,recurrent childhood optic nerve glioma,recurrent childhood osteosarcoma,recurrent childhood pilocytic astrocytoma,recurrent childhood pilomyxoid astrocytoma,recurrent childhood pineoblastoma,recurrent childhood pleomorphic xanthoastrocytoma,recurrent childhood protoplasmic astrocytoma,recurrent childhood rhabdomyosarcoma,recurrent childhood soft tissue sarcoma,recurrent childhood spinal cord neoplasm,recurrent childhood subependymal giant cell astrocytoma,"recurrent childhood supratentorial embryonal tumor, not otherwise specified",recurrent childhood t acute lymphoblastic leukemia,recurrent childhood undifferentiated high grade pleomorphic sarcoma of bone,recurrent childhood visual pathway astrocytoma,recurrent childhood visual pathway glioma,recurrent cholangiocarcinoma,recurrent chondrosarcoma,recurrent chordoma,recurrent chromophobe renal cell carcinoma,recurrent chronic leukemia,recurrent chronic lymphocytic leukemia,recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma,"recurrent chronic myelogenous leukemia, bcr-abl1 positive",recurrent chronic myelomonocytic leukemia,recurrent classic hodgkin lymphoma,recurrent clear cell renal cell carcinoma,recurrent clear cell sarcoma of soft tissue,recurrent colon adenocarcinoma,recurrent colon carcinoma,recurrent colorectal adenocarcinoma,recurrent colorectal carcinoma,recurrent combined thymic epithelial neoplasm,recurrent craniopharyngioma,recurrent cutaneous melanoma,recurrent cutaneous melanoma of the extremity,recurrent cutaneous squamous cell carcinoma of the head and neck,recurrent dedifferentiated chordoma,recurrent dedifferentiated liposarcoma,recurrent desmoid fibromatosis,recurrent desmoplastic small round cell tumor,recurrent differentiated thyroid gland carcinoma,recurrent diffuse astrocytoma,recurrent diffuse intrinsic pontine glioma,"recurrent diffuse midline glioma, h3 k27m-mutant",recurrent digestive system carcinoma,recurrent digestive system neuroendocrine carcinoma,recurrent digestive system neuroendocrine neoplasm,recurrent digestive system neuroendocrine tumor g1,recurrent distal bile duct adenocarcinoma,recurrent duodenal carcinoma,"recurrent ebv-positive diffuse large b-cell lymphoma, not otherwise specified",recurrent ebv-related lymphoma,recurrent ectomesenchymoma,"recurrent endocervical adenocarcinoma, usual-type",recurrent endometrial adenocarcinoma,recurrent endometrial adenosquamous carcinoma,recurrent endometrial carcinoma,recurrent endometrial clear cell adenocarcinoma,recurrent endometrial dedifferentiated carcinoma,recurrent endometrial endometrioid adenocarcinoma,recurrent endometrial mixed cell adenocarcinoma,recurrent endometrial mucinous adenocarcinoma,recurrent endometrial serous adenocarcinoma,recurrent endometrial squamous cell carcinoma,recurrent endometrial transitional cell carcinoma,recurrent endometrial undifferentiated carcinoma,recurrent endometrioid adenocarcinoma,recurrent enteropathy-associated t-cell lymphoma,recurrent ependymal tumor,recurrent ependymoma,recurrent epithelioid malignant peripheral nerve sheath tumor,recurrent epithelioid mesothelioma,recurrent epithelioid sarcoma,recurrent esophageal adenocarcinoma,recurrent esophageal carcinoma,recurrent esophageal squamous cell carcinoma,recurrent ewing sarcoma,recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor,recurrent extensive stage lung small cell carcinoma,recurrent extracranial malignant solid neoplasm,recurrent extragonadal seminoma,recurrent extrahepatic bile duct carcinoma,recurrent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,recurrent extrapulmonary small cell neuroendocrine carcinoma,recurrent extrarenal rhabdoid tumor of the ovary,recurrent extraskeletal ewing sarcoma,recurrent extraskeletal myxoid chondrosarcoma,recurrent extraskeletal osteosarcoma,recurrent fallopian tube adenocarcinoma,recurrent fallopian tube carcinoma,recurrent fallopian tube clear cell adenocarcinoma,recurrent fallopian tube endometrioid adenocarcinoma,recurrent fallopian tube high grade serous adenocarcinoma,recurrent fallopian tube mucinous adenocarcinoma,recurrent fallopian tube transitional cell carcinoma,recurrent fallopian tube undifferentiated carcinoma,recurrent female reproductive system carcinoma,recurrent fibrolamellar carcinoma,recurrent fibrosarcoma,recurrent follicular t-cell lymphoma,recurrent gallbladder carcinoma,recurrent gangliocytoma,recurrent ganglioneuroblastoma,recurrent gastric adenocarcinoma,recurrent gastric carcinoma,recurrent gastroesophageal junction adenocarcinoma,recurrent gastrointestinal stromal tumor,recurrent gestational trophoblastic tumor,recurrent giant cell glioblastoma,recurrent glioblastoma,"recurrent glioblastoma, idh-wildtype",recurrent glioma,recurrent gliomatosis cerebri,recurrent gliosarcoma,recurrent grade i lymphomatoid granulomatosis,recurrent grade ii lymphomatoid granulomatosis,recurrent grade iii lymphomatoid granulomatosis,recurrent her2-negative breast carcinoma,recurrent her2-positive breast carcinoma,recurrent hairy cell leukemia,recurrent hairy cell leukemia variant,recurrent head and neck carcinoma,recurrent head and neck squamous cell carcinoma,recurrent hematologic malignancy,recurrent hepatoblastoma,recurrent hepatocellular carcinoma,recurrent hepatosplenic t-cell lymphoma,recurrent hereditary thyroid gland medullary carcinoma,recurrent high grade burkitt-like lymphoma,recurrent histiocytic and dendritic cell neoplasm,recurrent hodgkin lymphoma,recurrent hormone receptor-positive breast carcinoma,recurrent human papillomavirus-related malignant neoplasm,recurrent hypopharyngeal carcinoma,recurrent hypopharyngeal squamous cell carcinoma,recurrent intracranial neoplasm,recurrent intrahepatic cholangiocarcinoma,recurrent invasive breast carcinoma of no special type,recurrent kaposi sarcoma,recurrent kidney carcinoma,recurrent kidney medullary carcinoma,recurrent kidney wilms tumor,recurrent langerhans cell histiocytosis,recurrent laryngeal carcinoma,recurrent laryngeal squamous cell carcinoma,recurrent laryngeal verrucous carcinoma,recurrent leiomyosarcoma,recurrent lentigo maligna melanoma,recurrent leukemia,recurrent lip basal cell carcinoma,recurrent lip and oral cavity carcinoma,recurrent lip and oral cavity squamous cell carcinoma,recurrent liposarcoma,recurrent liver carcinoma,recurrent lobular breast carcinoma,recurrent low grade astrocytoma,recurrent low grade fallopian tube serous adenocarcinoma,recurrent low grade glioma,recurrent lung adenocarcinoma,recurrent lung adenosquamous carcinoma,recurrent lung carcinoma,recurrent lung large cell carcinoma,recurrent lung neuroendocrine neoplasm,recurrent lung non-small cell carcinoma,recurrent lung non-small cell squamous carcinoma,recurrent lung non-squamous non-small cell carcinoma,recurrent lung small cell carcinoma,recurrent lung squamous cell carcinoma,recurrent lymphocyte-depleted classic hodgkin lymphoma,recurrent lymphocyte-rich classic hodgkin lymphoma,recurrent lymphoma,recurrent lymphomatoid granulomatosis,recurrent male reproductive system carcinoma,recurrent malignant abdominal neoplasm,recurrent malignant bladder neoplasm,recurrent malignant bone neoplasm,recurrent malignant brain neoplasm,recurrent malignant breast neoplasm,recurrent malignant choroid plexus neoplasm,recurrent malignant duodenal neoplasm,recurrent malignant endocervical neoplasm,recurrent malignant endocrine neoplasm,recurrent malignant extragonadal germ cell tumor,recurrent malignant extragonadal nongerminomatous germ cell tumor,recurrent malignant female reproductive system neoplasm,recurrent malignant gastric neoplasm,recurrent malignant genitourinary system neoplasm,recurrent malignant germ cell tumor,recurrent malignant glioma,recurrent malignant head and neck neoplasm,recurrent malignant hemangiopericytoma,recurrent malignant hypopharyngeal neoplasm,recurrent malignant lymphoid neoplasm,recurrent malignant male reproductive system neoplasm,recurrent malignant mastocytosis,recurrent malignant mesothelioma,recurrent malignant myoepithelioma,recurrent malignant nasopharyngeal neoplasm,recurrent malignant neoplasm,recurrent malignant neoplasm of multiple primary sites,recurrent malignant nongerminomatous germ cell tumor,recurrent malignant oral neoplasm,recurrent malignant ovarian brenner tumor,recurrent malignant ovarian granulosa cell tumor,recurrent malignant peripheral nerve sheath tumor,recurrent malignant pharyngeal neoplasm,recurrent malignant retroperitoneal neoplasm,recurrent malignant salivary gland neoplasm,recurrent malignant scrotal neoplasm,recurrent malignant skin neoplasm,recurrent malignant soft tissue neoplasm,recurrent malignant solid neoplasm,recurrent malignant spermatic cord neoplasm,recurrent malignant testicular germ cell tumor,recurrent malignant thymoma,recurrent malignant thyroid gland neoplasm,recurrent malignant urinary system neoplasm,recurrent mature t-cell and nk-cell neoplasm,recurrent mature t-cell and nk-cell non-hodgkin lymphoma,recurrent mediastinal lymphoma,recurrent medulloblastoma,"recurrent medulloblastoma, shh-activated","recurrent medulloblastoma, wnt-activated",recurrent melanoma,recurrent meningioma,recurrent merkel cell carcinoma,recurrent metastatic digestive system carcinoma,recurrent metastatic gastric carcinoma,recurrent metastatic malignant neoplasm,recurrent metastatic malignant neoplasm in the leptomeninges,recurrent metastatic melanoma,recurrent metastatic merkel cell carcinoma,recurrent metastatic skin squamous cell carcinoma,recurrent minor salivary gland adenocarcinoma,recurrent mixed cellularity classic hodgkin lymphoma,recurrent mixed phenotype acute leukemia,recurrent monomorphic epitheliotropic intestinal t-cell lymphoma,recurrent monomorphic post-transplant lymphoproliferative disorder,recurrent mucosal melanoma,recurrent multinodular and vacuolated neuronal tumor,recurrent mycosis fungoides,recurrent mycosis fungoides and sezary syndrome,recurrent myelodysplastic syndrome,recurrent myelodysplastic/myeloproliferative neoplasm,recurrent myeloid neoplasm,recurrent myeloproliferative neoplasm,recurrent myxoid glioneuronal tumor,recurrent myxoid liposarcoma,"recurrent nk-cell lymphoma, unclassifiable",recurrent nasal type extranodal nk/t-cell lymphoma,recurrent nasopharyngeal carcinoma,recurrent nasopharyngeal keratinizing squamous cell carcinoma,recurrent nasopharyngeal squamous cell carcinoma,recurrent nasopharyngeal undifferentiated carcinoma,recurrent neck squamous cell carcinoma of unknown primary,recurrent neoplasm,recurrent neoplastic post-transplant lymphoproliferative disorder,recurrent nervous system neoplasm,recurrent neuroblastoma,recurrent neuroendocrine carcinoma,recurrent neuroendocrine neoplasm,recurrent nevus,recurrent nodal peripheral t-cell lymphoma with tfh phenotype,recurrent nodular lymphocyte predominant hodgkin lymphoma,recurrent nodular sclerosis classic hodgkin lymphoma,recurrent non-cutaneous melanoma,recurrent non-hodgkin lymphoma,recurrent non-muscle invasive bladder urothelial carcinoma,recurrent ocular melanoma,recurrent olfactory neuroblastoma,recurrent oligoastrocytoma,recurrent oligodendroglioma,"recurrent oligodendroglioma, idh-mutant and 1p/19q-codeleted",recurrent oral cavity adenoid cystic carcinoma,recurrent oral cavity carcinoma,recurrent oral cavity mucoepidermoid carcinoma,recurrent oral cavity squamous cell carcinoma,recurrent oral cavity verrucous carcinoma,recurrent oropharyngeal carcinoma,recurrent oropharyngeal squamous cell carcinoma,recurrent oropharyngeal undifferentiated carcinoma,recurrent osteosarcoma,recurrent ovarian adenocarcinoma,recurrent ovarian carcinoma,recurrent ovarian carcinosarcoma,recurrent ovarian clear cell adenocarcinoma,recurrent ovarian cystadenocarcinoma,recurrent ovarian endometrioid adenocarcinoma,recurrent ovarian germ cell tumor,recurrent ovarian high grade serous adenocarcinoma,recurrent ovarian low grade serous adenocarcinoma,recurrent ovarian mucinous adenocarcinoma,recurrent ovarian seromucinous carcinoma,recurrent ovarian serous adenocarcinoma,recurrent ovarian serous cystadenocarcinoma,recurrent ovarian transitional cell carcinoma,recurrent ovarian undifferentiated carcinoma,recurrent paget disease of the anal canal,recurrent pancreatic acinar cell carcinoma,recurrent pancreatic adenocarcinoma,recurrent pancreatic carcinoma,recurrent pancreatic cystadenocarcinoma,recurrent pancreatic ductal adenocarcinoma,recurrent pancreatic neuroendocrine carcinoma,recurrent paraganglioma,recurrent paranasal sinus squamous cell carcinoma,recurrent parathyroid gland carcinoma,recurrent parotid gland acinic cell carcinoma,recurrent parotid gland adenoid cystic carcinoma,recurrent parotid gland carcinoma,recurrent parotid gland carcinoma ex pleomorphic adenoma,recurrent parotid gland mucoepidermoid carcinoma,recurrent parotid gland squamous cell carcinoma,recurrent parotid gland undifferentiated carcinoma,recurrent penile carcinoma,recurrent pericardial malignant mesothelioma,recurrent peripheral primitive neuroectodermal tumor,recurrent peripheral primitive neuroectodermal tumor of bone,"recurrent peripheral t-cell lymphoma, not otherwise specified",recurrent peritoneal malignant mesothelioma,recurrent ph-like acute lymphoblastic leukemia,recurrent pharyngeal carcinoma,recurrent pharyngeal squamous cell carcinoma,recurrent pilocytic astrocytoma,recurrent pineal parenchymal cell neoplasm,recurrent plasma cell myeloma,recurrent plasma cell neoplasm,recurrent platinum-resistant fallopian tube carcinoma,recurrent platinum-resistant ovarian carcinoma,recurrent platinum-resistant primary peritoneal carcinoma,recurrent pleural malignant mesothelioma,recurrent polymorphic post-transplant lymphoproliferative disorder,recurrent polymorphous low grade neuroepithelial tumor of the young,recurrent poorly differentiated thyroid gland carcinoma,recurrent primary amyloidosis,recurrent primary bone lymphoma,recurrent primary central nervous system neoplasm,recurrent primary cutaneous anaplastic large cell lymphoma,"recurrent primary cutaneous diffuse large b-cell lymphoma, leg type",recurrent primary cutaneous lymphoma,recurrent primary cutaneous t-cell non-hodgkin lymphoma,recurrent primary diffuse large b-cell lymphoma of the central nervous system,recurrent primary effusion lymphoma,recurrent primary malignant central nervous system neoplasm,recurrent primary malignant neoplasm,recurrent primary mediastinal (thymic) large b-cell lymphoma,recurrent primary myelofibrosis,recurrent primary peritoneal adenocarcinoma,recurrent primary peritoneal carcinoma,recurrent primary peritoneal clear cell adenocarcinoma,recurrent primary peritoneal endometrioid adenocarcinoma,recurrent primary peritoneal high grade serous adenocarcinoma,recurrent primary peritoneal low grade serous adenocarcinoma,recurrent primary peritoneal serous adenocarcinoma,recurrent primary peritoneal transitional cell carcinoma,recurrent primary peritoneal undifferentiated carcinoma,"recurrent primary systemic anaplastic large cell lymphoma, alk-positive",recurrent primary vitreoretinal diffuse large b-cell lymphoma,recurrent primary vitreoretinal non-hodgkin lymphoma,recurrent primitive neuroectodermal tumor,recurrent prostate acinar adenocarcinoma,recurrent prostate adenocarcinoma,recurrent prostate carcinoma,recurrent pseudomyxoma peritonei,recurrent rectal adenocarcinoma,recurrent rectal carcinoma,recurrent rectosigmoid carcinoma,recurrent renal cell carcinoma,recurrent renal pelvis urothelial carcinoma,recurrent renal pelvis and ureter urothelial carcinoma,recurrent respiratory papillomatosis,recurrent retinoblastoma,recurrent rhabdoid tumor,recurrent rhabdoid tumor of the kidney,recurrent rhabdomyosarcoma,recurrent salivary duct carcinoma,recurrent salivary gland carcinoma,recurrent salivary gland squamous cell carcinoma,recurrent sarcoma,recurrent sarcoma of the extremity,recurrent schwannoma,recurrent sezary syndrome,recurrent sinonasal carcinoma,recurrent sinonasal inverted papilloma,recurrent sinonasal squamous cell carcinoma,recurrent skin angiosarcoma,recurrent skin carcinoma,recurrent skin squamous cell carcinoma,recurrent small cell glioblastoma,recurrent small cell neuroendocrine carcinoma,recurrent small intestinal carcinoma,recurrent small lymphocytic lymphoma,recurrent soft tissue sarcoma,recurrent soft tissue sarcoma of the trunk and extremities,recurrent spinal cord neoplasm,recurrent spindle cell sarcoma,recurrent splenic marginal zone lymphoma,recurrent squamous cell carcinoma,recurrent subcutaneous panniculitis-like t-cell lymphoma,recurrent submandibular gland acinic cell carcinoma,recurrent submandibular gland adenoid cystic carcinoma,recurrent submandibular gland carcinoma,recurrent submandibular gland carcinoma ex pleomorphic adenoma,recurrent submandibular gland mucoepidermoid carcinoma,recurrent submandibular gland squamous cell carcinoma,recurrent submandibular gland undifferentiated carcinoma,recurrent subsequent malignant neoplasm,recurrent supratentorial glioblastoma,recurrent synovial sarcoma,recurrent systemic anaplastic large cell lymphoma,recurrent t acute lymphoblastic leukemia,recurrent t lymphoblastic leukemia/lymphoma,recurrent t lymphoblastic lymphoma,recurrent t-cell large granular lymphocyte leukemia,recurrent t-cell prolymphocytic leukemia,recurrent tectal glioma,recurrent testicular lymphoma,recurrent thymic carcinoma,recurrent thyroid gland anaplastic carcinoma,recurrent thyroid gland carcinoma,recurrent thyroid gland follicular carcinoma,recurrent thyroid gland medullary carcinoma,recurrent thyroid gland oncocytic carcinoma,recurrent thyroid gland papillary carcinoma,recurrent transformed chronic lymphocytic leukemia,recurrent transformed mycosis fungoides,recurrent transformed t-cell non-hodgkin lymphoma,recurrent triple-negative breast carcinoma,recurrent undifferentiated pleomorphic sarcoma,recurrent ureter carcinoma,recurrent ureter urothelial carcinoma,recurrent urethral carcinoma,recurrent urethral urothelial carcinoma,recurrent urinary system carcinoma,recurrent urothelial carcinoma,recurrent uterine corpus cancer,recurrent uterine corpus carcinosarcoma,recurrent uterine corpus sarcoma,recurrent uveal melanoma,recurrent vaginal carcinoma,recurrent vaginal squamous cell carcinoma,recurrent visual pathway glioma,recurrent vulvar carcinoma,recurrent vulvar squamous cell carcinoma,recurrent who grade 1 glioma,recurrent who grade 2 glioma,recurrent who grade 3 glioma,recurrent primary malignant neoplasm of left female breast,recurrent primary malignant neoplasm of right female breast,refractory al amyloidosis,refractory abdominal neuroendocrine neoplasm,refractory acute bilineal leukemia,refractory acute biphenotypic leukemia,refractory acute leukemia,refractory acute leukemia of ambiguous lineage,refractory acute lymphoblastic leukemia,refractory acute monoblastic and monocytic leukemia,refractory acute myeloid leukemia,refractory acute myeloid leukemia with myelodysplasia-related changes,refractory acute myelomonocytic leukemia,refractory acute undifferentiated leukemia,refractory adenocarcinoma,refractory adenoid cystic carcinoma,refractory adrenal cortical carcinoma,refractory adrenal gland pheochromocytoma,refractory adult acute lymphoblastic leukemia,refractory adult spinal cord neoplasm,refractory adult t-cell leukemia/lymphoma,refractory aggressive nk-cell leukemia,refractory aggressive non-hodgkin lymphoma,refractory alveolar rhabdomyosarcoma,refractory alveolar soft part sarcoma,refractory ampulla of vater carcinoma,refractory anal canal squamous cell carcinoma,refractory anal carcinoma,refractory anaplastic astrocytoma,refractory anaplastic ependymoma,refractory anaplastic ganglioglioma,refractory anaplastic large cell lymphoma,refractory anaplastic oligodendroglioma,refractory anaplastic pleomorphic xanthoastrocytoma,refractory anemia,refractory anemia with excess blasts in transformation,refractory angioimmunoblastic t-cell lymphoma,refractory appendix adenocarcinoma,refractory appendix carcinoma,refractory atypical teratoid/rhabdoid tumor,refractory b acute lymphoblastic leukemia,refractory b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1,refractory b lymphoblastic lymphoma,refractory b-cell lymphoma,"refractory b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma",refractory b-cell prolymphocytic leukemia,refractory bile duct carcinoma,refractory biliary tract carcinoma,refractory bladder carcinoma,refractory bladder urothelial carcinoma,refractory blastic plasmacytoid dendritic cell neoplasm,refractory brain neoplasm,refractory breast adenocarcinoma,refractory breast carcinoma,refractory breast implant-associated anaplastic large cell lymphoma,refractory breast lymphoma,refractory burkitt leukemia,refractory carcinoma,refractory central nervous system lymphoma,refractory central nervous system non-hodgkin lymphoma,refractory centroblastic lymphoma,refractory cervical adenocarcinoma,refractory cervical carcinoma,refractory cervical squamous cell carcinoma,refractory childhood acute lymphoblastic leukemia,refractory childhood acute myeloid leukemia,refractory childhood brain neoplasm,refractory childhood central nervous system neoplasm,refractory childhood hodgkin lymphoma,refractory childhood lymphoma,refractory childhood malignant germ cell tumor,refractory childhood malignant neoplasm,refractory childhood malignant solid neoplasm,refractory childhood osteosarcoma,refractory childhood rhabdomyosarcoma,refractory childhood soft tissue sarcoma,refractory childhood spinal cord neoplasm,refractory cholangiocarcinoma,refractory chordoma,refractory chronic leukemia,refractory chronic lymphocytic leukemia,refractory chronic lymphocytic leukemia/small lymphocytic lymphoma,"refractory chronic myelogenous leukemia, bcr-abl1 positive",refractory chronic myelomonocytic leukemia,refractory classic hodgkin lymphoma,refractory clear cell renal cell carcinoma,refractory clear cell sarcoma of soft tissue,refractory colon adenocarcinoma,refractory colon carcinoma,refractory colorectal adenocarcinoma,refractory colorectal carcinoma,refractory cutaneous melanoma,refractory cutaneous squamous cell carcinoma of the head and neck,refractory cytopenia of childhood,refractory dedifferentiated chordoma,refractory dedifferentiated liposarcoma,refractory desmoid fibromatosis,refractory desmoplastic small round cell tumor,refractory differentiated thyroid gland carcinoma,refractory diffuse intrinsic pontine glioma,refractory diffuse large b-cell lymphoma,refractory digestive system carcinoma,refractory digestive system neuroendocrine carcinoma,refractory digestive system neuroendocrine neoplasm,refractory distal bile duct adenocarcinoma,refractory double-hit lymphoma,"refractory ebv-positive diffuse large b-cell lymphoma, not otherwise specified",refractory ebv-related lymphoma,refractory endometrial adenocarcinoma,refractory endometrial carcinoma,refractory endometrial clear cell adenocarcinoma,refractory endometrial dedifferentiated carcinoma,refractory endometrial endometrioid adenocarcinoma,refractory endometrial mixed cell adenocarcinoma,refractory endometrial mucinous adenocarcinoma,refractory endometrial serous adenocarcinoma,refractory endometrial squamous cell carcinoma,refractory endometrial transitional cell carcinoma,refractory endometrial undifferentiated carcinoma,refractory enteropathy-associated t-cell lymphoma,refractory ependymoma,refractory epithelioid malignant peripheral nerve sheath tumor,refractory epithelioid sarcoma,refractory erdheim-chester disease,refractory esophageal adenocarcinoma,refractory esophageal carcinoma,refractory esophageal squamous cell carcinoma,refractory ewing sarcoma,refractory ewing sarcoma/peripheral primitive neuroectodermal tumor,refractory extensive stage lung small cell carcinoma,refractory extracranial malignant solid neoplasm,refractory extrahepatic bile duct carcinoma,refractory extranodal diffuse large b-cell lymphoma,refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,refractory extrarenal rhabdoid tumor of the ovary,refractory extraskeletal myxoid chondrosarcoma,refractory fallopian tube adenocarcinoma,refractory fallopian tube carcinoma,refractory fallopian tube clear cell adenocarcinoma,refractory fallopian tube endometrioid adenocarcinoma,refractory fallopian tube high grade serous adenocarcinoma,refractory fallopian tube mucinous adenocarcinoma,refractory fallopian tube transitional cell carcinoma,refractory fallopian tube undifferentiated carcinoma,refractory female reproductive system carcinoma,refractory fibrosarcoma,refractory follicular lymphoma,refractory follicular t-cell lymphoma,refractory gallbladder carcinoma,refractory ganglioneuroblastoma,refractory gastric adenocarcinoma,refractory gastric carcinoma,refractory gastroesophageal junction adenocarcinoma,refractory giant cell glioblastoma,refractory glioblastoma,refractory glioma,refractory gliosarcoma,refractory her2-negative breast carcinoma,refractory her2-positive breast carcinoma,refractory hairy cell leukemia,refractory hairy cell leukemia variant,refractory head and neck carcinoma,refractory head and neck squamous cell carcinoma,refractory hematologic malignancy,refractory hepatoblastoma,refractory hepatocellular carcinoma,refractory hepatosplenic t-cell lymphoma,refractory high grade burkitt-like lymphoma,refractory histiocytic and dendritic cell neoplasm,refractory hodgkin lymphoma,refractory hormone receptor-positive breast carcinoma,refractory human papillomavirus-related malignant neoplasm,refractory hypopharyngeal squamous cell carcinoma,refractory indolent adult non-hodgkin lymphoma,refractory intrahepatic cholangiocarcinoma,refractory intravascular b-cell lymphoma,refractory kaposi sarcoma,refractory kidney carcinoma,refractory kidney medullary carcinoma,refractory langerhans cell histiocytosis,refractory laryngeal squamous cell carcinoma,refractory leiomyosarcoma,refractory leukemia,refractory liposarcoma,refractory liver carcinoma,refractory low grade astrocytoma,refractory low grade fallopian tube serous adenocarcinoma,refractory low grade glioma,refractory lung adenocarcinoma,refractory lung carcinoma,refractory lung non-small cell carcinoma,refractory lung non-small cell squamous carcinoma,refractory lung non-squamous non-small cell carcinoma,refractory lung small cell carcinoma,refractory lung squamous cell carcinoma,refractory lymphoblastic lymphoma,refractory lymphocyte-depleted classic hodgkin lymphoma,refractory lymphocyte-rich classic hodgkin lymphoma,refractory lymphoma,refractory lymphoplasmacytic lymphoma,refractory male reproductive system carcinoma,refractory malignant bone neoplasm,refractory malignant brain neoplasm,refractory malignant endocrine neoplasm,refractory malignant female reproductive system neoplasm,refractory malignant gastrointestinal stromal tumor,refractory malignant germ cell tumor,refractory malignant glioma,refractory malignant glomus tumor,refractory malignant head and neck neoplasm,refractory malignant leptomeningeal neoplasm,refractory malignant lymphoid neoplasm,refractory malignant male reproductive system neoplasm,refractory malignant mastocytosis,refractory malignant mesothelioma,refractory malignant myoepithelioma,refractory malignant neoplasm,refractory malignant neoplasm of multiple primary sites,refractory malignant oral neoplasm,refractory malignant ovarian brenner tumor,refractory malignant peripheral nerve sheath tumor,refractory malignant pharyngeal neoplasm,refractory malignant salivary gland neoplasm,refractory malignant skin neoplasm,refractory malignant soft tissue neoplasm,refractory malignant solid neoplasm,refractory malignant testicular germ cell tumor,refractory malignant thymoma,refractory malignant thyroid gland neoplasm,refractory malignant urinary system neoplasm,refractory mantle cell lymphoma,refractory marginal zone lymphoma,refractory mature b-cell lymphoma,refractory mature t-cell and nk-cell neoplasm,refractory mature t-cell and nk-cell non-hodgkin lymphoma,refractory mediastinal lymphoma,refractory medulloblastoma,"refractory medulloblastoma, shh-activated","refractory medulloblastoma, wnt-activated",refractory melanoma,refractory meningioma,refractory merkel cell carcinoma,refractory metastatic digestive system carcinoma,refractory metastatic melanoma,refractory metastatic pancreatic adenocarcinoma,refractory microsatellite stable colorectal carcinoma,refractory microsatellite stable endometrial carcinoma,refractory mixed cellularity classic hodgkin lymphoma,refractory mixed phenotype acute leukemia,refractory monomorphic epitheliotropic intestinal t-cell lymphoma,refractory monomorphic post-transplant lymphoproliferative disorder,refractory mucosal melanoma,refractory mycosis fungoides,refractory mycosis fungoides and sezary syndrome,refractory myelodysplastic syndrome,refractory myelodysplastic/myeloproliferative neoplasm,refractory myeloid neoplasm,refractory myeloproliferative neoplasm,refractory myxoid liposarcoma,"refractory nk-cell lymphoma, unclassifiable",refractory nasal type extranodal nk/t-cell lymphoma,refractory nasopharyngeal carcinoma,refractory neoplasm,refractory neoplastic post-transplant lymphoproliferative disorder,refractory neuroblastoma,refractory neuroendocrine carcinoma,refractory neuroendocrine neoplasm,refractory neutropenia,refractory nodal marginal zone b-cell lymphoma,refractory nodal marginal zone lymphoma,refractory nodal peripheral t-cell lymphoma with tfh phenotype,refractory nodular lymphocyte predominant hodgkin lymphoma,refractory nodular sclerosis classic hodgkin lymphoma,refractory non-cutaneous melanoma,refractory non-hodgkin lymphoma,refractory non-muscle invasive bladder urothelial carcinoma,refractory ocular melanoma,refractory oral cavity squamous cell carcinoma,refractory oropharyngeal squamous cell carcinoma,refractory osteosarcoma,refractory ovarian adenocarcinoma,refractory ovarian carcinoma,refractory ovarian clear cell adenocarcinoma,refractory ovarian endometrioid adenocarcinoma,refractory ovarian high grade serous adenocarcinoma,refractory ovarian low grade serous adenocarcinoma,refractory ovarian mucinous adenocarcinoma,refractory ovarian seromucinous carcinoma,refractory ovarian serous adenocarcinoma,refractory ovarian squamous cell carcinoma,refractory ovarian transitional cell carcinoma,refractory ovarian undifferentiated carcinoma,refractory pancreatic adenocarcinoma,refractory pancreatic carcinoma,refractory pancreatic ductal adenocarcinoma,refractory pancreatic neuroendocrine carcinoma,refractory pancreatobiliary carcinoma,refractory paraganglioma,refractory paranasal sinus squamous cell carcinoma,refractory penile carcinoma,refractory peripheral primitive neuroectodermal tumor,"refractory peripheral t-cell lymphoma, not otherwise specified",refractory ph-like acute lymphoblastic leukemia,refractory plasma cell myeloma,refractory plasma cell neoplasm,refractory plasmablastic lymphoma,refractory pleural malignant mesothelioma,refractory polymorphic post-transplant lymphoproliferative disorder,refractory primary amyloidosis,refractory primary bone lymphoma,refractory primary central nervous system neoplasm,refractory primary cutaneous anaplastic large cell lymphoma,"refractory primary cutaneous diffuse large b-cell lymphoma, leg type",refractory primary cutaneous lymphoma,refractory primary cutaneous t-cell non-hodgkin lymphoma,refractory primary diffuse large b-cell lymphoma of the central nervous system,refractory primary effusion lymphoma,refractory primary malignant central nervous system neoplasm,refractory primary mediastinal (thymic) large b-cell lymphoma,refractory primary myelofibrosis,refractory primary peritoneal adenocarcinoma,refractory primary peritoneal carcinoma,refractory primary peritoneal clear cell adenocarcinoma,refractory primary peritoneal endometrioid adenocarcinoma,refractory primary peritoneal high grade serous adenocarcinoma,refractory primary peritoneal low grade serous adenocarcinoma,refractory primary peritoneal serous adenocarcinoma,refractory primary peritoneal transitional cell carcinoma,refractory primary peritoneal undifferentiated carcinoma,"refractory primary systemic anaplastic large cell lymphoma, alk-positive",refractory primary vitreoretinal diffuse large b-cell lymphoma,refractory primary vitreoretinal non-hodgkin lymphoma,refractory primitive neuroectodermal tumor,refractory prostate adenocarcinoma,refractory prostate carcinoma,refractory pseudomyxoma peritonei,refractory rectal adenocarcinoma,refractory rectal carcinoma,refractory rectal squamous cell carcinoma,refractory renal cell carcinoma,refractory renal pelvis urothelial carcinoma,refractory rhabdoid tumor,refractory rhabdoid tumor of the kidney,refractory rhabdomyosarcoma,refractory round cell liposarcoma,refractory salivary gland carcinoma,refractory sarcoma,refractory sezary syndrome,refractory sinonasal squamous cell carcinoma,refractory skin squamous cell carcinoma,refractory small cell glioblastoma,refractory small intestinal carcinoma,refractory small lymphocytic lymphoma,refractory soft tissue sarcoma,refractory spinal cord neoplasm,refractory spindle cell sarcoma,refractory splenic marginal zone lymphoma,refractory squamous cell carcinoma,refractory subcutaneous panniculitis-like t-cell lymphoma,refractory synovial sarcoma,refractory systemic anaplastic large cell lymphoma,refractory t acute lymphoblastic leukemia,refractory t lymphoblastic leukemia/lymphoma,refractory t lymphoblastic lymphoma,refractory t-cell large granular lymphocyte leukemia,refractory t-cell prolymphocytic leukemia,refractory t-cell/histiocyte-rich large b-cell lymphoma,refractory testicular lymphoma,refractory thrombocytopenia,refractory thymic carcinoma,refractory thyroid gland anaplastic carcinoma,refractory thyroid gland carcinoma,refractory thyroid gland follicular carcinoma,refractory thyroid gland medullary carcinoma,refractory thyroid gland oncocytic carcinoma,refractory thyroid gland papillary carcinoma,refractory transformed b-cell non-hodgkin lymphoma,refractory transformed chronic lymphocytic leukemia,refractory transformed lymphoma,refractory transformed mycosis fungoides,refractory transformed t-cell non-hodgkin lymphoma,refractory triple-negative breast carcinoma,refractory undifferentiated pleomorphic sarcoma,refractory ureter urothelial carcinoma,refractory urethral urothelial carcinoma,refractory urinary system carcinoma,refractory urothelial carcinoma,refractory uterine corpus cancer,refractory uterine corpus carcinosarcoma,refractory uveal melanoma,refractory vaginal carcinoma,refractory vaginal squamous cell carcinoma,refractory visual pathway glioma,refractory vulvar carcinoma,refractory vulvar squamous cell carcinoma,refractory who grade 1 glioma,refractory who grade 2 glioma,refractory who grade 3 glioma,refractory waldenstrom macroglobulinemia,refractory wilms tumor,refractory acute lymphoid leukaemia,region 17p13 allelic loss associated medulloblastoma,regional adrenal gland pheochromocytoma,regional digestive system neuroendocrine tumor g1,regional malignant ureter neoplasm,regional malignant urethral neoplasm,regional neuroblastoma,regional renal pelvis and ureter urothelial carcinoma,regional tumor implant,regional ureter carcinoma,regressed testicular germ cell tumor,regressing cutaneous melanoma,regressing melanoma,regressing nevus,regressing non-cutaneous melanoma,renal benign mesenchymoma,renal cell carcinoma,renal cell carcinoma associated with neuroblastoma,renal cell carcinoma associated with xp11.2 translocations/tfe3 gene fusions,renal cell carcinoma associated with inv(x)(p11;q12),renal cell carcinoma associated with t(x;1)(p11.2;p34),renal cell carcinoma associated with t(x;1)(p11.2;q21),renal cell carcinoma associated with t(x;17)(p11.2;q25),renal cell carcinoma with constitutional chromosome 3 translocations,renal cell carcinoma with t(6;11);(p21;q12); malat1-tfeb,renal papillary adenoma,renal pelvis adenocarcinoma,renal pelvis carcinoma,renal pelvis inverted papilloma,renal pelvis neoplasm,renal pelvis papillary urothelial carcinoma,renal pelvis papillary urothelial neoplasm,renal pelvis squamous cell carcinoma,renal pelvis urothelial carcinoma,renal pelvis urothelial papilloma,renal pelvis and ureter carcinoma,renal pelvis and ureter urothelial carcinoma,renal vein leiomyosarcoma,renomedullary interstitial cell tumor,reproductive endocrine neoplasm,reproductive system neoplasm,resectable adenocarcinoma of unknown primary,resectable bile duct adenocarcinoma,resectable bladder urothelial carcinoma,resectable breast carcinoma,resectable carcinoma,resectable carcinoma of unknown primary,resectable cholangiocarcinoma,resectable colon carcinoma,resectable colorectal carcinoma,resectable cutaneous squamous cell carcinoma of the head and neck,resectable dedifferentiated liposarcoma,resectable digestive system carcinoma,resectable duodenal carcinoma,resectable extrahepatic bile duct adenocarcinoma,resectable extrahepatic bile duct carcinoma,resectable glioblastoma,resectable glioma,resectable head and neck squamous cell carcinoma,resectable hepatoblastoma,resectable hepatocellular carcinoma,resectable intrahepatic cholangiocarcinoma,resectable leiomyosarcoma,resectable liposarcoma,resectable liver and intrahepatic bile duct carcinoma,resectable lung non-small cell carcinoma,resectable malignant bone neoplasm,resectable malignant female reproductive system neoplasm,resectable malignant liver neoplasm,resectable malignant mesothelioma,resectable malignant neoplasm,resectable neuroblastoma,resectable oropharyngeal squamous cell carcinoma,resectable osteosarcoma,resectable pancreatic acinar cell carcinoma,resectable pancreatic adenocarcinoma,resectable pancreatic adenosquamous carcinoma,resectable pancreatic carcinoma,resectable pancreatic ductal adenocarcinoma,resectable periampullary adenocarcinoma,resectable platinum-resistant malignant germ cell tumor,resectable pleural malignant mesothelioma,resectable renal cell carcinoma,resectable sarcoma,resectable skin carcinoma,resectable skin squamous cell carcinoma,resectable small intestinal carcinoma,resectable soft tissue sarcoma,resectable undifferentiated pleomorphic sarcoma,respiratory system neoplasm,rete ovarii adenocarcinoma,rete ovarii adenoma,rete ovarii cystadenofibroma,rete ovarii cystadenoma,rete ovarii neoplasm,rete testis adenocarcinoma,rete testis adenoma,rete testis neoplasm,reticulosarcoma,reticulosarcoma involving spleen,retiform hemangioendothelioma,retinal astrocytoma,retinal cavernous hemangioma,retinal cell neoplasm,retinal hemangioblastoma,retinal hemangioma,retinal melanoma,retinal neoplasm,retinal neuroblastoma,retinal pigment epithelium adenocarcinoma,retinoblastoma,retinocytoma,retro-orbital neoplasm,retromolar trigone squamous cell carcinoma,retroperitoneal carcinoma,retroperitoneal ganglioneuroma,retroperitoneal gastrointestinal stromal tumor,retroperitoneal germ cell tumor,retroperitoneal hemangiopericytoma,retroperitoneal inflammatory myofibroblastic tumor,retroperitoneal leiomyosarcoma,retroperitoneal lymphoma,retroperitoneal malignant peripheral nerve sheath tumor,retroperitoneal neoplasm,retroperitoneal rhabdomyosarcoma,retroperitoneal sarcoma,retroperitoneal undifferentiated pleomorphic sarcoma,retropharyngeal neoplasm,rhabdoid meningioma,rhabdoid tumor,rhabdoid tumor of the kidney,rhabdomyoma,rhabdomyosarcoma,rhabdomyosarcoma with mixed embryonal and alveolar features,rosette-forming glioneuronal tumor,rosette-forming glioneuronal tumor of the fourth ventricle,round cell liposarcoma,round cell liposarcoma nci grade 2,round cell liposarcoma nci grade 3,round cell sarcoma with ewsr1-nfatc2 gene fusion,round cell sarcoma with ewsr1-patz1 gene fusion,round cell sarcoma with ewsr1-non-ets fusion,round cell sarcoma with fus-nfatc2 gene fusion,samd9-associated familial myelodysplastic syndrome,samd9l-associated familial myelodysplastic syndrome,smarcb1 schwannomatosis 1,sacral chordoma,sacral intraspinal meningioma,sacral spine neoplasm,sacrococcygeal teratoma,salivary duct carcinoma,salivary gland acinic cell carcinoma,salivary gland adenocarcinoma,"salivary gland adenocarcinoma, not otherwise specified",salivary gland adenoid cystic carcinoma,salivary gland adenoma,salivary gland adenosquamous carcinoma,salivary gland basal cell adenocarcinoma,salivary gland basal cell adenoma,salivary gland canalicular adenoma,salivary gland carcinoma,salivary gland carcinoma ex pleomorphic adenoma,salivary gland carcinosarcoma,salivary gland clear cell carcinoma,salivary gland cystadenocarcinoma,salivary gland cystadenoma,salivary gland diffuse large b-cell lymphoma,salivary gland ductal papilloma,salivary gland epithelial-myoepithelial carcinoma,salivary gland follicular lymphoma,salivary gland hemangioma,salivary gland hodgkin lymphoma,salivary gland intraductal carcinoma,salivary gland intraductal papilloma,salivary gland inverted ductal papilloma,salivary gland large cell carcinoma,salivary gland large cell neuroendocrine carcinoma,salivary gland lipoma,salivary gland lymphadenoma,salivary gland lymphoepithelial carcinoma,salivary gland lymphoma,salivary gland monomorphic adenoma,salivary gland mucinous adenocarcinoma,salivary gland mucoepidermoid carcinoma,salivary gland mucosa-associated lymphoid tissue lymphoma,salivary gland myoepithelial carcinoma,salivary gland myoepithelial tumor,salivary gland myoepithelioma,salivary gland neoplasm,salivary gland neuroendocrine carcinoma,salivary gland nodular fasciitis,salivary gland non-hodgkin lymphoma,salivary gland oncocytic carcinoma,salivary gland oncocytoma,salivary gland pleomorphic adenoma,salivary gland polymorphous adenocarcinoma,salivary gland poorly differentiated carcinoma,salivary gland poorly differentiated squamous cell carcinoma,salivary gland sebaceous adenoma,salivary gland sebaceous carcinoma,salivary gland sebaceous lymphadenoma,salivary gland secretory carcinoma,salivary gland sialadenoma papilliferum,salivary gland sialoblastoma,salivary gland small cell neuroendocrine carcinoma,salivary gland squamous cell carcinoma,salivary gland undifferentiated carcinoma,sarcoma,sarcoma nci grade 1,sarcoma nci grade 2,sarcoma nci grade 3,sarcoma by nci grade,sarcoma of the extremity,sarcoma with bcor genetic alterations,sarcomatoid carcinoma,sarcomatoid carcinoma of the penis,sarcomatoid hepatocellular carcinoma,sarcomatoid intrahepatic cholangiocarcinoma,sarcomatoid mesothelioma,sarcomatoid renal cell carcinoma,sarcomatoid transitional cell carcinoma,schistosoma hematobium-related bladder squamous cell carcinoma,schistosoma hematobium-related bladder verrucous carcinoma,schwannoma,schwannoma of the seventh cranial nerve,schwannoma of the twelfth cranial nerve,schwannomatosis,scirrhous adenocarcinoma,scirrhous hepatocellular carcinoma,sclerosing atypical lipomatous tumor/well differentiated liposarcoma,sclerosing epithelioid fibrosarcoma,sclerosing odontogenic carcinoma,sclerosing pecoma,sclerosing pneumocytoma,sclerosing polycystic adenosis,sclerosing rhabdomyosarcoma,sclerosing thymoma,scrotal basal cell carcinoma,scrotal carcinoma,scrotal hemangioma,scrotal liposarcoma,scrotal melanoma,scrotal neoplasm,scrotal paget disease,scrotal sarcoma,scrotal squamous cell carcinoma,sebaceoma,sebaceous adenoma,sebaceous carcinoma,sebaceous gland neoplasm,seborrheic keratosis,second primary malignant neoplasm,second primary tumor,secondary acute myeloid leukemia,secondary carcinoma,"secondary central atypical cartilaginous tumor/chondrosarcoma, grade 1",secondary central chondrosarcoma,secondary central nervous system hodgkin lymphoma,secondary central nervous system lymphoma,secondary central nervous system non-hodgkin lymphoma,secondary cerebral hodgkin lymphoma,secondary chondrosarcoma,secondary choroidal non-hodgkin lymphoma,secondary glioblastoma,secondary heart lymphoma,secondary malignant neoplasm,secondary myelodysplastic syndrome,secondary osteosarcoma,secondary peripheral atypical cartilaginous tumor,"secondary peripheral atypical cartilaginous tumor/chondrosarcoma, grade 1",secondary peripheral chondrosarcoma,secondary prostate urothelial carcinoma,secondary supratentorial anaplastic astrocytoma,secretory meningioma,sellar chondroid chordoma,sellar chordoma,sellar choriocarcinoma,sellar dedifferentiated chordoma,sellar embryonal carcinoma,sellar gangliocytoma,sellar germ cell tumor,sellar germinoma,sellar immature teratoma,sellar mature teratoma,sellar meningioma,sellar mixed germ cell tumor,sellar neuroblastoma,sellar neurocytoma,sellar paraganglioma,sellar region neoplasm,sellar schwannoma,sellar solitary fibrous tumor,sellar teratoma,sellar teratoma with malignant transformation,sellar yolk sac tumor,seminal vesicle adenocarcinoma,seminal vesicle angiosarcoma,seminal vesicle cystadenoma,seminal vesicle leiomyoma,seminal vesicle leiomyosarcoma,seminal vesicle mammary-type myofibroblastoma,seminal vesicle mixed epithelial and stromal tumor,seminal vesicle neoplasm,seminal vesicle schwannoma,seminal vesicle soft tissue neoplasm,seminal vesicle squamous cell carcinoma,seminoma,serous adenocarcinoma,serous adenofibroma,serous cystadenocarcinoma,serous cystadenoma,serous endometrial intraepithelial carcinoma,serous neoplasm,serous surface papillary carcinoma,serous surface papilloma,serous tubal intraepithelial carcinoma,serous tubal intraepithelial lesion,serrated lesions and polyps,sex cord-stromal tumor,sex hormone-producing adrenal cortical adenoma,sezary syndrome,shared neoantigen-positive malignant solid neoplasm,sialolipoma,sigmoid colon carcinoma,sigmoid colon neuroendocrine tumor g1,signet ring cell carcinoma,signet ring cell intrahepatic cholangiocarcinoma,signet ring cell/histiocytoid carcinoma,signet ring melanoma,simple endometrial hyperplasia,simple endometrial hyperplasia with atypia,sinonasal adenocarcinoma,"sinonasal adenocarcinoma, intestinal-type","sinonasal adenocarcinoma, intestinal-type with colonic pattern","sinonasal adenocarcinoma, intestinal-type with mixed pattern","sinonasal adenocarcinoma, intestinal-type with mucinous pattern","sinonasal adenocarcinoma, intestinal-type with papillary pattern","sinonasal adenocarcinoma, intestinal-type with solid pattern","sinonasal adenocarcinoma, non-intestinal-type","sinonasal adenocarcinoma, non-salivary-type","sinonasal adenocarcinoma, salivary-type",sinonasal ameloblastoma,sinonasal angiosarcoma,sinonasal carcinoma,sinonasal desmoid fibromatosis,sinonasal epithelioid hemangioendothelioma,sinonasal ewing sarcoma/peripheral primitive neuroectodermal tumor,sinonasal exophytic papilloma,sinonasal extranodal nk/t-cell lymphoma,sinonasal fibrosarcoma,sinonasal glomangiopericytoma,sinonasal hemangioma,sinonasal human papillomavirus-related carcinoma with adenoid cystic-like features,sinonasal inverted papilloma,sinonasal keratinizing squamous cell carcinoma,sinonasal large cell neuroendocrine carcinoma,sinonasal leiomyoma,sinonasal leiomyosarcoma,sinonasal lymphoepithelial carcinoma,sinonasal lymphoma,sinonasal malignant peripheral nerve sheath tumor,sinonasal mucosal melanoma,sinonasal nut carcinoma,sinonasal neoplasm,sinonasal neuroendocrine carcinoma,sinonasal neurofibroma,sinonasal non-hodgkin lymphoma,sinonasal non-keratinizing squamous cell carcinoma,sinonasal olfactory neuroblastoma,sinonasal oncocytic papilloma,sinonasal papilloma,sinonasal plasmacytoma,sinonasal pleomorphic adenoma,sinonasal poorly differentiated carcinoma,sinonasal rhabdomyosarcoma,sinonasal sarcoma,sinonasal schwannoma,sinonasal small cell neuroendocrine carcinoma,sinonasal soft tissue neoplasm,sinonasal solitary fibrous tumor,sinonasal spindle cell squamous cell carcinoma,sinonasal squamous cell carcinoma,sinonasal synovial sarcoma,sinonasal teratocarcinosarcoma,sinonasal undifferentiated carcinoma,sinonasal undifferentiated pleomorphic sarcoma,sinusoidal hemangioma,skeletal muscle neoplasm,skin acantholytic squamous cell carcinoma,skin adamantinoid basal cell carcinoma,skin adenoid basal cell carcinoma,skin adenosquamous carcinoma,skin angiolipoma,skin angiosarcoma,skin appendage adenoma,skin appendage neoplasm,skin atypical lipomatous tumor/well differentiated liposarcoma,skin basal cell carcinoma,skin basal cell carcinoma with adnexal differentiation,skin basal cell carcinoma with sarcomatoid differentiation,skin basal cell carcinoma with sebaceous differentiation,skin basaloid carcinoma,skin basosquamous cell carcinoma,skin carcinoma,skin cavernous hemangioma,skin clear cell basal cell carcinoma,skin clear cell squamous cell carcinoma,skin cystic basal cell carcinoma,skin epithelioid hemangioma,skin ewing sarcoma,skin fibroblastic neoplasm,skin fibroepithelial basal cell carcinoma,skin fibrohistiocytic neoplasm,skin fibrous histiocytoma,"skin fibrous histiocytoma, cellular variant","skin fibrous histiocytoma, epithelioid variant","skin fibrous histiocytoma, fibroblastic variant","skin fibrous histiocytoma, histiocytic variant",skin follicular basal cell carcinoma,skin glomangioma,skin glomus tumor,skin hemangioendothelioma,skin hemangioma,skin hemangiopericytoma,skin infiltrating basal cell carcinoma,skin infundibulocystic basal cell carcinoma,skin intermediate fibrohistiocytic neoplasm,skin kaposi sarcoma,skin keratotic basal cell carcinoma,skin leiomyoma,skin lipoma,skin lipomatous neoplasm,skin liposarcoma,skin lymphangioleiomyomatosis,skin lymphangioma,skin lymphangiosarcoma,skin lymphoepithelioma-like carcinoma,skin melanocytic neoplasm,skin metatypical carcinoma,skin micronodular basal cell carcinoma,skin myoepithelioma,skin myxofibrosarcoma,skin myxoma,skin neoplasm,skin nodular basal cell carcinoma,skin nodular solid basal cell carcinoma,skin nodulo-ulcerative basal cell carcinoma,skin papilloma,skin pigmented basal cell carcinoma,skin pleomorphic lipoma,skin pleomorphic liposarcoma,skin pseudovascular squamous cell carcinoma,skin radiation-related angiosarcoma,skin sarcoma,skin sclerosing/morphoeic basal cell carcinoma,skin signet ring cell basal cell carcinoma,skin smooth muscle neoplasm,skin soft tissue neoplasm,skin spindle cell lipoma,skin spindle cell squamous cell carcinoma,skin spindle cell/pleomorphic lipoma,skin squamous cell carcinoma,skin squamous cell carcinoma in situ,skin squamous cell carcinoma with osteoclast-like giant cells,skin squamous cell carcinoma with sarcomatoid differentiation,skin squamous cell papilloma,skin undifferentiated pleomorphic sarcoma,skin vascular neoplasm,skin verrucous carcinoma,skull base chordoma,skull base meningioma,skull base neoplasm,skull neoplasm,skull osteoma,small cell adenocarcinoma,"small cell carcinoma, fusiform cell type",small cell glioblastoma,small cell intermediate cell carcinoma,small cell neuroendocrine carcinoma,small cell osteosarcoma,small cell sarcoma,small cell undifferentiated hepatoblastoma,small cell variant anaplastic large cell lymphoma,small congenital melanocytic nevus,small duct intrahepatic cholangiocarcinoma,small hepatocellular carcinoma,small intestinal adenocarcinoma,small intestinal adenoma,small intestinal adenosquamous carcinoma,small intestinal angiosarcoma,small intestinal atypical burkitt/burkitt-like lymphoma,small intestinal b-cell non-hodgkin lymphoma,small intestinal burkitt lymphoma,small intestinal carcinoma,small intestinal composite gangliocytoma/neuroma and neuroendocrine tumor,small intestinal diffuse large b-cell lymphoma,small intestinal enterochromaffin cell serotonin-producing neuroendocrine tumor,small intestinal enteropathy-associated t-cell lymphoma,small intestinal fibrosarcoma,small intestinal follicular lymphoma,small intestinal gastrin-producing neuroendocrine tumor,small intestinal gastrointestinal stromal tumor,small intestinal high grade intraepithelial neoplasia,small intestinal hodgkin lymphoma,small intestinal intraepithelial neoplasia,small intestinal kaposi sarcoma,small intestinal l-cell glucagon-like peptide-producing neuroendocrine tumor,small intestinal large cell neuroendocrine carcinoma,small intestinal leiomyoma,small intestinal leiomyosarcoma,small intestinal lipoma,small intestinal low grade intraepithelial neoplasia,small intestinal lymphoma,small intestinal mantle cell lymphoma,small intestinal medullary carcinoma,small intestinal mixed adenoneuroendocrine carcinoma,small intestinal monomorphic epitheliotropic t-cell lymphoma,small intestinal mucinous adenocarcinoma,small intestinal mucosa-associated lymphoid tissue lymphoma,small intestinal myeloid sarcoma,small intestinal neoplasm,small intestinal neuroendocrine carcinoma,small intestinal neuroendocrine neoplasm,small intestinal neuroendocrine tumor,small intestinal neuroendocrine tumor g1,small intestinal neuroendocrine tumor g2,small intestinal neuroendocrine tumor g3,small intestinal non-hodgkin lymphoma,small intestinal sarcoma,small intestinal signet ring cell carcinoma,small intestinal small cell neuroendocrine carcinoma,small intestinal somatostatin-producing neuroendocrine tumor,small intestinal squamous cell carcinoma,small intestinal t-cell non-hodgkin lymphoma,small intestinal tubular adenoma,small intestinal tubulovillous adenoma,small intestinal undifferentiated carcinoma,small intestinal vip-producing neuroendocrine tumor,small intestinal villous adenoma,small lymphocytic lymphoma variant,small progressed hepatocellular carcinoma,small size posterior uveal melanoma,smoldering adult t-cell leukemia/lymphoma,smoldering systemic mastocytosis,smoldering systemic mastocytosis with an associated hematological neoplasm,smooth muscle neoplasm,soft palate benign granular cell tumor,soft palate carcinoma,soft palate pleomorphic adenoma,soft palate squamous cell carcinoma,soft tissue amyloid neoplasm,soft tissue angiosarcoma,soft tissue chondroma,soft tissue fibrosarcoma,soft tissue neoplasm,soft tissue perineurioma,soft tissue sarcoma,soft tissue sarcoma of the trunk and extremities,soft tissue tumor of uncertain differentiation,solar radiation-related cutaneous melanoma,solar radiation-related malignant neoplasm,solar radiation-related skin squamous cell carcinoma,solid alveolar rhabdomyosarcoma,solid angioleiomyoma,solid carcinoma,solid glomus tumor,solid lung adenocarcinoma,solid neoplasm,solid pseudopapillary carcinoma of the pancreas,solid pseudopapillary neoplasm of the ovary,solid pseudopapillary neoplasm of the pancreas,solid/multicystic ameloblastoma,solid/trabecular variant thyroid gland papillary carcinoma,solitary adult fibroma,solitary circumscribed neuroma,solitary mastocytoma of the skin,solitary osteochondroma,solitary plasmacytoma of bone,somatic-type malignancy,somatostatin-producing neuroendocrine tumor,somatotroph pituitary neuroendocrine tumor,somatotroph-lactotroph pituitary neuroendocrine tumor,sparsely granulated corticotroph pituitary neuroendocrine tumor,sparsely granulated lactotroph pituitary neuroendocrine tumor,sparsely granulated somatotroph pituitary neuroendocrine tumor,spermatic cord lipoma,sphenocavernous meningioma,sphenoid sinus inverted papilloma,sphenoid sinus neoplasm,sphenoid sinus papilloma,sphenoid sinus squamous cell carcinoma,sphenoorbital meningioma,spinal chordoma,spinal cord astrocytoma,"spinal cord embryonal tumor, not otherwise specified",spinal cord ependymoma,"spinal cord ependymoma, mycn amplified",spinal cord glioma,spinal cord lipoma,spinal cord lymphoma,spinal cord melanoma,spinal cord meningioma,spinal cord neoplasm,spinal cord neuroblastoma,spinal cord neurofibroma,spinal cord oligodendroglioma,spinal cord sarcoma,spinal hemangioblastoma,spinal meningioma,spinal multifocal clear cell meningioma,spinal neoplasm,spindle cell hemangioma,spindle cell lipoma,spindle cell melanoma,spindle cell neoplasm,spindle cell nevus,spindle cell oncocytoma,spindle cell rhabdomyosarcoma,spindle cell sarcoma,spindle cell squamous cell carcinoma,spindle cell synovial sarcoma,spindle cell type atypical fibroxanthoma,spindle cell type gastrointestinal stromal tumor,spindle cell variant thyroid gland papillary carcinoma,spindle cell/pleomorphic lipoma,spindle cell/sclerosing rhabdomyosarcoma,spindle-cell predominant trichodiscoma,spiradenocarcinoma,spiradenocylindrocarcinoma,spiradenocylindroma,spiradenoma,spitz melanoma,spitz nevus,splenic angiosarcoma,splenic b lymphoblastic lymphoma,"splenic b-cell lymphoma/leukemia, unclassifiable",splenic burkitt lymphoma,splenic diffuse large b-cell lymphoma,splenic diffuse red pulp small b-cell lymphoma,splenic follicular lymphoma,splenic hemangioma,splenic hodgkin lymphoma,splenic lymphoblastic lymphoma,splenic lymphoma,splenic manifestation of b-cell prolymphocytic leukemia,splenic manifestation of chronic lymphocytic leukemia,"splenic manifestation of chronic myelogenous leukemia, bcr-abl1 positive",splenic manifestation of hairy cell leukemia,splenic manifestation of leukemia,splenic manifestation of prolymphocytic leukemia,splenic manifestation of t-cell large granular lymphocyte leukemia,splenic manifestation of t-cell prolymphocytic leukemia,splenic marginal zone lymphoma,splenic neoplasm,splenic non-hodgkin lymphoma,splenic plasmacytoma,splenic t lymphoblastic lymphoma,spongioneuroblastoma,spontaneously regressed retinoblastoma,sporadic breast carcinoma,sporadic cylindroma,sporadic gastric adenocarcinoma,sporadic gastric diffuse adenocarcinoma,sporadic malignant peripheral nerve sheath tumor,sporadic papillary renal cell carcinoma,sporadic retinoblastoma,sporadic thyroid gland medullary carcinoma,sporadic thyroid gland micromedullary carcinoma,squamoid eccrine ductal carcinoma,squamous cell carcinoma,squamous cell carcinoma in situ of the nipple,squamous cell carcinoma in situ with questionable stromal invasion,squamous cell carcinoma of unknown primary,squamous cell carcinoma of the penis,"squamous cell carcinoma of the penis, usual type",squamous cell carcinoma with horn formation,"squamous cell carcinoma, clear cell type",squamous cell intraepithelial neoplasia,squamous cell neoplasm,squamous cell papilloma,squamous odontogenic tumor,squamous papillomatosis,stage 0 chronic lymphocytic leukemia,stage 0 extrahepatic bile duct cancer,stage 0 oral cavity verrucous carcinoma,stage 0 pharyngeal cancer,stage 0 skin cancer,stage 0 squamous cell carcinoma,stage 0 transitional cell carcinoma,stage 1 neuroblastoma,stage 2 neuroblastoma,stage 2a neuroblastoma,stage 2b neuroblastoma,stage 3 neuroblastoma,stage 4 neuroblastoma,stage 4s neuroblastoma,stage a chronic lymphocytic leukemia,stage a prostate cancer,stage b chronic lymphocytic leukemia,stage b prostate cancer,stage c chronic lymphocytic leukemia,stage c prostate cancer,stage d prostate cancer,stage i adult diffuse large cell lymphoma,stage i adult diffuse mixed cell lymphoma,stage i adult diffuse small cleaved cell lymphoma,stage i borderline ovarian surface epithelial-stromal tumor,stage i centroblastic follicular lymphoma,stage i childhood large cell lymphoma,stage i chronic lymphocytic leukemia,stage i cutaneous t-cell non-hodgkin lymphoma,stage i extragonadal mixed germ cell tumor,stage i extragonadal non-seminomatous germ cell tumor,stage i extragonadal seminoma,stage i extrahepatic bile duct cancer,stage i high grade burkitt-like lymphoma,stage i kidney wilms tumor,stage i malignant mediastinal germ cell tumor,stage i oral cavity verrucous carcinoma,stage i ovarian choriocarcinoma,stage i paranasal sinus cancer,stage i pharyngeal cancer,stage i retinoblastoma,stage i small intestinal gastrointestinal stromal tumor,stage i splenic marginal zone lymphoma,stage i t lymphoblastic leukemia/lymphoma,stage ia gastric gastrointestinal stromal tumor,stage ia retinoblastoma,stage ib gastric gastrointestinal stromal tumor,stage ib retinoblastoma,stage ii adult diffuse large cell lymphoma,stage ii adult diffuse mixed cell lymphoma,stage ii adult diffuse small cleaved cell lymphoma,stage ii borderline ovarian surface epithelial-stromal tumor,stage ii centroblastic follicular lymphoma,stage ii childhood large cell lymphoma,stage ii chronic lymphocytic leukemia,stage ii contiguous adult diffuse large cell lymphoma,stage ii contiguous adult diffuse mixed cell lymphoma,stage ii contiguous adult diffuse small cleaved cell lymphoma,stage ii cutaneous t-cell non-hodgkin lymphoma,stage ii extragonadal mixed germ cell tumor,stage ii extragonadal non-seminomatous germ cell tumor,stage ii extragonadal seminoma,stage ii extrahepatic bile duct cancer,stage ii gastric gastrointestinal stromal tumor,stage ii high grade burkitt-like lymphoma,stage ii kidney wilms tumor,stage ii malignant mediastinal germ cell tumor,stage ii non-contiguous adult diffuse large cell lymphoma,stage ii non-contiguous adult diffuse mixed cell lymphoma,stage ii non-contiguous adult diffuse small cleaved cell lymphoma,stage ii oral cavity adenoid cystic carcinoma,stage ii oral cavity mucoepidermoid carcinoma,stage ii oral cavity verrucous carcinoma,stage ii ovarian choriocarcinoma,stage ii pharyngeal cancer,stage ii retinoblastoma,stage ii small intestinal gastrointestinal stromal tumor,stage ii splenic marginal zone lymphoma,stage ii t lymphoblastic leukemia/lymphoma,stage iia bladder cancer,stage iia nasopharyngeal carcinoma,stage iia nasopharyngeal keratinizing squamous cell carcinoma,stage iia retinoblastoma,stage iib bladder cancer,stage iib nasopharyngeal carcinoma,stage iib nasopharyngeal keratinizing squamous cell carcinoma,stage iib retinoblastoma,stage iic adult soft tissue sarcoma,stage iic retinoblastoma,stage iic soft tissue sarcoma,stage iii adult diffuse large cell lymphoma,stage iii adult diffuse mixed cell lymphoma,stage iii adult diffuse small cleaved cell lymphoma,stage iii borderline ovarian surface epithelial-stromal tumor,stage iii childhood large cell lymphoma,stage iii chronic lymphocytic leukemia,stage iii cutaneous t-cell non-hodgkin lymphoma,stage iii extragonadal mixed germ cell tumor,stage iii extragonadal non-seminomatous germ cell tumor,stage iii extragonadal seminoma,stage iii extrahepatic bile duct cancer,stage iii high grade burkitt-like lymphoma,stage iii kidney wilms tumor,stage iii malignant mediastinal germ cell tumor,stage iii oral cavity verrucous carcinoma,stage iii ovarian choriocarcinoma,stage iii pharyngeal cancer,stage iii retinoblastoma,stage iii splenic marginal zone lymphoma,stage iii t lymphoblastic leukemia/lymphoma,stage iiia gastric gastrointestinal stromal tumor,stage iiia retinoblastoma,stage iiia small intestinal gastrointestinal stromal tumor,stage iiib breast  inflammatory carcinoma,stage iiib gastric gastrointestinal stromal tumor,stage iiib retinoblastoma,stage iiib small intestinal gastrointestinal stromal tumor,stage iv adult diffuse large cell lymphoma,stage iv adult diffuse mixed cell lymphoma,stage iv adult diffuse small cleaved cell lymphoma,stage iv borderline ovarian surface epithelial-stromal tumor,stage iv breast  inflammatory carcinoma,stage iv childhood large cell lymphoma,stage iv chronic lymphocytic leukemia,stage iv cutaneous t-cell non-hodgkin lymphoma,stage iv extragonadal non-seminomatous germ cell tumor,stage iv extragonadal seminoma,stage iv extrahepatic bile duct cancer,stage iv gastric cancer with metastasis,stage iv gastric cancer without metastasis,stage iv gastric gastrointestinal stromal tumor,stage iv high grade burkitt-like lymphoma,stage iv kidney wilms tumor,stage iv major salivary gland carcinoma with metastasis,stage iv malignant mediastinal germ cell tumor,stage iv nasal cavity cancer,stage iv oral cavity verrucous carcinoma,stage iv ovarian choriocarcinoma,stage iv pharyngeal cancer,stage iv retinoblastoma,stage iv small intestinal gastrointestinal stromal tumor,stage iv splenic marginal zone lymphoma,stage iv t lymphoblastic leukemia/lymphoma,stage iv testicular non-seminomatous germ cell tumor,stage iva bladder cancer,stage iva esophageal adenocarcinoma,stage iva esophageal cancer,stage iva esophageal squamous cell carcinoma,stage iva extrahepatic bile duct cancer,stage iva oral cavity verrucous carcinoma,stage iva pancreatic cancer,stage iva pharyngeal cancer,stage ivb bladder cancer,stage ivb esophageal adenocarcinoma,stage ivb esophageal cancer,stage ivb esophageal squamous cell carcinoma,stage ivb extrahepatic bile duct cancer,stage ivb oral cavity verrucous carcinoma,stage ivb pancreatic cancer,stage ivb pharyngeal cancer,stage ivc oral cavity verrucous carcinoma,stage ivc pharyngeal cancer,stage v kidney wilms tumor,steatohepatitic hepatocellular carcinoma,sternal chondromyxoid fibroma,sternal intraosseous schwannoma,sternal lymphoma,sternal neoplasm,steroid lipomatosis,storiform-pleomorphic malignant fibrous histiocytoma nci grade 2,storiform-pleomorphic malignant fibrous histiocytoma nci grade 3,stromal neoplasm,stromal predominant kidney wilms tumor,stromal sarcoma,struma ovarii,strumal carcinoid,subcutaneous hemangioma,subcutaneous nodular fasciitis,subcutaneous panniculitis-like t-cell lymphoma,subependymal giant cell astrocytoma,subependymoma,subglottic carcinoma,subglottic hemangioma,subglottic squamous cell carcinoma,subglottic verrucous carcinoma,subglottis neoplasm,sublingual gland adenocarcinoma,sublingual gland carcinoma,sublingual gland neoplasm,submandibular gland acinic cell carcinoma,submandibular gland adenocarcinoma,submandibular gland adenoid cystic carcinoma,submandibular gland carcinoma,submandibular gland carcinoma ex pleomorphic adenoma,submandibular gland mucoepidermoid carcinoma,submandibular gland neoplasm,submandibular gland squamous cell carcinoma,submandibular gland undifferentiated carcinoma,submucosal invasive colon adenocarcinoma,subungual exostosis,subungual glomus tumor,succinate dehydrogenase-deficient renal cell carcinoma,superficial angiomyxoma,superficial atypical lipomatous tumor/well differentiated liposarcoma,superficial basal cell carcinoma,superficial cd34-positive fibroblastic tumor,superficial epithelioma with sebaceous differentiation,superficial fibromatosis,superficial multifocal basal cell carcinoma,superficial spreading adenocarcinoma,superior sulcus lung carcinoma,superior vena cava angiosarcoma,superior vena cava leiomyosarcoma,superior and inferior paraaortic paraganglioma,supraglottic carcinoma,supraglottic squamous cell carcinoma,supraglottic verrucous carcinoma,supraglottis neoplasm,suprasellar germ cell tumor,suprasellar germinoma,suprasellar meningioma,"supratentorial embryonal tumor, not otherwise specified",supratentorial ependymoma,supratentorial ependymoma yap1 fusion-positive,supratentorial ependymoma zfta fusion-positive,"supratentorial ependymoma, not elsewhere classified","supratentorial ependymoma, not otherwise specified","supratentorial ependymoma, yap1-mamld1 fusion-positive","supratentorial ependymoma, zfta-rela fusion-positive",supratentorial glioblastoma,supratentorial gliosarcoma,supratentorial meningioma,supratentorial neoplasm,supratentorial pleomorphic xanthoastrocytoma,sweat gland adenoma,sweat gland carcinoma,sweat gland neoplasm,sweat gland tubular carcinoma,sympathetic paraganglioma,sympathetic schwannoma,synchronous bilateral breast carcinoma,synchronous multifocal osteosarcoma,synovial chondromatosis,synovial chondrosarcoma,synovial hemangioma,synovial neoplasm,synovial sarcoma,syringoacanthoma,syringocystadenocarcinoma papilliferum,syringocystadenoma papilliferum,syringofibroadenoma,syringoma,systemic anaplastic large cell lymphoma,systemic ebv-positive t-cell lymphoma of childhood,systemic mastocytosis,systemic mastocytosis associated with germ cell tumor,systemic mastocytosis with an associated hematological neoplasm,t acute lymphoblastic leukemia,t lymphoblastic leukemia/lymphoma,t lymphoblastic lymphoma,t-cell chronic lymphocytic leukemia,t-cell large granular lymphocyte leukemia,t-cell large granular lymphocyte leukemia expressing the t-cell receptor gamma-delta,"t-cell large granular lymphocyte leukemia, common variant",t-cell non-hodgkin lymphoma by ann arbor stage,t-cell proliferation of uncertain malignant potential,t-cell prolymphocytic leukemia,"t-cell prolymphocytic leukemia, cerebriform cell variant","t-cell prolymphocytic leukemia, small cell variant",t-cell and nk-cell neoplasm,t-zone variant peripheral t-cell lymphoma,t-cell lymphoma,tall cell variant thyroid gland papillary carcinoma,tanycytic ependymoma,tdt negative acute lymphoblastic leukemia,tdt positive acute lymphoblastic leukemia,tectal glioma,telangiectatic glomangioma,telangiectatic osteosarcoma,temporal lobe anaplastic astrocytoma,temporal lobe neoplasm,temporal lobe pleomorphic xanthoastrocytoma,tendon sheath fibroma,tendon sheath lipoma,tenosynovial giant cell tumor,"tenosynovial giant cell tumor, diffuse type","tenosynovial giant cell tumor, localized type",teratoma,teratoma with endocrine differentiation,teratoma with somatic-type malignancy,testicular brenner tumor,testicular choriocarcinoma,testicular dermoid cyst,testicular diffuse large b-cell lymphoma,testicular embryonal carcinoma,testicular fibroma,testicular follicular lymphoma,testicular germ cell neoplasia in situ with extratubular extension,testicular germ cell tumor,testicular gonadoblastoma,testicular granulosa cell tumor,testicular large cell calcifying sertoli cell tumor,testicular leukemia,testicular leydig cell tumor,testicular lymphoma,testicular mixed choriocarcinoma and embryonal carcinoma,testicular mixed choriocarcinoma and seminoma,testicular mixed choriocarcinoma and teratoma,testicular mixed choriocarcinoma and yolk sac tumor,testicular mixed embryonal carcinoma and seminoma,testicular mixed embryonal carcinoma and teratoma,testicular mixed embryonal carcinoma and teratoma with seminoma,testicular mixed embryonal carcinoma and yolk sac tumor,testicular mixed embryonal carcinoma and yolk sac tumor with seminoma,testicular mixed germ cell tumor,testicular mixed germ cell-sex cord-stromal tumor,"testicular mixed germ cell-sex cord-stromal tumor, unclassified",testicular mixed yolk sac tumor and teratoma,testicular mixed yolk sac tumor and teratoma with seminoma,testicular monophasic choriocarcinoma,testicular myeloid sarcoma,testicular nasal type extranodal nk/t-cell lymphoma,testicular neoplasm,testicular neuroendocrine tumor g1,testicular non-seminomatous germ cell tumor,testicular plasmacytoma,testicular polyembryoma,testicular pure germ cell tumor,testicular rhabdomyosarcoma,testicular sarcoma,testicular sclerosing sertoli cell tumor,testicular seminoma,testicular seminoma with high mitotic index,testicular seminoma with syncytiotrophoblastic cells,"testicular seminoma, cribriform variant","testicular seminoma, pseudoglandular variant","testicular seminoma, tubular variant",testicular sertoli cell tumor,"testicular sertoli cell tumor, lipid rich variant",testicular sex cord-stromal tumor,testicular signet ring stromal tumor,testicular spermatocytic tumor,testicular spermatocytic tumor with sarcoma,testicular teratoma,testicular teratoma with somatic-type malignancy,testicular thecoma,testicular trophoblastic tumor,testicular tumor of the thecoma/fibroma group,testicular typical seminoma,testicular yolk sac tumor,"testicular yolk sac tumor, endodermal sinus/perivascular pattern","testicular yolk sac tumor, enteric pattern","testicular yolk sac tumor, glandular-alveolar pattern","testicular yolk sac tumor, hepatoid pattern","testicular yolk sac tumor, macrocystic pattern","testicular yolk sac tumor, microcystic pattern","testicular yolk sac tumor, myxomatous pattern","testicular yolk sac tumor, papillary pattern","testicular yolk sac tumor, polyvesicular vitelline pattern","testicular yolk sac tumor, solid pattern",thalamic neoplasm,therapy-related acute myeloid leukemia,therapy-related cytogenetically normal acute myeloid leukemia,therapy-related leukemia,therapy-related malignant neoplasm,therapy-related myelodysplastic syndrome,therapy-related myelodysplastic/myeloproliferative neoplasm,therapy-related myeloid neoplasm,therapy-related neoplasm,third ventricle germinoma,third ventricle pilocytic astrocytoma,thoracic chordoma,thoracic esophagus adenocarcinoma,thoracic esophagus squamous cell carcinoma,thoracic intraspinal meningioma,thoracic nut carcinoma,thoracic neoplasm,thoracic smarca4-deficient undifferentiated tumor,thoracic spine neoplasm,throat carcinoma,thymic adenocarcinoma,thymic adenosquamous carcinoma,thymic atypical carcinoid tumor,thymic basaloid carcinoma,thymic carcinoid tumor,thymic carcinoma,thymic carcinoma with adenoid cystic carcinoma-like features,thymic clear cell carcinoma,thymic enteric-type adenocarcinoma,thymic epithelial neoplasm,thymic hepatoid adenocarcinoma,thymic hodgkin lymphoma,thymic large cell neuroendocrine carcinoma,thymic low grade papillary adenocarcinoma,thymic lymphoepithelial carcinoma,thymic lymphoma,thymic mucoepidermoid carcinoma,thymic mucosa-associated lymphoid tissue lymphoma,thymic neuroendocrine carcinoma,thymic neuroendocrine neoplasm,thymic sarcomatoid carcinoma,thymic small cell neuroendocrine carcinoma,thymic squamous cell carcinoma,thymic typical carcinoid tumor,thymic undifferentiated carcinoma,thymoliposarcoma,thymoma,thymoma type a,thymoma type ab,thymoma type b,thymoma type b1,thymoma type b2,thymoma type b3,thymus lipofibroadenoma,thymus neoplasm,thymus solitary fibrous tumor,thyroblastoma,thyroid carcinoma arising in struma ovarii,thyroid gland adenocarcinoma,thyroid gland anaplastic carcinoma,"thyroid gland anaplastic carcinoma, osteoclastic variant","thyroid gland anaplastic carcinoma, squamous cell carcinoma pattern",thyroid gland angiosarcoma,thyroid gland benign vascular neoplasm,thyroid gland black follicular adenoma,thyroid gland carcinoma,thyroid gland cavernous hemangioma,thyroid gland clear cell follicular adenoma,thyroid gland cribriform morular carcinoma,thyroid gland diffuse large b-cell lymphoma,thyroid gland follicular adenoma,thyroid gland follicular adenoma with bizarre nuclei,thyroid gland follicular adenoma with papillary architecture,thyroid gland follicular adenoma with papillary hyperplasia,thyroid gland follicular carcinoma,"thyroid gland follicular carcinoma, clear cell variant","thyroid gland follicular carcinoma, encapsulated angioinvasive","thyroid gland follicular carcinoma, minimally invasive","thyroid gland follicular carcinoma, signet ring cell variant","thyroid gland follicular carcinoma, widely invasive",thyroid gland follicular dendritic cell sarcoma,thyroid gland follicular lymphoma,thyroid gland follicular tumor of uncertain malignant potential,thyroid gland hemangioma,thyroid gland histiocytic and dendritic cell neoplasm,thyroid gland hodgkin lymphoma,thyroid gland hyalinizing trabecular tumor,thyroid gland hyperfunctioning adenoma,thyroid gland immunoblastic lymphoma,thyroid gland langerhans cell histiocytosis,thyroid gland leiomyoma,thyroid gland leiomyosarcoma,thyroid gland lipoadenoma,thyroid gland lymphangioma,thyroid gland lymphoma,thyroid gland macrofollicular adenoma,thyroid gland malignant peripheral nerve sheath tumor,thyroid gland medullary carcinoma,thyroid gland medullary carcinoma with amyloid stroma,thyroid gland microfollicular adenoma,thyroid gland mixed medullary and follicular carcinoma,thyroid gland mixed medullary and follicular cell-derived carcinoma,thyroid gland mixed medullary and papillary carcinoma,thyroid gland mucinous carcinoma,thyroid gland mucinous follicular adenoma,thyroid gland mucoepidermoid carcinoma,thyroid gland mucosa-associated lymphoid tissue lymphoma,thyroid gland neoplasm,thyroid gland non-hodgkin lymphoma,thyroid gland noninvasive follicular neoplasm with papillary-like nuclear features,thyroid gland oncocytic adenoma,thyroid gland oncocytic carcinoma,thyroid gland oncocytic neoplasm,thyroid gland papillary carcinoma,thyroid gland papillary carcinoma with fibromatosis/fasciitis-like/desmoid-type stroma,thyroid gland papillary microcarcinoma,thyroid gland papillary and follicular carcinoma,thyroid gland paraganglioma,thyroid gland sarcoma,thyroid gland schwannoma,thyroid gland sclerosing mucoepidermoid carcinoma with eosinophilia,thyroid gland secretory carcinoma,thyroid gland signet ring cell follicular adenoma,thyroid gland solitary fibrous tumor,thyroid gland spindle cell follicular adenoma,thyroid gland spindle epithelial tumor with thymus-like elements,thyroid gland teratoma,thyroid gland tumor of uncertain malignant potential,thyroid gland undifferentiated small cell carcinoma,thyroid gland well-differentiated tumor of uncertain malignant potential,thyrotroph pituitary neuroendocrine tumor,tibial adamantinoma,tobacco-related carcinoma,tongue adenoid cystic carcinoma,tongue adenosquamous carcinoma,tongue carcinoma,tongue lipoma,tongue liposarcoma,tongue mucoepidermoid carcinoma,tongue neoplasm,tongue sarcoma,tongue squamous cell carcinoma,tonsillar carcinoma,tonsillar diffuse large b-cell lymphoma,tonsillar lipoma,tonsillar lymphoma,tonsillar mantle cell lymphoma,tonsillar neoplasm,tonsillar squamous cell carcinoma,tonsillar undifferentiated carcinoma,topoisomerase ii inhibitor-related acute myeloid leukemia,trabecular adenocarcinoma,trabecular adenoma,tracheal adenoid cystic carcinoma,tracheal carcinoma,tracheal carcinoma in situ,tracheal leiomyoma,tracheal lymphoma,tracheal neoplasm,tracheal sarcoma,tracheal squamous cell carcinoma,traditional serrated adenoma,transformed chronic lymphocytic leukemia to diffuse large b-cell lymphoma,transformed mycosis fungoides,transformed lymphoma,transient abnormal myelopoiesis associated with down syndrome,transitional cell carcinoma,transitional cell intraepithelial neoplasia,transitional cell neoplasm,transitional cell papilloma,transitional meningioma,transplant-related bladder urothelial carcinoma,transplant-related carcinoma,transplant-related hematologic malignancy,transplant-related hepatocellular carcinoma,transplant-related kaposi sarcoma,transplant-related lung carcinoma,transplant-related malignant neoplasm,transplant-related renal cell carcinoma,transplant-related skin squamous cell carcinoma,transplant-related squamous cell carcinoma,transverse colon neuroendocrine tumor g1,traumatic myositis ossificans,trichilemmal carcinoma,trichilemmoma,trichoadenoma,trichoblastic carcinoma,trichoblastic carcinosarcoma,trichoblastoma,trichoepithelial carcinoma,trichofollicular carcinoma,trichofolliculoma,trigeminal nerve neoplasm,trigeminal schwannoma,trilateral retinoblastoma,triple-class refractory plasma cell myeloma,triple-negative breast carcinoma,trochlear nerve neoplasm,trophoblastic tumor,true histiocytic lymphoma,tuberculum sellae meningioma,tubular adenocarcinoma,tubular adenoma,tubular apocrine adenoma,tubular neoplasm,tubulocystic renal cell carcinoma,tubulovillous adenoma,tufted angioma,tumor implant,tumor of specialized prostatic stroma,tumor of the follicular infundibulum,tumors derived from langerhans cells,turban tumor,tympanic paraganglioma,type 1 papillary renal cell carcinoma,type 1 renal papillary adenoma,type 2 papillary renal cell carcinoma,type 2 renal papillary adenoma,type a lymphomatoid papulosis,type a spindle cell melanoma,type b lymphomatoid papulosis,type b spindle cell melanoma,type c lymphomatoid papulosis,type d lymphomatoid papulosis,type e lymphomatoid papulosis,type i endometrial adenocarcinoma,type i pleuropulmonary blastoma,type ii endometrial adenocarcinoma,type ii pleuropulmonary blastoma,type iii pleuropulmonary blastoma,typical acute promyelocytic leukemia,typical ovarian thecoma,ulcerative colitis-associated colorectal adenocarcinoma,unclassified hepatocellular adenoma,unclassified renal cell carcinoma,unclassified testicular sex cord-stromal tumor,undifferentiated carcinoma,undifferentiated carcinoma of unknown primary,undifferentiated carcinoma with osteoclast-like giant cells,undifferentiated epithelioid sarcoma,undifferentiated high grade pleomorphic sarcoma of bone,undifferentiated malignant neoplasm,undifferentiated neuroblastoma,undifferentiated pleomorphic sarcoma,undifferentiated pleomorphic sarcoma with osteoclast-like giant cells,"undifferentiated pleomorphic sarcoma, inflammatory variant",undifferentiated retinoblastoma,undifferentiated round cell sarcoma,"undifferentiated sarcoma, not otherwise specified",undifferentiated soft tissue sarcoma,undifferentiated spindle cell sarcoma,undifferentiated stromal sarcoma,unfavorable hodgkin lymphoma,unicystic ameloblastoma,unilateral breast carcinoma,unilateral retinoblastoma,unresectable abdominal neuroendocrine neoplasm,unresectable acral lentiginous melanoma,unresectable adenoid cystic carcinoma,unresectable adrenal cortical carcinoma,unresectable adrenal gland pheochromocytoma,unresectable alveolar soft part sarcoma,unresectable ampulla of vater carcinoma,unresectable anal canal squamous cell carcinoma,unresectable anal squamous cell carcinoma,unresectable angiosarcoma,unresectable basal cell carcinoma,unresectable bile duct carcinoma,unresectable biliary tract carcinoma,unresectable bladder carcinoma,unresectable bladder urothelial carcinoma,unresectable bone sarcoma,unresectable breast carcinoma,unresectable breast inflammatory carcinoma,unresectable carcinoma,unresectable castration-resistant prostate carcinoma,unresectable cervical adenocarcinoma,unresectable cervical adenosquamous carcinoma,unresectable cervical carcinoma,unresectable cervical squamous cell carcinoma,unresectable cholangiocarcinoma,unresectable chordoma,unresectable clear cell renal cell carcinoma,unresectable colon adenocarcinoma,unresectable colon carcinoma,unresectable colorectal adenocarcinoma,unresectable colorectal carcinoma,unresectable craniopharyngioma,unresectable cutaneous melanoma,unresectable dedifferentiated liposarcoma,unresectable desmoid fibromatosis,unresectable desmoplastic small round cell tumor,unresectable differentiated thyroid gland carcinoma,unresectable digestive system adenocarcinoma,unresectable digestive system carcinoma,unresectable digestive system mixed adenoneuroendocrine carcinoma,unresectable digestive system neuroendocrine carcinoma,unresectable digestive system neuroendocrine neoplasm,unresectable digestive system neuroendocrine tumor g1,unresectable digestive system neuroendocrine tumor g2,unresectable distal bile duct adenocarcinoma,unresectable distal esophagus adenocarcinoma,unresectable endometrial carcinoma,unresectable epithelioid hemangioendothelioma,unresectable epithelioid sarcoma,unresectable esophageal adenocarcinoma,unresectable esophageal carcinoma,unresectable esophageal squamous cell carcinoma,unresectable ewing sarcoma,unresectable extrahepatic bile duct carcinoma,unresectable fallopian tube adenocarcinoma,unresectable fallopian tube carcinoma,unresectable fallopian tube endometrioid adenocarcinoma,unresectable fallopian tube high grade serous adenocarcinoma,unresectable fibrolamellar carcinoma,unresectable fibrosarcoma,unresectable gallbladder carcinoma,unresectable gastric adenocarcinoma,unresectable gastric carcinoma,unresectable gastroesophageal junction adenocarcinoma,unresectable gastroesophageal junction neuroendocrine carcinoma,unresectable glioblastoma,unresectable glioma,unresectable her2-negative breast carcinoma,unresectable her2-positive breast carcinoma,unresectable head and neck carcinoma,unresectable head and neck squamous cell carcinoma,unresectable hepatoblastoma,unresectable hepatocellular carcinoma,unresectable hereditary thyroid gland medullary carcinoma,unresectable hilar cholangiocarcinoma,unresectable hormone receptor-positive breast carcinoma,unresectable hypopharyngeal squamous cell carcinoma,unresectable intrahepatic cholangiocarcinoma,unresectable kidney carcinoma,unresectable kidney medullary carcinoma,unresectable large cell neuroendocrine carcinoma,unresectable laryngeal squamous cell carcinoma,unresectable leiomyosarcoma,unresectable liposarcoma,unresectable liver and intrahepatic bile duct carcinoma,unresectable low grade glioma,unresectable lung adenocarcinoma,unresectable lung carcinoid tumor,unresectable lung carcinoma,unresectable lung large cell neuroendocrine carcinoma,unresectable lung neuroendocrine neoplasm,unresectable lung non-small cell carcinoma,unresectable lung non-small cell squamous carcinoma,unresectable lung non-squamous non-small cell carcinoma,unresectable lung small cell carcinoma,unresectable lymphoma,unresectable malignant digestive system neoplasm,unresectable malignant gastric neoplasm,unresectable malignant gastrointestinal stromal tumor,unresectable malignant glomus tumor,unresectable malignant liver neoplasm,unresectable malignant mesothelioma,unresectable malignant neoplasm,unresectable malignant peripheral nerve sheath tumor,unresectable malignant solid neoplasm,unresectable malignant thoracic neoplasm,unresectable melanoma,unresectable meningioma,unresectable merkel cell carcinoma,unresectable midgut neuroendocrine tumor,unresectable mucosal melanoma,unresectable myxofibrosarcoma,unresectable myxoid liposarcoma,unresectable nut carcinoma,unresectable nasal cavity squamous cell carcinoma,unresectable nasopharyngeal carcinoma,unresectable nasopharyngeal squamous cell carcinoma,unresectable neuroblastoma,unresectable neuroendocrine carcinoma,unresectable neuroendocrine neoplasm,unresectable neuroendocrine tumor,unresectable neuroendocrine tumor g1,unresectable oral cavity squamous cell carcinoma,unresectable oropharyngeal squamous cell carcinoma,unresectable osteosarcoma,unresectable ovarian carcinoma,unresectable ovarian endometrioid adenocarcinoma,unresectable ovarian high grade serous adenocarcinoma,unresectable ovarian mucinous adenocarcinoma,unresectable ovarian serous adenocarcinoma,unresectable ovarian undifferentiated carcinoma,unresectable pancreatic adenocarcinoma,unresectable pancreatic carcinoma,unresectable pancreatic ductal adenocarcinoma,unresectable pancreatic neuroendocrine carcinoma,unresectable pancreatic neuroendocrine neoplasm,unresectable paraganglioma,unresectable paranasal sinus squamous cell carcinoma,unresectable paratesticular biphasic mesothelioma,unresectable paratesticular epithelioid mesothelioma,unresectable paratesticular malignant mesothelioma,unresectable paratesticular sarcomatoid mesothelioma,unresectable periampullary adenocarcinoma,unresectable peritoneal biphasic mesothelioma,unresectable peritoneal epithelioid mesothelioma,unresectable peritoneal malignant mesothelioma,unresectable peritoneal sarcomatoid mesothelioma,unresectable platinum-resistant ovarian carcinoma,unresectable pleomorphic liposarcoma,unresectable pleural biphasic mesothelioma,unresectable pleural epithelioid mesothelioma,unresectable pleural malignant mesothelioma,unresectable pleural sarcomatoid mesothelioma,unresectable plexiform neurofibroma,unresectable poorly differentiated thyroid gland carcinoma,unresectable primary central chondrosarcoma,unresectable primary peritoneal adenocarcinoma,unresectable primary peritoneal carcinoma,unresectable primary peritoneal endometrioid adenocarcinoma,unresectable primary peritoneal high grade serous adenocarcinoma,unresectable primary peritoneal serous adenocarcinoma,unresectable prostate carcinoma,unresectable rectal adenocarcinoma,unresectable renal cell carcinoma,unresectable renal pelvis urothelial carcinoma,unresectable renal pelvis and ureter urothelial carcinoma,unresectable rhabdoid tumor,unresectable rhabdomyosarcoma,unresectable round cell liposarcoma,unresectable salivary gland carcinoma,unresectable salivary gland squamous cell carcinoma,unresectable sarcoma,unresectable sarcomatoid renal cell carcinoma,unresectable sinonasal squamous cell carcinoma,unresectable skin basal cell carcinoma,unresectable skin carcinoma,unresectable skin squamous cell carcinoma,unresectable small intestinal adenocarcinoma,unresectable small intestinal carcinoma,unresectable soft tissue leiomyosarcoma,unresectable soft tissue sarcoma,unresectable solid neoplasm,unresectable synovial sarcoma,unresectable thymic carcinoma,unresectable thymic neuroendocrine neoplasm,unresectable thyroid gland anaplastic carcinoma,unresectable thyroid gland carcinoma,unresectable thyroid gland follicular carcinoma,unresectable thyroid gland medullary carcinoma,unresectable thyroid gland oncocytic carcinoma,unresectable thyroid gland papillary carcinoma,unresectable transitional cell carcinoma,unresectable triple-negative breast carcinoma,unresectable undifferentiated pleomorphic sarcoma,unresectable ureter urothelial carcinoma,unresectable urethral urothelial carcinoma,unresectable urothelial carcinoma,unresectable uterine corpus leiomyosarcoma,unresectable uveal melanoma,unresectable vaginal carcinoma,unresectable vulvar carcinoma,unresectable vulvar squamous cell carcinoma,upper alveolar ridge squamous cell carcinoma,upper clivus meningioma,upper gingival carcinoma,upper gingival squamous cell carcinoma,upper gingival verrucous carcinoma,ureter adenocarcinoma,ureter carcinoma,ureter inverted papilloma,ureter leiomyoma,ureter lymphoma,ureter neoplasm,ureter polyp,ureter schwannoma,ureter small cell neuroendocrine carcinoma,ureter squamous cell carcinoma,ureter undifferentiated carcinoma,ureter urothelial carcinoma,ureter urothelial papilloma,urethra neoplasm,urethral adenocarcinoma,urethral adenocarcinoma of skene gland origin,urethral carcinoma,urethral clear cell adenocarcinoma,urethral condyloma acuminatum,urethral inverted papilloma,urethral leiomyoma,urethral melanoma,urethral squamous cell carcinoma,urethral undifferentiated carcinoma,urethral urothelial carcinoma,urethral urothelial papilloma,urethral verrucous carcinoma,urethral villous adenoma,urinary system carcinoma,urinary system neoplasm,urinary system paraganglioma,urothelial carcinoma,urothelial neoplasm,urothelial papilloma,urticaria pigmentosa/maculopapular cutaneous mastocytosis,usual prostate adenocarcinoma with neuroendocrine differentiation,uterine angiosarcoma,uterine carcinosarcoma,"uterine carcinosarcoma, heterologous type","uterine carcinosarcoma, homologous type",uterine corpus adenofibroma,uterine corpus adenomatoid tumor,uterine corpus adenomyoma,uterine corpus adenosarcoma,uterine corpus apoplectic leiomyoma,uterine corpus atypical polypoid adenomyoma,uterine corpus bizarre leiomyoma,uterine corpus cancer,uterine corpus carcinofibroma,uterine corpus carcinosarcoma,uterine corpus cellular leiomyoma,uterine corpus central primitive neuroectodermal tumor,uterine corpus choriocarcinoma,uterine corpus degenerated leiomyoma,uterine corpus diffuse leiomyomatosis,uterine corpus dissecting leiomyoma,uterine corpus endometrial stromal sarcoma,uterine corpus endometrial stromal and related neoplasms,uterine corpus epithelioid leiomyoma,uterine corpus epithelioid leiomyosarcoma,uterine corpus epithelioid smooth muscle tumor of uncertain malignant potential,uterine corpus germ cell tumor,uterine corpus high grade endometrial stromal sarcoma,uterine corpus hydropic leiomyoma,uterine corpus inflammatory myofibroblastic tumor,uterine corpus intravenous leiomyomatosis,uterine corpus leiomyoma,"uterine corpus leiomyoma, mitotically active variant",uterine corpus leiomyosarcoma,uterine corpus lipoleiomyoma,uterine corpus low grade endometrial stromal sarcoma,uterine corpus malignant pecoma,uterine corpus metastasizing leiomyoma,uterine corpus mixed epithelial and mesenchymal neoplasm,uterine corpus myxoid leiomyoma,uterine corpus myxoid leiomyosarcoma,uterine corpus myxoid smooth muscle tumor of uncertain malignant potential,uterine corpus neoplasm,uterine corpus neuroendocrine neoplasm,uterine corpus neuroendocrine tumor g1,uterine corpus pecoma,uterine corpus rhabdomyosarcoma,uterine corpus sarcoma,uterine corpus smooth muscle neoplasm,uterine corpus smooth muscle tumor of uncertain malignant potential,uterine corpus soft tissue neoplasm,uterine corpus spindle smooth muscle tumor of uncertain malignant potential,uterine corpus tumor resembling ovarian sex cord tumor,uterine corpus undifferentiated sarcoma,uterine ligament adenomyoma,uterine ligament ependymoma,uterine ligament leiomyoma,uterine ligament neoplasm,uterine ligament papillary cystadenoma,uterine ligament papillary cystadenoma associated with von hippel-lindau disease,uterine ligament serous adenocarcinoma,uterine ligament wolffian tumor,uterine neoplasm,uveal class 1 melanoma,uveal class 1a  melanoma,uveal class 1b melanoma,uveal class 2 melanoma,uveal epithelioid cell melanoma,uveal intermediate cell type melanoma,uveal melanocytoma,uveal melanoma,uveal melanoma metastatic in the liver,uveal melanoma by gene expression profile,uveal mixed cell melanoma,uveal necrotic melanoma,uveal neoplasm,uveal nevus,uveal spindle cell melanoma,uveal spindle cell type a melanoma,uveal spindle cell type b melanoma,vip-producing neuroendocrine tumor,vagal paraganglioma,vaginal adenocarcinoma,vaginal adenocarcinoma of skene gland origin,vaginal adenoid basal carcinoma,vaginal adenoid cystic carcinoma,vaginal adenoma,vaginal adenosarcoma,vaginal adenosquamous carcinoma,vaginal angiomyofibroblastoma,vaginal basaloid carcinoma,vaginal blue nevus,vaginal botryoid-type embryonal rhabdomyosarcoma,vaginal carcinoma,vaginal carcinosarcoma,vaginal clear cell adenocarcinoma,vaginal condyloma acuminatum,vaginal deep (aggressive) angiomyxoma,vaginal dermoid cyst,vaginal endometrioid adenocarcinoma,vaginal endometrioid stromal and related neoplasms,vaginal germ cell tumor,vaginal glandular neoplasm,vaginal intraepithelial neoplasia,vaginal keratinizing squamous cell carcinoma,vaginal large cell neuroendocrine carcinoma,vaginal leiomyoma,vaginal leiomyosarcoma,vaginal low grade endometrioid stromal sarcoma,vaginal melanoma,vaginal mesonephric adenocarcinoma,vaginal mixed epithelial and mesenchymal neoplasm,vaginal mucinous adenocarcinoma,"vaginal mucinous adenocarcinoma, gastric-type","vaginal mucinous adenocarcinoma, intestinal-type",vaginal mullerian papilloma,vaginal neoplasm,vaginal neuroendocrine carcinoma,vaginal non-keratinizing squamous cell carcinoma,vaginal papillary carcinoma,vaginal rhabdomyoma,vaginal rhabdomyosarcoma,vaginal sarcoma,vaginal small cell neuroendocrine carcinoma,vaginal smooth muscle tumor of uncertain malignant potential,vaginal soft tissue neoplasm,vaginal solitary fibrous tumor,vaginal squamous cell carcinoma,"vaginal squamous cell carcinoma, not otherwise specified",vaginal squamous cell papilloma,vaginal squamous neoplasm,vaginal superficial myofibroblastoma,vaginal tubulovillous adenoma,vaginal undifferentiated carcinoma,vaginal undifferentiated sarcoma,vaginal verrucous carcinoma,vaginal villous adenoma,vaginal warty carcinoma,vaginal yolk sac tumor,vagus nerve neoplasm,vascular bone neoplasm,vascular neoplasm,venous angioleiomyoma,venous hemangioma,ventricular myxoma,verruca plantaris,verruca vulgaris,verrucous carcinoma,verrucous carcinoma of the penis,verrucous hemangioma,verrucous lesion,verrucous papilloma,very low risk colorectal gastrointestinal stromal tumor,very low risk esophageal gastrointestinal stromal tumor,very low risk gastric gastrointestinal stromal tumor,very low risk gastrointestinal stromal tumor,very low risk small intestinal gastrointestinal stromal tumor,vestibular schwannoma,vestibulocochlear nerve neoplasm,villoglandular endometrial endometrioid adenocarcinoma,villous adenocarcinoma,villous adenoma,villous neoplasm,virus-related carcinoma,virus-related lymphoma,virus-related malignant neoplasm,virus-related sarcoma,visceral angiosarcoma,visual pathway astrocytoma,visual pathway glioma,visual pathway medulloepithelioma,visual pathway melanocytoma,visual pathway meningioma,visual pathway neoplasm,von hippel lindau syndrome-associated pancreatic serous adenoma,vulvar acquired melanocytic nevus,vulvar adenocarcinoma,vulvar adenocarcinoma of mammary gland type,vulvar adenocarcinoma of sweat gland origin,"vulvar adenocarcinoma, intestinal-type",vulvar alveolar rhabdomyosarcoma,vulvar alveolar soft part sarcoma,vulvar angiomyofibroblastoma,vulvar angiomyxoma,vulvar angiosarcoma,vulvar apocrine adenocarcinoma,vulvar basal cell carcinoma,vulvar basaloid carcinoma,vulvar blue nevus,vulvar carcinoma,vulvar cellular angiofibroma,vulvar chondroid syringoma,vulvar clear cell hidradenocarcinoma,vulvar composite hidradenoma papilliferum and fibroadenoma,vulvar condyloma acuminatum,vulvar congenital melanocytic nevus,vulvar deep (aggressive) angiomyxoma,vulvar distal-type epithelioid sarcoma,vulvar dysplastic melanocytic nevus,vulvar eccrine adenocarcinoma,vulvar epithelioid sarcoma,vulvar ewing sarcoma,vulvar fibroadenoma,vulvar fibrolipoma,vulvar germ cell tumor,vulvar glandular neoplasm,vulvar granular cell tumor,vulvar hidradenoma papilliferum,vulvar intraepithelial neoplasia,"vulvar intraepithelial neoplasia, hpv-independent",vulvar inverted follicular keratosis,vulvar kaposi sarcoma,vulvar keratinizing squamous cell carcinoma,vulvar keratoacanthoma,vulvar large cell neuroendocrine carcinoma,vulvar leiomyoma,vulvar leiomyosarcoma,vulvar lipoblastoma-like tumor,vulvar lipoma,vulvar liposarcoma,vulvar melanocytic neoplasm,vulvar melanocytic nevus,vulvar melanoma,vulvar merkel cell carcinoma,vulvar neoplasm,vulvar neoplasm of skin appendage origin,vulvar neuroendocrine carcinoma,vulvar nodular hidradenoma,vulvar non-keratinizing squamous cell carcinoma,vulvar paget disease,vulvar phyllodes tumor,vulvar porocarcinoma,vulvar prepubertal fibroma,vulvar proximal-type epithelioid sarcoma,vulvar rhabdomyoma,vulvar rhabdomyosarcoma,vulvar sarcoma,vulvar sebaceous carcinoma,vulvar seborrheic keratosis,vulvar small cell neuroendocrine carcinoma,vulvar smooth muscle tumor of uncertain malignant potential,vulvar soft tissue neoplasm,vulvar solitary fibrous tumor,vulvar squamous cell carcinoma,vulvar squamous cell carcinoma with tumor giant cells,vulvar squamous cell papilloma,vulvar squamous cell papillomatosis,"vulvar squamous intraepithelial lesion, hpv-associated",vulvar squamous neoplasm,vulvar superficial angiomyxoma,vulvar superficial myofibroblastoma,vulvar syringoma,vulvar trichoepithelioma,vulvar verrucous carcinoma,vulvar warty carcinoma,vulvar yolk sac tumor,who grade 1 glioma,who grade 2 glioma,who grade 3 glioma,waldenstroem macroglobulinemia,warthin tumor,warthin-like variant thyroid gland papillary carcinoma,warty (bowenoid) penile intraepithelial neoplasia,warty carcinoma,warty carcinoma of the penis,warty dyskeratoma,warty-basaloid carcinoma of the penis,warty-basaloid penile intraepithelial neoplasia,water-clear cell adenocarcinoma,well differentiated fibrosarcoma,well differentiated hepatocellular carcinoma,well differentiated leiomyosarcoma,well differentiated malignant hemangiopericytoma,well differentiated malignant neoplasm,well differentiated ovarian sertoli-leydig cell tumor,well differentiated ovarian steroid cell tumor,well differentiated papillary mesothelial tumor,well differentiated prostate adenocarcinoma,widely invasive thymoma,wilms tumor,wolffian tumor,yolk sac tumor,yolk sac tumor with somatic-type malignancy,de novo myelodysplastic syndrome,p53-mutant endometrial endometrioid adenocarcinoma
"{Introduction}    The phase-field modeling technique involves finding and minimizing the free energy of one or more order parameters that describe a phase {Hohenberg1977,Provatas2010}. The method was originally introduced by Fix in 1983 {Fix1983} and has since been applied to modeling a wide range of problems including material microstructures {Chen2002,Li2017}, crack propagation {Spatschek_2011}, batteries {Wang2020}, biological membranes {Fan_2008}, cellular systems {Nonomura_2012,Palmieri2015} and even immune response {Najem2014}. Some recent advancements  include the phase-field crystal model {Elder2002} and its applications, see e.g., Refs.~{Achim_2006,Emmerich_2011,Faghihi2013,Kocher_2019,Alster2020}, and phase-field damage models {Wu_2017}.   The same field-based approach can also used for problems in which a free energy description is not readily available. In such a case, the equations of motion are, instead, derived phenomenologically. A well-known class of such problems are reaction-diffusion systems, including Turing~{Turing1952} and Gray--Scott models~{Gray_1985}. These exhibit complex morphologies which mimic nature~{Lee_1994,Leppaenen2002,Maini_2012} with far-reaching applications to biological systems~{Murray1989}.  With the phase-field approach gaining popularity, there is a growing need for  open source phase-field simulation software that generalizes some numerical strategies as has been discussed by Hong and Viswanathan~{Hong2020}. Phase-field simulation software can generally be divided between numerical solvers using finite element or finite difference methods. On the finite element side, some recent ones include, e.g., PRISMS-PF {DeWitt2020}, which uses a matrix free approach, as well as SfePy {Cimrman_2019}, FEniCS {Alnaes2015} and MOOSE {Permann2020}, of which the latter offers symbolic algebra functionality and automatic differentiation, allowing for instance, specification of free energy equations. The package FiPy {Guyer2009} is equipped with an accessible Python interface and equation specification.   While there are several packages for the finite element method to solve partial differential equations, much less is available for finite differences.  Current open software includes the Mesoscale Microstructure Simulation Project (MMSP) {Keller2019}, though development appears to have ceased shortly after its release, and  OpenPhase {Tegeler2017}, which employs parallelization and sparse storage  to solve large-scale multi-phase problems.  To improve upon the existing open source tools available using finite difference methods, we develop  extit{SymPhas}{}, an API and software package  that aims at advancing the ability to implement numerical  solutions of general phase-field problems by maximizing accessibility, flexibility and performance.  extit{SymPhas}{} uses a discrete-grid-based approach for the implementation of numerical solvers to allow simulations to scale well with the number of grid points and number of order parameters, regardless of dimension. This is supplemented with parallelization via the C++{} standard library and OpenMP~{Dagum_1998}.  The  extit{SymPhas}{} API allows the user to define and solve any phase-field model that can be formulated field-theoretically, up to three dimensions and with arbitrary numbers of order parameters and equations. This extends to reaction-diffusion problems as well. Phase-field problems are readily specified in the program using the dynamical equations provided in a completely unconstrained form using simple C++{}-macro-based grammar. We achieve this primarily in two ways: 1) Development of a symbolic algebra library to manipulate and transform mathematical constructs as expression trees and 2) a modular approach of Object Oriented Programming (OOP) that progressively layers more complexity as needed by a given application.  The symbolic algebra feature is implemented as compile-time constructs that directly formulate expression trees at the point of definition. This is a unique feature of  extit{SymPhas}{} that is, to the best of our knowledge, not present in any other phase-field software package.   A modular design is used to retain a simple interface for basic uses while simultaneously supporting complex tasks and implementations. This design applies template meta-programming to fully optimize program constructs and eliminate branching wherever possible. We also achieve considerable decoupling between elements, allowing individual functional elements of  extit{SymPhas}{} to remain distinct; this has the added benefit of supporting community development.   The modular approach also facilitates another key feature of  extit{SymPhas}{}: The ability to integrate a user-developed numerical solver into the workflow. The solver is seamlessly integrated via a class inheritance strategy designed to eliminate almost all API-specific restrictions on the solver implementation. In writing the solver, the user can leverage the significant set of features available in the symbolic algebra library and in the  extit{SymPhas}{} API overall.    Through extensive documentation and adherence to best programming practices, we provide  extit{SymPhas}{} as a codebase to be expanded and driven by community development. This is further facilitated by managing the build process with CMake~{cmake}, which provides  extit{SymPhas}{} with multi-platform support and grants users the ability to customize the compilation and installation procedure in a straightforward way.   {Methods}  To generate solutions to phase-field problems, an implementation that defines the problem and establishes the program control flow is written in C++{} using the  extit{SymPhas}{} API. This consists of three components:  {enumerate}    extbf{Model definitions file:} The phase-field description with the equations of motion are specified. These are written using C++{} macros provided by  extit{SymPhas}{} and follow a simple grammar structure. Putting this in a separate file is optional.    extbf{Solver file:} The implementation of a specific method which solves a phase-field problem using the equations of motion.    extbf{Driver file:} Specifies the workflow, data inputs and outputs. {enumerate}  We use OOP  and extensively apply the programming paradigm known as  extit{template meta-programming}; the use of objects and functions defined with arbitrary parameters or data types~{Meyers2005}.  These abstractions are either implicitly (by the compiler) or explicitly (by the user) specialized for concrete types. The benefit of this approach is that the type specialization gives the compiler full information about the call stack, allowing it to make optimizations not possible in different approaches (e.g. virtual inheritance). The other advantage is added extendability through type dependent implementations. The drawback is that since each specialization is unique, the library and executable will take longer to compile and result in a larger size when many specializations are used. For example, compiling five phase-field models of one or two order parameters with one solver defined with all available finite difference stencils -- see Section~ ef{methods:objects:stencils} -- results in a total size of approximately 3MB. As part of template meta-programming, we also apply the  extit{expression template technique}~{Veldhuizen1995,Vandevoorde2003}, commonly referred to as the  extit{curiously recurring template pattern} (CRTP) {Coplien1996}, mainly used in the implementation of the symbolic algebra functionality. A non-exhaustive list of familiar libraries using expression templates includes Armadillo~{Sanderson2016,Sanderson2018}, Blitz++~{Veldhuizen2000}, Boost BLAS~{Schaeling2011}, Dlib~{King2009}, Eigen~{GaeelGuennebaud2010}, Stan Math Library~{Carpenter2015} and xtensor~{xtensor}.    The OOP approach applies a modular design to program structure; this means that we minimize coupling and maximize cohesion~{Vanderfeesten_2008, Candela2016} of all classes in the API, as well as designing each element to support class inheritance or composition. The former is primarily accomplished by following best programming principles such as applying the single-responsibility principle for objects {Martin2002}. The latter implies that objects designed under this modular framework can be readily extended or modified without refactoring the existing code. Moreover, modularity is used to reflect the real world representation of a phase-field problem. The overall aim is to simplify and streamline the future development of  extit{SymPhas}{}.  Additionally, the build process is another aspect designed to be user friendly. Managed by CMake, the user has full control over program definitions and modules. The result of the build process is a shared library that can be linked in a g++ invocation or alternatively, imported into a separate user CMake {cmake} project.  {Overview of Modules}  There are four required and two supplementary modules as part of  extit{SymPhas}{}.  The necessary modules constituting the  extit{SymPhas}{} library are the basic functionality ({lib}), datatypes ({datatypes}), solution ({sol}) and symbolic algebra ({sym}) modules. The module {lib} is a dependency of all other modules, since it introduces components such as objects and types used throughout the program. There are two additional libraries which complete the feature set of  extit{SymPhas}{}: the configuration ({conf}) and the input/output ({io}) modules.  The {datatypes} module depends only on {lib}. It implements objects used in the discrete grid representations, the most important of which is the {Grid} class, a managed array for storing data of 1-, 2- and 3-dimensional problems.  The symbolic algebra library ({sym}) provides the core functionality  to interpret mathematical expressions. The implementation of {sym} contains all the mathematical objects and relations that are required to specify a phase-field equation of motion. It also specifies rules between these objects. The solution module ({sol}) provides the structural and functional framework used to describe and solve a phase-field problem. This is accomplished by defining two objects: One being the programmatic representation of a general phase-field problem and the other which implements a specific set of interface functions for time evolving the phase-field data.    {Objects in  extit{SymPhas}{}} {methods:objects}   The following is a list and brief description of the relevant objects in  extit{SymPhas}{}:  {itemize}   {Grid}: Basic array type for storing phase-field data of arbitrary type.   {Boundary}: Logical element for defining the properties of a grid boundary.   {Stencil}: Object which defines the finite difference stencils used to approximate derivatives in a uniform grid.   {OpExpression}: Interface object representing the node in an expression tree, based on CRTP.   {Solver}: Interface that is specialized for implementing the  solution procedure.   {Model}: Encapsulation of the problem representation, including the equations of motion. Primary interface for managing the solution of a phase-field model. {itemize}  {Uniform Grid}  The data of a grid is initialized in computer memory as a one-dimensional array, and the desired system dimension is logically imposed according to row major order where the first dimension is always the horizontal (-axis). This ensures fastest run time through memory localization.   An extension of {Grid} called {BoundaryGrid} enables the use of finite difference stencils at points near the boundary and implements routines to update boundary grid elements (for example, to apply periodic boundaries). This is accomplished by managing a list of indices that correspond to boundary elements. The number of layers of the boundary is predefined based on the extent of the largest finite difference stencil.  The design of the {Grid} class and any specialization thereof is based on template meta-programming, and allows the user to select the data type and the dimension.   {Finite Difference Stencils} {methods:objects:stencils}   Stencils are finite difference approximations of derivatives of a specified order. In  extit{SymPhas}{}, we implement second and fourth order accurate central-space stencils for various orders of derivatives. To this end, stencils are defined using three characteristics: 1) The order of derivative that is approximated, 2) the order of accuracy, and 3) the dimension of the system. An additional characterization is the number of points used in the approximation. A stencil family is a group of stencils with the same dimension and order of accuracy. We apply this categorization to the design of stencils in  extit{SymPhas}{} by implementing specialized template classes for each family.  Stencils are CRTP-based template classes with member functions for each order of derivative up to fourth order, and a member function for the generalized implementation of higher orders. In particular, the Laplacian, bilaplacian, gradlaplacian and gradient derivatives are explicitly defined according to those derived in {Patra2006}, including both anisotropic- and isotropic-type stencils that are second and fourth order accurate in two dimensions, and second order accurate in three dimensions. Using CRTP in the stencil implementation eliminates branching in the member function invocations; a significant optimization that improves performance since stencils are applied multiple times at each grid point for every solution iteration.   For second order accuracy approximations, the Laplacian is implemented by 5 and 9 point stencils for 2D, and 7, 15, 19, 21 and 27 point stencils in 3D; the gradlaplacian is implemented by 6, 8, 12 and 16 point stencils, and 10, 12, 28, 36 and 40 point stencils in 3D; and the bilaplacian is implemented by 13, 17 and 21 point stencils for 2D, and 21, 25, 41, 52 and 57 point stencils for 3D. For fourth order accuracy approximations, which are only in 2D, the Laplacian is implemented by 9, 17 and 21 point stencils; the gradlaplacian is implemented by 14, 18, 26 and 30 point stencils. The bilaplacian is implemented by 21, 25, 33 and 37 point stencils. The wide selection ensures that appropriate approximations can be used a problem as necessary.   {Expressions} {methods:objects:expression}  One of the primary features of  extit{SymPhas}{} is the symbolic algebra library, which represents mathematical expressions with expression trees formulated at compile time. An expression tree representation allows the equations of motion to be treated as a single object, i.e., they can be persisted as an object state and passed as a function parameter. Moreover, expression trees provide the ability to reorganize and manipulate mathematical expressions.  The symbolic algebra functionality is used to interpret equations of motion that are provided in a general form, and is exposed in a user-friendly way via the  extit{SymPhas}{} API.   Symbolic algebra is implemented in  extit{SymPhas}{} through an approach unique to phase-field simulations programs: CRTP is applied to generate compiled code for an expression tree evaluation so that it is as close as possible to writing the evaluation manually. In this regard, the symbolic algebra is considered ``compile-time constant'', since the expression representation is formulated at compile time. The type name of the CRTP base and expression tree node is {OpExpression}.  One motivation of this design choice is minimizing application runtime, since a design that applies a deterministic control flow to expression tree traversal can significantly increase performance.  The most significant corresponding improvement in performance is the reduction in the time spent by a numerical solver in evaluating the equation of motion of the phase-field model, which takes place for all points in the grid and for each iteration of the solver.  An implication is that, in general, each expression is a unique type (unique CRTP specializations of {OpExpression}).  {Solution Interface}  The base  extit{SymPhas}{} library consisting of the six aforementioned modules does not contain a solver implementation, though two solver implementations that are detailed in Section~ ef{methods:implementation} are provided in the  extit{SymPhas}{} package obtained from Github ({https://github.com/SoftSimu/SymPhas}). Instead, the  extit{solution interface}, {Solver}, declares three functions  which a concrete numerical solver must implement. The solver interface design uses CRTP and is based on applying a mediator design pattern via a special object that we refer to as the ``equation mediator object''. These are generated by the solver for each dynamical equation in a phase-field model before the simulation begins. Its purpose is to recast the equation of motion into a form that can be interpreted by the numerical scheme of the solver in order for the subsequent time index of the corresponding phase-field data to be computed. The equation mediator object is constructed by the solver member function {form_expr_one()}. By taking advantage of the modular framework, we design the solver interface to allow the equation mediator object to remain entirely specific to the implemented solver, maximizing third party development potential. A specialized solver implements the following three primary interface functions, where additional functions, such as derivatives, may also be written as necessitated: {itemize}   {form_expr_one()}: Given the set of equations of motion of a phase-field model, constructs the equation mediator object for a specified equation of motion.  This function is only called once. It performs as much computational work as possible to ensure maximum program performance.   {equation()}: Using the phase-field data and the equation mediator objects, performs an initial time evolution step,  typically writing intermediate results to working memory.   {step()}: Using the phase-field data and intermediate results computed by {equation()}, obtain the next iteration in the solution. {itemize}  {Problem Encapsulation}  To represent the physical phase-field problem in the code domain, objects of basic functionality are successively encapsulated to build necessary functionality. For instance, the {Grid} class is encapsulated by {System} to add information such as the spatial intervals and discretization width. A further encapsulation will specialize {System} into {PhaseFieldSystem}, adding functionality such as data persistence and the ability to populate array values with initial conditions. Using template meta-programming, the {PhaseFieldSystem} object allows the user to select the data type and dimension used for the instantiated type. It also allows encapsulating {Grid} or any of its specializations to modify the basic implementation features as required by the problem or solver.   All of the aspects which constitute a phase-field model are encapsulated in the class {Model}, of which the responsibility is to manage the phase-field data and numerical solver and initialize all phase-field data in a standardized way. It is also the primary interface to the phase-field data and interacting with the solver.  {Model} is itself specialized in order to manage a specific set of equations of motion corresponding to a phase-field problem. The user is responsible for this final specialization through the procedure defined in Section~ ef{methods:capabilities:models}.   {Capabilities} {methods:capabilities}   To produce solutions to  phase-field problems,  extit{SymPhas}{} offers a number of capabilities. These include convenient parameter specification alongside a rich feature set for specifying the equations of motion and managing the phase-field problem. In this section, we briefly list the capabilities relevant in typical use cases and outline the steps for generating a simple driver file in  extit{SymPhas}{}.  {Symbolic Algebra} {methods:capabilities:algebra}  Data are used in the symbolic algebra by linking it with a specialized expression type that represents a ``variable'' term (e.g., in the context of an equation of motion, each order parameter is a ``variable'' linked to the respective phase-field data). The symbolic algebra also defines value literals and spatial derivative operators. Value literals include special constructs representing the positive and negative multiplicative identity (the numbers  and ) and the additive identity (the number ). These are mainly used to facilitate symbolic algebra rules. Some common functions are defined as well, including ,  and the exponential. For less common cases, the convolution operator is also defined. Since the structure of expression trees is managed at compile time, type-based rules defined by specific expression tree structures are applied to formulate expressions, such as when addition, subtraction, multiplication and division operations are used. Rules include simplification, distribution, factorization.  While the primary purpose of the symbolic algebra feature is to represent an equation of motion for a phase-field problem and support the user in implementing a specialized solver, the same functionality can be applied in more general applications.  Features such as the ability to name variables and print formatted expressions to an output stream in either simple text or {} format are included. Moreover, the symbolic algebra can be used to perform high-performance pointwise operations on arrays, include new symbols to the algebra ruleset, and even define identities for the new and existing symbols that would be applied automatically.   {Defining New Phase-Field Models} {methods:capabilities:models}   extit{SymPhas}{} provides convenient C++{} macro-based grammar to allow a user to define a new phase-field model in a completely unconstrained way, a novel feature among phase-field simulations software. Each new definition generates a specialization of the {Model} class. Upon recompiling the program, the new model is fully functional without the pitfalls of verbose implementation details. Moreover, the same definition can be interpreted by all solvers available in  extit{SymPhas}{}.  A model is defined in three parts: 1) The model name as it appears in the compilation unit, which must be unique for all models, 2) a list of the order parameters and their types, and 3) the equations of motion. An additional optional section between the order parameter type list and equations of motion can be specified to define virtual variables. These can be used to measure desired system quantities or used in the equations of motion to optimize the runtime by pre-computing values. An example of defining a two-phase model with a virtual variable is demonstrated in Figure~ ef{fig:model_definition}. Specific details including all available macros are offered in the manual.   {figure}               {lstlisting} MODEL(MC,    (SCALAR, SCALAR),   PROVISIONAL_DEF(     (SCALAR),     var(1) = c5 * op(1) * op(2))   MODEL_PREAMBLE_DEF(     ( auto op13 = c2 * op(1) * op(1) * op(1);       auto op23 = c4 * op(2) * op(2) * op(2); )     dop(1) = lap(op(1)) + c1 * op(1) - op13 + lit(2.) * var(1),     dop(2) = -bilap(op(2)) - lap(c3 * op(2) - op23 + c5 * op(1) * op(1))) )     {lstlisting}     {An example of specifying a phase-field model. Model~C~{Hohenberg1977}, which represents eutectic growth with two order parameters~{Elder1994}, is implemented. It is associated with the given name ``{MC}'', which defines the type alias of the model in the code and therefore must be unique. The keywords {op(N)} and {dop(N)} refer to the {N}th order parameter and its time derivative, respectively, and the keyword {var(N)} refers to the {N}th virtual variable. The keyword {SCALAR} specifies that the field types are real-valued. The keyword {lit(v)} is used to represent a numeric constant of value {v} in the symbolic algebra expression. The keywords {lap} and {bilap} apply the 2nd and 4th spatial derivative to their arguments, respectively. The enumerated terms {c1} to {c5} are parameters passed to the model upon instantiation. Variables can be defined before the equations of motion using the macro {MODEL_PREAMBLE_DEF}, demonstrated here with the cubic terms, {op13} and {op23}. This option exists chiefly for convenience and does not affect the structure of the expression tree formulated for the equation of motion. If this section is omitted and only the dynamical equations are provided, then the macro {MODEL_DEF} is used instead.}     {fig:model_definition} {figure}    {Creating Custom Solvers}  The user may develop their own solver using the  extit{SymPhas}{} API and seamlessly integrate it into an existing workflow. Implementation of a solver entails extending the provided {Solver} interface.  A major benefit of the design is provided by the equation mediator object, since it remains completely internal to the functionality of the implemented solver and does not interact with the other parts of the API or program. This allows the solver implementation to be decoupled as much as possible from the surrounding implementation and allows the user to leverage the capabilities of the API without being limited by extensive requisite knowledge.  Additionally, if the built-in {SolverSystem} and its specializations are insufficient, the user may develop a new specialization. This has some constraints and requirements, including following a specific naming style, inheritance requirements and recompilation of the solution module {sol}.    {Standardized Problem Parameter Management}  The parameters of the problem are managed by a specialized object tasked with managing data that fully describes a phase-field problem.  This information includes the initial conditions, the interval data and information about the boundary conditions, the latter which can be specified on an individual basis. There are a number of phase-field initialization routines available to the user, each tuned by user-provided parameters. Initialization routines defined by the user can also be used.   This approach allows the user to have a unified approach to initializing, accessing, and passing problem information, simplifying the workflow and ensuring flexibility.   {Input/Output}  The configuration module provides the user with the ability to write a configuration file with phase-field problem and data persistence parameters, which can be used to construct the problem parameters object.   The  extit{SymPhas}{} API includes data persistence capabilities through the {io} module, which introduces functions and objects for reading and writing phase-field data. The user is also provided with the ability to persist phase-field data at regular checkpoints throughout the simulation, which can later be used to recover simulation data from the last saved point if it is interrupted for any reason. This supports program reliability and convenience, particularly for extended simulations.  Currently, there are three output/input formats: 1) Plain text matrix (the matrix format is amenable to plotting utilities such as gnuplot), 2) plain text column (an ordered list of vectors and values), and 3) binary output in the xdrfile format, popularized by GROMACS {Lindahl2021}. This functionality is available to the user when {io} is compiled with  extit{SymPhas}{} through CMake.   Input can also be given to  extit{SymPhas}{} through the command line; this method allows configuring some program-level parameters. Unlike the configuration file, this a base component of  extit{SymPhas}{}. Command line parameters allow  extit{SymPhas}{} to change some of its behavior, largely with regards to the initial condition generation. The basic set of program level parameters are introduced in {lib}, and {io} introduces more parameters. The list of all configurable parameters and their details are provided in the manual.   {figure}      %  %  [2][]{%   {(Inkscape) Color is used for the text in Inkscape, but the package 'color.sty' is not loaded}%    enewcommand[2][]{}%  }%   ransparent[1]{%   {(Inkscape) Transparency is used (non-zero) for the text in Inkscape, but the package 'transparent.sty' is not loaded}%    enewcommand ransparent[1]{}%  }%   otatebox[2]{#2}%   ewcommand*{@size pt elax}%   ewcommand*[1]{{}{#1}}%  %  {}{419.73992097bp}%  %   elax%  %  {}{ *  eal{}}%  %  %  {}{}%  %  %  %  %  {picture}(1,0.55151926)%   {1}%    abcolsep{0pt}%   (0,0){[width=,page=1]{implementation_small_v2.pdf}}%   (0.16157335,0.46704034){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Initialize configuration{tabular}}}}%   (0,0){[width=,page=2]{implementation_small_v2.pdf}}%   (0.49225814,0.5319947){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Driver{tabular}}}}%   (0.82377576,0.5319947){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}{Model}{tabular}}}}%   (0,0){[width=,page=3]{implementation_small_v2.pdf}}%   (0.16104047,0.42347701){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}[Load Checkpoint?]{tabular}}}}%   (0.48547551,0.10795121){[rgb]{0,0,0}(0,0)[lt]{{minipage}{0.67051006} aggedright {minipage}}}%   (0.16333496,0.5319947){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Solve Phase-Field Problem{tabular}}}}%   (0,0){[width=,page=4]{implementation_small_v2.pdf}}%   (0.49065199,0.39721209){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Define problem parameters{tabular}}}}%   (0,0){[width=,page=5]{implementation_small_v2.pdf}}%   (0.16099403,0.34815596){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Read backup file{tabular}}}}%   (0,0){[width=,page=6]{implementation_small_v2.pdf}}%   (0.48967667,0.34821582){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Initialize {Model} list{tabular}}}}%   (0.49295187,0.22960868){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Select next {Model}{tabular}}}}%   (0.23460284,0.38343563){[rgb]{0,0,0}(0,0)[lt]{{1.25}{{tabular}[t]{l} extit{No}{tabular}}}}%   (0.16829113,0.37616843){[rgb]{0,0,0}(0,0)[lt]{{1.25}{{tabular}[t]{l} extit{Yes}{tabular}}}}%   (0.49056795,0.31364469){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}[All models simulated?]{tabular}}}}%   (0,0){[width=,page=7]{implementation_small_v2.pdf}}%   (0.49659382,0.26355095){[rgb]{0,0,0}(0,0)[lt]{{1.25}{{tabular}[t]{l} extit{No}{tabular}}}}%   (0.43775105,0.27644197){[rgb]{0,0,0}(0,0)[lt]{{1.25}{{tabular}[t]{l} extit{Yes}{tabular}}}}%   (0.82129282,0.23042956){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Update system ({update}){tabular}}}}%   (0,0){[width=,page=8]{implementation_small_v2.pdf}}%   (0.82129282,0.18497542){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Compute dynamics ({equation}){tabular}}}}%   (0,0){[width=,page=9]{implementation_small_v2.pdf}}%   (0.82129282,0.1395214){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Time evolve ({step}){tabular}}}}%   (0,0){[width=,page=10]{implementation_small_v2.pdf}}%   (0.82110556,0.09609849){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}[Reached final index?]{tabular}}}}%   (0,0){[width=,page=11]{implementation_small_v2.pdf}}%   (0.82148597,0.01546429){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Persist solution data{tabular}}}}%   (0,0){[width=,page=12]{implementation_small_v2.pdf}}%   (0.78188778,0.34903378){[rgb]{0,0,0}(0,0)[t]{{1.25}{{tabular}[t]{c}Model parameters{tabular}}}}%   (0,0){[width=,page=13]{implementation_small_v2.pdf}}%   (0.76108252,0.05424335){[rgb]{0,0,0}(0,0)[lt]{{1.25}{{tabular}[t]{l} extit{No}{tabular}}}}%   (0.83023066,0.04574204){[rgb]{0,0,0}(0,0)[lt]{{1.25}{{tabular}[t]{l} extit{Yes}{tabular}}}}%   (0,0){[width=,page=14]{implementation_small_v2.pdf}}%  {picture}%  %      {Control flow diagram for the  extit{SymPhas}{} driver used to run simulations in this work. A list of models is generated using parameters from a configuration file. The number of models that is initialized depends on the configuration.   The  extit{SymPhas}{} library provides a function to perform the solution loop illustrated under {Model}.  }  {fig:flow4} {figure}% {figure}               {lstlisting} #include ""symphas.h"" #define psi op(1) #define dpsi dop(1) MODEL(EX, (SCALAR), MODEL_DEF(   dpsi = lap(psi) + (c1 - c2 * psi * psi) * psi))    int main(int argc, char* argv[]) {   double dt = 0.5;   symphas::problem_parameters_type pp{ 1 };   symphas::b_data_type bdata;   symphas::interval_data_type vdata;   symphas::init_data_type tdata{ Inside::UNIFORM, { -1, 1 } };      symphas::interval_element_type interval;   interval.set_interval_count(0, 80, 128);      bdata[Side::LEFT] = BoundaryType::PERIODIC;   bdata[Side::RIGHT] = BoundaryType::PERIODIC;   bdata[Side::TOP] = BoundaryType::PERIODIC;   bdata[Side::BOTTOM] = BoundaryType::PERIODIC;   vdata[Axis::X] = interval;   vdata[Axis::Y] = interval;      pp.set_boundary_data(&bdata);   pp.set_initial_data(&tdata);   pp.set_interval_data(&vdata);   pp.set_problem_time_step(dt);    model_EX_t<2, SolverSP<Stencil2d2h<5, 9, 6>>> model{ pp };   symphas::find_solution(model, dt, 100); }     {lstlisting}     {Example of a simple driver program which includes the model definition.     A phase-field problem of one order parameter named {EX} is defined. System boundaries are defined to be periodic on each edge and initial conditions are set by seeding valuing with the uniform distribution . Identical  and  intervals are defined and provided, resulting in a square  grid. When the model is created, the solver ({SolverSP}) is passed as a template type parameter and the {find_solution} function is called to perform 100 solver iterations. This program can be compiled through CMake or by providing the directories of the installed header and library to gcc.}     {fig:driver_implementation} {figure}  {Implementation} {methods:implementation}  The entire  extit{SymPhas}{} API is available on Github ( exttt{https://github.com/SoftSimu/SymPhas}) alongside two solvers (forward Euler, Sec.~ ef{sec:feuler} and the Semi-Implicit Fourier Spectral, Sec.~ ef{sec:spectral}), model definitions and driver file examples. The program control flow of the driver file used to to generate the simulations in this paper is illustrated in Figure~ ef{fig:flow}, and is found in the directory {examples/simultaneous-configs} relative to the source code root.  This driver performs several steps, including data persistence, as part of data collection, but a fully functional driver file can be as simple as is written in Figure~ ef{fig:driver_implementation} and included with the source code in {examples/simple-driver}. It is presented here to illustrate relevant  extit{SymPhas}{} API elements, but primarily demonstrate its ease of use.   {Forward Euler Solver} {sec:feuler}  A forward Euler solver is a well-known  explicit numerical method for partial differential equations. It is a first order method and it is known to have instabilities especially when solving stiff systems. It is provided as a base method.  Since it is well-known and taught in virtually every course in numerical methods, we will not discuss it further but refer the reader to one of the standard references such as Press  extit{et al.}~{Press1992}.  {Semi-Implicit Spectral Solver} {sec:spectral}   Consider a phase-field problem for the order parameter ; the equation of motion for this problem may be expressed in the form {equation}  { }{ t} = {L}( abla^{n}) ight + _i{{{N}}_i( abla^{m_i}) f_i() ight},  {eq:spectralphasefield} {equation} where  is a linear combination of derivatives up to order  applied to , and each term in the sum over  is a unique linear differential operator, , of derivatives up to order  that is applied to a nonlinear function .  Under periodic boundary conditions, the semi-implicit Fourier spectral solver approximates the solution to  by first applying the Fourier transform of Equation~( ef{eq:spectralphasefield}): {align}  { {}_{{k}}}{ t} &= {L(k^n)}{}_{{k}} + _i{{N_i}(k^{m_i}) {f}_{i}()_{{k}}}   ,  {eq:phasefieldfourier} {align} where  indicates the Fourier transform of the respective term, ,  is a vector in Fourier space and . Also, since  (and correspondingly ) under a Fourier transform in an infinite domain, the linear operator  becomes the function , a linear combination of the Fourier transformed derivatives, and likewise for .   A difference scheme {Provatas2010} to Equation~( ef{eq:phasefieldfourier}) is determined by solving it as a linear ordinary differential equation and approximating to 1st order, yielding {align}  {}(t +  t)  A{}_{{k}}(t) + B_i N_i(k^{m_i}) {f}_n()_{{k}},  {eq:spectralscheme} {align} where {gather}  A = e^{{L}(k^n) t}   ext{and}  B = {e^{{L}(k^n) t} - 1}{{L}(k^n)}.  {eq:spectraloperators} {gather}  The spectral solver produces Equation~( ef{eq:spectralscheme}) from any given equation of motion, a significant advantage that generalizes the spectral solver to a multitude of problems. This demonstrates the adaptability of the solver and of the program design in general. The spectral solver also computes the values of  and   extit{a priori} to minimize the runtime. The procedure is as follows: {enumerate}   Split the equation into linear and nonlinear parts.  Call the linear part  and the nonlinear part , analogous to the notation in Equation~( ef{eq:spectralphasefield}).   Further split the linear part by separating out terms which do not involve , along with terms that cannot be expressed using a linear operator.   Call the expression formed by these terms  and the expression formed by all other terms . Thus, .   Obtain  by removing  from terms in  and interchanging the derivative terms with the Fourier space transformed derivatives. Generate values for  by evaluating .   Create the new expression  by exchanging all order parameters in  with the Fourier transformed counterparts.     {step:make_D} Let  be represented as the sum of its unique derivatives  applied to expressions , viz.:  {L}_* = _n{d_n  e_n}.    Form the set .     Apply Step~ ef{step:make_D} for the terms of , producing the list . Form the set  where  denotes the Fourier transform of the respective term.       Define the following sets:   {align}    {D}_1 &= (d_n, e_n, e_m)  (d_n, e_n)  {D}_{*}, (d_m, e_m)  {D}_{{N}}, d_n = d_m  ,    {D}_2 &= (d_n, e_n, 0)  (d_n, e_n)  {D}_{*}, (d_m, e_m)  {D}_{{N}}, d_n  ot d_m ,    {D}_3 &= (d_m, 0, e_m)  (d_m, e_m)  {D}_{{N}}, (d_n, e_n)  {D}_{*}, d_m  ot d_n  .  {align}  Define . In other words, generate elements of  by pairing together the expressions in elements from  and  that match based on the derivatives , and if there is no matching derivative in the other set, use 0 in place of the associated expression.     Define two sequences  where  is as defined in Equation~( ef{eq:spectraloperators}) and , using the elements: (d_i, e_{n_i}, e_{m_i})  {D}.  With respect to Equation~( ef{eq:spectralscheme}),  and .   Return the set . {enumerate}  The scheme applied by the implemented spectral solver is then given by: {equation}  {}^{n+1} = A{}^n(t) + _i {B}_i ( {E}^0_i + {E}^1_i  ight), {equation} where  is the approximate solution to   ( for time step ),  and  are the sets of the first and second elements of , respectively, and subscript  represents the indexed elements of their respective sets.    {Simulations and Verification} {sec:results}  Using the semi-implicit spectral solver, we performed simulations of the Allen--Cahn equation (Model A in the Hohenberg--Halperin classification {Hohenberg1977}) describing a non-conserved order parameter  {Allen1975}, the Cahn--Hilliard equation (Model B in the Hohenberg--Halperin classification {Hohenberg1977}) describing a conserved order parameter , and a two order-parameter problem which couples a conserved order parameter  with a non-conserved order parameter  (Model C in the Hohenberg--Halperin classification {Hohenberg1977}). The systems were simulated in both two and three dimensions. Since these systems are well-known and described in literature and since the main goal here is to demonstrate the software, we will not describe the above models in more detail but refer the reader to standard references such as the classic article by Hohenberg and Halperin {Hohenberg1977} and the book by Provatas and Elder {Provatas2010}. We also include a simulation of the phase-field crystal model of Elder et al.~{Elder2002}.   The Allen--Cahn equation describes the dynamics of a non-conserved order parameter  {Hohenberg1977,Provatas2010, Allen1975} as  {equation}         { }{ t} =  abla^2  + c_1 -  c_3^3.         {eq:modelb} {equation} The Cahn--Hilliard equation, on the other hand, describes the phase separation dynamics of a conserved order parameter  {Hohenberg1977,Provatas2010,Cahn1958} as {equation}     { m}{ t} = - abla^4 m -  abla^2 (c_1m - c_2m^3  ight),     {eq:modela} {equation} In addition to these, we simulated a two order parameter problem which couples a conserved order parameter  with a non-conserved order parameter  (Model C~{Hohenberg1977}) through a nonlinear term in the free energy functional: {align}     { }{ t} &=       abla^2  +c_1 - c_2^3 + 2c_5  m     { m}{ t} &= - abla^4 m -  abla^2 (c_3 m - c_4 m^3 + c_5 ^2 ight).     {eq:modelc} {align} This model has been used to describe eutectic growth~{Elder1994}.  The phase-field crystal model was developed to include periodic structure to the standard phase-field free energy functional in order to represent elastic and plastic interactions in a crystal {Elder2002, Elder_2004}. For a conserved density field , the dynamical equation of a phase-field crystal model is given by: {equation}  { n}{ t} =  abla^2( n^2 + n^3 + ((q_0 +  abla^2)^2 -  ight)n  ight). {eq:pfc} {equation}    Coarsening of the phase-field at any point during the transition can be quantified by the radial average of the static structure factor, . The static structure factor, , measures incident scattering in a solid {Lovesey1984, Squires1978}. In the Born approximation for periodic systems,  {Lindgard1994}. The term  is the Fourier transform of , the particle occupancy at the position  in the lattice, which is 1 in the solid phase and 0 elsewhere. Correspondingly, for computing the structure factor of the continuous order parameter field , the positive phase is chosen to represent solidification, that is,  when  and  otherwise.   For both the conserved and non-conserved phase-field models, the radial average of the structure factor should correspond to Porod's law~{Bray_2002}: {equation}     S(k)  (Lk^{d+1})^{-1},     {eq:porodslaw} {equation} where  is the size of the system and  is the dimension.  We use this to establish that  extit{SymPhas}{} generates correct solutions by validating that the relationship holds for  measured from simulations of the Allen--Cahn and Cahn--Hilliard models, representing the non-conserved and conserved dynamics, respectively~{Puri1997}. We proceed by computing  from the average of 10 independent simulations of these models in both 2D and 3D and verifying that the scaling is consistent to Porod's law, Equation~( ef{eq:porodslaw}), for the corresponding dimension.   The implementations of the simulated models with the  extit{SymPhas}{} model definitions macros are provided in Figure~ ef{fig:models_abc_definitions}. As the figure shows, models are defined in a compact and intuitive way.  The initial conditions of models A, B and C are uniformly distributed noise, and the equation parameters , , ,  and  are set to unity. For the phase-field crystal model, 128 randomly arranged seeds containing large fluctuations are initially distributed throughout the system, and the parameters of the equation and simulation were selected from Elder et al.~{Elder2002}. The simulation results for the non-conserved Allen--Cahn model (Model A, Equation~( ef{eq:modela})) are displayed in Figure~ ef{fig:modelab:a} and results for the conserved Cahn--Hilliard model (Model B, Equation~( ef{eq:modela})) are displayed in Figure~ ef{fig:modelab:b}. The structure factor results of these two models are presented in Figure~ ef{fig:model-a_sf} and Figure~ ef{fig:model-b_sf}, respectively. The results for the eutectic model consisting of two coupled equations of motion~{Elder1994} (Model C, Equation~( ef{eq:modelc})) are shown in Figure~ ef{fig:modelc} and the phase-field crystal model~{Elder2002} (Equation~( ef{eq:pfc})) with a conserved field is displayed in Figure~ ef{fig:pfc}.   {figure}      {subfigure}{1. extwidth}          {lstlisting} MODEL(MA, (SCALAR),   MODEL_DEF(     dpsi = lap(psi) + (c1 - c2 * psi * psi) * psi))     {lstlisting}     {}     {fig:modeldef:a} {subfigure}% {subfigure}{1.0 extwidth}          {lstlisting} MODEL(MB, (SCALAR),   MODEL_DEF(     dpsi = -bilap(m) - lap((c1 - c2 * m * m) * m)))     {lstlisting}     {}     {fig:modeldef:b} {subfigure} {subfigure}{1.0 extwidth}          {lstlisting} MODEL(MC, (SCALAR, SCALAR),   MODEL_PREAMBLE_DEF(     ( auto psi3 = c2 * psi * psi * psi;       auto m3 = c4 * m * m * m; ),     dpsi = lap(psi) + c1 * psi - psi3 + lit(2.) * c5 * psi * m,     dm = -bilap(m) - lap(c3 * m - m3 + c5 * psi * psi)))     {lstlisting}     {}     {fig:modeldef:c} {subfigure}% {subfigure}{1.0 extwidth}  {lstlisting} PFC_TYPE(PC,    DEFAULTS(     DEFAULT_DYNAMIC(PFC_CONSERVED)   ),    (SCALAR))     {lstlisting}     {}     {fig:modeldef:pfc} {subfigure}     {Macro implementations of ({fig:modeldef:a}) the Allen--Cahn model {Allen1975} from Equation~( ef{eq:modela}),  ({fig:modeldef:b}) the Cahn--Hilliard model {Cahn1958} from Equation~( ef{eq:modelb}),  and  ({fig:modeldef:c}) Model C {Elder1994} from Equation~( ef{eq:modelc}).      The order parameter names in the macro specification are chosen to correspond to the variable names in the respective equations of motion, and the keys {c1} to {c5} correspond to the coefficients  to . (d) The phase-field crystal model (Equation~ ef{eq:pfc}) specification uses different macro keywords that allow selecting the phase-field crystal model as a type of problem, dispensing with equation specification and allowing selection of the dynamics.     }          {fig:models_abc_definitions} {figure}% {figure}      {minipage}{0.48 extwidth}         %     {subfigure}{ extwidth}                               {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,1872.00)%      {%      }%      {%        LTb       (1714,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (3341,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (4963,1924){(0,0)[r]{{}index }}%        LTb       (218,0){(0,0){{}}}%       (1404,0){(0,0){{}}}%       (2590,0){(0,0){{}}}%       (3776,0){(0,0){{}}}%       (4963,0){(0,0){{}}}%      }%            (0,0){{model-a-2d_data0_20000.pdf}}%           {picture}%               {}     {fig:modelab:a:2d}     {subfigure}     %     {subfigure}{ extwidth}          [width=0.33 extwidth]{modela50.png}%     [width=0.33 extwidth]{modela200.png}%     [width=0.33 extwidth]{modela2000.png}     {}     {fig:modelab:a:cs}     {subfigure}{10pt}     %     {subfigure}{ extwidth}                                    {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,1872.00)%      {%      }%      {%        LTb       (1714,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (3341,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (4963,1924){(0,0)[r]{{}index }}%        LTb       (218,0){(0,0){{}}}%       (1404,0){(0,0){{}}}%       (2590,0){(0,0){{}}}%       (3776,0){(0,0){{}}}%       (4963,0){(0,0){{}}}%      }%            (0,0){{model-a-3d_data0_2000.pdf}}%           {picture}%                    {}     {fig:modelab:a:3d}     {subfigure}     {Snapshots from simulations of a 2D () and 3D () Allen--Cahn model {Allen1975}:     ({fig:modelab:a:2d}) the 2D system is shown at three intervals at solution index 500, 2,000 and 20,000.  ({fig:modelab:a:cs}) the 3D system is visualized using VTK {vtk} at solution index 50, 200 and 2,000 with a cross-section highlighted for visibility, where ({fig:modelab:a:3d}) shows the cross sections.     The simulations use a time step of  and are initially seeded with random values between -1 and 1.     }     {fig:modelab:a} {minipage} {minipage}{0.48 extwidth}                  {subfigure}{ extwidth}                                    {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,1872.00)%      {%      }%      {%        LTb       (1714,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (3341,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (4963,1924){(0,0)[r]{{}index }}%        LTb       (218,0){(0,0){{}}}%       (1404,0){(0,0){{}}}%       (2590,0){(0,0){{}}}%       (3776,0){(0,0){{}}}%       (4963,0){(0,0){{}}}%      }%            (0,0){{model-b-2d_data0_200000.pdf}}%           {picture}%                    {}     {fig:modelab:b:2d}     {subfigure}     %     {subfigure}{ extwidth}          [width=0.33 extwidth]{modelb500.png}%     [width=0.33 extwidth]{modelb2000.png}%     [width=0.33 extwidth]{modelb20000.png}     {}     {fig:modelab:b:cs}     {subfigure}{10pt}     %     {subfigure}{ extwidth}                                    {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,1872.00)%      {%      }%      {%        LTb       (1714,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (3341,1924){(0,0)[r]{{}index }}%      }%      {%      }%      {%        LTb       (4963,1924){(0,0)[r]{{}index }}%        LTb       (218,0){(0,0){{}}}%       (1404,0){(0,0){{}}}%       (2590,0){(0,0){{}}}%       (3776,0){(0,0){{}}}%       (4963,0){(0,0){{}}}%      }%            (0,0){{model-b-3d_data0_20000.pdf}}%           {picture}%                    {}     {fig:modelab:b:3d}     {subfigure}     {Snapshots from simulations of a 2D () and 3D () Cahn--Hilliard model {Cahn1958}: ({fig:modelab:b:2d}) the 2D system is shown at three intervals at solution index 5,000, 20,000 and 200,000; and ({fig:modelab:a:cs}) the 3D system is visualized using VTK {vtk} at solution index 2,500, 5,000 and 20,000 with a cross-section highlighted for visibility, where ({fig:modelab:a:3d}) shows the cross sections.     The simulations use a time step of , and are initially seeded with random values between -1 and 1.}     {fig:modelab:b}     % {minipage} {figure}% {figure}          {subfigure}{.5 extwidth}                                    {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(4320.00,5760.00)%      {%        LTb       (682,704){(0,0)[r]{{}-4}}%       (682,1255){(0,0)[r]{{}-3}}%       (682,1806){(0,0)[r]{{}-2}}%       (682,2356){(0,0)[r]{{}-1}}%       (682,2907){(0,0)[r]{{}0}}%       (682,3458){(0,0)[r]{{}1}}%       (682,4009){(0,0)[r]{{}2}}%       (682,4560){(0,0)[r]{{}3}}%       (682,5110){(0,0)[r]{{}4}}%       (1054,484){(0,0){{}}}%       (2138,484){(0,0){{}}}%       (3221,484){(0,0){{}}}%      }%      {%        LTb       (198,3121){ otatebox{-270}{(0,0){{}}}}%       (2368,154){(0,0){{}}}%       (2835,5333){(0,0){{}Model A, 2D}}%        LTb       (3200,4170){(0,0)[r]{{}500}}%        LTb       (3200,4456){(0,0)[r]{{}2,000}}%        LTb       (3200,4742){(0,0)[r]{{}20,000}}%        LTb       (3200,5028){(0,0)[r]{{}}}%      }%            (0,0){{model-a-2d_sa0_20000.pdf}}%           {picture}%                 {}  {fig:modela:sf2d}     {subfigure}%     {subfigure}{.5 extwidth}                                    {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(4320.00,5760.00)%      {%        LTb       (682,704){(0,0)[r]{{}-4}}%       (682,1587){(0,0)[r]{{}-2}}%       (682,2471){(0,0)[r]{{}0}}%       (682,3354){(0,0)[r]{{}2}}%       (682,4238){(0,0)[r]{{}4}}%       (682,5121){(0,0)[r]{{}6}}%       (1707,484){(0,0){{}}}%       (2984,484){(0,0){{}}}%      }%      {%        LTb       (198,3121){ otatebox{-270}{(0,0){{}}}}%       (2368,154){(0,0){{}}}%       (2835,5333){(0,0){{}Model A, 3D}}%        LTb       (3200,4170){(0,0)[r]{{}50}}%        LTb       (3200,4456){(0,0)[r]{{}200}}%        LTb       (3200,4742){(0,0)[r]{{}2,000}}%        LTb       (3200,5028){(0,0)[r]{{}}}%      }%            (0,0){{model-a-3d_sa0_2000.pdf}}%           {picture}%                 {}  {fig:modela:sf3d}     {subfigure}     {The radially averaged structure factor, , for the Allen--Cahn model {Allen1975} in ({fig:modela:sf2d}) 2D and ({fig:modela:sf3d}) 3D, corresponding to the simulation parameters described in Figure~ ef{fig:modelab:a} and computed using the average of 10 simulations. The results demonstrate scaling to Porod's law~(solid line, Equation~( ef{eq:porodslaw})) for  and , respectively~{Puri1997}.}     {fig:model-a_sf} {figure} {figure}          {subfigure}{.5 extwidth}                               {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(4320.00,5760.00)%      {%        LTb       (682,704){(0,0)[r]{{}-4}}%       (682,1671){(0,0)[r]{{}-2}}%       (682,2638){(0,0)[r]{{}0}}%       (682,3605){(0,0)[r]{{}2}}%       (682,4572){(0,0)[r]{{}4}}%       (682,5539){(0,0)[r]{{}6}}%       (1054,484){(0,0){{}}}%       (2138,484){(0,0){{}}}%       (3221,484){(0,0){{}}}%      }%      {%        LTb       (198,3121){ otatebox{-270}{(0,0){{}}}}%       (2368,154){(0,0){{}}}%       (2835,5333){(0,0){{}Model B, 2D}}%        LTb       (3200,4170){(0,0)[r]{{}5,000}}%        LTb       (3200,4456){(0,0)[r]{{}20,000}}%        LTb       (3200,4742){(0,0)[r]{{}200,000}}%        LTb       (3200,5028){(0,0)[r]{{}}}%      }%            (0,0){{model-b-2d_sa0_200000.pdf}}%           {picture}%                 {}  {fig:modelb:sf2d}     {subfigure}%     {subfigure}{.5 extwidth}                                    {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(4320.00,5760.00)%      {%        LTb       (682,823){(0,0)[r]{{}-3}}%       (682,1360){(0,0)[r]{{}-2}}%       (682,1897){(0,0)[r]{{}-1}}%       (682,2435){(0,0)[r]{{}0}}%       (682,2972){(0,0)[r]{{}1}}%       (682,3509){(0,0)[r]{{}2}}%       (682,4046){(0,0)[r]{{}3}}%       (682,4583){(0,0)[r]{{}4}}%       (682,5120){(0,0)[r]{{}5}}%       (1394,484){(0,0){{}}}%       (2851,484){(0,0){{}}}%      }%      {%        LTb       (198,3121){ otatebox{-270}{(0,0){{}}}}%       (2368,154){(0,0){{}}}%       (2835,5333){(0,0){{}Model B, 3D}}%        LTb       (3200,4170){(0,0)[r]{{}500}}%        LTb       (3200,4456){(0,0)[r]{{}2,000}}%        LTb       (3200,4742){(0,0)[r]{{}20,000}}%        LTb       (3200,5028){(0,0)[r]{{}}}%      }%            (0,0){{model-b-3d_sa0_20000.pdf}}%           {picture}%                 {}  {fig:modelb:sf3d}     {subfigure}     {The radially averaged structure factor, , for the Cahn--Hilliard model {Cahn1958} in ({fig:modelb:sf2d}) 2D and ({fig:modelb:sf3d}) 3D, corresponding to the simulation parameters described in Figure~ ef{fig:modelab:b} and computed using the average of 10 simulations. The results demonstrate scaling to Porod's law~(solid line, Equation~( ef{eq:porodslaw})) for  and , respectively~{Puri1997}. }     {fig:model-b_sf} {figure}  {figure} {minipage}{0.48 extwidth}          {subfigure}{ extwidth}                               {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,1872.00)%      {%      }%      {%        LTb       (1714,1924){(0,0)[r]{{}}}%      }%      {%      }%      {%        LTb       (3341,1924){(0,0)[r]{{}}}%      }%      {%      }%      {%        LTb       (4963,1924){(0,0)[r]{{}}}%        LTb       (218,0){(0,0){{}}}%       (1404,0){(0,0){{}}}%       (2590,0){(0,0){{}}}%       (3776,0){(0,0){{}}}%       (4963,0){(0,0){{}}}%      }%            (0,0){{model-c-2d_data0_1000000.pdf}}%           {picture}%          %     {15pt}                          {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,1872.00)%      {%      }%      {%        LTb       (1714,1924){(0,0)[r]{{}}}%      }%      {%      }%      {%        LTb       (3341,1924){(0,0)[r]{{}}}%      }%      {%      }%      {%        LTb       (4963,1924){(0,0)[r]{{}}}%        LTb       (218,0){(0,0){{}}}%       (1404,0){(0,0){{}}}%       (2590,0){(0,0){{}}}%       (3776,0){(0,0){{}}}%       (4963,0){(0,0){{}}}%      }%            (0,0){{model-c-2d_data1_1000000.pdf}}%           {picture}%               {}     {fig:modelc:2d}     {subfigure}     {subfigure}{ extwidth}          [width=0.33 extwidth]{modelc02500.png}%     [width=0.33 extwidth]{modelc010000.png}%     [width=0.33 extwidth]{modelc0100000.png}     [width=0.33 extwidth]{modelc12500.png}%     [width=0.33 extwidth]{modelc110000.png}%     [width=0.33 extwidth]{modelc1100000.png}     {}     {fig:modelc:3d}     {subfigure}                                 {Snapshots from simulations of 2D () and 3D () Model C {Elder1994}, Equation~( ef{eq:modelc}):     ({fig:modelc:2d}) the 2D system is shown at three intervals at solution index 25,000, 100,000 and 1,000,000.  ({fig:modelc:3d}) the 3D system  visualized using VTK {vtk}, with a cross-section highlighted for visibility, at three intervals at solution index 2,500, 10,000 and 100,000.     The simulations use a time step of , and were initially seeded with random values between -1 and 1.      The first row illustrates the evolution of the non-conserved field coalescing into droplet formations. The conserved field illustrated on the second row represents the density of the material.     }     {fig:modelc} {minipage}% {minipage}{0.48 extwidth}          {subfigure}{ extwidth}                               {cp1252}%          [2][]{%      {(gnuplot) spaces}{%       Package color not loaded in conjunction with       terminal option `colourtext'%      }{See the gnuplot documentation for explanation.%      }{Either use 'blacktext' in gnuplot or load the package       color.sty in LaTeX.}%       enewcommand[2][]{}%     }%     [2][]{%      {(gnuplot) spaces}{%       Package graphicx or graphics not loaded%      }{See the gnuplot documentation for explanation.%      }{The gnuplot epslatex terminal needs graphicx.sty or graphics.sty.}%       enewcommand[2][]{}%     }%      otatebox[2]{#2}%     ifundefined{ifGPcolor}{%       ewif           }{}%     ifundefined{ifGPblacktext}{%       ewif           }{}%         @addto@macro         {}%     {}%                   #1{}%     #1{}%                   #1{[rgb]{#1}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{[rgb]{1,0,0}}%      LT1{[rgb]{0,1,0}}%      LT2{[rgb]{0,0,1}}%      LT3{[rgb]{1,0,1}}%      LT4{[rgb]{0,1,1}}%      LT5{[rgb]{1,1,0}}%      LT6{[rgb]{0,0,0}}%      LT7{[rgb]{1,0.3,0}}%      LT8{[rgb]{0.5,0.5,0.5}}%              #1{{black}}%     #1{[gray]{#1}}%      LTw{{white}}%      LTb{{black}}%      LTa{{black}}%      LT0{{black}}%      LT1{{black}}%      LT2{{black}}%      LT3{{black}}%      LT4{{black}}%      LT5{{black}}%      LT6{{black}}%      LT7{{black}}%      LT8{{black}}%               {}{0.0500bp}%     %      ewlength{}%      ewlength{}%      ewsavebox{}%     %     {}{0.5pt}%     {}{1pt}%     {picture}(5182.00,4896.00)%      {%        LTb       (671,979){(0,0)[r]{{}}}%       (671,1400){(0,0)[r]{{}}}%       (671,1822){(0,0)[r]{{}}}%       (671,2243){(0,0)[r]{{}}}%       (671,2664){(0,0)[r]{{}}}%       (671,3086){(0,0)[r]{{}}}%       (671,3507){(0,0)[r]{{}}}%       (671,3928){(0,0)[r]{{}}}%       (671,4350){(0,0)[r]{{}}}%       (803,759){(0,0){{}}}%       (1248,759){(0,0){{}}}%       (1694,759){(0,0){{}}}%       (2139,759){(0,0){{}}}%       (2584,759){(0,0){{}}}%       (3029,759){(0,0){{}}}%       (3475,759){(0,0){{}}}%       (3920,759){(0,0){{}}}%       (4365,759){(0,0){{}}}%      }%      {%        LTb       (803,181){(0,0){{}}}%       (1696,181){(0,0){{}}}%       (2590,181){(0,0){{}}}%       (3483,181){(0,0){{}}}%       (4377,181){(0,0){{}}}%      }%            (0,0){{pfc_finished.pdf}}%           {picture}%               {}     {fig:modelpfc:2d}     {subfigure}     {subfigure}{ extwidth}          [width= extwidth]{pfc3d_side.png}     {}     {fig:modelpfc:3d}     {subfigure}     {Snapshots from simulations of the phase-field crystal model. Parameters were taken from from Elder et al.~{Elder2002},  and , and the constants in the dynamical equation (Equation~( ef{eq:pfc})) were chosen to be  and . ({fig:modelpfc:2d}) Shows the 2D () simulation at 700,000 iterations, representing approximately 700 diffusion time-lengths. ({fig:modelpfc:3d}) shows the visualization of the 3D system after 70,000 iterations, where a view of the interior is provided by removing a portion of the system along a sloped plane.     }     {fig:pfc} {minipage} {figure}  {Performance}  Performance was measured on three different hardware and operating system platforms using Models A and C with the solution taken after 10,000 iterations. The performance was measured by the runtime length of the entire program execution, in seconds. Since this includes all program activity between program initialization and termination, the data includes both time spent generating the spectral form and printing the final results to a file. All recorded measurements are listed in Table~ ef{table:performance}, and the details of the hardware platforms are listed in Table~ ef{table:hardware}.  Data was collected by repeating the simulations 10 times. From the system size, it is expected that the second test case is approximately 16 times longer than the first, and the third test case is similar to the second test case, for each model. Additionally, it is expected that Model C results are approximately twice as long as Model A (although the derivatives are of a higher order, and there is a coupling term). The data shows that typically the second test is much longer than the first test, which is the result of the ability for the processor to perform caching on the smaller system. Otherwise, these results correspond well to expectations.   {table}     {Runtime data was recorded for three different hardware and operating system environments, for two models and three different grid sizes. The entries of the table show the results of taking the minimum and maximum runtime values (in seconds) for each individual configuration across 10 individual simulations, in the format ``minimum value/maximum value''. The hardware and operating system specifications of the environments used are given in Table~ ef{table:hardware}.}               {tabular}{|c|l|l|l|l|l|l|}                  {2}{*}{Label} & {3}{c}{Model A} & {3}{|c|}{Model C}          & {} & {} & {} & {} & {} & {}           Win7 & 2.0/2.4 & 33.9/36.4 & 37.1/40.1 & 5.0/5.7 & 118.5/125.1 & 113.9/122.6           Win10 & 1.7/1.8 & 32.6/33.4 & 31.1/31.6 & 4.1/4.2 & 102.8/106.3 & 96.7/97.3          Arch & 2.0/2.0 & 49.8/50.1 & 45.8/46.2 & 5.5/5.7 & 175.0/177.8 & 158.7/160.3               {tabular}          {table:performance} {table}  {table}     {The hardware and operating system specifications of the environments used to generate runtime data.}               {tabular}{|c|l|l|}                  Label & {Clock speed} & {OS (Compiler)}           Win7 & i7-6800K (3.40 GHz) & Windows 7 (msvc 14.28)           Win10 & i7-7700HQ (2.80 GHz) & Windows 10 (msvc 14.27)          Arch & i5-6500 (3.20 GHz) & Arch Linux (gcc 10.2)               {tabular}     {table:hardware} {table}    {Requirements and Limitations} {Hardware and Software Environment}  Table~ ef{table:compilers} lists compilers, operating systems and target architectures that were used in testing  extit{SymPhas}{}. The minimum C++{} standard is C++{}17. The minimum gcc version required to build  extit{SymPhas}{} is gcc7.5. This version notably introduces constructor template deduction guides, a necessary part of the compile time expression algebra. The latest Microsoft Visual C++{} Compiler (abbreviated as MSVC++{} or MSVC) version is highly recommended. As a result of the heavy usage of meta-programming, earlier versions of MSVC++{} are not guaranteed to successfully build  extit{SymPhas}{}.   When compiling  extit{SymPhas}{}, four of the modules are required for the minimum build and there is only one required external dependency, FFTW. These are listed in Table~ ef{table:dependencies} alongside the minimum tested versions.  {table}     {The environments used for testing and compiling  extit{SymPhas}{}. The target architecture is specified in the third column. The minimum gcc version required to build  extit{SymPhas}{} is gcc7.5. The latest MSVC++{} version is highly recommended. }      {tabular}{|l|l|l|l|}            Compiler & Operating System & Target Arch. & Compiles?              MSVC++{} 14.28 & Windows 7 Professional (64-bit) & x64 & Yes       MSVC++{} 14.28 & Windows 10 Home (64-bit) & x64 & Yes       clang 11.0.1 & Arch Linux (64-bit) & x86-64 & Yes       g++ 10.2 & Arch Linux (64-bit) & x86-64 & Yes       g++ 7.5 & Arch Linux (64-bit) & x86-64 & Yes       g++ 5.5 & Arch Linux (64-bit) & x86-64 & No        {tabular}     {table:compilers} {table}  {table}     {List of the dependencies of each module. Modules that are required in the base build of  extit{SymPhas}{} are emphasized using bold print. Optional modules are always an optional dependency. The version of the external dependency with which  extit{SymPhas}{} has been tested is indicated in parentheses. The dependency tbb enables parallelism when using the execution header.}          {threeparttable}         {tabular}{|l|l|l|}                          Module & Internal Dependency & External Dependency                              extbf{{lib}} & None & FFTW (3.3.7) {Frigo_2005}, tbb*               extbf{{datatypes}} & {lib} & None                 extbf{{sym}} & {datatypes} & None               extbf{{sol}} & {sym}, {io} & VTK {vtk} (9.0)**               {io} & {datatypes} & libxdrfile (2.1.2)**              {conf} & {sol}, {io} & None                       {tabular}         {tablenotes}                                       *Library is only required for compiling in Linux.             **Library is optional.         {tablenotes}     {threeparttable}     {table:dependencies} {table}  {Limitations}  When the equations of motion and equations for virtual variables are written, a corresponding expression tree will be constructed by the symbolic algebra functionality. However, virtual variables used in the equations of motion will be substituted directly as data variables rather than as expression trees, meaning that the expression tree associated with the virtual variable will not be used to construct the expression tree for the equation of motion. One implication of this design is that computing the derivative of a virtual variable that is defined in terms of a derivative will apply a stencil twice, resulting in a poor approximation.  This also means that when using the spectral solver with equations of motion involving virtual variables, the spectral operators may be malformed if a virtual variable is written using a term necessary to correctly construct the operator. Refer to Section~ ef{sec:spectral} which explains the procedure of constructing the operators.  The Euler solver will assume that it can approximate derivatives of any order, but is only able to compute derivatives for which the stencils are implemented. See Section~ ef{methods:objects:stencils} for the exhaustive list of stencils.  Only scalar values can be provided to the model arguments for initializing the values of {c1}, {c2}, , and cannot be other types like matrices or complex types. When the model equations should use other types, then an appropriate number of scalar arguments should be provided in order to construct the term in the model preamble.   {Conclusions}  With  extit{SymPhas}{}, we have developed a high-performance, highly flexible API that allows a user to simulate phase-field problems in a straightforward way. This applies to any phase-field problem which may be formulated field-theoretically, including reaction-diffusion systems. Simulated models are written using the equations of motion in an unconstrained form specified through simple grammar that can interpret mathematical constructs. Here,  extit{SymPhas}{} was tested in both 2- and 3-dimensions against the well-known Cahn--Hilliard~{Cahn1958} and Allen--Cahn~{Allen_1972} models, a model of two coupled equations of motion for eutectic systems~{Elder1994}, and a phase-field crystal model~{Elder2002}. The results demonstrate that  extit{SymPhas}{} produces correct solutions of phase-field problems. Overall,  extit{SymPhas}{} successfully applies a modular design and supports the user by providing individual modules for each functional component alongside a highly detailed documentation.   With the growing interest in phase-field methods outside traditional materials and microstructure modeling, subjects such as wave propagation in cardiac activity and properties of biological tissues are other potential application fields  {Courtemanche_1996, Raina_2015, Gueltekin2016}.  extit{SymPhas}{}  offers very short definition-to-results workflow  facilitating rapid implementation of new models. In addition to being a tool for direct simulations,  extit{SymPhas}{} can generate large volumes of training data for new machine learning simulations of phase-field models. For instance, this type of approach has been applied in recent works that focused on formulating a free energy description from the evolving microstructure {Teichert_2019, Zhang_2020} and in developing machine-guided microstructure evolution models for spinodal decomposition {OcaZapiain2021}.   extit{SymPhas}{} will continue to be developed and have features added over time, which will include items such as upgrades to performance, additional symbolic algebra functionality, stochastic options and more solvers. The software is available at  exttt{https://github.com/SoftSimu/SymPhas}.      extbf{Supporting Information}  Supporting Information is available  from the authors.     extbf{Conflict of Interest}  The authors declare no conflict of interest.     extbf{Acknowledgments}   M.K. thanks  the  Natural  Sciences  and  Engineering  Research  Council  of  Canada (NSERC) and Canada Research Chairs Program for financial support.  S.A.S. thanks NSERC for financial support through the Undergraduate Student Research Award (USRA), the Canada Graduate Scholarships - Master's (CGSM) programs and Mitacs for support through the Mitacs Globalink Research Award.  SharcNet  and  Compute  Canada  are acknowledged for  computational resources.          {document}",0,2021-09-07T02:38:34,en,2109.02598,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,22,154,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,17159,0,0,17159,0,17159,0,0,0,0,0,0,17159,17159,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,17159,0,0,0,0,0,17159,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,17159,17159,17159,17159,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,0,0,0,0,17159,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,17159,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,17159,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,17159,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,17159,0,0,17159,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,17159,0,17159,17159,0,0,17159,17159,17159,17159,0,0,17159,0,0,17159,0,0,0,0,0,0,17159,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,17159,0,0,0,0,17159,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,17159,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,0,17159,0,0,0,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,17159,17159,17159,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,17159,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,17159,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,17159,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"{Experimentation Details}  When { continuing pre-training} BERT-continue/RoBERTa-continue in Table~ ef{tab:continue}, we follow~{kocijan19acl} and set learning rate to , batch size to , and train the model for only one epoch.   When { fine-tuning} the models in Sec~ ef{sec:exp:glue} and Sec~ ef{sec:exp:introduction}, we train the models for  epochs. We use grid search to select their learning rates and batch sizes from  and , respectively.   {Statistics of Commonsense Descriptions} In Table~ ef{tab:stat:wsc} and Table~ ef{tab:stat:glue}, we report statistics about down-stream tasks and their commonsense descriptions. Our report includes the size of the train/test splits for the downstream tasks, the proportion of samples that matched to at least one commonsense description ({ Matched proportion}) in each task, the average number of matched commonsense descriptions per sample ({ Average }), and the average length of each matched commonsense description ({ Average length of }).  From the results, we found that more than half of the samples matched to at least one commonsense description in most of the datasets. This indicates that the OOD commonsense used in this paper is generalizable to different datasets. Also, the average length of the matched commonsense descriptions is short (about ), thus encoding them via Transformer is efficient. {Conclusion}  In this paper, we study how to use commonsense to enhance the general text representation. We first analyzed the challenges brought by the domain discrepancy of commonsense. Then, we propose OK-Transformer to allow commonsense integration and enhancement. In the experiments, we verified the effectiveness of our proposed models in a variety of scenarios, including commonsense reasoning, general text classification, and low-resource commonsense. Our models consistently outperform the baselines. We have also empirically analyzed other properties (e.g. interpretability) of the model.  {Experiments} {sec:exp}  We evaluate the effectiveness of our proposed models in three scenarios: cloze-style commonsense reasoning, text classification, and low-resource commonsense settings. All the experiments run over a computer with 4 Nvidia Tesla V100 GPUs.   {table}[]   {Statistical Result on WSC Datasets} {tabular}{lccccc}  oprule[1pt] Dataset               & WSC    & WSCR   & PDP    & WinoGender & WinoGrande   Dataset Size          & 273    & 1185   & 60     & 720        & 40938/1267  matched proportion    & 0.67   & 0.63   & 0.83   & 0.65       & 0.71        Average number of  & 129.71 & 115.42 & 189.68 & 80.63      & 140.56      Average length of  & 17.88  & 17.75  & 17.91  & 16.83      & 17.91    [1pt] {tabular} {table}  {table}[]   {Statistical results on GLUE} {tabular}{lcccccc}  oprule[1pt] Dataset               & MRPC     & CoLA      & RTE      & QNLI        & STS-B     & SST-2       Dataset Size          & 3668/408 & 8551/1043 & 2490/277 & 104743/5463 & 5749/1500 & 67349/872  matched proportion    & 0.59     & 0.40      & 0.72     & 0.52        & 0.56      & 0.25       Average number of  & 80.71    & 84.85     & 122.60   & 81.35       & 117.00    & 83.07      Average length of  & 17.47    & 17.60     & 17.71    & 17.59       & 17.34     & 17.59     [1pt] {tabular} {table}   { Models} We consider adapting OK-Transformer to BERT and RoBERTa, which are denoted as OK-BERT and OK-RoBERTa, respectively. We use the BERT-base and RoBERTa-large from the HuggingFace Transformer library~{wolf2020transformers}.   { Implementation details for candidate knowledge retrieval} For a given text , we retrieve candidate commonsense from ATOMIC2020. We use the if-then descriptions in ATOMIC2020 (e.g. Fig.~ ef{fig:commonsense_list}). Since these descriptions cover 173k different verb phrases -- one of the fundamental elements of language -- the retrieval is applicable to a broad range of downstream text understanding tasks.  We use a simple retrieval method. We simply consider word segments with window size 5 of the input text . All the commonsense descriptions matching one of these text segments will be regarded as the candidate commonsense descriptions .    {Commonsense Reasoning}  {Setup}  { Datasets} We consider the following commonsense reasoning benchmarks: WSC273~{levesque2012winograd}, PDP~{morgenstern2016planning}, Winogender~{rudinger2018gender}, WinoGrande~{sakaguchi2019winogrande}, CommonsenseQA~{talmor2019commonsenseqa} and PhysicalQA~{bisk2020piqa}.   { Model details} Due to the different implementations between {kocijan19acl} and~{sakaguchi2019winogrande}, in this paper, we also follow their settings to compare with them, respectively. For~{kocijan19acl}, we conduct disambiguation tasks directly through masked language modeling in OK-BERT. For the latter one, we convert cloze-style problems to multiple-choice classification problems in OK-RoBERTa. In particular, we replace the target pronoun of one query sentence with each candidate reference, then put the new sentences into the language model. We use a single linear layer and a softmax layer over the encoding of its  token to compute the probability of each new sentence, and select the one with the highest probability as the pronoun disambiguation result.   { Hyperparameters of pre-training} We follow~{kocijan19acl,sakaguchi2019winogrande} to first pre-train models for 30 and 3 epochs over WSCR~{kocijan19acl} or WinoGrande~{sakaguchi2019winogrande}, respectively. Then we fine-tune models over specific tasks. We use AdamW as the optimizer with learning rate 5e-6, which is selected from . We set the batch size to 8.  {table}[!htb]  { abcolsep}{2pt}  {tabular}{l c c}  oprule Model & WSC & PDP   KEE{liu2016commonsense} & 52.8 & 58.3  WKH~{emami2018generalized} & 57.1 & -   MAS~{klein2019attention}  & 60.3  & 68.3   DSSM~{wang2019unsupervised} & 63.0 & 75.0   LM{trinh2018simple} & 63.8 & 70.0    CSS~{klein2020contrastive} & 69.6 & 90.0    GPT2~{radford2019language} & 70.7 & -     BERT-large+WSCR~{kocijan19acl} & 71.4 & 79.2  HNN~{he2019hybrid} & 75.1 & 90.0    Human~{sakaguchi2019winogrande}  & 96.5 & 92.5  BERT+WSCR  & 66.3 & 85.0  { OK-BERT+WSCR }         & { 67.4} & { 86.7 }    RoB.+WinoGrande  & 90.1 & 87.5  { OK-RoB.+WinoGrande } & { 91.6} & { 91.7}   {tabular} {Results on WSC and PDP. RoB. denotes RoBERTa.} {tab:main1} {table}  {table}[!htb]   { abcolsep}{2pt} { abcolsep}{1.3pt} {tabular}{lcc}      oprule     Model & WinoGen. & WinoGran.       WikiCREM~{kocijan2019wikicrem}                & 82.1 & -        WinoGrande~{sakaguchi2019winogrande} & 94.6 & 79.3       BERT+WSCR                      & 68.2 & 51.4      { OK-BERT+WSCR}                   & { 72.4} & { 53.4}       RoB.+WinoGrande            & 94.6 & 79.3      { OK-RoB.+WinoGrande }        & { 96.2} & { 79.6}       {tabular} {Results on WinoGender and WinoGrande.} {tab:main2} {table}  {table}[!htb]  { abcolsep}{2.2pt}  {tabular}{  l | c c}  oprule Model & CommonsenseQA & PhysicalQA   BERT               & 55.86 & 68.71    { OK-BERT}                   & { 56.27} & { 69.09}   RoBERTa           & 73.55 & 79.76  { OK-RoBERTa }        & { 75.92} & { 80.09}   {tabular} {Results on CommonsenseQA and PhysicalQA.} {tab:main3} {table}  {Results} We compare our models with state-of-the-art commonsense reasoning models in Table~ ef{tab:main1},~ ef{tab:main2}, and~ ef{tab:main3}. It can be seen that our models outperform other models in most settings. This verifies the effectiveness of our proposed models for commonsense reasoning.  { Ablations} In Table~ ef{tab:main1},~ ef{tab:main2}, and~ ef{tab:main3} we also compare OK-BERT with BERT. We found that OK-BERT with OK-Transformers effectively improved the accuracy of BERT with Transformers. Similar results can be found between OK-RoBERTa and RoBERTa. This shows that the proposed OK-Transformer improves pre-trained language models by adapting to them for free, i.e. without retraining on large-scale unsupervised corpora.  {General Text Classification} {sec:exp:glue} We use MRPC, CoLA, RTE, STS-B, SST-2, and QNLI in the GLUE dataset~{wang2018glue} to verify the effectiveness of the proposed models on general text classification tasks. We did not evaluate over MNLI, because our model needs to represent the corresponding  commonsense for each sentence, which is too costly for MNLI. We believe that this efficiency problem can be solved by further applying model compression~{iandola2020squeezebert}, but this is beyond the scope of this paper. It can be seen from Table~ ef{tab:glue} that OK-BERT and OK-RoBERTa outperform their baselines.   {table*}[!htb]  {     {tabular}{lcccccc}      oprule     GLUE Task       & MRPC & CoLA & RTE & QNLI & STS-B & SST-2       BERT       & 86.27/90.21 &  extbf{59.50} & 71.43 & 91.20 & 89.35/88.93 & 91.97      OK-BERT         &  extbf{87.25/90.84} & 58.29 &  extbf{73.65} &  extbf{91.58} &  extbf{89.82/89.46} &  extbf{93.69}       RoBERTa   & 90.44/93.15 & 66.57 & 84.11 & 94.00 & 91.83/91.95 & 95.70      OK-RoBERTa      &  extbf{91.91/94.24} &  extbf{66.89} &  extbf{86.28} &  extbf{94.41} &  extbf{92.41/92.20} &  extbf{96.10}           {tabular} } {Results on text classification tasks. Models are evaluated by the dev split from GLUE. } {tab:glue} {table*}  {Commonsense Introduction Methods} {sec:exp:introduction} { Continue pre-train} In the introduction section, we mentioned that a typical method of introducing textual knowledge is continuing pre-training~{gururangan2020don,sun2019finetune}. However, due to the domain discrepancy of commonsense, this method will cause catastrophic forgetting. To verify this intuition, in this subsection we compare with the continuing pre-trained model. We first continue pre-training the language model over ATOMIC2020, then fine-tune it over the target task.    { ExpBERT}~{murty2020expbert} We also compare our OK-Transformer with ExpBERT, another model that is able to introduce textual knowledge. In Sec~ ef{sec:intro}, we mentioned that ExpBERT is not applicable to large-scale commonsense knowledge bases for its disability to select related commonsense and ignore unrelated commonsense. To verify this, we use the retrieved candidate commonsense descriptions from ATOMIC2020 as the additional explanations for ExpBERT. ExpBERT concatenates all the embedding of a fixed number of commonsense, which is inflexible for ATOMIC2020. For this reason, we fix the number of commonsense to 48. If there are more than 48 candidate commonsense descriptions for one sample, we will randomly select 48 of them. Otherwise, we will pad null commonsense to it. In our experiments, we also apply ExpBERT to RoBERTa~{liu2019roberta} (i.e. ExpRoBERTa).  {table*}[!htb]  {tabular}{lccccccc}  oprule                  & MRPC        & CoLA  & RTE   & QNLI  & STS-B       & SST-2 & WSC273   BERT        & 86.27/90.21 &  extbf{59.50} & 71.43 & 91.20 & 89.35/88.93 & 91.97    & 66.30   BERT-continue & 83.58/88.81         & 54.70  & 62.09 & 90.24 & 87.41/87.46 & 91.74 & 63.00   ExpBERT         & 85.78/89.79 & 58.29 & 62.82 & 87.06 & 84.78/84.67 & 91.51 & --  { OK-BERT}    &  extbf{87.25/90.84} & 58.29 &  extbf{73.65} &  extbf{91.58} &  extbf{89.82/89.46} &  extbf{93.69}  &  extbf{67.40}   RoBERTa    & 90.44/93.15 & 66.57 & 84.11 & 94.00 & 91.83/91.95 & 95.70  & 90.10   RoBERTa-continue  & 87.01/90.38 & 61.74 & 74.01 & 93.61 & 89.57/89.66 & 95.99 & 87.91  ExpRoBERTa      & 89.46/92.22 &  extbf{66.90}  & 83.39 & 93.78 & 89.81/89.94 & 95.99 & --  { OK-RoBERTa} &  extbf{91.91/94.24} & 66.89 &  extbf{86.28} &  extbf{94.41} &  extbf{92.41/92.20} &  extbf{96.10} &  extbf{91.58}   {tabular} {Comparison of different commonsense introduction approaches. Continuing pre-training even injures the effectiveness. On the other hand, using OK-Transformers to introduce external knowledge achieves better results than using Transformer.} {tab:continue} {table*}  We show the results in Table~ ef{tab:continue}. We do not report the results of ExpBERT on WSC273, as ExpBERT cannot solve the cloze-style problems. It can be seen that the performance of language models was suffered when we simply continue pre-training the models on the commonsense knowledge base. This verifies that the continuing pre-training on the out-of-domain commonsense will cause catastrophic forgetting and injure the effectiveness. On the other hand, using OK-Transformer to introduce commonsense as the extra input significantly improves the accuracy. The results also suggest that ExpBERT is not applicable to large-scale commonsense knowledge bases.   {Why is OK-Transformer effective?}  We now analyze why OK-Transformer can effectively introduce out-of-domain commonsense without pre-training. We are inspired by an observation of language model fine-tuning LMs~{radiya2020fine}, i.e., the parameters after fine-tuning are close to those before fine-tuning. Therefore, we argue that the key to effective introduction is whether the parameters of the meta LM is good initialization for the commonsense-enhanced LM, that the parameters do not change much before and after fine-tuning.  To verify this, we compare the parameter changes of different knowledge integration methods. These methods include (1) OK-Transformer, (2) KnowBERT~{peters2019knowledge}, (3) using the original  token instead of the proposed knowledge token, and (4) abandoning the knowledge token and instead calculating the  of each verb phrase of the target sentence separately, and adding them to these verb phrases' hidden states in . We follow~{radiya2020fine} to use the  as the distance metric. {radiya2020fine} found that the main change in parameters occurs on the  matrix of the Transformer. Our experimental results also follow this phenomenon. Therefore, for greater clarity, we only show the distances of the  matrices after fine-tune. We show the distances of different methods in Fig.~ ef{fig:heatmap}, and their training losses in Fig.~ ef{fig:loss}.   {figure}[t]     [scale=.35]{figs/heatmap.pdf} { distances in parameter space between pre-trained and fine-tuned meta LMs. We show the metrics of  across the 12 Transformer layers.} {fig:heatmap} {figure}  {figure}[t]  {minipage}[t]{0.225 extwidth}     *{-} ewline[scale=.42]{figs/loss.pdf}   {Losses of different knowledge integration methods in SST-2. The [CLS] token method does not converge.} {fig:loss} {minipage} {0.2cm} {minipage}[t]{0.225 extwidth}    *{-} ewline[scale=.4]{figs/few-shot.pdf}     {0.2cm} {Effect in low-resource commonsense settings with different s over SST-2. }  {fig:low_resource} {minipage} {figure}  It can be seen that the distances of OK-Transformer are much smaller than other methods, except the [CLS] token method, which does not converge as shown in Fig.~ ef{fig:loss}.  This fits our intuition of reducing the parameter variations to introduce external knowledge more effectively.    {Effect in Low-Resource Commonsense Settings} Since there is a large number of commonsense descriptions in ATOMIC2020, a large portion of descriptions only occur a few times in the training set. In this subsection, we want to verify for these rare descriptions, can the model still benefit from it? If so, we think it means that the model uses the contextual information of the commonsense to improve the understanding of the commonsense.      To do this, we proposed a low-resource commonsense setting. We evaluate the effect of the model if the training dataset only contains  samples. Therefore the frequency of the appeared commonsense descriptions is low.  In order to exclude the influence of other samples, we only use test samples whose candidate commonsense descriptions have already occurred in the  training samples. For example, when , we randomly select  samples from the training set for training, and use all samples in the test set which contains the commonsense of the  training samples for evaluation. We show the results over the SST-2 dataset in Fig.~ ef{fig:low_resource}. It can be seen that our models still benefit from low-frequency commonsense.         {Comparison of Different Network Structures for Commonsense Enhancement} How to design an effective network structure to incorporate commonsense into text representation is the key problem in this paper. In this subsection, in addition to the layer-by-layer connection and knowledge update mechanism of the knowledge enhancement module in Sec~ ef{sec:knowledge:input}, we compare with other network structures, including: (1) replacing layer-by-layer connection with connecting all s in BERT1 to the final  layer in BERT2 ({ one-to-all}); (2) discard the extra knowledge token  and use  token as the knowledge token instead ({ remove }).  {table}[!htb] { abcolsep}{2.2pt}   {tabular}{@{}lccccc@{}}  oprule & WSC273 & MRPC  & CoLA  & RTE & Average   OK-BERT     & 66.70   & { 87.75} & 59.24 & { 72.20} & { 67.86}  one-to-all & 65.57  & 87.75 & 58.63 & 70.04 & 67.09  remove  & { 67.03}  & 85.04 & { 60.06} & 71.48 & 67.69   {tabular} {Effect of different network structures for commonsense enhancement.} {tab:enhance} {table}  We show the comparisons of these structures in Table~ ef{tab:enhance}. We found using an additional knowledge token  may have competitive results in some datasets, while layer-by-layer connections perform better overall.    {Does OK-Transformer Provide Interpretability?}  In this subsection, we try to answer if the integration of candidate commonsense descriptions by OK-Transformer is interpretable. To answer this question, we calculate the influence of different commonsense descriptions on the model's predictions. We follow~{wu2020perturbed} to quantify the influence of a commonsense description  as: If  is removed from , how much will the prediction change? This change is measured by the Euclidean distance between the prediction by  and by . The greater the change in the prediction, the greater the influence of this commonsense.  {table}[!htb] { abcolsep}{2.2pt}   {tabular}{@{}llll@{}}  oprule {4}{l}{John {promised} Bill to leave, so an hour later {[}John{]} left.}                 {4}{l}{PersonX promises PersonY.}    {4}{l}{1.  As a result, PersonX wants to fulfill his promise.}   {4}{l}{2.  PersonX is seen as truthful}                         {4}{l}{3.  PersonX is seen as trustworthy.}                     {4}{l}{4.  Before, PersonX needed to talk to PersonY.}          {4}{l}{5.  Before, PersonX needed to go to PersonY's house.}     {tabular} {A case study of top 5 commonsense descriptions.} {tab:interpret} {table}  Through the case studies of the samples in WSC273, we found that although commonsense with higher influence is somewhat interpretable for people, the interpretability is not significant. We show some examples in Table~ ef{tab:interpret}. We believe that this is because some commonsense for people has been learned in pre-training. Therefore, the out-of-domain commonsense that these pre-trained language models need to incorporate for downstream tasks is inconsistent with human understanding.   {Introduction} {sec:intro} Although unsupervised language models have achieved big success on many tasks~{devlin2018bert}, they are incapable of learning low-frequency knowledge. For example, in the masked language model task in Fig.~ ef{fig:commonsense_list}, even if we replace ``Kevin was'' (left) with ``Jim was'' (right), BERT~{devlin2018bert} still predicts the masked word as sick, crying, dying, etc. This is because similar texts in its training corpus rarely describe the subject of ``comforted''. To improve the model's ability to generalize and understand low-frequency knowledge, we propose to incorporate commonsense into language models. In Fig.~ ef{fig:commonsense_list}, to make correct predictions, we need to enhance the language model with the commonsense .  {figure*}[!htb]     [scale=.5]{figs/example.pdf} {The prediction of [MASK] by BERT. BERT cannot distinguish between { Jim} and { Kevin} in { Jim comforted Kevin because}. } {fig:commonsense_list} {-0.3cm} {figure*}   However, commonsense has the nature of { domain discrepancy}. The downstream task and the commonsense knowledge have distribution discrepancies. Taking the commonsense knowledge base we use (i.e. ATOMIC2020~{hwang2020comet}) as an example, the distribution discrepancy is specifically manifested in (1) their data formats. The format of a commonsense description usually belongs to some specific patterns (e.g. â€œ... As a result ...â€, â€œ... Because ...â€), while the downstream tasks can have arbitrary patterns. (2) The commonsense belongs to the domain of event causality, while the downstream tasks may belong to arbitrary domains.       Here we highlight the challenges caused by the domain discrepancy. To introduce external textual knowledge to a pre-trained language model, a common practice is to continue pre-training the language model on the corpus of the external knowledge~{gururangan2020don,sun2019finetune}. However, the study~{gururangan2020don} also found that continuing pre-training requires external knowledge and downstream tasks to have similar domains. Due to its domain discrepancy, introducing commonsense through continuing pre-training will cause catastrophic forgetting to downstream tasks, thereby injuring the effectiveness. We have verified this empirically in Sec~ ef{sec:exp:introduction}. Therefore, the domain discrepancy prevents us from introducing commonsense by continuing pre-training.  To enhance the representation of the target text with external commonsense, we propose to directly use its candidate commonsense as an extra input. Our setup is different from a typical natural language understanding setup since the latter one only takes the target text as the input~{devlin2018bert}. We argue that our setup -- where the commonsense is introduced explicitly as input -- is a more practicable setup to introduce out-of-domain commonsense that cannot be learned through pre-training. As far as we know, ExpBERT~{murty2020expbert} is the closest setup to us. It also uses external knowledge (manually constructed templates) as the input.    Another challenge is the { scale} of the commonsense. Although ExpBERT also allows extra textual commonsense as input, it only captures small-scale commonsense with a fixed size. In addition, when we introduce commonsense from a large-scale knowledge base for general purpose (i.e. ATOMIC2020), unrelated commonsense (e.g.  and  in Fig.~ ef{fig:commonsense_list}) will certainly occur. However, ExpBERT lacks the ability to distinguish related and unrelated commonsense. Therefore, the power of large-scale commonsense knowledge was restricted in ExpBERT. We will verify this empirically in Sec~ ef{sec:exp:introduction}.  In order to incorporate the large-scale out-of-domain commonsense, we propose the OK-Transformer ({O}ut-of-domain {K}nowledge enhanced {Transformer}) on the basis of Transformer~{vaswani2017attention}. OK-Transformer has two modules. The knowledge enhancement module is used to encode the target text with commonsense, and the knowledge integration module is used to encode and integrate all candidate commonsense. OK-Transformer has two advantages. First, it fully represents the contextual information of the textual commonsense. Second, it can be adapted to existing pre-trained language models (e.g. BERT and RoBERTa) for free. That is, we are able to adapt OK-Transformer to the pre-trained language models, without pre-training OK-Transformer over large-scale unsupervised corpora from scratch.  Some other methods are related to our work, such as introducing { structured} knowledge~{peters2019knowledge,zhang2019ernie,guan2020knowledge,zhou2018commonsense} and { plain text} knowledge~{guu2020realm} in language models. These methods do not represent the specific inductive bias of commonsense knowledge and therefore are not suitable to introduce commonsense. We will compare these studies with more details in Sec~ ef{sec:related}.    {OK-Transformer}  In this section, we propose OK-Transformer based on Transformer to introduce extra commonsense descriptions. We first show OK-Transformer on an abstract level in Sec~ ef{sec:framework}. Then we elaborate two modules within it, i.e. knowledge enhancement and knowledge integration, in Sec~ ef{sec:knowledge:input} and Sec~ ef{sec:method:output}, respectively.  {Framework} {sec:framework} In this subsection, we show how our OK-Transformer works at an abstract level. For the target sentence , OK-Transformer takes both  and  as inputs. To incorporate all the information of  and , the OK-Transformer contains three vanilla Transformers, denoted by . The knowledge enhancement module uses  to encode the target text. Compared with the vanilla Transformer,  leverages a new knowledge token to represent the commonsense that interacts with other words. The knowledge integration module encodes each individual commonsense description by , and then integrates all candidate commonsense descriptions by . This is shown in Fig.~ ef{fig:ok_transformer}.  {figure}[!tb]     [scale=.45]{figs/ok_transformer_new.pdf} {OK-Transformer.  encodes the target text  with enhanced commonsense .  encodes each individual commonsense description.  integrates all candidate commonsense descriptions and transfers knowledge to .} {fig:ok_transformer} {figure}   {figure}[!htb] {subfigure}[t]{0.45 extwidth}     [scale=.43]{figs/ok_transformer.pdf} {OK-Transformer.  represents the target text  with enhanced commonsense .  represents each individual commonsense description.  integrates all candidate commonsense descriptions and transfers knowledge to .} {fig:ok_transformer} {subfigure} {0.3cm} {subfigure}[t]{0.45 extwidth}      aisebox{3cm}{[scale=.43]{figs/ok_bert.pdf}} {OK-BERT: Adapt OK-Transformer to BERT. We only draw edges which connect to the -th layer.} {fig:ok_bert} {subfigure} {Architectures.}  {fig:effect_adaptive_gamma} {figure}   {Knowledge Enhancement Module} {sec:knowledge:input} The knowledge enhancement module allows commonsense knowledge to enhance the representation of the target text.  { Interaction between words and commonsense.} We use  to represent the interaction between words of the target text . In addition, we introduce a special token  to represent the commonsense knowledge. We denote it as the knowledge token.  encodes all words and the knowledge token together via multi-head attention. Formally, given word sequence ,  accepts a sequence of  word-piece tokens: . We denote the knowledge embedding and word embeddings produced by the -th layer of  as  and , respectively. The  block first uses a multi-head self-attention layer followed by a residual connection and a layer normalization to model their interactions: {equation}  {eqn:kh} {aligned}     & {k_i',{ H}_i'= LayerNorm( [k_{i-1},{ H}_{i-1}] +}       & {MultiHeadAttn([k_{i-1},{ H}_{i-1}],[k_{i-1},{ H}_{i-1}],[k_{i-1},{ H}_{i-1}]))}  {aligned} {equation} where  means appending  at the front of .  is used as the query, key, and value in the multi-head attention.  { Knowledge update} The vanilla Transformer projects  in Eq.~{eqn:kh} to the output space with a multi-layer perceptron neural network (MLP). Compared to the vanilla Transformer, we use an extra update operation to update the knowledge token by the integrated commonsense knowledge after the MLP. As in the vanilla Transformer, the update layer is followed by a residual connection and a layer normalization. This can be formulated by: {equation}  {aligned} &{k_{i}=LayerNorm(k_i'+MLP(k_i')+ cs_{emb})}  &{{ H}_{i}=LayerNorm({ H}_{i}'+MLP({ H}_i'))} {aligned} {equation} where  is the embedding of the commonsense computed by the knowledge integration module in Sec~ ef{sec:method:output}.   {Knowledge Integration Module} {sec:method:output} The knowledge integration module encodes all candidate commonsense descriptions and integrates them. We first use  to represent each candidate commonsense description. Then, we use  to integrate all candidate commonsense, and transfer the integrated knowledge to the knowledge enhancement module.    { Representing single commonsense} We use a vanilla Transformer as  to model each candidate commonsense description. For all the retrieved commonsense , we compute the embedding  of each commonsense description  by: {equation}  {emb_j = Transformer^{(2)}(c_j)} {equation}  { Knowledge integration} We integrate all candidate commonsense by . Since not all the candidate commonsense leads to high confidence prediction as we have discussed in Sec~ ef{sec:intro}, we need to select relevant commonsense and ignore irrelevant commonsense. Transformer is adequate to conduct this selection. Specifically, in the query-key-value mechanism in Transformer, we use the embedding of the knowledge token in  as the query of .  and the commonsense embeddings by  as keys and values of . Then, we integrate representations of all different commonsense descriptions based on their similarities with the knowledge token.   also uses multi-head attention to allow the knowledge token to interact with the candidate commonsense in multiple ways. The output of multi-head self-attention is followed by a residual connection and a layer normalization. {equation}  {aligned} {cs_{emb}}= & {LayerNorm(k_{i-1} }  & + {MultiHeadAttn(k_{i-1},{ emb},{ emb}))} {aligned} {equation} where  denotes the sequence of embeddings of all candidate commonsense descriptions. We then apply a residual connection and a layer normalization to it.  { Null Commonsense} Some target texts may not have valid commonsense from ATOMIC2020 to enhance their representations. Therefore, we refer to the settings of REALM~{guu2020realm} to add a null commonsense into the candidate commonsense of all target texts. We denote the null commonsense as . Matching to the null commonsense indicates that the commonsense knowledge base cannot help enhance the target text.  {Adaptation to Pre-trained Language Models} In this section, we take BERT as an example to illustrate how we adapt OK-Transfomer to existing pre-trained language models. We denote the adapted model as OK-BERT. An important manifestation of the effectiveness of the  Transformer structure is its applications in large-scale pre-trained models (e.g. BERT, RoBERTa). In order to introduce external knowledge, many other studies conduct training over large-scale unsupervised corpus~{peters2019knowledge,xiong2019pretrained}. However, OK-Transformer is able to directly adapt to the existing pre-trained language models for free. In other words, when adapting OK-Transformer to OK-BERT, we directly use the parameters of each Transformer layer of BERT to initialize the OK-Transformer layers of OK-BERT. This property greatly improves the applicability of OK-BERT. In the rest of this section, we will describe how , , and  are adapted respectively in Sec~ ef{sec:layer_adapt}, and how to fine-tune OK-BERT in Sec~ ef{sec:train}.  {Layer-by-Layer Adaptation} {sec:layer_adapt} The OK-BERT we designed uses two original BERTs to serve as  and , respectively. We denote them as BERT1 and BERT2. We connect the  and  in the corresponding layer of each BERT by . Therefore, OK-BERT makes full use of the multi-layer structure of BERT, while allowing commonsense in the knowledge token to fully interact with the target text in each layer. The architecture is shown in Fig.~ ef{fig:ok_bert}.  {figure}[!htb]     [scale=.45]{figs/ok_bert2.pdf} {The architecture of OK-BERT. We only draw edges that connect to the -th layer.} {fig:ok_bert} {figure}   We adapt the Transformer of BERT1 to  in the knowledge enhancement module of OK-Transformer. Note that the original BERT's tokens are  (for a single sentence) or  (for a sentence pair). We follow~{wang2020cross} and use a special token  as the knowledge token.  When tokenizing sentences, we insert the  token after the  token for each given text. In this way, the input tokens become  or  , respectively. This simple modification allows us to use  as the knowledge token in the knowledge enhancement module.    We adapt each Transformer layer of BERT2 to the  layer. The adaptation is straightforward since  uses the vanilla Transformer structure. We use the encoding of the  token in each corresponding layer as the commonsense representation  to enhance the representation of the corresponding layer in BERT1.   For each pair of corresponding  and  from the same layer, we use one  to connect them to transfer the information from BERT2 to BERT1.  In summary, when adapting to BERT-base with 12 Transformer layers, OK-BERT contains 12  layers for BERT1, 12  layers for BERT2, and 12  layers for layer-wise knowledge integration.   {Parameter Initialization and Model Training} {sec:train} In our implementation, BERT1 and BERT2 have independent parameters. We use the parameters of BERT to initialize both BERT1 and BERT2. The parameters of  layers are randomly initialized. For downstream tasks, we then fine-tune all the parameters in the fashion of end2end.  {How does OOD Commonsense Help: Explanation from OOD predictions}  {Related work} {sec:related} In this section, we compare different ways to introduce knowledge into language models. We divide the knowledge introduction methods into (1) continuing pre-training method~{gururangan2020don,sun2019finetune} and (2) explicit introduction in the downstream task~{guu2020realm,murty2020expbert}.   { Continuing pre-training} the language model is effective when the external knowledge is similar to the downstream task~{gururangan2020don,sun2019finetune}. However, commonsense and downstream tasks have domain discrepancies, so continuing pre-training is unsuitable for introducing commonsense. We have empirically verified this in Sec~ ef{sec:exp:introduction}.  { Introducing explicit knowledge in downstream tasks} We classify the knowledge into structured knowledge, plain text, and semi-structured knowledge, depending on its form. The entries of { structured knowledge} are represented as individual embeddings~{peters2019knowledge,zhang2019ernie,guan2020knowledge,zhou2018commonsense}, while commonsense descriptions in this paper can be represented more accurately by the contextual information of their word sequences.      {Problem Setup: Commonsense as the Extra Input}  We consider a text classification task where the text  and its label  are provided for training. Assuming that the candidate commonsense descriptions for enhancing  come from a large-scale commonsense knowledge base (i.e. ATOMIC2020), we retrieve candidate commonsense for  as the extra input. We denote the commonsense descriptions for  as , where each  is a commonsense description. The retrieval process will be shown in Sec~ ef{sec:exp}. The model takes both  and  as the input. Since ATOMIC2020 contains if-then knowledge for general purposes, the problem setup can be expanded to a broad range of text understanding tasks. The goal of training is to find parameter  that minimizes the loss of training examples given the texts and candidate commonsense descriptions: {equation}  {eqn:goal} {{}_{ heta} {E}_{(x,y) train} (f(x,cs(x)| heta),y)} {equation} where  is the model taking  and  as inputs,  is the loss function.    op{ {Explanation: Converting OOD Predictions to In-Distribution} {sec:rational}  To illustrate how we use the commonsense to enhance the representation of , we consider the example in Fig.~ ef{fig:commonsense_list}. We want to infer who ``he'' is (Kevin or Jim) from , that is, predicting . Here  and  are both natural language descriptions. This inference requires the joint distribution of  and . We show the corresponding frequency distribution in the training data in Fig.~ ef{fig:sphere}. In our example, this inference is hard if  is OOD in the training dataset.   To avoid directly predicting the OOD data , we introduce the commonsense . Instead of directly inferencing , we use  as the intermediate variable to reduce the difficulty of prediction. We have {equation}  {eqn:yx} {P(y|x)=_z P(y|x,c) P(c|x)} {equation}   In Eq.~{eqn:yx},  can be derived from the commonsense knowledge base. Predicting  rather than  is easier. Since { (crying, keep calm)} has high frequency in the training data, we infer that ``he'' denotes Kevin. Intuitively, the commonsense description  bridge the gap between  and  via the OOD commonsense media .   {figure}[!htb] {subfigure}[b]{0.46 extwidth}     [scale=.5]{figs/intuition2.pdf} {The reference of ``he'' can be inferred if we know the OOD commonsense .} {fig:commonsense_list} {subfigure} {subfigure}[b]{0.46 extwidth}     [scale=.5]{figs/intuition_draw2.pdf} {Distribution of the training dataset. Shallow blue means OOD. Deep blue means ID. With , we convert the OOD prediction  to the ID prediction }     {fig:sphere} {subfigure}  {An example of using OOD commonsense to convert OOD predictions to in-distribution.} {figure}   Note that for some candidate commonsense (e.g. , ), the corresponding  is still OOD. Therefore the model should distinguish different candidate commonsense. This is achieved by the knowledge integration module in Sec~ ef{sec:method:output}. } {Related Work}   { Commonsense reasoning} is considered to be a challenging task in natural language processing~{levesque2012winograd}. With the development of unsupervised language models in recent years~{devlin2018bert,peters2018deep,radford2019language}, people realized that commonsense can be derived from them. For example, {petroni2019language} found that we can extract structured factual knowledge (e.g. ConceptNet~{liu2004conceptnet}) from unsupervised language models. {weir2020existence} found that the unsupervised language model implicitly represents concepts and its associated properties. In some follow-up work, researchers found that language models can be used to solve the task of commonsense-based reference disambiguation. This is also the main task that this paper focuses on.  Zero-shot's commonsense reasoning of unsupervised language models aims to study how to design algorithms to better extract commonsense from unsupervised language models. For example, {trinh2018simple} found that we can use the joint probability of the sentence provided by the language model to determine whether a sentence conforms to commonsense. The author believes that sentences with high joint probability are more in line with commonsense. Therefore, the author completes the disambiguation by replacing the original pronoun with the candidate reference, and using the joint probability as the score of the sentence. Several subsequent works have used similar ideas. {klein2019attention} uses the attention-guided method to calculate the score. {tamborrino2020pre} uses a larger language model Roberta~{liu2019roberta}, and calculates the scores of candidate sentences based on the masked word probability. {shwartz2020unsupervised} provides additional clues for using generative language models (i.e. GPT-2~{radford2019language}) for the target task. These works have achieved good results on some commonsense reasoning tasks.  However, {zellers2019hellaswag} found that the language model is actually looking for sentences that are more in line with lexical cues, rather than sentences that are more in line with commonsense. We agree with the viewpoint of {zellers2019hellaswag}. Since the language model learns and represents the association of the text and its context, this is an inevitable result of a lot of commonsense not being written directly ({gordon2013reporting}). Since the representation learning of the language model is based on data association, it only models ID data, but cannot effectively represent OOD data. We believe that introducing commonsense into the language model is the only way for the language model to understand OOD data. This is also the main research direction of this article.  In contrast to the commonsense reasoning of the zero-shot unsupervised language model, some works believe that the current limitation of commonsense reasoning lies in the lack of relevant training data. Therefore, some data sets similar to common commonsense reasoning were constructed. The earliest data set similar to WSC is WSCR~{rahman2012resolving}. {kocijan19acl} found that if the unsupervised language model is fine-tuning on similar reference disambiguation data sets, the effect of the language model on commonsense-based reference disambiguation can be improved. Therefore, the author constructs MaskedWiki~{kocijan19acl} and WikiCREM~{kocijan2019wikicrem} through masking of Wikipedia data. {sakaguchi2019winogrande} constructed the WinoGrande data set, which has improved WSC in terms of scale and difficulty. Some language models themselves also add such data sets to pre-training corpus. For example, Roberta's pre-training corpus STORIES~{trinh2018simple} is a corpus similar to WSC. These datasets have indeed improved the effectiveness of specific commonsense reasoning tasks.  However, it is clear that the construction of these commonsense data sets is for specific tasks. Its essence is to expand the scope of the model's ID data. But the corpus is always limited. We believe that the introduction of larger data sets cannot solve the OOD problem of more general tasks. We believe that the introduction of task-independent commonsense data is the general way to solve the OOD problem.  { Incorporating External Knowledge into Language Representation Learning}   *{Acknowledgments and Disclosure of Funding} We thank Wenting Ba for her valuable plotting assistance. This paper was supported by National Natural Science Foundation of China (No. 61906116), by Shanghai Sailing Program (No. 19YF1414700).",1,2022-03-15T01:24:28,en,2109.02572,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,3464,0,0,3464,0,3464,0,0,0,0,0,0,3464,3464,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,3464,0,0,0,0,0,3464,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,3464,3464,3464,3464,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,0,0,0,0,3464,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,3464,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,3464,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,3464,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,3464,0,0,3464,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,3464,0,3464,3464,0,0,3464,3464,3464,3464,0,0,3464,0,0,3464,0,0,0,0,0,0,3464,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,3464,0,0,0,0,3464,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,3464,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,0,3464,0,0,0,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,3464,3464,3464,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,3464,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,3464,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,3464,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"{Introduction}{sec:introduction} {sections/introduction}   {Knowledge Graph Construction}{chap:datapreperation} {sections/datapreperation}  {KG Completion using Link Prediction}{chap:RQ1} {sections/RQ1}  {Career Pathfinding using Shortest Path Algorithms}{chap:RQ2} {sections/RQ2}  {Most Relevant Skills per Occupation Group}{chap:RQ3} {sections/RQ3}  {Conclusion}{chap:conclusion} {sections/conclusion}  {Discussion  Future research}{chap:discussion} {sections/discussion}   {acks} A special thanks to the thesis supervisors for the project Niels van Weeren and Prof. Aske Plaat as well as everybody at Randstad involved in this project. {acks}  {ACM-Reference-Format}  {Experimental setup} We employ link prediction to estimate the relatedness between skills and occupation nodes.  To evaluate and reliably compare different methods, we first split our KG into train, test, and validation sets.  More specifically, we sample 55 of all edges for training the link prediction algorithms (where applicable), leaving leave 30 for testing, and 15 for validation.  For each existing pair of occupation and skills node --- which we consider a positive sample in our train, test and validation sets --- we randomly generate a negative sample (i.e., a pair of skills and occupation nodes that do not exist in our KG).  An overview of the number of edges in each set is shown in Table~ ef{tab:train_val_test}.  {table}[!h]  {tabular}{@{}lrr@{}}  oprule                  & Positive & Negative   Training edges   & 2151     & 2151      Validation edges & 586      & 586       Test edges       & 1173     & 1173       Total            & 3910     & 3910       {tabular} [Number of positive and negative edges]{Number of positive and negative edges with a training (55), validation (15), test (30) split } {tab:train_val_test} {table}     {Link Prediction Methods} {Method 1: Preferential Attachment (PA)} {sec:method_pa} The first link prediction method is preferential attachment~{liben2007link}.  This method takes a set of nodes, i.e. node  and node , and calculates a closeness () between two nodes:  {equation} C(u,v) = |(u)|  imes |(v)|, {equation} where  denotes the neighbors of .  A higher score here corresponds to a larger probability the nodes are connected.  The intuition behind this is that if both nodes have a high amount of neighbors the nodes might function as a hub.  Most graphs have the property that hubs have a higher chance to be connected.   To compute all scores, we represent our KG as a matrix, where each node is represented as a row and a column. Note that this matrix is symmetric since the value for row  and column  is equal to the value at row  and column .  At the intersecting cell of two nodes, we store the preferential attachment.  We normalize this matrix by dividing each score by the maximum Closeness score, to ensure that each value is between 0 and 1.  We consider the resulting normalized Closeness score as the probability the corresponding nodes are related.   {Method 2: Node2Vec (N2V)} {sec:method_n2v} The second link prediction method we use is the Node2Vec algorithm~{grover2016node2vec}.  This algorithm can have a number of configurations.  For this paper we use the following parameters:  {itemize}  dimensions = 1024  walk length = 4  number of walks = 2500   (return parameter) = 1    (in-out parameter) = 1 {itemize}  These parameters were selected after a grid search on a large number of possible combinations of parameters.   {Results} Table  ef{tab:F1-results} shows the performance of both Preferential Attachment (PA) and Node2Vec (N2V).  {table}[!h]  {tabular}{@{}llllll@{}}  oprule                                          & class    & precision & recall & f1-score   {2}{*}{PA} & 0.0      &  extbf{0.83}      & 0.64   & 0.72                                              & 1.0      & 0.71      &  extbf{0.87}   &  extbf{0.78}      {2}{*}{N2V}                & 0.0      & 0.66      &  extbf{0.90}   &  extbf{0.76}                                              & 1.0      &  extbf{0.84}      & 0.53   & 0.65      {tabular} [Precision, recall and F1-scores of multiple link prediction algorithms]{Precision, recall and F1-scores of multiple link prediction algorithms with an equal number of positive and negative edges used for training} {tab:F1-results} {table}  When the number of positive and negative edges in the test set is equal, PA outperforms the more complex N2V method, with an f1-score for the positive class of  against .  In most realistic situations however, we may want to explore how a node can be linked to any other node, making the number of comparisons, or edges to predict 1-to-(N-1), i.e., for each node we compare each other node (excluding self).  To approximate this real world performance the ratio of negative to positive edges should reflect these more realistic proportions.  To do so we compute F1-score at increasing ratios of positive-to-negative edges, ranging from 1 (as shown in Table~ ef{tab:F1-results}) to 7.  Results are shown in Figure~ ef{fig:f1-score}. The figure shows that up to ratio of 3:1, N2V is on par with PA, but as ratios increase, N2V outperforms PA, suggesting N2V is better suited for most real world situations.    {figure}[!h]  [width=]{figs/f1-score_v2} [Comparison of Node2Vec and Preferential Attachment]{Comparison of Node2Vec and Preferential Attachment for different ratio's negative edges / positive edges} {fig:f1-score} {figure}   {Analysis} Now that it has been established that N2V is more suitable for our task, we aim to employ this algorithm to predict the relationships between occupations and skills.  When doing so we need to realize that the graph which we use as input is imperfect in terms of correctness and completeness~{paulheim2017knowledge}.   Looking at the false positives of the algorithm, skills that are --- according to our dataset --- incorrectly linked to occupations can be identified.  For KG completion, we aim to identify those skills that are not linked to occupations, but should be.  Table~ ef{tab:example_node2vec} shows a random sample of False Positives: it reinforces our intuition that link prediction can be employed for KG completion, as some of the predicted edges make sense, e.g., the skill: ``preparing materials for dental procedures'' is shown as a relevant skill for the occupation: ``dentist.'' By consulting domain experts, skills can be efficiently added to enrich the current graph.   {table*}[t]  {tabular}{@{}lll@{}}  oprule ISCO-Code & Occupation & Predicted Skill   1341  & Child care services managers  & children's physical development  2261  & Dentists  & prepare materials for dental procedures  3251  & Dental assistants and therapists  & dentistry science  4110  & General office clerks  & demonstrate professional attitude to clients  5411  & Fire fighters  & safety engineering  6121  & Livestock and dairy producers  & promote animal welfare  7132  & Spray painters and varnishers  & spray pesticides  8344  & Lifting truck operators  & hazardous materials transportation  9111  & Domestic cleaners and helpers  & provide lawn care   {tabular} {False positives: edges predicted by N2V that do not exist in our KG} {tab:example_node2vec} {table*}  To further explore these intuitions, in Figure~ ef{fig:tb} we show the edges to skill nodes predicted by N2V, for the node representing ISCO code 2611: ``Lawyers.''  The y-axis shows skills edges, and the x-axes show the link prediction probabilities, for all predictions with a probability0.5 (i.e., positive predictions by the method).  The green bars denote True Positives (i.e., correctly predicted edges between the skill and occupation), and blue bars depict False Positives (skills that are predicted to have an edge with the occupation, but do not exist in our KG). % The figure shows ``education law'' and ``investigation research methods'' as newly identified skills for lawyers, not found in the original ESCO taxonomy nor in co-occurrences in job postings.   {figure}[h]  [width = ]{figs/lawyer} [Predictions of the Node2Vec algorithm]{Predictions of the Node2Vec algorithm for ISCO group  (Lawyers)} {fig:tb} {figure}  {Skills-based Occupation Similarity} To determine the feasibility of an occupation transfer, we propose to model the distance between occupations with Jaccard distance.  We compute Jaccard distances between occupations by representing each occupation as the set of its required skills (which we extract from our KG), and computing the overlap between two sets of skills.  See Figure for an illustration~ ef{fig:jaccard}.  {figure}[h]  [width = 0.6]{figs/jac_graph} [Jaccard distance in a graph]{Jaccard distance in a graph where nodes A, B are occupations and nodes C, D, E, F are skills. Solid lines denote direct connections, dashed lines denote Jaccard distance.} {fig:jaccard} {figure}  In our KG a total of  links can be made between pairs of skills and pairs of occupations.  From these pairs  is between skills and  between occupations.  To gain insight in the overall similarity of skills and occupations, we study the distribution of jaccard distances in Figure~ ef{fig:jaccard_dist}.  {figure}[!h]  [width = ]{figs/jaccard_2} [Distribution of the jaccard distance ]{Distribution of the jaccard distance where the orange color represents the skills and the blue color represent the occupations} {fig:jaccard_dist} {figure}  Looking at the distribution of Jaccard distance one can see that on average, skills are more similar to one another than occupations.  This becomes apparent when looking at the mean value of both distributions: for occupations the mean is , and for skills around .  Over 99 of occupations have a Jaccard distance between 0.8 and 1, meaning that occupations require distinct skillsets.  Both distributions are skewed to the left, meaning that the mean (average of the observations) is left of the mode (most observed value).   In the distribution we see a number of spikes, which can be explained by the prevalence of some fractions over others, e.g., if half of the neighbors are shared, the Jaccard distance will be , which can be achieved in a number of different ways.  Other spikes occur at additional common fractions such as  and .    {table}[!h] {tabular}{@{}lrrr@{}}  oprule       & Skill  & Occupation & Total    count & 107959 & 12993      & 120952  mean  & 0.825  & 0.938      & 0.837   std   & 0.163  & 0.070      & 0.160   min   & 0.000  & 0.000      & 0.000   25  & 0.800  & 0.928      & 0.800   50  & 0.875  & 0.960      & 0.888   75  & 0.923  & 0.977      & 0.933   max   & 0.985  & 0.993      & 0.993    {tabular} {Statistics of the jaccard distribution} {tab:jacard_distibution} {table}  In Table  ef{tab:jacard_distibution} we show a description of the distance distributions.  For both skills and occupations the minimum distance is 0, meaning that a skill is shared by every occupation where the skill is connected to or that two occupations share every skill.  An example is  extit{``Food service counter attendants''} and  extit{``Hotel receptionists,''} both share the same skillset and thus have a Jaccard distance of 0.  Skills with a distance of 0 are for example  extit{``Lop trees''} and  extit{``Pruning techniques.''}  The highest distance found in the dataset is , this corresponds with the occupations  extit{``Electronics engineers''} and  extit{``Policy administration professionals.''}  They share at least one skill but are --- next to the shared skill --- completely different.  The common skill in this example is  extit{``perform project management.''}   {Career Pathfinding using Dijkstra's algorithm} With the distances between each occupation and between skills, we can proceed to identify the most efficient transition between every pair of occupations.  This is done by assigning the Jaccard distance scores as edge weights between nodes in our graph, to enable computational methods for finding the most efficient path between a start node (the current occupation) and an end node (the desired occupation).  We show an example of such a transition in Figure~ ef{fig:path_example}: here we set a threshold for the maximum possible distance at . This threshold was determined to be optimal based on eye-balling and comparing a different cutoff points. If two occupations are further apart than  we consider the step too large.   {figure}[h]  [width=0.5 ]{figs/transition.pdf} [Example of distance between occupations]{Distance between the occupations . Black lines denote distances lower than . Red lines denote distances higher than .} {fig:path_example} {figure}  In this example we start at node  and want to go to node .  We are not able to directly transition between  and  because the occupations are not similar enough ().   {Method} Finding the most efficient path in an undirected weighted graph can be done by applying shortest path algorithms.  For this paper we turn to Dijkstra's algorithm~{dijkstra1959note}, because of its proven speed and widespread availability of implementations.  According to Dijkstra's algorithm, the shortest allowed path between  and  in Figure~ ef{fig:path_example} is via node .   We show a real world example in Figure~ ef{fig:covid_example}.  Due to the COVID-19 pandemic a lot of people find themselves out of a job, especially individuals that work in restaurants.  Using the described model we can calculate which occupation has the smallest distance to the occupation: ``cook.''  Dijkstra's algorithm yields ``bakers, pastry-cooks and confectionery makers'' as most feasible transition.   {figure}[h]  [width=1]{figs/Cooks.PNG} [The shortest path between occupations]{The shortest path between the occupation ``Cook'' and the closest connected occupation, in this case ``Bakers, pastry-cooks and confectionery makers.''} {fig:covid_example} {figure}    {Problem Statement}{sec:PS}  To facilitate candidate to job posting matching, it is important to know which skills are relevant, in demand, and in supply.  Here, the need for a flexible data representation for skills arises.  This representation should facilitate various tasks, such as a skills similarity metric to be able to quantify likeliness between skills, skills-to-occupation similarity metrics, to help people navigate the labor market and find new occupations, and understanding which skills relate to which occupations to inform which skills are needed for desired occupations.  And since relations between skills and occupations are not static and need robust and accurate updating methods to ensure the information does not get outdated.    In this paper we address the task of skills and occupation graph construction which we describe in Section~ ef{chap:datapreperation}, and apply this data representation to the following set of use-cases:  link prediction for identifying novel skills-occupation relations in Section~ ef{chap:RQ1},  skills-based occupational similarity for career pathfinding in Section~ ef{chap:RQ2}, and  identifying distinctive skills per occupational group for learning  development in Section~ ef{chap:RQ3}.  {Method} The two criteria described above fit naturally to the Term Frequencyâ€“Inverse Document Frequency (TF-IDF) weighting scheme for terms~{schutze2008introduction}.  This statistic is chosen as it directly models the desired criteria described in the previous section, more specifically, TF-IDF is used to assign weights to words in a corpus of documents, where a word is deemed more important if it (i) is observed frequently within the document but (ii) not frequently across different documents in the corpus.   {equation}  TF-IDF(t,d) = tf_{t,d}  imes ({N}{df_{t} + 1}), {equation} where  denotes the Term Frequency of  in ,  denotes the number of documents containing , and  denotes the total number of documents in the corpus.  We ``transplant'' this TF-IDF weighting scheme from terms in documents to skills associated to occupations.  TF-IDF consists of two parts:  Term Frequency (TF) is the frequency of a word (skill) used in a given document (observed with an occupation),  Inverse Document Frequency (IDF) is a way to discount highly common terms, i.e., it is high when a word (skill) appears in a smaller number of documents (observed with a low number of occupations).  Common terms (skills) will thus yield a lower IDF score.   For our TF-IDF-based model, we consider skills identified in job postings terms, and documents can be modeled as a collection of job postings belonging to an ISCO group.  The counts of skills, which model term frequency, correspond to the number of times a skill is found in a job posting associated to a certain ISCO code.    {Results and analysis} {Level 1 ISCO groups} The resulting score provides us with skills that are common for a given occupation (group) but uncommon in all other occupation(s) (groups).  Table~ ef{tab:skill_relevance} shows the top 5 skills for the level 1 ISCO groups.   In this table  extit{Microsoft Office} appears both in the  extit{Managers} and  extit{Clerical support workers} groups. For this skill to score high in multiple contexts (occupation groups) the frequencies need to be substantial in both, to be able to compensate for the IDF component of the metric.  In the Managers group,  extit{Microsoft Office} has a TF of 9 and in  extit{Clerical support workers} a TF of 5.   {Multiple ISCO levels} ISCO level 1 helps us to understand which skills are relevant for the least granular level; to deepen our understanding we look at the development of multiple layers of ISCO group 2 in Figure~ ef{fig:skill_relevance}. Here, we show the 3 most relevant skills for several ISCO levels of the ``Professionals'' ISCO group.  We notice the following: First, communication-related skills appear in multiple forms across occupation groups.  The terms  extit{communication},  extit{communication sciences},  extit{communication studies},  extit{ICT communication protocols},  extit{manage online communications} and  extit{communication disorders} seem to be closely related.  Because these skills are defined as distinct skills, each skill receives its own ranking. This concept can appear multiple times.   Next, ``Nursing professionals'' and ``Nursing and midwifery professionals'' share the same set of relevant skills, which are highly similar to those of their parent group ``Health professionals''. Skills that appear in those groups are the most frequent skills in the parent group.    Finally, the further down the figure we go, the more specialized the skills appear to be, and more specialized skills, such as ``dental studies,'' are more commonly observed in level 4 ISCO groups. A possible explanation for this is that specialized skills do only appear at specialized occupations.      {figure}  [width=]{figs/skill_relevance} {Three most relevant skills for multiple levels in major ISCO group 2} {fig:skill_relevance} {figure}   {table*}[]  esizebox{ extwidth}{!}{{tabular}{@{}ll|l|l@{}}  oprule   & Managers & Professionals & Technicians and associate professionals   1 & Microsoft Office & Network Marketing & Marker Making  2 & Service-oriented Modelling & Manage Online Communications & Electronic Communication  3 & Communication Principles & Communication & Service-oriented Modelling  4 & Electronic Communication & Explain Accounting Records & Education Administration  5 & Coordinate Patrols & Accounting & Manage Standard ERP System     & Clerical support workers & Service and sales workers & Skilled agricultural, forestry and fishery workers   1 & Execute Administration & Security Panels & Leadership Principles  2 & Perform Clerical Duties & Electronic Communication & Agricultural Information Systems and Databases  3 & Microsoft Office & Create Solutions to Problems & Pruning Techniques  4 & Education Administration & Execute Administration & Spray Pesticides  5 & Human Resource Management & Recreation Activities & Lop Trees     & Craft and related trades workers & Plant and machine operators, and assemblers & Elementary occupations   1 & Attend to Detail in Casting Processes & Mechatronics & Inventory Management Rules   2 & Attention to Detail & Mechanical Engineering & Have Computer Literacy  3 & Adobe Illustrator & Electrical Engineering & Carpentry  4 & Adobe Photoshop & Operate Soldering Equipment & Place Concrete Forms  5 & ML (computer programming) & Act Reliably & Operate on-board Computer Systems   {tabular}} {Five most relevant skills per major ISCO group based in the TF-IDF matric} {tab:skill_relevance} {table*}     {Occupations (ISCO) and skills (ESCO)} The first step involves constructing a shared Skills  Occupational Knowledge Graph, through combining the existing ISCO and ESCO taxonomies.   {ISCO (occupations)} The International Standard Classification of Occupations (ISCO) is ordered as a taxonomy of occupational groups with four granularity levels across ten different major groups.  An occupation is defined as  extit{``a set of jobs whose main tasks and duties are characterized by a high degree of similarity''}, where a job is defined as  extit{``a set of tasks and duties performed, or meant to be performed, by one person, including for an employer or in self-employment.''~{ilo}} Take, for example: the occupation ``computer programmer,'' which is defined by the level 4 ISCO code: 2132.  The occupation then belongs to the the level 3 group ``computing professionals'' (ISCO-code 213), which in turn belongs the level 2 group ``computing, engineering and science professionals'' (ISCO-code 21), which, finally, falls in the level 1 group ``professionals'' (ISCO-code 2).   {table}[h]  {tabular}{@{}ll@{}}  oprule Group Number & Major Group Name                                     1            & Managers                                            2            & Professional                                        3            & Technicians and associate professionals             4            & Clerical support workers                            5            & Service and sales workers                           6            & Skilled agricultural, forestry and fishery workers  7            & Craft and related trades workers                    8            & Plant and machine operators, and assemblers         9            & Elementary occupations                              10           & Armed forces occupations                             {tabular} {The 10 major job groups of the ISCO-08} {tab:isco} {table}    {ESCO (skills)} We define our initial high-level occupation groups by using the ISCO standard. For skills, we turn to The European Skills, Competences, Qualifications and Occupations (ESCO) taxonomy~{ESCO}.  ESCO defines a skill as follows:  {description} [Skill]  extit{``the ability to apply knowledge and use know-how to complete tasks and solve problems''} {description}  The ESCO covers 13,485 skills, connected to 2,942 occupations (in 27 languages).   We link our ISCO occupations to ESCO by using the direct links that are defined between ISCO level 4 groups (most fine-grained/lowest level of the taxonomy) and ESCO concepts, in the ESCO.  These links between ESCO and ISCO are not (necessarily) 1-to-1, as multiple ESCO occupations can be linked to a single (level 4) ISCO group.   In Figure~ ef{fig:TheStructureOfTheOccupationsPillar} we illustrate this connection between ISCO and ESCO.  ESCO occupations are shown in blue, with ISCO occupation groups in purple.  In addition to the ESCO occupations shown in the image, ESCO also defines skills (not shown), e.g., the ESCO occupation ``Cattle breeder,'' has skills linked to them such as ``feed livestock'' and ``assist animal birth.''   {figure}[t]  [width=1.0]{figs/TheStructureOfTheOccupationsPillar.PNG} {The structure of the occupations pillar {ESCO}} {fig:TheStructureOfTheOccupationsPillar} {figure}   {KG enrichment through job posting data} Now that we have our high-level KG structure based on ISCO and ESCO, which defines occupations and skills as nodes, and edges as links between ESCO and ISCO objects, we turn to job posting data to account for the dynamic nature of associations between skills and occupations, as described in Section~ ef{sec:introduction}.  To make sure our KG reflects the current status of the labor market, we use information from job postings to enrich the structure of our KG.  More specifically, we create additional edges by identifying and extracting ESCO skills for each job posting's ISCO occupation group, and assign weights to edges by relying on co-occurrence statistics of skills and occupations.   This second step of our process revolves around extracting skills from job postings.  We describe our job posting dataset in Section  ef{Vacancy Parser}, our approach for skill extraction in Section  ef{Vacancy Parser}, and how we match extracted skills to ESCO skills in~ ef{Skill Matching}.        {Vacancy data}{Vacancy data} Our vacancy dataset consists of sample of 600,000 Dutch vacancies collected by Jobdigger~{Jobdigger}, each job posting is labeled with a level 4 ISCO code.  Our sample was chosen by selecting a uniform distribution of ISCO level 1 occupations, to make sure our set covers the entire breadth of the labor market.  Prior to sampling our set at the ISCO level 1, the initial dataset was cleaned by discarding low quality and noisy job postings, such as postings that represented multiple occupations, or job postings that contained a low number of sentences. Here, we treat vacancy data as a proxy for the demand in the job market. By doing so, internal promotions and career paths and informal channels are not taken into account.   {Skill Extraction}{Vacancy Parser} For skill extraction we rely on the % industry-standard Textkernel Extract~{TextKernel} parser.  For each vacancy text, Textkernel Extract returns a json object with corresponding skills, represented by the surface form identified in the job posting (skill mention), a unique identifier representing the skill (skill id), and finally, a confidence score that quantifies the likelihood of the extracted skill to be correct.  {Skill Matching}{Skill Matching}  Given the skills extracted by Textkernel, we match them to the skill nodes in our KG, by relying on the surface forms of the skills (skill mentions). More specifically, we leverage character -grams Jaccard similarity between the normalized skill mention and the normalized ESCO skill names.  We set the similarity threshold to , which was empirically determined to be optimal using a smaller set of our  Textkernel skills to ESCO skill-mappings.  The high-level process is shown in Figure~ ef{fig:skill_match_flow}.  {figure}[t] [width = 0.8]{figs/skill_match_flow} [Overview of skill matching process]{Overview of skill matching process} {fig:skill_match_flow} {figure}  {Final Skills  Occupational Knowledge Graph} Our final KG, resulting from the process shown in Figure~ ef{fig:flow} and described in the previous section, consists of 1,220 nodes, of which 983 represent (ESCO) skills, and 237 (ISCO) occupations.  These nodes are connected through  edges, with an average node degree of .   This KG is a subset of the full ESCO ( skills), and ISCO ( occupations) taxonomies.  There are several reasons why our KG is a subset and does not span the entirety of the ISCO and ESCO taxonomies.  First, it is conceivable that not all ISCO occupations are in current demand, e.g., we found that there were no vacancies for ISCO occupation code 8111: ``mining-plant operators,'' which is not surprising with currently no mines in operation in The Netherlands.  Next, it is likely we are dealing with coverage issues, from (i) the likely incomplete coverage of the TextKernel Extract method we use for skill extraction, and  (ii) our skills matching methodology further reducing the number of identified skills.  As the focus of this paper is on downstream applications, we consider matching out of scope, and rely on our naive but solid character -grams-based method.",2,2021-09-07T02:37:32,en,2109.02554,0,1,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,2573,0,0,2573,0,2573,0,0,0,0,0,0,2573,2573,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,2573,0,0,0,0,0,2573,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,2573,2573,2573,2573,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,0,0,0,0,2573,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,2573,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,2573,0,0,0,0,0,10,0,0,0,2573,0,0,0,0,0,0,0,2573,2573,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,2573,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,2573,0,0,2573,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,2573,0,2573,2573,0,0,2573,2573,2573,2573,0,0,2573,0,0,2573,0,0,0,0,0,0,2573,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,2573,0,0,0,0,2573,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,2573,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,0,2573,0,0,0,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,2573,2573,2573,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,2573,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,2573,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,2573,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"{GAN-based Abstraction}{sec:abstraction}  {Model Abstraction}  The underlying idea is the following: given a stochastic process  with transition probabilities , we aim at finding another stochastic process whose trajectories are faster to simulate but similar to the original ones. Time has to be discretized, meaning we fix an initial time  and a time step  that suits our problem. We define , . In addition,  given a fixed time horizon , we define time-bounded trajectories as . Given a state  and a set of parameters , we can represent a trajectory of length  as a realization of a random variable over the state space . The probability distribution for such random variable is given by the product of the transition probabilities at each time step:  . The CTMC, , is now expressed as a time-homogeneous Discrete Time Markov Chain .  An additional approximation has to be made: the abstract model takes values in , a continuous space in which the state space  is embedded. In constructing the approximate probability distribution for trajectories we can decide to restrict our attention to arbitrary aspects of the process, rather than trying to preserve the full behavior. A {projection}  from  to an arbitrary space  can be used to reach this purpose,  for instance, to monitor the number of molecules belonging to a certain subset of chemical species, i.e., .  Note that  is a random variable over .  Such flexibility could be extremely helpful in capturing the dynamics of systems in which some species are not observable.  {Abstraction accuracy.} Another important ingredient is a meaningful quantification of the error introduced by the abstraction procedure, i.e., the reconstruction accuracy. Such quantification must be based on a distance, , among distributions.  We choose the Wasserstein distance, together with the absolute and relative difference among means and variances of the histograms. Given a distribution over initial states  and a distribution over parameters , we would like to measure the expected error at every time instant  with . Formally, we want to measure  where  denotes the -th time components of the projected trajectory .  To estimate such quantity we use a well-known unbiased estimator, which is the average over the distances computed over a large sample set of  initial settings. Computing the distance among SSA and abstract distributions at each time step quantifies how small the expected error is and, more importantly,  how it evolves in time. As a matter of fact, it shows whether the error tends to propagate or not and how much each species contributes to the abstraction error.  In practice, we compute  distances among distributions over  as we want to know how each species contributes in the reconstruction error.   {-0.2cm}  {Dataset Generation}  {Training set.}  Choose a set of  initial settings and for each setting simulate  SSA trajectory of length . The training set is composed of  pairs initial setting-trajectory, i.e. pairs  for  and .  {Test set.}   Choose a set of  initial settings and for each setting simulate a large number, , of SSA trajectory of length . The test set is composed of  pairs initial setting-trajectory, i.e. pairs  for  and .   {Partial observability.} In case of partial observability, ,  we fix an initial condition for species in , and simulate a pool of trajectories each time sampling the initial value of species in . As a result, we are learning and abstract distribution that marginalizes over unobserved variables.  {-0.2cm}  {cWCGAN-GP architecture}   The critic  takes as input a batch of initial states, , a batch of parameters, , and a batch of subsequent trajectories, . For each  the inputs, ,  and , are concatenated to form an input with dimension . Formally, .  To enforce the Lipschitz property over  we add a gradient penalty term over . Samples of  are generated by sampling uniformly along straight lines connecting points coming from a batch of real trajectories and points coming from a batch of generated trajectories.  On the other hand, the generator  takes as input a batch of initial states, , a batch of parameters, , and a batch of random noise, , with dimension , a user-defined hyper-parameter. For each  the two inputs are, once again, concatenated to form an input with dimension . The generator outputs a batch of generated trajectories . Formally, , such that . See the pseudocode for the algorithm in Appendix~ ef{sec:algorithm} of [XXX].  {-0.2cm}  {Model Training} The cWCGAN-GP-based model abstraction framework consists in training two different CNNs. The loss function, introduced in Eq.~{eq:wassdist_gp}, is a parametric function depending both on the generator weights  and the critic weights .  When training the critic, we keep the generator weights constant , and we maximize  w.r.t. .   Formally, we solve the problem  {equation*}        w_c^* = {w_c}{{argmax}}{L}(w_c, {w}_g).  {equation*} On the other hand, in training the generator, we keep the critic weights constant ,  and we minimize  w.r.t. .  Formally, we solve the problem  {equation*}          w_g^* = {w_g}{{argmin}} {L}({w}_c,w_g) =  {w_g}{{argmin}}   -{E}_{z,(s_0, heta)}[C_{{w}_c}(G_{w_g}(z,s_0, heta),s_0, heta)]. {equation*} As mentioned in Section  ef{sec:background}, the loss function derives from the Wasserstein distance between the real and generated distributions, see {arjovsky2017wasserstein,gulrajani2017improved} for the mathematical details.  Intuitively, the generator generates a batch of samples, and these, along with real examples from the dataset, are provided to the critic, which is then updated to get better at estimating the distance between the real and the abstract distribution. The generator is then updated based on scores obtained by the generated samples from the critic. An important collateral advantage is that WGANs have a loss function that correlates with the quality of generated examples.  Training the cWCGAN-GP has a cost. Nonetheless, once it has been trained, its evaluation is extremely fast. Details about training and evaluation costs are discussed in Section~ ef{sec:experiments}.     {Abstract Model Simulation.} Once the training is over, we can discard the critic and focus only on the trained generator . In order to generate an abstract trajectory starting from a state  with parameters , we just have to sample a value  from the random noise variable  and evaluate the generator on the pair . The output is a stochastic trajectory of length : . The stochasticity is provided by the random noise variable, de facto the generator acts as a distribution transformer that maps a simple random variable  into a complex distribution. In order to generate a pool of  trajectories, we simply sample  different values from the random noise variable: . Therefore, the generation of a trajectory has a fixed computational cost.  {Case Studies}{sec:casestudies} {itemize}   extbf{SIR Model (Absorbing state).}  The SIR epidemiological model describes a population divided in three mutually exclusive groups: susceptible (S), infected (I) and recovered (R). The system state at time  is . The possible reactions, given by the interaction of individuals (representing the molecules of a CRN), are the following: {itemize}       (infection),        (recovery). {itemize} The model describes the spread, in a population, of an infectious disease that grants immunity to those who recover from it. As the SIR model is well-known and stable, we use it as a testing ground for our GAN-based abstraction procedure. The ranges for the initial state are . An important aspect of the SIR model is the presence of an absorbing states. In fact, when  or when  no more reaction can take place.     extbf{Ergodic SIRS Model.} Small perturbations of the SIR model force the system to be ergodic. We called this revised version ergodic SIRS (eSIRS). This model has no absorbing state. In particular, we assume that the population is not perfectly isolated, meaning there is always a chance of getting infected from some external individuals. In addition, we also assume that immunity is only temporary. The possible reactions are now the following: {itemize}       (infection),        (recovery),        (immunity loss), {itemize} Both epidemiological models are essentially unimodal. The ranges for the initial state are  such that . In our experiments . The range for parameter  is .    extbf{Genetic Toggle Switch Model (Bistability).}  The toggle switch is a well-known bistable biological circuit. Briefly, this system consists of two genes,  and , that mutually repress each other. The system displays two stable equilibrium states in which either of the two gene products represses the expression of the other gene. The possible reactions are: {itemize}      , for ;,      , for  and  resp.;      , for  and  resp.;      , for . {itemize} The ranges for the initial state are  and  .    extbf{Oscillator Model.}  The oscillator circuit consists of three species A, B and C and three reactions, in which A converts B to itself, B converts C to itself, and C converts A to itself. The three species regulate each other in a cyclic manner. This circuit was found to exhibit oscillations in the concentrations of the three species.  {itemize}       (B transformation),       (C transformation),       (A transformation). {itemize}   The ranges for the initial state are .     extbf{MAPK Model.}  Mitogen-activated protein kinase cascade is a particular type of signal transduction into protein phosphorylation (PP) whose function is the amplification of a signal. The sensitivity increases with the number of cascade levels, such that a small change in a stimulus results in a large change in the response. Negative feedback from MAPK-PP to the MAKKK activating reaction with ultra-sensitivity to a input stimulus, governed by parameter .  {itemize}  ,    ,    ,    ,    ,    ,    ,  ,       ,       .  {itemize}  {itemize} The ranges for the initial state are:  such that ;  such that ;  such that . {Additional Plots} {sec:plots} Here we present the remaining plots showing a qualitative evaluation of the performances of the abstract models. For each model, we present a small batch of trajectories, both real and abstract (plots on the left column). From the plots of such trajectories we can appreciate if the abstract trajectories are similar to real ones and if they capture the most important macroscopic behaviors. We also show the histograms of the empirical distributions at time  for each species (plots on the right column) to quantify the behavior over all the K trajectories present in the test set. In particular, Fig.  ef{fig:sir_trajectories} shows the results for the SIR case study, Fig.  ef{fig:esir_trajectories_one_par} shows the results for the e-SIRS model with one varying parameter, Fig.  ef{fig:ts_trajectories} shows the results for the Toggle Switch model and, finally, Fig.  ef{fig:clock_trajectories} shows the results for the Oscillator model.  {figure}[ht]      [scale=0.25]{imgs/SIR/SIR_Trajectories5.png}     [scale=0.25]{imgs/SIR/SIR_hist_comparison_last_timestep_5.png}          {SIR     model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue);  extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance on a randomly chosen test point represented by three trajectories: the top one (species S), the central one (species I) and the bottom one (species R).{-0.5cm}}     {fig:sir_trajectories_extra}     {figure}           {figure}[ht]          [scale=0.25]{imgs/eSIRS/eSIRS_Rescaled_Trajectories2_tight.png}     [scale=0.25]{imgs/eSIRS/eSIRS_rescaled_hist_comparison_-1th_timestep_2_tight.png}     [scale=0.25]{imgs/eSIRS/eSIRS_Rescaled_Trajectories16_tight.png}     [scale=0.25]{imgs/eSIRS/eSIRS_rescaled_hist_comparison_-1th_timestep_16_tight.png}     {e-SIRS     model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue);  extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance for two, randomly chosen, test points. Each point is represented by a pair of trajectories: the top one (species S) and the bottom one is for  (species I).{-0.5cm}}     {fig:esir_trajectories}     {figure}  {figure}[ht]           [scale=0.25]{imgs/TS/ToggleSwitch_Rescaled_Trajectories18_tight.png}     [scale = 0.25]{imgs/TS/ToggleSwitch_rescaled_hist_comparison_-1th_timestep_18_tight.png}          {Toggle Switch model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue);  extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance for a randomly chosen, test point represented by a pair of trajectories: the top one (species P1) and the bottom one (species P2).{-0.5cm}}     {fig:ts_trajectories_extra} {figure}  {figure}[ht]            [scale=0.25]{imgs/Oscillator/Oscillator_Rescaled_Trajectories4.png}    [scale=0.25]{imgs/Oscillator/Oscillator_rescaled_hist_comparison_-1th_timestep_4.png}     {Oscilator model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue); extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance on a randomly chosen test point represented by three trajectories: the top one (species A), the central one (species B) and the bottom one (species C). {-0.5cm}    }{fig:clock_trajectories_extra} {figure}  {figure}[ht]               [eSIRS]{  [scale=0.23]{imgs/eSIRS/eSIRS_avg_mean_distance_1000epochs_32steps.png}}     [eSIRS-1P]{       [scale=0.23]{imgs/eSIRS_1P/Scaled_avg_mean_distance_1epochs_32steps.png}}     [SIR]{       [scale=0.23]{imgs/SIR/Scaled_avg_mean_distance_500epochs_16steps.png}}     [Oscillator]{       [scale=0.23]{imgs/Oscillator/Oscillator_avg_mean_distance_1000epochs_32steps.png}}     [Toggle Switch]{       [scale=0.23]{imgs/TS/ToggleSwitch_avg_mean_distance_2000epochs_32steps.png}}      [MAPK]{       [scale=0.23]{imgs/MAPK/MAPK_avg_mean_distance_1500epochs_32steps_scaling.png}}      {Plots of the average difference in the means over time for each model and each species. Errors are computed over the entire test set. Generated trajectories have been keep scaled to the interval  so that the scale of the system does not affect the scale of the error measure.}{fig:avg_means_errors}           [eSIRS]{  [scale=0.23]{imgs/eSIRS/eSIRS_avg_mean_relative_distance_1000epochs_32steps.png}}     [eSIRS-1P]{       [scale=0.23]{imgs/eSIRS_1P/eSIRS_1P_avg_mean_relative_distance_1epochs_32steps.png}}     [SIR]{       [scale=0.23]{imgs/SIR/SIR_avg_mean_relative_distance_500epochs_16steps.png}}     [Oscillator]{       [scale=0.23]{imgs/Oscillator/Oscillator_avg_mean_relative_distance_999epochs_32steps.png}}     [Toggle Switch]{       [scale=0.23]{imgs/TS/ToggleSwitch_avg_mean_relative_distance_2000epochs_32steps.png}}      [MAPK]{       [scale=0.23]{imgs/MAPK/MAPK_avg_mean_relative_distance_1500epochs_32steps_scaling.png}}      {Plots of the average relative difference in the means over time for each model and each species. Errors are computed over the entire test set. Generated trajectories have been keep scaled back to .}{fig:avg_means_rel_errors} {figure}  {figure}[ht]          [eSIRS]{       [scale=0.23]{imgs/eSIRS/eSIRS_avg_var_distance_1000epochs_32steps.png}}     [eSIRS-1P]{       [scale=0.23]{imgs/eSIRS_1P/Scaled_avg_var_distance_1epochs_32steps.png}}     [SIR]{       [scale=0.23]{imgs/SIR/Scaled_avg_var_distance_500epochs_16steps.png}}     [Oscillator]{       [scale=0.23]{imgs/Oscillator/Oscillator_avg_var_distance_1000epochs_32steps.png}}     [Toggle Switch]{       [scale=0.23]{imgs/TS/ToggleSwitch_avg_var_distance_2000epochs_32steps.png}}     [MAPK]{       [scale=0.23]{imgs/MAPK/MAPK_avg_var_distance_1500epochs_32steps_scaling.png}}      {Plots of the average difference in the variances over time for each model and each species. Errors are computed over the entire test set. Generated trajectories have been keep scaled to the interval  so that the scale of the system does not affect the scale of the error measure.}{fig:avg_vars_errors}          [eSIRS]{  [scale=0.23]{imgs/eSIRS/eSIRS_avg_var_relative_distance_1000epochs_32steps.png}}     [eSIRS-1P]{       [scale=0.23]{imgs/eSIRS_1P/eSIRS_1P_avg_var_relative_distance_1epochs_32steps.png}}     [SIR]{      [scale=0.23]{imgs/SIR/SIR_avg_var_relative_distance_500epochs_16steps.png}}     [Oscillator]{       [scale=0.23]{imgs/Oscillator/Oscillator_avg_var_relative_distance_999epochs_32steps.png}}     [Toggle Switch]{       [scale=0.23]{imgs/TS/ToggleSwitch_avg_var_relative_distance_2000epochs_32steps.png}}      [MAPK]{       [scale=0.23]{imgs/MAPK/MAPK_avg_var_relative_distance_1500epochs_32steps_scaling.png}}      {Plots of the average relative difference in the variances over time for each model and each species. Errors are computed over the entire test set. Generated trajectories have been keep scaled back to .}{fig:avg_vars_rel_errors} {figure}   {figure}[ht]               [Means abs. err.]{     [scale=0.12]{imgs/eSIRS/eSIRS_mean_distance.png}}         [Means rel. err.]{     [scale=0.12]{imgs/eSIRS/eSIRS_mean_relative_distance.png}}     [Variances abs. err.]{     [scale=0.12]{imgs/eSIRS/eSIRS_var_distance.png}}     [Variances rel. err.]{     [scale=0.12]{imgs/eSIRS/eSIRS_var_relative_distance.png}}     [Wass. dist.]{     [scale=0.12]{imgs/eSIRS/eSIRS_wass_distance.png}}     {Histogram distance landscapes for the two-dimensional  extbf{eSIRS} model.}     {fig:eSIRS_distance_landscapes} {figure}  {figure}[ht]               [Means abs. err.]{     [scale=0.12]{imgs/TS/ToggleSwitch_mean_distance.png}}             [Means rel. err.]{     [scale=0.12]{imgs/TS/ToggleSwitch_mean_relative_distance.png}}     [Variances abs. err.]{     [scale=0.12]{imgs/TS/ToggleSwitch_var_distance.png}}     [Variances rel. err.]{     [scale=0.12]{imgs/TS/ToggleSwitch_var_relative_distance.png}}     [Wass. dist.]{     [scale=0.12]{imgs/TS/ToggleSwitch_wass_distance.png}}     {Histogram distance landscapes for the two-dimensional  extbf{Toggle Switch} model.}     {fig:TS_distance_landscapes} {figure}       {figure}[ht]          [Wass. dist.]{     [scale = 0.24]{imgs/MAPK/MAPK_wass_distance.png}}     [Means abs. err.]{     [scale = 0.24]{imgs/MAPK/MAPK_mean_distance.png}}     [Means rel. err.]{     [scale = 0.24]{imgs/MAPK/MAPK_mean_relative_distance.png}}     [Variances abs. err.]{     [scale = 0.24]{imgs/MAPK/MAPK_var_distance.png}}     [Variances rel. err.]{     [scale = 0.24]{imgs/MAPK/MAPK_var_relative_distance.png}}          {Histogram distance landscapes for the  extbf{MAPK} model.}     {fig:mapk_distance_landscapes} {figure}  {figure}          [scale=0.245]{imgs/eSIRS_1P/analysis_avg_wass_distance_1epochs_32steps.png}     [scale=0.245]{imgs/eSIRS_1P/analysis_avg_wass_distance_1epochs_32steps_100in.png}     [scale=0.245]{imgs/eSIRS_1P/analysis_avg_wass_distance_1epochs_32steps_100par.png}     {Analysis of the generalization capabilities of the abstract model on various test sets: 100 different pairs   extbf{(left)}, fixed parameter and 100 different initial states  extbf{(middle)} and a fixed initial state with 100 different parameters  extbf{(right)}. For each test set we compute the mean  and the standard deviation of the distribution of Wasserstein distances over such sets.}     {fig:esirs_1p_analysis} {figure}   {Satisfaction probability}{sec:satisf} {figure}[ht]          [scale=0.17]{imgs/eSIRS/esirs_satisfability.png}      [scale=0.17]{imgs/SIR/sir_sanity_check_absorption.png}      [scale=0.17]{imgs/TS/ts_satisfability.png}     { extbf{(eSIRS)} Given the property ``eventually the number of infected stays below a threshold of 25 individual"", we check for each test point (x axis) the percentage of SSA (orange) and abstract (blue) trajectories that satisfy such property.      extbf{(SIR)} For abstract trajectories of the SIR model we check, for each test point, the percentage of valid trajectories, i.e. such that the state  is absorbing.      extbf{(Toggle Switch)} Given the property ``eventually the level of protein P2 stays above a threshold of 50"", we check for each test point (x axis) the percentage of SSA (orange) and abstract (blue) trajectories that satisfy such property.     {-0.25cm}}     {fig:satisf} {figure}  We seek a formal way to quantify whether the abstract model captures and preserves the emergent macroscopic behaviors of the original system. In order to do so, we can resort to formal languages, such as Signal Temporal Logic (STL) {maler2004monitoring}. The first step is to express formally the property that we would like abstract trajectories to preserve. Then we can measure the satisfaction probability of such property for both real and abstract trajectories and check if it is similar on a large pool of initial settings. Examples are shown in Fig.  ef{fig:satisf}. For the e-SIRS model we consider the property ``eventually the number of infected remains below a threshold of 25 individual"". For abstract trajectories of the SIR model we check, for each test point, the percentage of valid trajectories, i.e. such that the state  is absorbing. Finally,  for the Toggle Switch model we check the property ``eventually the level of protein  stays above a threshold of "", meaning we check for each test point the percentage of SSA and abstract trajectories that satisfy such property. It can be written as . These comparisons produce a measurable qualitative estimate of how good the reconstruction is. As future work, we intend to use such qualitative measure as a query strategy for an active learning approach, so that the obtained abstract model is driven in the desired direction.    {Statistical tests}{sec:stat_test} {figure}[ht]          [scale=0.245]{imgs/SIR/SIR_pvalues_no_rescaled_Energy.png}     [scale=0.245]{imgs/eSIRS/eSIRS_pvalues_no_rescaled_Energy.png}     [scale=0.245]{imgs/TS/ToggleSwitch_pvalues_no_rescaled_Energy.png}     [scale=0.245]{imgs/Oscillator/Oscillator_pvalues_no_rescaled_Energy.png}     [scale=0.245]{imgs/MAPK/MAPK_pvalues_no_rescaled_Energy_1500epochs.png}     {Average over the initial setting of the p-values (with confidence interval) for each species computing by the two-sample statistical test w.r.t. the number of samples present in the empirical distributions.}     {fig:stat_test} {figure} In this section we show the results of a two-sample statistical test over all the cases studies. In particular, we use a statistical test based on the energy distance among distributions {szekely2013energy}. For each initial setting and for each species we compute the distance statistics and the p-value among the empirical approximation of the SSA distribution and the empirical approximation of the abstract distribution over the trajectory space, i.e. a -dimensional space. In Fig.  ef{fig:stat_test} we report the mean and the standard deviation of p-values over the initial settings present in the test set. Clearly the p-value decreases as the number of samples used to approximate the distributions increases. Fig.  ef{fig:stat_test} shows how the p-values for each species varies according to the number of samples used. These results come with no surprise as the abstract model was trained having only  observations for each initial setting. It is interesting to observe how the Energy test is passed by a large percentage of points when the number of samples is around . In order to enhance the resilience of the abstract model to such statistical tests we should increase the number of samples per point in the training set. This comes at the cost of reducing the number of initial setting, so that the resulting training set is not too large. In this regard, the active learning technique proposed in Section  ef{sec:satisf} can be extremely beneficial.  {cWCGAN-GP Algorithm}{sec:algorithm}   {algorithm}[ht]   {The gradient penalty coefficient , the number of epochs , the number of critic iterations per generator iteration , the batch size , Adam hyper-parameters .}  {}{   {}{   {}{         Sample real data , latent variable , a random number                                               }         {          Adam          }    }    {    Sample a batch of latent variables and a batch of random conditions      Adam     }        {}  }  {Conditional WGAN with gradient penalty. Default values used for hyper-parameters: , , , , . Variable  denotes the trajectories of length  (), whereas variable  denotes the condition, i.e., the initial setting of the system (pairs . } {algorithm} {Background}{sec:background}  {Chemical Reaction Networks}   Consider a system with  species evolving according to a stochastic model defined as a Chemical Reaction Network. Under the well-stirred assumption, the time evolution can be modelled as a Continuous Time Markov Chain (CTMC) on a discrete state space.  The vector  denotes the state vector at time , where  is the number of individuals in species  at time . The dynamics is encoded by a set of  reactions with parametric propensity functions that depends on the state of the system. Due to the memoryless property of CTMC,  the probability of finding the system in state  at time  given that it was in state  at time  can be expressed as a system of ODEs known as Chemical Master Equation (CME). Since in general the CME is a system with countably many differential equations, its analytic or numeric solution is almost always unfeasible. An alternative computational approach is to generate trajectories using stochastic algorithms for simulation, like the well-known Gillespieâ€™s SSA~{gillespie1977exact} which produces statistically correct trajectories, i.e., sampled according to the stochastic process described by the CME.  {-0.2cm}  {Generative Adversarial Nets}{sec:gan_intro}  Every dataset can be considered as a set of observations drawn from an unknown distribution . Generative models aim at learning a model that mimics this unknown distribution as closely as possible, i.e., learn a distribution  as similar as possible to , in order to then get samples from it that are new but look as if they could have belonged to the original dataset. Generative Adversarial Nets (GANs)~{goodfellow2014generative} are deep learning-based generative models, that, given a dataset, are capable of generating new random but plausible examples.   {Wasserstein GAN.} In this work we consider the Wasserstein version of GAN (WGAN)~{arjovsky2017wasserstein,gulrajani2017improved} as it is known to be more stable and less sensitive to the choice of model architecture and hyperparameters compared to a traditional GAN. WGANs use the Wasserstein distance (also known as Earth-Mover's distance), rather than the Jensen Shannon divergence, to measure the difference between the model distribution  and the target distribution . Because of  Kantorovich-Rubinstein duality {villani2008optimal} such distance can be computed as the supremum over all the 1-Lipschitz functions : {equation}{eq:wassdist}   W({P}_r,{P}_{w_g}) =  _{||f||_L 1} ( {E}_{x{P}_{r}}[f(x)]-{E}_{x{P}_{w_g}}[f(x)]  ight). {equation} We approximate these functions  with a neural net  parametrized by weights .  To enforce the Lipschitz constraint we follow {gulrajani2017improved} and introduce a penalty over the norm of the gradients. It is known that a differentiable function is 1-Lipchitz if and only if it has gradients with norm at most 1 everywhere.  The objective function, to be maximized w.r.t. , becomes: {equation}{eq:wassdist_gp}   {L}({w_c}, w_g) := {E}_{x{P}_{r}}[C_{w_c}(x)]-{E}_{x{P}_{w_g}}[C_{w_c}(x)]- {E}_{{x}{P}_{{x}}} (   abla_{{x}}C_{w_c} ({x})  _2-1 )^2]  , {equation} where  is the penalty coefficient and  is defined by sampling uniformly along straight lines between pairs of points sampled from  and . This is actually a softer constraint that however performs well in practice~{gulrajani2017improved}. The  network is referred to as  extit{critic} and it outputs different scores for real and fake samples, its objective function (Eq.~{eq:wassdist_gp}) provide an estimate of the Wasserstein distance among the two distributions. On the other hand, the distribution  is parametrized by ; we seek the parameters that make it as close as possible to . To achieve this, we consider a random variable  with a fixed simple distribution  and pass it through a parametric function, the  extit{generator},  that generates samples following the distribution . Therefore, the WGAN architecture consists of two deep neural nets, a generator that proposes a distribution and a critic that estimate the distance between the proposed and the real (unknown) distribution. Using WGAN brings several important advantages compared to traditional GAN: it avoids the mode collapse problem, which makes WGAN more suitable for capturing stochastic dynamics, it drastically reduces the problem of vanishing gradients and it also have an objective function that correlates with the quality of generated samples, making the results easier to interpret.   {Conditional GAN.} Conditional Generative Adversarial Nets (cGAN)~{mirza2014conditional} are a type of GANs that involves the conditional generation of examples, i.e., the generator produces examples of a required type, e.g. examples that belong to a certain class, and thus they introduce control over the desired generated output. In our application, we want the generation of stochastic trajectories to be conditioned on some model parameters and on the initial state of the system.  Furthermore, dealing with inputs that are trajectories, i.e. sequences of fixed length, requires the use of convolutional neural networks (CNNs)~{goodfellow2016deep} for both the generator and the critic.  The architecture used in this work is thus a conditional Wasserstein Convolutional GAN with gradient penalty, it is going to be referred to as cWCGAN-GP.   {Experimental Results}{sec:experiments}  In this section we validate our GAN-based model abstraction procedure on the following case studies. More details  are provided in Appendix~ ef{sec:casestudies}. {itemize}       extbf{SIR Model (Absorbing state).}  The SIR epidemiological model describes the spread, in a population, of an infectious disease that grants immunity to those who recover from it. The population is divided in three mutually exclusive groups: susceptible (S), infected (I) and recovered (R). The possible reactions, given by the interaction of individuals are infection and recovery. An important feature is the presence of an absorbing states.       extbf{Ergodic SIRS Model.}      A SIR model in which the population is not perfectly isolated, meaning there is always a chance of getting infected from some external individuals, and in which immunity is only temporary. As a consequence, this model has no absorbing state.       extbf{Genetic Toggle Switch Model (Bistability).}  The toggle switch is a well-known bistable biological circuit consisting of two genes,  and , that mutually repress each other in the production of proteins  and  respectively. The system displays two stable equilibria.        extbf{Oscillator Model.}  The circuit consists of three species A, B and C and three cyclic reactions: A converts B to itself, B converts C to itself, and C converts A to itself. The concentrations of the three species oscillates in time.    extbf{MAPK Model.} The mitogen-activated protein kinase cascade models the amplification of an output signal () thorough a multi-level cascade with negative feedback which is ultra-sensitive to an input stimulus (). The output signal shows either stable or oscillating behaviour, depending on the input signal.  {itemize}   In order to evaluate the performance of our abstraction procedure we consider two important measures: the accuracy of the abstract model, evaluated for each species at each time step of the time grid, and the computational gain compared to SSA simulation time.   {Experimental Settings.}  The workflow can be divided in steps: (1) define a CRN model, (2) generate the synthetic datasets via SSA simulation, (3) learn the abstract model by training the cWCGAN-GP and, finally, (4) evaluate such abstraction. All the steps have been implemented in Python.  In particular, CRN models are defined in the  exttt{.psc} format, CRN trajectories are simulated using Stochpy~{maarleveld2013stochpy} (stochastic modeling in Python) and PyTorch~{paszke2017automatic} is used to craft the desired architecture for the cWCGAN-GP and to evaluate the latter on the test data. All the experiments were performed on a  Intel Xeon Gold 6140 with 24 cores and a 128GB RAM. The source code for all the experiments can be found at the following link: {https://github.com/francescacairoli/WGAN_ModelAbstraction}.    {Datasets.} For each case study with fixed parameters, the training set consists of K different SSA trajectories. In particular, K and .  The test set, instead, consists of  new initial settings  and from each of these we simulate K trajectories, so to obtain an empirical approximation of the distribution targeted by model abstraction. When a parameter is allowed to vary, the training set consists of K SSA trajectories (K and ).  We manually choose  and  so that the system is close to steady state at time , without spending there too many steps. The time interval should be small enough to capture the full transient behavior of the system. For systems with no steady state, such as the oscillating models, we choose  and  so to observe a full period of oscillation. The chosen values are the following: SIR: , ; e-SIRS: , ; Toggle Switch: , ; Oscillator: , ; MAPK: , .  {Data Preparation.}  Data have been scaled to the interval  to enhance the performance of the two CNNs and to avoid sensitivity to different scales in species counts. During the evaluation phase, the trajectories have been scaled back. Hence, results and errors are shown in the original scale.  {-0.2cm}  {cWCGAN-GP architecture}  The same architecture and the same set of hyper-parameters works well for all the analyzed case studies, showing great stability and usability of the proposed solution. The Wasserstein formulation of GANs, with gradient penalty , strongly contributes to such stability. Traditional GANs have been tested as well, but they do not have such strength. The details of the archictecture follows the best practice suggestions provided in~{gulrajani2017improved}.  The critic network has two hidden one-dimensional convolutional layers, with  channels, each containing  filters of size  and stride . We use a leaky-ReLU activation function with slope , we do layer normalization and at each layer we introduce a dropout with probability . An additional dense layer, with linear activation function, is used to connect the single output node, that contains the critic value. In order to enforce the Lipschitz constraint on the criticâ€™s model we add a gradient penalty term, as described in Section~ ef{sec:gan_intro}. On the other hand, the generator network takes as input the noise and the initial settings and it embeds the inputs in a larger space with  channels ( in our experiments) through a dense layer. Four one-dimensional convolutional transpose layers are then inserted, containing respectively , ,  and  filters of size  with stride . Here we do batch normalization and use a leaky-ReLU activation function with slope . Finally, a traditional convolutional layer is introduced to reduce the number of output channels to .  The Adam algorithm~{bengio2015rmsprop} is used to optimize loss function of both the critic and the generator. The learning rate is set to  and . The above settings are shared by all the case studies, the only exception is the more complex MAPK model for which a deeper cWCGAN-GP architecture is selected: a critic with five layers, each containing  filters of size  and stride , and a generator with five layers, containing respectively , , ,  and  filters of size  with stride .  Training times depend on the dimension of the dataset, on the size of mini-batches, on the number of species, and on the architecture of the cWCGAN-GP. The latter has been kept constant for all the case studies. Batches of  samples have been used and the number of epochs varies from  to  depending on the complexity of the model. Moreover, each training iteration of the generator correspond to  iterations of the critic, to balance the power of the two player. The average time required for each training epoch is around one minute.  Therefore, training the cWCGAN-GP model for  epochs takes around  hours leveraging the GPU.  {-0.2cm}  {Results}  {Computational gain.} The time needed to generate abstract trajectories does not depend on the complexity of the original system. Moreover, as the cWCGAN-GP architecture is shared by all the case studies, the computational time required to generate abstract trajectories is the same for all the case studies. In particular, considering a noise variable of size , it takes around  milliseconds (ms) to simulate a single trajectory. However, when generating batches of at least 200 trajectories the overhead reduces and the time to generate a single trajectory stabilizes around 0.8 ms. The same does not hold for the SSA trajectories, whose computational costs depends on the complexity of the model and on the chosen reaction rates. In the case studies considered the time required to simulate a single trajectory varies from  to  seconds, but it easily increases for more complex models or for smaller reaction rates, whereas the cost of abstract simulation stays constant. Details about the computational gain for each model are presented in Table~ ef{table:comp_times}. Computations are performed exclusively on a single CPU processor, to perform a fair comparison. However, the evaluation of cWCGAN-GP can be further sped up using GPUs, especially for large batches of trajectories, but this would have introduced a bias in their favour. It is important to stress how GPU parallelization is extremely straightforward in PyTorch and how the time to generate a single trajectory decrease to 1.9  seconds when generating a batch of at least  trajectories (see last line of Table~ ef{table:comp_times}).  The training phase introduces a fixed overhead that affects the overall computational gain. For instance, the training phase of the MAPK model takes around 8 hours, which is equivalent to the time needed to generate 140K SSA trajectories. It follows that, together with the trajectories needed to generate the training set, the cost of the training procedure is paid off when we simulate at least 200K trajectories. In a typical biological multi-scale scenario in which we seek to simulate the evolution in time of a tissue containing millions of cells, having additional internal pathways, the number of trajectories needed for the training phase becomes negligible and the training time is soon paid off.  {table}  {Measures of performance.} Results are presented as follows. For each model, we present a small batch of trajectories, both real and abstract. From the plots of such trajectories we can appreciate if the abstract trajectories are similar to real ones and if they capture the most important macroscopic behaviors. We also show the histograms of empirical distributions at time  for each species to quantify the behavior over all the K trajectories present in the test set (see Fig.~ ef{fig:sir_trajectories}-~ ef{fig:mapk_trajectories}). Additional plots are shown in Appendix~ ef{sec:plots} (Fig.~ ef{fig:sir_trajectories_extra}-~ ef{fig:clock_trajectories_extra}).     {figure}[ht]          [eSIRS]{   [scale=0.235]{imgs/eSIRS/eSIRS_avg_wass_distance_1000epochs_32steps.png}}              [eSIRS-1P]{       [scale=0.235]{imgs/eSIRS_1P/Scaled_avg_wass_distance_1epochs_32steps.png}}              [SIR]{       [scale=0.235]{imgs/SIR/Scaled_avg_wass_distance_500epochs_16steps.png}}          {-0.25cm}          [Oscillator]{       [scale=0.235]{imgs/Oscillator/Oscillator_avg_wass_distance_1000epochs_32steps.png}}              [Toggle Switch]{       [scale=0.235]{imgs/TS/ToggleSwitch_avg_wass_distance_2000epochs_32steps.png}}              [MAPK]{       [scale=0.235]{imgs/MAPK/MAPK_avg_wass_distance_1500epochs_32steps_scaling.png}}  {-1}  {Plots of the error over time for each model and each species. Errors are computed using the Wasserstein distance over the entire test set. Generated trajectories have been keep scaled to the interval  so that the scale of the system does not affect the scale of the error measure.{-0.5cm}}{fig:wass_errors} {figure}  {Measuring error propagation.} The reconstruction accuracy of the proposed abstraction procedure is performed on test sets consisting of  different initial settings. For each of these points K SSA trajectories represent the empirical approximation of the true distribution over .  From each of these initial settings we also simulate K abstract trajectories. Given a species  and a time step , we have the real one-dimensional distribution  and the generated abstract distribution , where  denotes the counts of species  at time  in a trajectory . In order to quantify the reconstruction error, we compute five quantities: the Wasserstein distance among the two one-dimensional distributions, the absolute and relative difference among the two means and the absolute and relative difference among the two variances. By doing so, we are capable of seeing whether the error propagates in time and whether some species are harder to reconstruct than others. The error plots for the Wasserstein distance are shown in Figure~ ef{fig:wass_errors}. Plots of means and variances distances are provided in Appendix~ ef{sec:plots} (Fig.~ ef{fig:avg_means_errors}-~ ef{fig:avg_vars_rel_errors}). In addition, for two-dimensional models, i.e. eSIRS, Toggle Switch and MAPK, we show the landscapes of these five measures of the reconstruction error at three different time steps: step , step  and step  (Fig.~ ef{fig:eSIRS_distance_landscapes}- ef{fig:mapk_distance_landscapes} in Appendix~ ef{sec:plots}).  We observe that, in all the models, each species seems to contribute equally to the global error and, in general, the error stays constant w.r.t. time, i.e., it does not propagate. This was a major concern in previous methods, based on the abstraction of transition kernels.  In fact, in order to simulate a trajectory of length  the abstract kernel has to be applied iteratively  times. As a consequence, this results in a propagation of the error introduced in the approximation of the transition kernel.   {figure}[ht]               [scale=0.25]{imgs/SIR/SIR_Trajectories14.png}     [scale=0.25]{imgs/SIR/SIR_hist_comparison_last_timestep_14.png}          {-1}          {SIR     model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue);  extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance on a randomly chosen test point represented by three trajectories: the top one (species S), the central one (species I) and the bottom one (species R).{-0.5cm}}     {fig:sir_trajectories} {figure}     {figure}[ht]          [scale=0.25]{imgs/eSIRS_1P/eSIRS_1P_Trajectories0.png}     [scale=0.25]{imgs/eSIRS_1P/eSIRS_1P_hist_comparison_last_timestep_0.png}     [scale=0.25]{imgs/eSIRS_1P/eSIRS_1P_Trajectories1.png}     [scale=0.25]{imgs/eSIRS_1P/eSIRS_1P_hist_comparison_last_timestep_1.png}          {-1}          {e-SIRS model with one varying parameter:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue);  extbf{(right)} comparison of the real and generated histogram at the last timestep.      {fig:esir_trajectories_one_par}                   [scale=0.25]{imgs/TS/ToggleSwitch_Rescaled_Trajectories0_tight.png}     [scale = 0.25]{imgs/TS/ToggleSwitch_rescaled_hist_comparison_-1th_timestep_0_tight.png}          {-1}          {Toggle Switch model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue);  extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance for a randomly chosen test point represented by a pair of trajectories: the top one (species P1) and the bottom one (species P2).{-0.5cm}}     {fig:ts_trajectories} {figure}  {figure}[ht]        [scale=0.25]{imgs/Oscillator/Oscillator_Rescaled_Trajectories2.png}    [scale=0.25]{imgs/Oscillator/Oscillator_rescaled_hist_comparison_-1th_timestep_2.png}        {-1}         {Oscilator model:  extbf{(left)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue); extbf{(right)} comparison of the real and generated histogram at the last timestep. Performance on a randomly chosen test point represented by three trajectories: the top one (species A), the central one (species B) and the bottom one (species C). {-0.5cm}    }{fig:clock_trajectories} {figure}  {figure}[ht]        [scale=0.19]{imgs/MAPK/MAPK_Rescaled_Trajectories8.png}    [scale=0.19]{imgs/MAPK/MAPK_Rescaled_Trajectories15.png}    [scale=0.19]{imgs/MAPK/MAPK_Rescaled_Trajectories22.png}    [scale=0.19]{imgs/MAPK/MAPK_rescaled_hist_comparison_-1th_timestep_8.png}    [scale=0.19]{imgs/MAPK/MAPK_rescaled_hist_comparison_-1th_timestep_15.png}    [scale=0.19]{imgs/MAPK/MAPK_rescaled_hist_comparison_-1th_timestep_22.png}        {-1}         {MAPK model:  extbf{(top)} comparison of trajectories generated with a cWCGAN-GP (orange) and the trajectories generated with the SSA algorithm (blue); extbf{(bottom)} comparison of the real and generated histogram at the last timestep. Performance on three, randomly chosen, test points. Each point is represented by the ouput species MAPKPP. {-0.5cm}    }{fig:mapk_trajectories} {figure}   extbf{SIR.} The results for the SIR model are presented in Fig.~ ef{fig:sir_trajectories} and Fig.~ ef{fig:sir_trajectories_extra} (Appendix~ ef{sec:plots}), which shows the performance on two, randomly chosen, test points. Each point is represented by three trajectories, the top one is for species S, the central one is for species I and the bottom one is for species R. The population size, given by , is variable. The abstraction was trained on a dataset with fixed parameters, . Likewise, in the test set only the initial states are allowed to vary. We observe that our abstraction method is able to capture the absorbing nature of SIR trajectories. It is indeed very important that once state  or state  are reached, the system should not escape from it. Abstract trajectories satisfy such property without requiring the imposition of any additional constraint. The empirical distributions, real and generated, at time  are almost indistinguishable.   extbf{e-SIRS.} The e-SIRS model represents our baseline. We train two abstractions: in the first case the model is trained on a dataset with fixed parameters, , and in the second case we let parameter  vary as well. Results are very accurate in both scenarios In the fixed-parameters case, Fig.~ ef{fig:esir_trajectories} (Appendix~ ef{sec:plots}), the results are shown for two, randomly chosen, initial states. In the second case, Fig.~ ef{fig:esir_trajectories_one_par}, the results are shown on two, randomly chosen, pairs . Each point is represented by a pair of trajectories, the top one is for species S and the bottom one is for species I. We performed a further analysis on the generalization capabilities of the abstraction learned on the dataset with one varying parameter, using larger test sets and computing mean and standard deviation of the distribution of Wasserstein distances over such sets. The mean stays around  with a tight standard deviation ranges from  to , showing little impact of the chosen conditional setting (see Fig.~ ef{fig:esirs_1p_analysis} in Appendix~ ef{sec:plots}).   extbf{Toggle Switch.} The results for the Toggle Switch model, on two, randomly chosen, test points, are shown in Fig.~ ef{fig:ts_trajectories}) and Fig.~ ef{fig:ts_trajectories_extra} (Appendix~ ef{sec:plots}). The abstraction was trained on a dataset with fixed symmetric parameters ( for ). Likewise, in the test set only the initial states are allowed to vary. In this model, we tried to abstract only trajectories of the proteins  and , which are typically the observable species, ignoring the state of the genes. By doing so, we reduce the dimensionality of the problem but we also lose some information about the full state of the system. Nonetheless, the cWCGAN-GP abstraction is capable of capturing the bistable behaviour of such trajectories. In Fig.~ ef{fig:ts_trajectories}, each point is represented by two trajectories, the top one is for species , whereas the bottom one is for species .     extbf{Oscillator.} The results for the Oscillator model, on two, randomly chosen, test points, are shown in Fig.~ ef{fig:clock_trajectories} and Fig.~ ef{fig:clock_trajectories_extra} (Appendix~ ef{sec:plots}). The abstraction was trained on a dataset with fixed parameter (). Likewise, in the test set only the initial states are allowed to vary. Each point is represented by three trajectories, the top one is for species , the central one is for species  and the bottom one is for species . The abstract trajectories well capture the oscillating behaviour of the system.    extbf{MAPK.} The results for the MAPK model, on three, randomly chosen, test points, are shown in Fig.~ ef{fig:mapk_trajectories}. The abstraction was trained on a dataset considering only a varying  parameter and the dynamics of species .  This case study represents a complex scenario in which the abstract distribution should capture the marginalization over the other seven unobserved variables. Moreover, the emergent behaviour of the only observed variable, , is strongly influenced by the input parameter  and further  amplified by the multi-scale nature of the cascade: for some values of  the system oscillates, whereas for others it stabilizes around an equilibrium. Results show that our abstraction technique is flexible enough to capture such sensitivity.  {-0.2cm}  {Discussion} Previous approaches to model abstraction, see Related work in Section~ ef{sec:introduction}, focus on approximating the transition kernel, meaning the distribution of possible next states after a time , rather than learning the distribution of full trajectories of length . The main reason for such choice is the limited scalability of the tool used for learning the abstraction. In fact, learning a distribution over  with a Mixture Density Network is unfeasible even for small . Moreover, in learning to approximate the transition kernel one must split the SSA trajectories of the dataset in pairs of subsequent states. By doing so, a lot of information about the temporal correlation among states is lost. Having a tool strong and stable enough to learn distributions over  allows us to preserve this information and make abstraction possible even for systems with a complex dynamics, which the abstraction of the transition kernel was failing to capture. For instance, we are now able to abstract the transient behaviour of multi-stable or oscillating systems. When attempting to abstract the transition kernel, either via MDN or via c-GAN, for such complex systems, we did not succeed in learning meaningful solutions. A collateral advantage in generating full trajectories, rather than single subsequent states, is that it introduces an additional computational speed-up in the time required to generate a large pool of trajectories of length . For instance, if a cWGAN is used to approximate the transition kernel, it takes around  seconds to simulate the K trajectories of length  present in the test set. Our trajectory-based method takes only  seconds to generate the same number of trajectories. Furthermore, our cWCGAN-GP was trained with relative small datasets, which leaves room for further improvements where needed. An additional strength of our method is that one can train the abstract model only on species that are observable, reducing the complexity of the CRN model while preserving an accurate reconstruction for the species of interest. Once again, this was not possible with transition kernels and it may be extremely useful in real world applications.  In general, the cWCGAN-GP approximation does not provide any statistical guarantee about the reconstruction error. In addition, the set of observations used to learn the abstraction is rather small, typically  samples for each initial setting. Therefore, it is not surprising that the real and the abstract distributions are not indistinguishable from a statistical point of view, as shown in Appendix~ ef{sec:stat_test}. However, the abstract model is actually capable of capturing, from the little amount of information provided, the emergent features of the behaviour of the original system, such as multimodality or oscillations.  In this regard, formal languages can be used to formalize and check such qualitative properties. In particular, we can check whether the satisfaction probability (of non rare events) is similar in real and abstract trajectories. Examples are shown in Appendix~ ef{sec:satisf}. Furthermore, such quantification of qualitative properties can be used to measure how good the reconstruction is. As future work, we intend to use it as query strategy for an active learning approach, so that the obtained abstract model is driven in the desired direction.    {Introduction}{sec:introduction}  A wide range of complex systems can be modeled as a network of chemical reactions. Stochastic simulation is typically the only feasible analysis approach that scales in a computationally tractable manner with the increase in system size, as it avoids the explicit construction of the state space. The well known Gillespie Stochastic Simulation Algorithm~{gillespie1977exact} is widely used for simulating models, as it  samples from the exact distribution over trajectories. This algorithm is  effective to simulate systems of moderate complexity, but it does not scale well to systems with many species and reactions, large populations, or internal stiffness. In these scenarios, a more effective choice is to rely on approximate simulation algorithms such as tau-leaping~{cao2006efficient} and hybrid simulation~{pahle2009biochemical}.  Nonetheless, when the  number of simulations required is extremely large and possibly costly, e.g. when one needs to simulate a large population of heterogeneous cells in a multi-scale model of a tissue or to simulate many heterogeneous individuals in an population ecology scenario,  all these methods become extremely computationally demanding, even for HPC facilities.   A viable approach to address such problem is model abstraction, which aims at reducing the underlying complexity of the model, and thus reduce its simulation cost. However, building effective model abstractions is difficult, requiring a lot of ingenuity and man power. Here we advocate the strategy of learning an abstraction from simulation data. Our strategy is to frame model abstraction as a supervised learning problem, and learn an abstract probabilistic model using state of the art deep learning. The probabilistic model should then be able to generate approximate trajectories efficiently and in constant time, i.e., independent on the complexity of the original system, thus sensibly reducing the simulation cost. {Related work.} The idea of using machine learning as a model abstraction tool to approximate and simplify the dynamics of a Markov Population Process has received some attention in recent years.  In~{bortolussi2018deep} the authors use a Mixture Density Network (MDN)~{bishop2006pattern} to approximate the transition kernel of the stochastic process. In~{petrov2020automated} the authors extend the previous approach by introducing an automated search of the MDN architecture that better fit the data. In~{bortolussi2019bayesian} the authors present a Bayesian model abstraction technique, based on Dirichlet Processes, that allows  the quantification of the reconstruction uncertainty. In all cases, what is learned is an approximate transition kernel,  i.e., the probabilistic distribution of a single simulation step.   In this paper we address a more general and more complex problem. Instead of learning an approximate transition kernel, we learn the distribution of an entire trajectory of fixed length. This latter problem is not solvable with any of the previously adopted approaches, and its major goal is to keep abstraction error under control. In fact, training the abstract model on a full trajectory, rather than on pairs of subsequent states, allows the abstract model to retain and capture more information about the dynamics of the Markov process.  {Contributions.} Our approach leverages Generative Adversarial Nets (GAN), which are one of the most strong and flexible techniques to learn probabilistic models. In fact, the GAN-based model abstraction technique is capable of learning a conditional distribution over the trajectory space, keeping into account the correlation, both spatial and temporal, among all the different species and conditioning both on initial states and model parameters. All the previous approaches focus on learning the distribution of the state of the system after a time , the so called  extit{transition kernel}. However, such approaches perform poorly when the time interval is small and the dynamics is transient, showing a clear propagation of the error as the approximate kernel is applied iteratively to form a trajectory.  Furthermore, producing a full trajectory reduces even more the computational cost of simulating a large pool of trajectories for different initial settings.   {Paper structure.} The paper is organized as follows: in Section~ ef{sec:background} the relevant background notions are introduced, in Section~ ef{sec:abstraction} we describe in detail the abstraction procedure, Section~ ef{sec:experiments} presents the case studies and the experimental evaluation. Conclusions are drawn in Section~ ef{sec:conclusions}.  {Conclusions}{sec:conclusions} In the paper we presented a technique to abstract the simulation process of stochastic trajectories for various CRNs. The WGAN-based abstraction improves considerably the computational efficiency, which is no more related to the complexity of the underlying CRN.  This would be extremely helpful in all those applications in which a large number of simulations is required, i.e., applications whose solution is unfeasible via SSA simulation. It would enable the simulation of multi-scale models for very large populations, it would speed-up statistical model checking {younes2006statistical} and it can be used in particular cases of parameter estimation, for example when only few parameters have to be estimated multiple times. In conclusion, the c-WCGAN-based solution to model abstraction perform well in scenarios that are very complex and challenging, requiring relatively little data and very little fine-tuning.  As future work, we plan to study how our abstraction technique works on real data. In this regard, we do not aim at capturing the underlying dynamical system, but we would rather be able to reproduce the trajectories observed in real applications.  A great strength of our method, compared to state of the art solutions, is that it is able to generate trajectories only for a subset of the species present in the system domain, ignoring the information that is not observable, even during the training phase. Another interesting extension is to adapt our technique to sample bridging trajectories, where both the initial and the terminal states are fixed. Typically, the simulation of such trajectories requires expensive Monte Carlo simulations, which makes clear the benefits of resorting to model abstraction.  {   oindent extbf{Acknowledgements} This work has been partially supported by  the Italian PRIN project ``SEDUCE'' n.2017TWRCNB.}   {splncs04}",3,2021-06-25T02:17:54,en,2106.12981,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,4269,0,0,4269,0,4269,0,0,0,0,0,0,4269,4269,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,4269,0,0,0,0,0,4269,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,4269,4269,4269,4269,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,0,0,0,0,4269,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,4269,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,4269,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,4269,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,4269,0,0,4269,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,4269,0,4269,4269,0,0,4269,4269,4269,4269,0,0,4269,0,0,4269,0,0,0,0,0,0,4269,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,4269,0,0,0,0,4269,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,4269,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,0,4269,0,0,0,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,0,0,0,0,0,0,4269,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,4269,4269,4269,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,4269,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,4269,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,4269,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"{{sec:Intro}Introduction}  oindent In a He gas discharge, two long-lived, excited (``metastable'') atomic levels are formed by electron-impact excitation from the S electronic ground level: the S level (electronic energy eV {NIST_ASD}, natural lifetime s {Hodgman2009}) and the S level (eV {NIST_ASD}, ms {VanDyck1971}). In the following, the metastable He atoms are referred to as spin-polarized, when only a single magnetic sub-level of He(S) is populated. Such spin-polarized metastable He (He) is used for a wide range of applications. Special interest is currently devoted to He magnetometry for the quantum sensing of very small magnetic fields, e.g. see Refs.{Heil2017, Wang2020}. In metastable atom electron spectroscopy {Harada1997}, also referred to as metastable de-excitation spectroscopy, He has, for example, been used for probing surface magnetism {Onellion1984}. In atom optics, He has found applications in nanolithography, as well as in atomic waveguides and beamsplitters for atom interferometry {Baldwin2005, Vassen2012}. He also serves as a source of polarized electrons {McCusker1969,McCusker1972} and ions {Schearer1969}, e.g., for atomic and high-energy nuclear scattering experiments. Besides that, spin-polarized samples of He(S) are used for biomedical imaging, e.g., to visualize the human lung {Walker1997, Kauczor1998, Nikolaou2015}.  Supersonic beams of He are typically produced by optical pumping {Happer1972}, as well as by magnetic (de-)focusing and magnetic deflection. Optical pumping of He(S) via the PS transition (where ) at a wavelength of  nm has first been achieved by Franken, Colegrove and Schaerer using a helium lamp {Franken1958, Colegrove1960, Schearer1961}. A few years later, also the optical pumping of the S level of the He isotope has been demonstrated using a similar setup {Phillips1962, Colegrove1963}. The more recent use of narrowband laser radiation has proven to be particularly efficient for the optical pumping of He {Giberson1982, Lynn1990, Wallace1995, Granitza1995}.  Apart from that, also the interaction of a spin with an inhomogeneous magnetic field has been used for producing spin-polarized atomic beams of He(S) and He(S), respectively. These level-preparation techniques include Stern-Gerlach deflection {Kato2012,Rubin2004,Zheng2017,Zheng2019,Chen2020,Smiciklas2010} , magnetic hexapole focusing {Jardine2001, Woestenenk2001, Watanabe2006, Chaustowski2007,Kurahashi2008,Kurahashi2021,Baum1988} and Zeeman deceleration {Dulitz2015a, Cremers2017b}.    A comparison between the different techniques for He preparation in a supersonic beam is of paramount importance for experimental design considerations. In this article, we describe the results of a comparative study aimed at the laser optical pumping of He(S) into a single  sub-level (where ) and at the magnetic hexapole focusing (defocusing) of the  () sub-level of He(S) using an array of two magnetic hexapoles. We have determined the efficiency for -sub-level selection using low-cost fluorescence and surface-ionization detectors, respectively, which can easily be implemented in other experiments.  {{sec:Setup}Experiments}  oindent Major parts of the experimental setup have already been described elsewhere {Grzesiak2019,Guan2019}. Briefly, a pulsed He beam is produced by a supersonic expansion of He gas from a high-pressure reservoir (bar) into the vacuum using a home-built CRUCS valve {Grzesiak2018} (s pulse duration). An electron-seeded plate discharge (attached to the front plate of the valve) is used to excite an  fraction of He atoms from the S electronic ground level to the two metastable levels, 2S and 2S, referred to as He hereafter {Grzesiak2019}. After passing through an mm-diameter skimmer at a distance of mm from the valve exit, the supersonic beam enters a second vacuum chamber, in which a specific magnetic sub-level of the 2S level is prepared using laser optical pumping or selected using magnetic hexapole focusing (see below). The distance between the skimmer tip and the center of the optical pumping region (hexapole magnets) is mm (mm). The He flux and the He beam velocity are determined using Faraday cup detection at well-known positions along the supersonic beam axis .   For the experiments on optical pumping, the pulsed valve is operated at room temperature resulting in a supersonic beam of He with a mean longitudinal velocity of m/s (m/s full width at half maximum, FWHM). For the experiments on magnetic hexapole focusing, the pulsed valve is cooled by a cryocooler (CTI Cryogenics, 350CP), and the valve temperature is actively stabilized to K using PID-controlled resistive heating. This results in a supersonic beam of He with a mean longitudinal velocity of m/s (m/s FWHM).  {{sec:setup.optPump} Laser optical pumping}  oindent The energy-level schemes and the experimental setup used for laser optical pumping are shown in Figs. ef{fig:Setup} (a) and (b), respectively. Optical pumping is achieved by laser excitation via the PS transition or via the PS transition at  1083 nm, respectively. The laser light for optical pumping is generated by a combination of a fiber laser and a fiber amplifier (NKT Photonics, Koheras BOOSTIK Y10 PM FM, W output power, kHz line width). The laser frequency is stabilized using frequency-modulated, saturated absorption spectroscopy in a He gas discharge cell. Since the frequency difference between the P and P spin-orbit levels is only GHz {NIST_ASD}, the laser frequency can be changed in between the different transitions without effort.  The laser light is guided to the vacuum chamber using a polarization-maintaining single-mode fiber, where it is collimated to a beam diameter of mm ( is the Gaussian beam waist). Before the laser beam enters the vacuum chamber, it passes a polarizing beam splitter for polarization clean-up, and a quarter wave plate for the production of circularly polarized light. Inside the vacuum chamber, the laser beam crosses the supersonic beam at right angles and parallel to the direction of the magnetic field produced by two coils in near-Helmholtz configuration (radius cm). The thus produced homogeneous magnetic field of  provides a uniform quantization axis for all He atoms in the supersonic beam.  The level-preparation efficiency is determined by measuring the laser induced-fluorescence (LIF) of the He atoms in the direction perpendicular to the supersonic beam and the laser beam. The fluorescence light is collected and focused onto an InGaAs photodiode (Hamamatsu, mm active area diameter, photosensivity of A/W at ) using two anti-reflection-coated, aspheric lenses (Thorlabs, mm diameter, mm focal length). Due to the symmetric lens configuration (as shown in Fig. ef{fig:Setup} (b)), the fluorescence collection region in the  plane is expected to be of the same size as the detection region, which is given by the active area of the photodiode. The output of the photodiode is amplified using a home-built transimpedance amplifier with a gain of . A rotatable linear polarizer (Thorlabs, extinction ratio  at ) is mounted in between the lenses in order to analyze the polarization of the fluorescence light. All the optical components of the fluorescence detector are placed into a single lens tube system to ensure the correct alignment of the optical parts. The entire detector assembly is positioned on a translational stage outside the vacuum chamber which can be moved along the  axis.  Under normal operating conditions, the number of He atoms in the S level is /pulse, as inferred from the signal on the Faraday-cup detector {Grzesiak2019}. For excitation via the PS transition, the time-dependent signal of the photodiode has a peak voltage of  and an FWHM of 27 s. The peak flux of detected photons is then inferred from  using {align}  {N}_{ ext{ph,max}} = {U_{ ext{PD,max}} }{h  u R_ ext{PD} G_{ ext{PD}}}  7  10^{11}{ ext{photons}}{ ext{s}}, {align} where  is Planck's constant and  is the corresponding transition frequency. From these measurements, we infer a root-mean-square noise amplitude of  for a single measurement which improves to  by averaging over 300 gas pulses. This results in a signal-to-noise ratio of  {align}  SNR = {U_{ ext{PD,max}}^2}{U_{ ext{noise}}^2} =  {cases}  16.2 ext{dB}   ext{single measurement}  40.3 ext{dB}   ext{300 averages}  {cases} {align} At , we thus infer a detection limit of photons/s (photons/s) for a single measurement (300 averages).   {figure}[hbt!]   {fig1.pdf}  {{fig:Setup}   (a) Left: He energy levels relevant for the experiments described in the main text. The level energies are taken from Ref.{NIST_ASD}. Right: Transitions relevant for the laser optical pumping of He(S) via the P (top), the P (middle) and the P (bottom) levels, respectively. The relative transition strengths for ,  and  excitation are labeled in pink, green and blue color, respectively.  (b) Schematic illustration of the experimental setup used for optical pumping and fluorescence detection. HHC = Helmholtz coil, PBS = polarizing beam splitter,  = quarter wave plate, PD = photodiode, P = polarizer, L = aspheric lens.  (c) Schematic drawing of a magnetic hexapole array in Halbach configuration.  (d) Sketch of the detection system for magnetic hexapole focusing including the two Halbach arrays (HA), the wire detector (W) and a Faraday cup detector (FC). All dimensions in (b)-(d) are given in units of mm, and they are not to scale.} {figure}  {{sec:setup.magDefl} Magnetic hexapole focusing}  oindent For the magnetic focusing of He(2S, ), we use a set of two Halbach arrays {Halbach1980, Halbach1981} in hexapole configuration, sketched in Fig. ef{fig:Setup} (c), whose design has already been described previously {Dulitz2014a, Dulitz2016}. Each hexapole array consists of 12 magnetized segments (Arnold Magnetic Technologies, NdFeB, N42SH, remanence of T) which are glued into an aluminium housing and placed on a position-adjustable rail at a center-to-center distance of mm.  To determine the focusing properties of the magnet assembly, a thin stainless-steel wire (diameter mm, labelled as ``W'' in Fig. ef{fig:Setup} (d)) is used as a position-sensitive Faraday-cup-type detector. Its position along the  and  axes can be varied by a maximum of mm and mm, respectively, using a set of two precision linear translators. A second Faraday-cup detector (labelled as ``FC'' in Fig. ef{fig:Setup} (d)), i.e., a stainless-steel plate of mm diameter, is placed behind the wire detector to determine the He beam velocity.   {Results and Discussion} {{sec:optPump} Laser optical pumping}  oindent In general, the level preparation efficiency relies on the polarization state of the laser radiation, on the energy-level structure of the involved electronic levels and on the transition strengths for photon absorption and emission. If atoms are excited with -polarized light, the change in angular momentum between the upper and lower level is  for every photon-scattering event, where  and  are the magnetic projection quantum numbers for the upper and the lower magnetic sub-levels, respectively. For excitation with -polarized light, .  The transition strengths for the PS transitions (where ) in He are shown in Fig. ef{fig:Setup} (a). As can be seen from the figure, all  transitions strengths for the PS transition are non-zero. Hence, in this case, multiple excitation cycles with -polarized light lead to equal populations in the 2S,  and 2P,  sub-levels, respectively. In this case, photon emission via this transition continues to occur as long as the atoms are subject to laser excitation. In contrast to that, the emission of photons ceases after a few pumping cycles for  excitation of the PS transition, since all population is trapped in the 2S,  sub-level. Likewise, the excitation of the PS transition using -polarized light leads to a transfer of population into the S sub-level and photon emission stops as a result of the zero transition strength for the PS transition.  As can be inferred from Fig. ef{fig:Setup} (a), the selective population of a single  sub-level in He(S) via the PS transition is more complicated, as it requires two different laser polarization states. Therefore, we have focused our experimental work on the optical pumping of He(S) via the PS and PS transitions, respectively. In the following, we provide a brief description of the different optical pumping schemes and the methods used for analyzing and optimizing the sub-level preparation efficiencies. Furthermore, we compare our results with literature values.  {{sec:optPumpAnalysis3P2} Optical pumping via the PS transition}  oindent As stated above, the excitation of the PS transition with -polarized light leads (after a few excitation cycles) to the optical cycling between the S,  sub-level and the 2P,  sub-level. In this case, the atomic fluorescence only consists of -polarized light as . During the first optical pumping cycles, and for a non-perfect circular polarization of the input light, also sub-levels with  are populated and can decay back to the S level while emitting - and -polarized photons as well. Therefore, the polarization purity of the emitted fluorescence provides information about the sub-level preparation efficiency. Since the polarization of fluorescence photons are given with respect to the quantization axis, which is the pointing of the external magnetic field vector, fluorescence photons of  polarization that are detected along an axis perpendicular to the quantization axis, are projected onto a linear polarization. The direction of this projected linear polarization is again perpendicular to the quantization axis. Furthermore, fluorescence photons of  polarization are linearly polarized parallel to the quantization axis. Therefore, we analyze the purity of the emitted light using a linear polarizer plate and the fluorescence intensity can be ascribed to  polarization ( polarization) if the transmission axis of the polarizer  is perpendicular (parallel) to the magnetic field component , respectively {Hubele2015}. For example, the results of fluorescence measurements at different polarizer angles are shown in Fig. ef{fig:P2FLmodulation}.  In order to compare the sub-level preparation efficiencies, we define {equation} _i = { ho(M_{J^{''}_i})}{_{i}{ ho(M_{J^{''}_i})}}, {equation} for producing a specific magnetic sub-level population  of He(2S) (where ). For the PS transition, the efficiency for optical pumping into the S sub-level is thus obtained using {align} _{+1(- 1)} = 1 - {I_{{F}}(P  B_z)}{I_{{F}}(P  B_z) + I_{{F}}(P  B_z)}, {align} where  and  are the fluorescence intensities for emission at polarizer axes  and , respectively. {figure}[hbt!]  [width=8cm]{fig2.eps    {{fig:P2FLmodulation} Fluorescence intensity as a function of polarizer angle for excitation with -polarized light via the PS transition. The experimental data points are shown as red circles. The black curve is a sine fit to the data. The dashed vertical lines represent the two angles at which the transmission axis of the polarizer  is perpendicular or parallel to the magnetic field component , respectively. Here, an efficiency of  is determined from the fit to the data.} {figure}  {{sec:optPumpAnalysis3P1} Optical pumping via the SP transition}  oindent Excitation via the PS transition allows for the selective optical pumping into each of the  sub-levels in He(S). When the atoms are excited with pure -polarized light, all population is pumped into the S sub-level. Since this is a dark sub-level, fluorescence emission should only occur in the first few pumping cycles. However, by using a mixture of - and -polarized excitation light, the dark sub-level is remixed, so that optical cycling (and thus fluorescence emission) continues to occur. In the present configuration, the input polarization is changed by varying the angle  of the quarter wave plate compared to the axis of the incident linear laser polarization. The observed change of the fluorescence intensity as a function of quarter wave plate angle is shown in Fig. ef{fig:P1FLmodulation}. The efficiency for pumping into the S sub-level is determined using {align} _{+1(- 1)} = 1 - {I_{ ext{F}}(^{+(-)})}{I_{ ext{F}}(^{+} + ^{-})}, {align} where  and  are the fluorescence intensities for excitation with pure  polarization and with a mixture of  and  polarization, respectively. {figure}[hbt!]  [width=8cm]{fig3.eps   {{fig:P1FLmodulation} Red circles: Measured fluorescence intensity for excitation via the PS transition as a function of quarter wave plate angle . The quarter wave plate angles for excitation with pure -polarized light and with an equal mixture of - and -polarized light are indicated as dashed vertical lines. The inset shows the results of a measurement in a region around  taken under different experimental conditions  } {figure}  For optical pumping into the S sub-level, we have used an additional coil pair in near-Helmholtz configuration (radius of mm, distance of mm), placed at right angles to the other Helmholtz-coil pair, to generate a well-defined quantization axis along the  direction. As a result, the laser beam direction is perpendicular to the magnetic field component . In addition to that, the quarter wave plate is replaced by a half wave plate. By rotating the half wave plate, the angle of polarization is adjusted to be either parallel or perpendicular to . In the latter case, the excitation light is projected onto an equal mixture of  and  input polarization which again causes a remixing of the otherwise dark sub-level S. Fig. ef{fig:P1M0FLmodulation} shows the change of the fluorescence intensity as a function of half wave plate angle. For pumping into the S sub-level, the sub-level preparation efficiency is thus obtained using {align} _{0} = 1 - {I_{ ext{F}}(  B_x)}{I_{ ext{F}}(  B_x)}, {align} where  and  are the fluorescence intensities for excitation using -polarized light in a direction parallel and perpendicular to the magnetic field component , respectively. {figure}[hbt!]  [width=8cm]{fig4.eps   {{fig:P1M0FLmodulation} Red circles: Measured fluorescence intensity for excitation via the PS transition as a function of half wave plate angle . The half wave plate angles for excitation with -polarized light parallel and perpendicular to the magnetic field direction  are indicated as dashed vertical lines.  } {figure}  {{sec:optPumpPosition} Optimization of the sub-level preparation efficiency}  oindent We have identified several parameters which strongly affect the sub-level preparation efficiency: the interaction time between the excitation laser light and the sample, the laser intensity, the magnetic field strength and the purity of the input polarization.  During the excitation process, an atom typically scatters several photons before it is pumped to the designated magnetic sub-level. Since the radiative lifetime of the 2P levels in He is long compared to typical optical pumping transitions in other atoms ( {NIST_ASD}), a comparably long interaction time between the laser beam and the sample has to be achieved. In our case, we have found that a large 1/ laser beam diameter of  is most practical for this purpose. For a supersonic beam with a mean velocity of m/s, this beam diameter translates into an interaction time of .  We have studied the influence of the interaction time on the sub-level preparation efficiency  by monitoring the fluorescence intensity at different fluorescence detector positions along the  axis. As can be seen from the colored markers in Fig. ef{fig:optPumpPosition}, the efficiency  for  excitation of the PS and PS transitions, respectively, increases to a nearly constant value as the detector is moved towards the midpoint of the excitation laser beam. This confirms that, in our experiment, the interaction time does not limit the sub-level preparation efficiency.   We have simulated the population transfer process using rate-equation calculations. A detailed description of the rate-equation model can be found in App.  ef{app:ratEqns}. The best fit to our experimental data for excitation via the PS transition and via the PS transition, respectively, is found by assuming that the excitation light is a mixture of  - and  -polarized light. The admixture of wrongly polarized light also explains why the observed sub-level preparation efficiency is below . In addition to that, as can be seen from Fig. ef{fig:Setup} (a), the relative transition strengths for optical pumping with wrongly polarized light is  for the PS transition, while it is only  for the PS transition. Thus, optical pumping via the PS transition is more sensitive to wrongly polarized excitation light which explains the observed difference in the sub-level preparation efficiency. In our setup, such an admixture of wrong input polarization might be caused by imperfections of the quarter wave plate or by the birefringence of the vacuum window. {figure}[hbt!]  [width=8cm]{fig5.eps   {{fig:optPumpPosition} sub-level preparation efficiencies  for  excitation of the PS and PS transitions (see legend), respectively, at different positions of the fluorescence detector along the  axis. The origin of the position axis denotes the midpoint of the laser beam.  Experimental values are shown as markers, and the results of the rate-equation calculations are shown as solid lines. In the calculations, a mixture of  - and  -polarized light is assumed for both excitation schemes.} {figure}  Secondly, the laser intensity has to be high enough so that the laser-induced power broadening compensates for a detuning of the laser frequency from the atomic resonance. This detuning is caused by the Doppler broadening due to the transverse velocity of the atoms ( FWHM) and by the Zeeman shift of the atomic levels (). The FWHM of the power broadening can be expressed as {align} _{ ext{power}} = {}{2 }  {1 + {I}{I_ ext{sat}}}, {align} where  is the intensity of the laser light and mW/cm (assuming a two-level system) is the saturation intensity of the transition. Therefore, in order to compensate for the Doppler broadening and for the Zeeman shift, the laser intensity has to be , corresponding to a laser power of  for our experiments. From Fig. ef{fig:optPumpPower}, we can see that the sub-level preparation efficiency for  excitation of the PS transition is constant for laser powers . Unfortunately, measurements of the sub-level preparation efficiency at lower laser powers suffer from low signal intensities and are thus less representative. For  excitation of the PS transition, we observe that more than 300 mW of laser power are required to reach a constant sub-level preparation efficiency. This power difference might be attributed to a weaker power broadening of the PS line compared to the PS line as a result of a higher saturation intensity for this transition. As both transitions have the same line width, the same initial level and approximately the same transition frequency, we can see from Eq. {eq:dmd} that the squared dipole matrix elements  are proportional to the degeneracy factors . As , it follows that PSPS. {figure}[hbt!]  {0.5cm}  [width=8cm]{fig6.eps   {{fig:optPumpPower} sub-level preparation efficiency  for  excitation of the PS and PS transitions (see legend), respectively, at different laser powers. The data are taken at a mm distance downstream from the midpoint of the laser beam in order to represent the efficiencies at equilibrium.} {figure}  Thirdly, the magnetic bias field has to be large enough to ensure a uniform quantization axis within the optical pumping region so that the contributions of stray fields along other spatial directions is small.   In Fig. ef{fig:optPumpBfiled}, a scan of the sub-level preparation efficiency  for  excitation of the PS and PS transitions, respectively, is shown as a function of the magnetic field component . The highest efficiency is achieved at field strengths between  for both transitions. This magnetic field range is in line with previous observations reported in the literature {Gillot2013,Wallace1995,Schearer1990a}. At magnetic field strengths , the sub-level preparation efficiency for excitation via the PS (PS) transition is decreased (remains constant) compared to the optimum  field range. This is consistent with a decreased scattering rate at higher magnetic fields caused by the increased Zeeman detuning.  {figure}[hbt!]  [width=8cm]{fig7.eps   {{fig:optPumpBfiled} sub-level preparation efficiency    for  excitation of the PS and PS transitions (see legend), respectively, at different bias magnetic field strengths. The data are taken at a mm distance downstream from the midpoint of the laser beam in order to represent the efficiencies at equilibrium.} {figure}  We have also analyzed the influence of stray magnetic fields along the  and  directions. Using a high-accuracy, three-axis Gauss probe (Stefan Mayer Instruments, , mG resolution), we obtain  and . At , this results in an angle of   between the magnetic field and the  axis (cf. Gillot et al. {Gillot2013}). We have observed that a further compensation of the magnetic stray fields using additional coils along the  axis (resulting in ) does not result in an improved sub-level preparation efficiency. In addition to that, a non-perfect alignment of the laser propagation direction parallel to the quantization axis can induce a similar limit to the achievable sub-level preparation efficiency as the presence of magnetic stray fields. Furthermore, small magnetic-field inhomogeneities within the interaction region, resulting from e.g. a not perfect Helmholtz coil arrangement or electronic devices in the laboratory, may also limit the sub-level-preparation efficiency.  In summary, we conclude that the imperfect polarization of the laser light (see discussion above) is the main limiting factor for the sub-level preparation efficiency.  {{sec:compOPlit} Comparison with literature values}  oindent In Tab. ef{tab:optPumpEfficiencies}, we present a summary of the maximum sub-level preparation efficiencies  obtained from our experimental data, and a comparison with literature values. As can be seen from the table, our  values are in good agreement with previous results for the laser optical pumping of He(S). To the best of our knowledge, we are the first to obtain a maximum efficiency  for optical pumping into . The only previous attempt to selectively populate  has been by Giberson et al. {Giberson1982} using linearly polarized light resonant with the PS transition and propagating along the quantization axis.  For optical pumping into the spin-stretched sub-levels (), we report a somewhat lower maximum efficiency than previous groups which we attribute to the aforementioned imperfect laser polarization in our experiments. In addition, we see a deviation of  for optical pumping with  and -polarized light especially while exciting via the PS transition. This might be induced by a systematic asymmetry in our setup resulting from e.g. small magnetic-field inhomogeneities as discussed above. {table}[ht!]  {{tab:optPumpEfficiencies} Summary of maximum efficiencies  obtained for the laser optical pumping of He(S) into selected  sub-levels in our experiment, and comparison with literature values. The given uncertainties (two standard deviations) of our experimental results are statistical only.}  {threeparttable}   {tabular}{@{}lcccccc@{}}     oprule[0.7pt]    && {5}{c}{ (in )}    [0.7pt]{3-7}    &&  &&  &&      [0.7pt]    PS transition &&  &&  &&     This work &&  && -- &&      Granitza et al. (1995) {Granitza1995} &&  && -- &&      Lynn et al. (1990) {Lynn1990} &&  && -- &&      Giberson et al. (1982) {Giberson1982} &&  && -- &&      [0.7pt]    PS transition &&  &&  &&     This work &&  &&  &&      Granitza et al. (1995) {Granitza1995} &&  note{a} && -- &&  note{a}     Wallace et al. (1995) {Wallace1995} &&  && -- &&      [0.7pt]    PS transition &&  &&  &&     Kato et al. (2012) {Kato2012} &&  && -- &&      Schearer  Tin  (1990) {Schearer1990a} && -- && -- &&      Giberson et al. (1982) {Giberson1982} && -- &&  && --     [0.7pt]   {tabular}   {tablenotes}    [a] No specific values given.   {tablenotes}  {threeparttable} {table}  {{sec:magDefl} Magnetic hexapole focusing}  oindent The red circles in Fig. ef{fig:Halbachres} show the results of a series of measurements which were obtained using the setup for the magnetic hexapole focusing of He(S, ) (cf. Figs. ef{fig:Setup} (c) and (d)). In order to interpret these results, we did numerical three-dimensional particle trajectory simulations in MATLAB. For these simulations, we use random number distributions for the particle positions and velocities (deduced from the experimental data obtained at the Faraday-cup detector) and a velocity-Verlet algorithm. An intial number of  particles in each Zeeman sub-level of He(S) and He(S) are propagated at a time. The magnetic field by the two Halbach arrays is implemented using the analytical expressions given in Ref.{Dulitz2016}. Particles are removed from the simulation if their transverse position inside a Halbach array exceeds the 3.0 mm inner radius of the assembly (cf. Fig. ef{fig:Setup} (c)).  In each  detection plane, the output of the trajectory simulation (black lines in Fig. ef{fig:Halbachres}) is analyzed over a certain interval of  positions corresponding to the diameter of the wire detector. The experimental results are matched to the simulated data by comparing the ratio of areas beneath two Gaussian distributions fitted to the datasets (not shown). Very good agreement between the experimental and simulated datasets is achieved by using an effective remanence of  and an effective wire diameter of  in the simulations. The decreased remanence compared to  could be due to the demagnetization of the material as a result of the prolonged storage time of the magnets. Likewise, deviations from the ideal Halbach configuration may also be possible as a result of manufacturing defects.   The analysis of the simulated results suggests that the strong increase of the He signal intensity around  is due to the transverse focusing of the  sub-level of the S level. The strongest signal increase, corresponding to the focal point of the device, is at a distance of mm from the center of the two Halbach arrays. The remaining signal intensity is mainly due to a mixture of He atoms in the S,  and S,  sub-levels. This is also consistent with previous observations {Watanabe2006}. At time , we assume a He(S)/He(S) ratio of  which is in line with the results of previous measurements in our laboratory {Guan2019}. At the focal point, the signal contribution by He atoms in the S,  sub-level is decreased by more than a factor of 7 compared to the signal intensity by atoms in the S,  sub-level. This is a result of the strong transverse magnetic defocusing forces which are exerted onto the atoms in the  sub-level.  The output of the simulation also provides an estimate of the sub-level selection efficiency for He(S, ), . Under the conditions of our experiment,  is nearly constant over a region of mm around the focal point. However, the efficiency strongly depends on the He beam diameter considered for the analysis. If we assume that the supersonic beam is collimated to the diameter of the wire detector (i.e., mm) just in front of this device, we obtain a maximum efficiency  at the focal point. If we assume the same He beam diameter as in the optical pumping experiments described above (i.e., mm), the maximum efficiency  at the focal point is reduced to . To further improve the sub-level selectivity, we suggest the use of a bent magnetic guide {Beardmore2009, Mazur2014, Osterwalder2015, Dulitz2016, Toscano2018} or by the use of a central stop behind the Halbach arrays  {Chaustowski2007,Kurahashi2008,Kurahashi2021,Baum1988}.  {figure}[hbt!]    [width=8cm]{fig8.pdf}  {{fig:Halbachres} Red circles: Measured He signal intensities on the wire detector at different positions  along the supersonic beam axis and at different transverse positions  after magnetic hexapole focusing. The -axis scale is given relative to the center of the two Halbach arrays. Black lines: He signal intensities obtained from a numerical particle trajectory simulation.  } {figure}  {Conclusion}  oindent We conclude that both laser optical pumping and magnetic hexapole focusing are very efficient methods for the selective preparation of magnetic sub-levels of He(2S) in a supersonic beam. We find that optical pumping into the spin-stretched sub-levels of He(2S) via the PS transition is more efficient than excitation via the PS transition. The best performance is achieved for  excitation via the PS transition yielding a maximum efficiency of  () for optical pumping into  ().  Magnetic hexapole focusing is observed to be highly sub-level selective at low forward velocities of the supersonic beam. At m/s and at the focal point of the hexapole lens system, we infer that up to  of the metastable atoms are in the  sub-level, if an mm-diameter region around the center of the supersonic beam axis is considered. The magnetic-hexapole-sub-level-selection technique is attractive, because it allows for the quantum-state manipulation of all atomic and molecular species with non-zero spin. Compared to optical pumping, the mechanical setup for magnetic focusing is rather simple, especially when commercial magnets are used {Osterwalder2015}.  However, optical pumping has several advantages compared to magnetic hexapole focusing. While magnetic focusing is limited to the preparation of sub-level-selected samples in low-field-seeking sub-levels only, optical pumping allows for the selective population of all  sub-levels, as shown here for the PS transition in He. For optical excitation with -polarized light, we obtain an efficiency of  for population transfer into . The creation of a pure  sub-level might be possible by using magnetic focusing as well but would require a strong overfocusing of the low-field seeking quantum states. In our experiments, this may be realized by further reducing the forward velocity of the He* atoms or by using a longer hexapole magnet array. However, we observe that the number of metastable helium atoms decreases by a factor of  when the valve temperature is decreased from K to K. At the same time, the peak He flux within the gas pulse decreases by a factor of , as the longer flight time to the detection region leads to a larger longitudinal spreading of the beam. Optical pumping can be applied independently of the velocity of the atoms as long as the discussed requirements for reaching the equilibrium sub-level efficiency are fulfilled. Thus, this technique results in a greater flexibility in choosing the valve temperature and, as mentioned above, running the valve at higher temperatures leads to much higher peak fluxes of -sub-level-selected atoms. These high peak fluxes are particularly important for applications which benefit from high local densities, such as collision experiments. Besides that, optical pumping relies on a transfer of population from a statistical mixture of  sub-levels into a single sub-level, whereas magnetic hexapole focusing relies on the spatial focusing (defocusing) of the desired (unwanted) -sub-level population. Further transmission losses are due to an aperture which has to be inserted into the beam path behind the magnet assembly in order to eliminate contributions by the S,  and S,  sub-levels, whose motion is not influenced by a magnetic field.  In the future, we will use the presented sources of -sub-level-selected He(2S) for quantum-state-controlled Penning-ionization studies {Grzesiak2019}. Furthermore, magnetic-sub-level-selected beams of He(2S) are useful as a starting point for the generation of coherent superposition states. The coherent control of Penning and associative ionization cross sections with such superposition states, for instance, involving the  sub-level of He(2S), has been predicted {Omiste2018}. In addition to that, helium is of particular interest for high-precision tests of few-electron quantum electrodynamics theory, as it is the simplest two-electron atom {Morton2006,Pachucki2017}. Accurate transition frequency measurements have been performed on ultracold trapped samples {vanRooij2011,Notermans2014,Rengelink2018} as well as on atomic beams {Pastor2004,Pastor2012,Zheng2017} of He(2S) atoms. The measurement of transitions with zero first-order Zeeman shift (i.e., S transitions) would greatly reduce the experimental uncertainty.  {acknowledgments}  oindent We thank J. Toscano (JILA) and B. Heazlewood (University of Oxford) for the loan of the magnetic hexapole arrays and for fruitful discussions. This work is supported financially by the German Research Foundation (Project No. DU1804/1-1), by the Fonds der Chemischen Industrie (Liebig Fellowship to K. Dulitz) and by the University of Freiburg (Research Innovation Fund). {acknowledgments}",4,2021-06-25T02:19:02,en,2106.13016,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,65,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,1952,0,0,1952,0,1952,0,0,0,0,0,0,1952,1952,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,1952,0,0,0,0,0,1952,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,1952,1952,1952,1952,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,0,0,0,0,1952,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,1952,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,1952,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,1952,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,1952,0,0,1952,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,1952,0,1952,1952,0,0,1952,1952,1952,1952,0,0,1952,0,0,1952,0,0,0,0,0,0,1952,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,1952,0,0,0,0,1952,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,1952,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,0,1952,0,0,0,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,1952,1952,1952,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,1952,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,1952,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,1952,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"{Introduction}   Online social media forums play a critical role in health-related information sharing~{record2018sought}.  Health experts have noted that they can help reduce healthcare inequalities and improve access to health care, for instance by empowering coalitions of people living with chronic illness or specific disabilities~{griffiths2012social}, or by providing an anonymous forum for people seeking emotional support~{de2014mental}. On the other hand, these forums elevate concerns about spreading medically inaccurate, misleading, or unsound information {dominguez2015pediatric,gage2018cancer}, which has had harmful public health impacts {poland2011age,nobles2019requests}. One study concluded that health information seekers in forums such as Reddit are likely to enact suggested behaviors regardless of perceived credibility {record2018sought}. However, the researchers also noted that this openness to information could be an opportunity for experts to encourage healthy behaviors through information sharing.  In this landscape, it is critical to understand the dynamics that cultivate safe communities that benefit the health and well-being of their participants and the broader implications for health communication {chou2009social}. Health experts are thus considering social media's role in their interactions with patients and broader public health issues, and their role in engaging with the platforms~{dominguez2015pediatric,nobles2019requests,nobles2020examining}. This motivates an important research direction: understanding how experts engage with users in online platforms. This can inform platform design, moderation decisions, and health promotion efforts by experts.  This work focuses on understanding the engagement with professionals in the domain of mental health with two main research questions: (RQ1) Do experts have distinct influences as compared to non-experts in their interactions with support-seekers in online mental health?; and (RQ2) Do the experts' behaviors reflect established counseling principles and findings regarding behaviors associated with positive counseling outcomes? To answer these questions, we analyze responses from self-identified mental health professionals (MHP) to support-seekers in mental health and support communities on Reddit, and compare them to responses from other users who we refer to as  extit{peers}. This is an important comparison, as many peers share similar health experiences, which prior work has found is associated with higher empathic concern~{hodges2010giving}.   First, we test whether a text classifier can distinguish between responses to support seekers from MHPs and peers. We find that it can, with 70 accuracy (well above random chance of 50). Second, we analyze comments leading to further engagement with the support-seeking posters, as existing counseling principles emphasize the importance of eliciting client engagement in expert counseling sessions~{miller2012motivational,perez2018analyzing}. Third, we analyze the users' linguistic tendencies, drawing inspiration from analyses of counseling conversations, which have offered insight into counselor behaviors associated with high quality sessions grounded in existing theories from psychology and counseling research using computational methods~{althoff2016large,perez2018analyzing,zhang2019finding,miller2012motivational}.  The main contributions of this work are: (1) We construct a dataset of mental health conversations from Reddit users with self-identified counseling expertise, covering a set of mental health subreddits annotated with categories denoting the type of mental health concern; (2) We develop a classifier that can distinguish between the language of MHPs and that of peers; (3) We perform an analysis of the differences in language use between MHPs and peers; and (4) We provide insight into language that leads to further engagement with support-seekers, comparing responses to peers and MHPs.    {Related Work}    {table*}[t]   {.24}{                           {tabular}{lr}              oprule             Subreddits & 77              Posts & 12,140              Poster Replies & 24,357              MHPs & 283              Peers & 56,701                           {2}{c}{Comments}                           MHP & 9,685              Peer & 92,698              Total & 102,383                           {2}{c}{Thread Length}                           Mean & 8.4              Median & 4              Max & 64                       {tabular}         {Dataset statistics.}         {tab:data_stats}     }          {.72}{                           {tabular}{ll}               oprule               extbf{Post:} & u/peeruserX                             {2}{p{0.9}}{I've recently been struggling with paranoid thoughts, for which I was hospitalized for my own safety. I do not feel suicidal anymore, however everyday is a long struggle of thinking everyone is an undercover agent out to get me or keep tabs on what I'm doing. I was hoping to hear some tips and stories if anyone else has dealt with similar thoughts and overcome them? Or are they something I will have to deal with for the rest of my life? Thanks in advance}                                 extbf{Comment:} & u/MHPuser              {tikzpicture}                  ikz[baseline={([yshift=-0.4em]current bounding box.north)}] [rounded corners=5pt,xshift=1.0em] (-0.4,-0.2) rectangle (0.4,0.2) node[pos=.5] {LPC};             {tikzpicture}                                          {2}{p{0.9}}{Paranoid thoughts are scared thoughts, justified or not. If you ignore the specific content of the thoughts and focus on the emotional valence (scared), is there something you can do in those moments to feel safer?}                             extbf{Poster Reply:} & u/peeruserX                             {2}{p{0.9}}{That's a good way of thinking about the situations as they arise. I will try to do that}                        {tabular}         {Example of an initial post, a reply from an MHP with the flair  extit{LPC} (Licensed Professional Counselor), and a reply from the original user.}         {tab:data_sample4}     } {table*}   Studies within the education and health domains have shown that advice and help-seeking interactions in online communities contribute positively to users' well-being, learning, and skills development~{Campbell16,wang2015eliciting}. This is particularly true for applications such as computer programming, career development, mentoring, coping with chronic or life-threatening diseases, and mental health issues~{baltadzhieva-chrupala-2015,Tomprou19,wang2015eliciting,de2014mental}.  In the mental health domain, studies have explored online support communities and many have found positive outcomes associated with anonymity, perceived empathy, and active user engagement~{de2014mental, rheingold1993virtual, hodges2010giving, welbourne2009supportive, nambisan2011information}. Computational approaches have aided studies in mental health forums, helping reveal positive relationships between linguistic accommodation and social support across subreddits~{sharma2018support}. One example of insights from this work is that topic-focused communities like subreddits may enable more peer-engagement than non-community based platforms~{sharma2020engagement}. Other studies have revealed certain trade-offs of online support platforms, such as disparities in the level of support offered toward support-seekers of various demographics~{wang2018s,nobles2020examining} and in condolences extended across different topics of distress~{zhou2020condolences}. Studying MHP behaviors in such scenarios might help develop approaches that balance these trade-offs.   Computational approaches applied in these forums have also shed light on population-level health trends and health information needs, with examinations into how depression and post-traumatic stress disorder (PTSD) affect different demographic strata~{amir2019mental}. Data mining has also been applied to understand adverse drug reactions~{wang2014sideeffectptm} and public reactions towards infectious diseases~{park2017tracking}. {nobles2018std} highlighted the potential for these forums to aid targeted health communication, for example by sharing information in r/STD, a subreddit about sexually transmitted diseases. Another case study of r/STD revealed the prevalence of diagnoses requests, and suggested that health professionals could partner with social media platforms to positively influence crowd-sourced diagnoses and help mitigate harmful misdiagnoses~{nobles2019requests}. {record2018sought} found that health information seeking Reddit users are likely to enact suggested behaviors regardless of perceived credibility, providing further reason for health expert engagement to intervene when harmful information sharing occurs and promote healthy behavior.    Fewer studies have analyzed expert interactions in online forums. A study in a large QA community found that experts are more likely to provide help than peers and that their participation in discussions resulted in increased length and substance of discussions~{Procaci17}. Recent studies have compared interactions with experts to interactions with peers in broader scientific communities~{park2020trust} and r/AskDocs on Reddit~{nobles2020examining}. The latter paper closely relates to our study, as they also consider posts from experts on Reddit, but solely within r/AskDocs about different health topics and with users of varying demographics.   The insights discussed above motivate investigations into how health experts and other users promote scientifically sound advice and offer supportive responses to health information seekers in online forums. In this work, we aim to contribute additional insights into expertise influence in online mental health communities by studying the dynamics of the communication process between support seekers and support providers.    {Data Collection}{sec:dataset}  We seek to understand the tendencies of users with professional experience, and more specifically counseling expertise, when interacting with support-seekers in online mental health and support-related forums. In uncovering which tendencies are associated with expertise, we enable further investigation into their role in the social dynamics of online support-seeking interactions, and potential applications of insight-driven recommendations for moderators and users of these forums.    {figure*}      {tikzpicture} {axis}[     width=,     height=3.5cm,     grid=both,     bar width=.25cm,     legend style={font=},     legend pos=north west,     symbolic x coords={health, tentat, work, anx, you, differ, discrep, they, foc.future, interrog, cogproc, quant, insight, risk, relig, assent, sad, motion, number, nonflu, we, ppron, time, leisure, ingest, family, body, home, anger, friend, filler, shehe, informal, foc.past, female, sexual, male, I, netspeak, swear},      xtick=data,     enlarge x limits=0.01,     x tick label style={rotate=60, anchor=east, font=},     ytick={0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2},     y tick label style={anchor=east, font=}]     [ybar,fill=lightgray,ybar legend] coordinates  {      (health, 0.7959860332257565)      (tentat, 0.8055825728949596)      (work, 0.8110132828134121)      (anx, 0.8111684471647727)      (you, 0.8210292413944864)      (differ, 0.8553742434797355)      (discrep, 0.8692382037337468)      (they, 0.8751238940358339)      (foc.future, 0.8915196663317453)      (interrog, 0.8989293471898235)      (cogproc, 0.9000317012729139)      (quant, 0.9003896144608834)      (insight, 0.9057980632031888)      (risk, 0.9078690597633751)      (relig, 1.1016018716659848)      (assent, 1.1058051745294315)      (sad, 1.111442609622524)      (motion, 1.1147313092899014)      (number, 1.123251240900814)      (nonflu, 1.1346822371433698)      (we, 1.1514960646135939)      (ppron, 1.1743292153901252)      (time, 1.1760614995095569)      (leisure, 1.1907022197071266)      (ingest, 1.268569982423503)      (family, 1.3287365916478084)      (body, 1.332310541479952)      (home, 1.3387387079172697)      (anger, 1.352991457094508)      (friend, 1.4228051728743212)      (filler, 1.4910379699677137)      (shehe, 1.506362829049222)      (informal, 1.5087378339468138)      (foc.past, 1.519990107618276)      (female, 1.553857654748661)      (sexual, 1.575562715003554)      (male, 1.6370479733076038)      (I, 1.7324946157824643)      (netspeak, 1.8811274256235888)      (swear, 2.1973744687818817)     }; {Peers}     [ybar,fill=white,ybar legend] coordinates  {      (health, 0.7959860332257565)      (tentat, 0.8055825728949596)      (work, 0.8110132828134121)      (anx, 0.8111684471647727)      (you, 0.8210292413944864)      (differ, 0.8553742434797355)      (discrep, 0.8692382037337468)      (they, 0.8751238940358339)      (foc.future, 0.8915196663317453)      (interrog, 0.8989293471898235)      (cogproc, 0.9000317012729139)      (quant, 0.9003896144608834)      (insight, 0.9057980632031888)      (risk, 0.9078690597633751)     }; {MHPs}     [draw=blue,ultra thick,smooth]      coordinates {(health, 1)(tentat, 1)(work, 1)(anx, 1)(you, 1)(differ, 1)(discrep, 1)(they, 1)(foc.future, 1)(interrog, 1)(cogproc, 1)(quant, 1)(insight, 1)(risk, 1)(relig, 1)(assent, 1)(sad, 1)(motion, 1)(number, 1)(nonflu, 1)(we, 1)(ppron, 1)(time, 1)(leisure, 1)(ingest, 1)(family, 1)(body, 1)(home, 1)(anger, 1)(friend, 1)(filler, 1)(shehe, 1)(informal, 1)(foc.past, 1)(female, 1)(sexual, 1)(male, 1)(I, 1)(netspeak, 1)(swear, 1)};     {axis}      ode[align=center,rotate=90,font=] at (-1.15cm, 0.9cm) {Dominance};      ode[align=center,rotate=90,font=] at (-0.8cm, 0.9cm) {(peer/MHP)};     {tikzpicture}     {LIWC category dominance scores, computed as the relative use by peers divided by the relative use by MHPs, so that equal use is at  (blue line), higher dominance by peers at  (grey bars) and higher dominance by MHPs at  (white bars). Showing categories where frequency of use differs by at least 10.}     {fig:liwc}  {figure*}   {Source.} We use Reddit for its quantity of publicly available interactions in communities called  extit{subreddits} that discuss mental health issues. In addition, Reddit has a system that allows users to indicate their professional expertise (Reddit Flairs), which we use to identify a set of users with mental health professional background, identified as  extit{MHPs} during our study. We obtained flairs from the r/psychotherapy subreddit,{{https://old.reddit.com/r/psychotherapy/wiki/acronymswiki_degrees_and_licenses}{Degree and license flair descriptions from r/psychotherapy wiki.}} a decision motivated by their reliability, as the moderators of this community allow comments and posts only by licensed therapy providers who may be asked to submit proof if concerns of falsely posing as a therapist arise.{See rule 2 and 9 in {https://www.reddit.com/r/psychotherapy/}, also listed in Appendix~ ef{sec:appendix_flairs}.} Sample flair tags in this set are: Psychiatrist (sometimes accompanied by MD or DO), LPC (or Licensed Professional Counselor), LMFT (or Licensed Marriage and Family Therapist), PsyD (or Doctorate of Psychology).  We use an existing list of mental health subreddits from r/ListOfSubreddits{{https://www.reddit.com/r/ListOfSubreddits/comments/dmic6o/advice_mental_health_subreddits/}{r/ListOfSubreddit's compilation of mental health and advice subreddits.}} with additions from manual observations; all of the subreddits in our dataset with their number of comments are in Appendix~ ef{sec:appendix_datacollection} in Table~ ef{tab:appendix_subbreddits_and_comments}. From these, we retrieve threads where an MHP submitted a direct reply. During this step, we also kept posts made by peers i.e., individuals who did not use any of the mental health care professional flairs. Our collection spans threads created between November 29, 2009 and December 21, 2020. Table~ ef{tab:data_stats} shows descriptive statistics for the final composition of the dataset, and  Table~ ef{tab:data_sample4} shows a sample interaction demonstrating the structure we use for our analysis. This study focuses on direct replies to the poster, thus we attempt to eliminate  extit{megathreads} which tend not to focus in individual support-seekers by removing those above the 95th percentile in their number of direct replies; we leave analysis of deeper nested replies for future work.     {table}[t]               {tabular}{ll}   oprule Key & Topic   Trauma & Trauma  Abuse  Anx & Psychosis  Anxiety  Compuls. & Compulsive Disorders  Cope & Coping  Therapy  Mood & Mood Disorders  Addict. & Addiction  Impulse Control  Body & Eating  Body   Neurodiv. & Neurodevelopmental Disorders   Health & General  Social & Broad Social       {tabular}     {Health condition and other subreddit topics. Keys are shortened names we use to refer to the topics.}     {tab:subreddit_health_categories} {table}  {Health Topics.} To understand whether particular topics influence interactions with support-seekers, we group the subreddits into broader topics based on related health domains. We begin by following the categorization of subreddits by {sharma2018support}, who used the -means clustering algorithm to generate initial clusters on the -grams  of the posts and manually refined the categories based the community descriptions in their subreddit home pages. Next, we adjust the categories and their associated subreddits based on the World Health Organization's ICD-10 classification system of mental and behavioural disorders.{{https://www.who.int/substance_abuse/terminology/icd_10/en/}} The resulting topic categories are listed in Table~ ef{tab:subreddit_health_categories} alongside shortened names which we use to refer to them. The full list of subreddits assigned to each topic are listed in Appendix~ ef{sec:appendix_datacollection} in Table~ ef{tab:appendix_subreddit_categories}.    {Distinguishing MHPs and Peers}{sec:classification}  To begin our investigation into the linguistic behaviors of MHPs and peers, we test whether simple text classifiers are able to distinguish between comments authored by either MHPs or peers. We build three classifiers with different feature sets; the first are unigram counts for unigrams occurring at least five times, the second includes counts for the 73 word classes in the LIWC (Linguistic Inquire and Word Count) lexicon~{pennebakerlinguistic}, and the third encodes a subset of LIWC word classes associated with perspective shifts (i.e.,  extit{focusfuture, focuspast, focuspresent, I, ipron, negemo, posemo, ppron, pronoun, shehe, they, we,} and  extit{you})~{althoff2016large}; we elaborate on the psychological meaning behind these features in our analyses in the next section.   Due to the class imbalance between the peer and MHPs classes, we first downsampled the peer class to get a balanced distribution with the MHP class. This resulted in a set of 9,685 instances per class. We conduct our evaluations using ten-fold cross validation. Across these folds, the number of features ranges from 8,668 to 8,703. We use a Naive Bayes model, implemented with Sklearnâ€™s MultinomialNB module,~{{https://scikit-learn.org/stable/modules/generated/sklearn.naive_bayes.MultinomialNB.html}} which outperformed a logistic regression model and an SVM in preliminary experiments.{Runs in 40 seconds per fold on one AMD Ryzen 7 3700U CPU.}    All models outperform a random baseline{ using a permutation test~{dror-etal-2018-hitchhikers2}} with all LIWC features bringing the accuracy to 59.12, LIWC perspective features to 59.14, and unigram features to 70.80. Overall, the classification results indicate language differences exist between the MHPs and peers. Motivated by this result, we proceed to several analyses to gain insights.  {Linguistic and Dialogue Analysis}{sec:ling_and_dialog}  We analyze the linguistic behaviors of MHPs and peers responding to support-seeking posts, and their potential influence in eliciting further engagement with the support-seeker. Our analyses are inspired by psychology and computational studies that have shown that conversational behavioral aspects such as word usage, client engagement, and language matching are positively related to successful counseling interactions~{gonzales2010language,althoff2016large,perez2018analyzing,zhang2019finding}.     {figure}[t]      {tikzpicture} {axis}[     width=8.25cm,     height=3cm,     grid=both,     symbolic x coords={Disgust, Surprise, Anger, Fear, Sadness, Joy},     xtick=data,     x tick label style={rotate=0, font=},      ytick={0.9, 1.1, 1.3, 1.5, 1.7},     y tick label style={anchor=east, font=}]     [ybar,fill=lightgray] coordinates  {      (Disgust, 1.71028997750357)      (Surprise, 1.3983259978898)      (Anger, 1.14086998542706)      (Fear, 1.06922731579117)      (Sadness, 1.06749537047073)      (Joy, 1.00660420378226)     };  {axis}  ode[align=center,rotate=90,font=] at (-0.8cm, 0.7cm) {Dominance}; {tikzpicture}     {WordNet Affect usage (peers / MHPs)}     {fig:wordnet_affect} {figure}  {Linguistic Ethnography}{sec:linguistic_ethno}   Numerous studies have demonstrated relationships between the dominant usage of certain word categories with  individuals' psychological and physical health~{tausczik2010psychological,weintraub1981verbal,rude2004language}.  In alignment with these studies, we investigate the usage of such word categories using the LIWC and WordNet-Affect lexicons~{pennebakerlinguistic,wordnet-affect}.  For each group of users, we first compute the proportion of their words that fall in each category. Then, we compute the dominant use by dividing the proportion for peer users over the proportion for MHPs~{mihalcea2009linguistic}. Figure~ ef{fig:liwc} shows  LIWC categories where the rate of use differs by at least 10, and results for WordNet Affect categories are shown in Figure~ ef{fig:wordnet_affect}.  Some observations such as the higher dominance of swear words ( extit{swear}) and internet speak ( extit{netspeak}) might be expected if professionals avoid such language. An interesting contrast in peers' language is the dominant use of first-person pronouns ( extit{I, we}) and focus on the past ( extit{focuspast}). In contrast, MHPs seem to use more non-first person pronouns ( extit{you, they}) and focus on the future ( extit{focusfuture}) instead.  Peers' use of first person pronouns might arise when they share similar experiences with support-seekers. MHPs' use of second-person pronouns might suggest they are focusing on the support-seekers' experiences as a counselor would with a client in a counseling encounter. We also observe higher dominance of all WordNet Affect categories among peers, however the  extit{joy} category (the most positive), is nearly equal with MHPs.   These observations of the peers' language are compelling because they align with existing theories linking depression to negative views of the future (i.e.,  extit{focuspast} and negative WordNet affects)~{pyszczynski1987depression} and self-focusing style (i.e., first-person pronouns)~{pyszczynski1987self,campbell2003secret}. Likewise, clients of SMS-based crisis counseling conversations were more likely to report feeling better after the encounter if they exhibited perspective shifts from these categories to their counterparts (i.e., toward  extit{focusfuture}, non-first person pronouns, and positive sentiment)~{althoff2016large}.  Interestingly, the same study found clients were more likely to shift perspective when their counselors exhibited use of the counterpart categories first, suggesting that the counselors may play a key role in helping drive the perspective shift. Given those positive outcomes, observing the same dominant linguistic aspects among MHPs is encouraging and potentially signals a connection between how counselors apply conversational behaviors in practice and in online forum interactions. Future work can investigate the progression of dialogue between MHPs and support-seekers to find if support-seekers similarly exhibit the perspective shifts associated with the positive outcomes of the prior study, and likewise whether users of the forums also experience positive outcomes where this occurs.   {figure*}[t]    {.53}{                           {tikzpicture} {axis}[     width=1.1,     height=3.7cm,     grid=both,     symbolic x coords={filler, health, body, bio, cause, tentat, you, affect, time, nonflu, certain, netspeak, hear, affiliation, foc.past, female, number, shehe, friend, leisure, male, ingest, anger, feel, sexual, informal, i, swear, assent, relig},     xtick=data,     enlarge x limits=0.01,     bar width=.15cm,     x tick label style={rotate=60, anchor=east, font=},     ytick={0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3},     y tick label style={anchor=east, font=}]     [ybar,fill=white] coordinates  {         (filler, 1.3694959488399698)         (health, 1.2199518622464156)         (body, 1.1963945578342048)         (bio, 1.1361700435532724)         (cause, 1.0795619328576351)         (tentat, 1.0684715763913766)         (you, 1.0647948805231773)         (affect, 0.952284583106825)         (time, 0.9517636175949772)         (nonflu, 0.9511736159516474)         (certain, 0.9483112140262707)         (netspeak, 0.9463188721091061)         (hear, 0.9389897621251143)         (affiliation, 0.9356603838607868)         (foc.past, 0.932086788032833)         (female, 0.9316496264858395)         (number, 0.9205180739190895)         (shehe, 0.9183051123944717)         (friend, 0.8982679230950917)         (leisure, 0.8969320017601914)         (male, 0.890290971657498)         (ingest, 0.8876147841875732)         (anger, 0.8792607168321827)         (feel, 0.8702617564065401)         (sexual, 0.8668272078839886)         (informal, 0.8624389844393203)         (i, 0.8066956501832807)         (swear, 0.7870234652664857)         (assent, 0.7822245598953113)         (relig, 0.6755071110674885)     };     [draw=blue,ultra thick,smooth]     coordinates {(filler, 1.0)(health, 1.0)(body, 1.0)(bio, 1.0)(cause, 1.0)(tentat, 1.0)(you, 1.0)(affect, 1.0)(time, 1.0)(nonflu, 1.0)(certain, 1.0)(netspeak, 1.0)(hear, 1.0)(affiliation, 1.0)(foc.past, 1.0)(female, 1.0)(number, 1.0)(shehe, 1.0)(friend, 1.0)(leisure, 1.0)(male, 1.0)(ingest, 1.0)(anger, 1.0)(feel, 1.0)(sexual, 1.0)(informal, 1.0)(i, 1.0)(swear, 1.0)(assent, 1.0)(relig, 1.0)}; {axis}  ode[align=center,rotate=90,font=] at (-1.0cm, 1.0cm) {Dominance Score}; {tikzpicture}              }     1em     {.39}{                           {tikzpicture} {axis}[     width=1.2,     height=3.7cm,     grid=both,     symbolic x coords={you, foc.future, interrog, shehe, filler, male, health, nonflu, affiliation, motion, anger, home, number, informal, certain, leisure, assent, netspeak, swear, relig, i, friend, we, death},     xtick=data,     enlarge x limits=0.01,     bar width=.15cm,     x tick label style={rotate=60, anchor=east, font=},     ytick={0.7, 0.8, 0.9, 1.0, 1.1},     y tick label style={anchor=east, font=}]     [ybar,fill=lightgray] coordinates  {         (you, 1.1056504063587804)         (foc.future, 1.0832136349699277)         (interrog, 1.0690181983665104)         (shehe, 1.0677545462122848)         (filler, 1.0562119255014193)         (male, 1.052349793324354)         (health, 1.0510277322615278)         (nonflu, 0.9500031679667199)         (affiliation, 0.9457110526134682)         (motion, 0.9432732829160265)         (anger, 0.9416776171900192)         (home, 0.9377753113453201)         (number, 0.9338331405276905)         (informal, 0.9324061632862549)         (certain, 0.9316400785214803)         (leisure, 0.927558556791122)         (assent, 0.9206957666641701)         (netspeak, 0.9202391071079117)         (swear, 0.9141919663144525)         (relig, 0.9118338999145017)         (i, 0.9117467370956133)         (friend, 0.8866945520809406)         (we, 0.8279335154078911)         (death, 0.8171034372572407)     };     [draw=blue,ultra thick,smooth]     coordinates {(you, 1.0)(foc.future, 1.0)(interrog, 1.0)(shehe, 1.0)(filler, 1.0)(male, 1.0)(health, 1.0)(nonflu, 1.0)(affiliation, 1.0)(motion, 1.0)(anger, 1.0)(home, 1.0)(number, 1.0)(informal, 1.0)(certain, 1.0)(leisure, 1.0)(assent, 1.0)(netspeak, 1.0)(swear, 1.0)(relig, 1.0)(i, 1.0)(friend, 1.0)(we, 1.0)(death, 1.0)}; {axis} {tikzpicture}     }     {Dominance of LIWC categories, computed as the category relative frequencies among comments that  extbf{prompt support-seeker responses} divided by the relative frequencies among comments that do not, computed separately for MHPs (left) and peers (right).}     {fig:engagement_dominance} {figure*} {Engaging Support-Seekers}{sec:engagement}  To understand if linguistic behaviors are associated with prompting further engagement with the support-seeker, we compare the dominance of LIWC categories in comments receiving replies compared to comments that do not by dividing the usage rates of the former by the latter. Figure~ ef{fig:engagement_dominance} shows these ratios for categories that differ by at least 5. A compelling observation is the dominance of the categories  extit{health},  extit{tentat}, and  extit{you} in the MHP comments prompting poster-replies, and  extit{you},  extit{focusfuture},  extit{interrog}, and  extit{health} in the peer comments prompting poster-replies, as was exhibited among MHPs (see Figure~ ef{fig:liwc} in Section~ ef{sec:linguistic_ethno}); on the other end, the categories are more dominant in comments that do not engage a reply such as  extit{I},  extit{we},  extit{death},  extit{friend},  extit{relig},  extit{swear}, were similarly represented as dominant categories in the peer group.  To gain further insight into these observations, we perform the following analysis: for each user group (peers and MHPs) we use a foreground corpus of their comments that were replied to by the support-seekers, and a background corpus of their comments that were not, and compute the dominance of LIWC categories of the foreground over the background as a ratio of their relative frequencies.  We then rank the categories by highest to lowest dominance scores, and refer to this ranking by  exttt{DRR} (for  extbf{D}ominance  extbf{R}ank for  extbf{R}eplied comments). We compare the  exttt{DRR}s of each user group to the ranking of LIWC category usage among MHP users and among peer users separately (from Section~ ef{sec:linguistic_ethno}) by computing the Kendall Tau's coefficient between them. A positive correlation would thus indicate that the more (or less) dominant categories among a group's replied comments are also more (or less) dominant among the other group overall. The correlation coefficients are shown in Table~ ef{tab:ranked_comparison}.  {table}               {tabular}{llrr}          oprule          exttt{DRR} Group & OR Group &   & p-value                   Peer & MHP & .191 & .017          MHP & MHP & .158 & .048          Peer & Peer & -.031 & .689          MHP & Peer & .008 & .916               {tabular}     {Kendall 's coefficient between the LIWC category dominance ranking in the replied comments ( exttt{DRR}) of the user group on the left and the overall ranking of LIWC category usage ( exttt{OR}) by the user group to the right.     }     {tab:ranked_comparison} {table}  Interestingly, we observe a slight positive correlation between the  exttt{DRR}s for both MHPs and peers with the overall LIWC category usage ranking for MHPs. On the other hand, we see no correlations with the LIWC usage ranks for peers. Intuitively, it appears that for both MHPs and peers, the comments prompting further engagement with the poster appear to reflect the overall dominant linguistic aspects captured by LIWC of MHPs, but not peers. As counseling principles have emphasized the importance of mutual engagement between counselors and clients~{miller2012motivational} and other work has shown that higher quality counseling sessions are associated with higher client engagement~{perez2018analyzing}, it is compelling to observe associations between linguistic aspects of MHPs with the aspects associated with poster-engagement.    {Linguistic Style Matching}{sec:lsm}  Linguistic Style Matching (LSM) measures the extent to which one speaker matches another~{gonzales2010language}. It compares two parties' relative use of function words as these words are more indicative of style rather than content~{ireland2010language}.  Previous studies in counseling conversations have measured LSM to understand the extent that counselors and clients match their language. {perez2019makes} showed higher LSM for high quality counseling sessions whereas {althoff2016large} showed lower LSM for higher quality sessions. {perez2019makes} attributed this to the differences between the conversations they analyzed, theirs being synchronous face-to-face interactions while {althoff2016large}'s was of asynchronous text messages, as well as differences in counseling styles.  We follow {nobles2020examining}'s approach leveraging {ireland2010language}'s procedure to measure LSM between support seekers and support providers.  {figure*}            {tikzpicture}       {axis}[       width  = -2cm,       height = 3cm,       ybar=2*,       ylabel={LSM Score},       ylabel style={font=},       ymajorgrids = true,       symbolic x coords={Trauma,Anx,Compuls.,Cope,Mood,Addict.,Body,Neurodiv.,Health,Social,All},       x tick label style={rotate=0, font=},       xtick = data,       scaled y ticks = false,       ymin=0.4,       legend cell align=left,     legend style={at={(1.01,0.4)},anchor=west}       ]       [style={fill=white},error bars/.cd, y dir=both, y explicit]           coordinates { (Trauma,0.6310119156541756) += (0,0.029962442897110475) -= (0,0.03081514525447937) (Anx,0.5997199013986588) += (0,0.01519174511662591) -= (0,0.015544352706185927) (Compuls.,0.6281754095486042) += (0,0.0357519342555046) -= (0,0.03738872492676926) (Cope,0.6473266495067116) += (0,0.010066984978184701) -= (0,0.010552935538052588) (Mood,0.6437280427655686) += (0,0.009180262091117664) -= (0,0.009328442085683064) (Addict.,0.5709948285212645) += (0,0.015199256087097268) -= (0,0.015134390184438407) (Body,0.5887944659204036) += (0,0.04432956318398418) -= (0,0.04696878984370534) (Neurodiv.,0.6309063259324916) += (0,0.01391890784736749) -= (0,0.014303173962970095) (Health,0.6144863767231595) += (0,0.007425543475062746) -= (0,0.007746525814329885) (Social,0.5060244756989379) += (0,0.00862992954522357) -= (0,0.00859438033560228) (All,0.5887940258624854) += (0,0.004103442535799973) -= (0,0.0041157209528478456)           };       [style={fill=lightgray},error bars/.cd, y dir=both, y explicit,error bar style=black]            coordinates { (Trauma,0.6378865787475075) += (0,0.0119576476105826) -= (0,0.012096314353275406) (Anx,0.5922057266084959) += (0,0.004617719809004162) -= (0,0.004731922540469169) (Compuls.,0.5856424758280658) += (0,0.017818249302948175) -= (0,0.017936496148185377) (Cope,0.5887105654136473) += (0,0.0045978888128952455) -= (0,0.004486067568766683) (Mood,0.6105143832329811) += (0,0.004169661426287274) -= (0,0.004238386512265935) (Addict.,0.5408042001923349) += (0,0.0038984385211480177) -= (0,0.00395860140679527) (Body,0.6155639543382515) += (0,0.01529421389797847) -= (0,0.01587817947763348) (Neurodiv.,0.5992797132344616) += (0,0.0036899641469281264) -= (0,0.0036385952314014203) (Health,0.6089407444992813) += (0,0.0027053359645056174) -= (0,0.002665433221403779) (Social,0.6184805035707305) += (0,0.002843520445438563) -= (0,0.0028728095634809048) (All,0.5969832369722273) += (0,0.0013587580377160124) -= (0,0.0013578362432092872)           };       {MHPs, peers}   {axis}   {tikzpicture}  {LSM scores with 95 confidence intervals calculated with non-parametric bootstrap resampling.}  {fig:lsm} {figure*} For a text sequence, we compute the percentage of words that belong to each of nine function-word categories  from the LIWC lexicon, which include  extit{auxiliary verbs, articles, common adverbs, personal/impersonal pronouns, prepositions, negations, conjunctions,} and  extit{quantifiers}. Then, we compute the LSM of each word category  as shown in Equation  ef{eq:lsm} where  represents  extit{post} and  represents the response. The composite LSM score for  and  is the mean of all category LSM scores. For each thread, we separate the MHP and peer replies, and take the mean of all composite LSM scores.   {equation}{eq:lsm}     LSM_c = 1 - {abs(cat_p - cat_r)}{cat_p + cat_r + .0001} {equation}  We compute these LSM scores over all data together as well as separately for each subreddit topic (named in Table~ ef{tab:subreddit_health_categories}). The resulting scores are shown in Figure~ ef{fig:lsm}.   We observe LSM scores vary by topic, and most are similar for peers and MHPs or have overlapping confidence intervals. Compared to their LSMs in other topics, MHPs score lower in { Social}, which covers broad social issues that are less specialized to health conditions than the others. However, peers have high LSMs in { Social} relative to most other topics, and notably higher LSMs than the MHPs. Additionally, MHPs have higher LSMs than those of peers and relative to their own in communities that cover topics of specific compulsive, mood, and neurodevelopmental disorders ({ Compuls., Mood,} and { Neurodiv.}), communities that orient toward counseling purposes ({ Cope}), or toward advice-seeking communities for health and social concerns ({ Health}). The influences in these results require further investigation, but a possible explanation could be that expert knowledge and experience may offer more benefit to specialized condition-related issues than to broader social issues.     {Language Modeling}  We further examine differences in word usage by building separate language models for MHPs and peers. We seek to identify language use that is indicative of one group or another by running the language model of one on the data of the other and analyzing words with high perplexity. To run these experiments, we use the language model of {merity2018analysis,merity2018regularizing}, which is a recent LSTM-based language model that achieved state-of-the-art performance by combining several regularization techniques.{{htts://github.com/salesforce/awd-lstm-lm}}  Our implementation uses a fixed vocabulary of 20,907 tokens for both the peer and MHP language models. This is determined by a minimum count of five across the set of posts from both groups. Each language model is trained for 50 epochs.{Validation set perplexities for expert and score groups: peer on peer: 44, peer on MHP: 52, MHP on peer: 91, MHP on MHP: 74, low on high: 39, low on low: 43, high on high: 50, high on low: 57. The difference in perplexity is due to the difference in volume of posts between groups. Runs in 2 min per epoch on a GeForce RTX 2080 Ti GPU.}   {figure*}[t]               {tikzpicture}     {axis}[         yshift=0.0cm, xshift=0.0cm,         width=0.29,         height=3cm,         grid=both,         symbolic x coords={leisure,sexual,number,article,relig,money,we,negate,friend,netspeak},         xtick=data,         legend style={font=},         legend pos=south west,         enlarge x limits=0.1,         ymin=0.0, ymax=0.70,         bar width=.2cm,         x tick label style={rotate=60, anchor=east, font=},         y tick label style={anchor=east, font=}]         [ybar,fill=white,ybar legend] coordinates  {             (leisure, 0.70)(sexual, 0.67)(number, 0.61)(article, 0.60)(relig, 0.57)(money, 0.56)(we, 0.56)(negate, 0.55)(friend, 0.55)(netspeak, 0.54)         }; {MHP on Peer}     {axis}          {axis}[         yshift=0.0cm, xshift=3.35cm,         width=0.29,         height=3cm,         grid=both,         symbolic x coords={filler,swear,anger,article,ingest,body,home,leisure,sexual,money},         xtick=data,         enlarge x limits=0.1,         ymin=0.0, ymax=0.70,         legend style={font=},         bar width=.2cm,         x tick label style={rotate=60, anchor=east, font=},         yticklabels={,,}         ]         [ybar,fill=white,ybar legend] coordinates  {          (filler, 0.30)(swear, 0.26)(anger, 0.26)(article, 0.25)(ingest, 0.23)(body, 0.23)(home, 0.22)(leisure, 0.22)(sexual, 0.22)(money, 0.21)         }; {High on Low}     {axis}          {axis}[         yshift=0cm, xshift=7.35cm,         width=0.29,         height=3cm,         grid=both,         symbolic x coords={discrep,interrog,auxverb,cause,I,foc.future,foc.present,negate,verb,ipron},         xtick=data,         enlarge x limits=0.1,         ymin=-0.15, ymax=0.0,         legend style={font=},         bar width=.2cm,         x tick label style={rotate=60, anchor=east, font=},         yticklabel style={                 /pgf/number format/fixed,                 /pgf/number format/precision=5,                 font=         },         scaled y ticks=false         ]         [ybar,fill=lightgray,ybar legend] coordinates  {             (discrep, -0.08)(interrog, -0.11)(auxverb, -0.11)(cause, -0.12)(I, -0.12)(foc.future, -0.12)(foc.present, -0.12)(negate, -0.12)(verb, -0.13)(ipron, -0.14)         }; {Peer on MHP}     {axis}          {axis}[         yshift=0cm, xshift=10.7cm,         width=0.29,         height=3cm,         grid=both,         symbolic x coords={discrep,assent,foc.future,insight,differ,negate,friend,tentat,foc.present,cogproc},         xtick=data,         legend style={font=},         legend pos=south west,         enlarge x limits=0.1,         ymin=-0.15, ymax=0.0,         bar width=.2cm,         x tick label style={rotate=60, anchor=east, font=},         yticklabels={,,}         ]         [ybar,fill=lightgray,ybar legend] coordinates  {          (discrep, -0.05)(assent, -0.05)(foc.future, -0.07)(insight, -0.07)(differ, -0.08)(negate, -0.08)(friend, -0.08)(tentat, -0.08)(foc.present, -0.08)(cogproc, -0.08)         }; {Low on High}     {axis}           ode[align=center,rotate=90,font=] at (-1.0cm, 0.2cm) {Entropy Difference};     {tikzpicture}     {Entropy differences for LIWC word categories when running both language models on one group's data. High entropy scores on one dataset indicate word types that are harder for the opposite group's model to predict.}     {fig:ent_diff_charts} {figure*}  We use the language model trained on MHP data to find words with high entropy in peer data and vice versa. Since we are concerned with the  extit{difference} in predictability of words between the MHP and peer language models, we subtract the entropy given by the model trained on that data from the entropy assigned by the model that was not trained on that data. In other words, to find words difficult to predict in B's data, we subtract each word's entropy calculated by the model trained on B from the entropy calculated by the model trained on A as follows, for a set of words, X:   {equation}     E_{A,B} = -{1}{ X } _{x  X} log(p_{A}(x)) - log(p_{B}(x)) {equation}  If we calculate the entropy difference for each LIWC category and for each assignment of the MHP and peer groups to A and B, we find the highest differences for each category shown in the first and third plots of Figure~ ef{fig:ent_diff_charts}. We find highest entropy scores for words relating to  extit{leisure},  extit{sex}, and  extit{numbers} when running the MHP language model on peer data. Likewise, when running the peer model on MHP data, the category of  extit{discrepancy} contains words whose accuracy is improved the least by the peer model, again showing that these words are more indicative of the MHP group.  We perform a similar analysis, creating a language model for posts which have the highest score (or tied for highest) and another model for all other posts. We measure entropy differences and show the highest scoring categories for each group in the second and fourth plots. Some of the categories indicative of MHP language are also indicative of higher scoring posts;  extit{discrepancy},  extit{present} and  extit{future} words, and  extit{negation} words, while other categories like  extit{assent} and  extit{insight} words are more dominant in higher scoring posts. The lower scoring posts have the highest entropy differences for some types of words in the peer data, however, we also see that  extit{filler},  extit{anger}, and  extit{swear} words had the highest entropy differences for the low scoring group. Qualitative example sentences with word-level entropy and LIWC annotations are shown in the appendix in Table~ ef{tab:examples_mhp_data}.   {Discussion and Future Work}   In comparing linguistic aspects of MHP and peer comments, we find MHP tendencies align with established counseling principles and findings in counselor behaviors from recent literature. In particular, they align in the use of words that increase the likelihood of desired perspective shifts associated with clients feeling better after text counseling sessions (RQ2)~{althoff2016large}. We also found unique differences in the behavior of MHPs as compared to peers in how they respond to information seekers (RQ1). Although, comments by peers that prompt support-seeker replies also make use of similar word categories to MHPs, which shows that comparing MHPs to peers can offer insight into peer interactions as well.  It is important to note that our analyses rely heavily on the LIWC lexicon. While LIWC and other lexicons can help uncover variational language across groups at an exploratory stage, their use alone does not explain why variations are present. Certain limitations of LIWC are clear, such as when certain words that occur in multiple categories misleadingly boost the prominence of the categories equally. {kross2019does}'s and {jaidka2020estimating}'s studies have also demonstrated limitations of the use of LIWC when working with word counts to correlate with well-being metrics and an individualâ€™s emotional state. We utilize LIWC to understand linguistic behavior differences in conversations with peers and MHPs rather than to evaluate the emotional or mental health state of individuals; however, it is important to consider how these limitations could pertain to our interpretations of their differences, especially as we explore them more deeply in future work. In our study, we explore the patterns we find in the context of previous findings from related literature such as {althoff2016large} and {nobles2020examining}, however it warrants another study into nuanced aspects of the patterns to infer their social functions in support seeking forums in particular.  Although our findings align MHP behaviors with certain counselor behaviors associated with positive outcomes, our analyses do not support claims that MHP behaviors are more beneficial to individuals seeking support; rather, we have shown that the general tendencies of MHPs are in accordance with principles and behaviors demonstrated by counselors in other settings. Understanding the outcomes of these interactions for individual support seekers remains as an area for future work, which could employ surveying methods from prior work to  measure perceived empathy in online communities~{nambisan2011information}. Our dataset also enables investigations into whether support-seekers exhibit perspective shifts in interacting with MHPs or peers, and what MHP and peer tendencies are associated with these perspective shifts.  Another direction for future work could focus on modeling social media-specific engagement patterns of MHP and peer interactions. Prior work developed a model that accounts for variables indicating the level of attention threads receive (i.e., thread lengths and number of unique commenters), and variables indicating the degree of interaction between posters and commenters (i.e., time between responses and whether the poster replies to commenters), and used this model to study peer-to-peer interactions in online mental health platforms~{sharma2020engagement}; this approach may enable studying supportive interactions in megathreads and threads involving back-and-forth dialog between two or more parties.  More questions arise if we consider MHP tenure and specific domain of expertise (e.g., specializations, licenses, academic degrees). Prior work that studied longitudinal changes in counselor linguistic behaviors indicated that systematic changes occur over time as counselors develop personal styles that are more distinct from other counselors and exhibit more diversity across interactions~{zhang2019finding}. Future work could model the language longitudinally for MHPs and peers that have longer-term histories of participating in mental health forums to investigate whether systematic changes occur online as well, and if so, whether they reflect similar changes found in prior work.       {Limitations and Ethical Considerations}   A number of unknowns exist in what we are able to extract from Reddit. For instance, we do not know if users that do not use flairs are mental health professionals. We assume that those who have used the MHP flairs are MHPs and those that have not used them are peers. Additionally, we have grouped all MHP flairs into one group for our analysis, though a more nuanced analysis based on particular professional roles (e.g., psychologists, psychiatrists, social workers) and specializations (e.g., motivational interviewing, cognitive behavioral therapy, family  marriage counseling) may reveal additional trends. Prior work found that disclosing credentials has impacts on engagements that vary by subreddit and linguistic patterns associated with different experience levels and expert domains~{park2020trust}, thus the effects of disclosing MHP credentials when responding to support-seekers should be investigated.  A classifier or language model used to distinguish between MHPs and peers or to generate the language of either could have negative implications. A generative model that provides feedback to users could generate language that is harmful for those seeking help. Our work could be used to devise a tool to train counselors, however we do not have a direct measure of what type of responses are helpful or meaningful. In such an application, there is potential to reinforce harmful behaviors due to the inaccuracy of our models. Future studies are needed to determine how to best design a tool to train counselors and how models derived from corpora such as ours correspond to advice that patients find useful.   {Conclusion}  As the role of social networks is becoming more critical in how people seek health-information, it is important to understand their broader implications to health communication and how health experts can engage to promote the soundest information and offer support to their vulnerable users. By elucidating techniques employed by mental health professionals in their interactions with support-seekers in mental health forums, we have contributed insights toward the broader research direction of understanding how health experts currently engage with these platforms. With evidence that MHP linguistic behaviors associate with further engagement with support-seekers and that these same behaviors are associated with positive counseling conversation outcomes, we have shown that analyzing MHP behavior is a promising direction for better understanding online interaction outcomes, which can further inform forum design and moderation, and expert health promotion efforts.   The code used for our experiments and analyses, and the post ids in our dataset can be accessed at {https://github.com/MichiganNLP/MHP-and-Peers-Reddit}.   *{Acknowledgments}  This material is based in part upon work supported by the Precision Health initiative at the University of Michigan, by the National Science Foundation (grant 1815291), and by the John Templeton Foundation (grant 61156). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author and do not necessarily reflect the views of the Precision Health initiative, the National Science Foundation, or John Templeton Foundation.     {acl_natbib}",5,2021-06-25T02:17:42,en,2106.12976,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,23,0,0,0,0,0,0,0,0,0,6,1,0,0,0,0,9,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,5678,0,0,5678,0,5678,0,0,0,0,0,0,5678,5678,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,5678,0,0,0,0,0,5678,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,5678,5678,5678,5678,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,0,0,0,0,5678,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,5678,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,5678,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,5678,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,5678,0,0,5678,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,5678,0,5678,5678,0,0,5678,5678,5678,5678,0,0,5678,0,0,5678,0,0,0,0,0,0,5678,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,5678,0,0,0,0,5678,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,5678,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,0,5678,0,0,0,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,5678,5678,5678,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,5678,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,5678,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,5678,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
